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Abstract 
The G protein-coupled receptor FFA2 is a key mediator of short chain fatty acid 
signalling, which are produced in the gut via fermentation of poorly digested 
carbohydrates by the gut microbiota. Therefore, FFA2 has attracted interest as a 
potential therapeutic target for metabolic and inflammatory diseases. However, 
several limitations have hindered validation of FFA2 as a drug target, including 
the limited understanding of the molecular determinants of ligand binding and 
species-specific differences in pharmacology. Herein, novel tool compounds and 
assay systems were developed for FFA2 and utilised to address some of these 
limitations. Following the characterisation of functional assays for detection of 
FFA2 signalling, these were employed to examine the structure-activity 
relationship and pharmacology of FFA2 agonists versus antagonists. To assess 
how the pharmacology of FFA2 ligands is defined by their mode of binding, a 
radioligand binding assay was developed using a tritiated form of FFA2 
antagonist GLPG0974 that was utilised in combination with site-directed 
mutagenesis and homology modelling to explore FFA2 ligand binding sites. These 
studies showed that FFA2 agonist binding was defined by an essential interaction 
between the ligand carboxylate and an orthosteric Arg-His-Arg triad. In contrast, 
FFA2 antagonists only required one orthosteric arginine for high-affinity binding 
and could tolerate modifications of the carboxylate moiety. This knowledge was 
applied to develop an antagonist-based fluorescent tracer for FFA2 that was 
utilised in BRET binding assays but displayed complex pharmacological behaviour 
that was shown to be based on the bitopic nature of FFA2 antagonists. The 
secondary binding site of FFA2 antagonists was also related to their lack of 
action at rodent orthologues of FFA2, whose molecular basis was explored using 
homology models of human and murine FFA2. This facilitated the identification 
of a single lysine to arginine variation at position 2.60 that might provide a basis 
for antagonist selectivity. Extending these studies to agonist function 
demonstrated that removal of the positive charge at this position produced a 
signalling-biased form of FFA2, in which only coupling to Gi G proteins was fully 
maintained. In summary, these findings contribute to understanding the complex 
pharmacology of FFA2 ligands and the underlying mechanisms that define their 
function, and conclusions drawn from these studies may help advance future 
efforts to validate the therapeutic potential of targeting FFA2. 
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1 Introduction 
1.1 Drug discovery and development 
1.1.1 Different approaches to drug discovery 
One of the defining features of human nature is the drive to expand our 
knowledge and exploit discoveries to guide the progress of society and enhance 
our quality of life. This has led to impressive scientific and technological 
advances that have transformed the way we live our lives including, possibly 
most importantly, drastically improved medical treatments and a revolutionised 
approach to the development of medicines. Some therapeutics that are still 
widely in use today were discovered centuries ago by pure serendipity. A 
prominent example is paracetamol, whose complex mechanism of action remains 
to be fully understood and recent studies have highlighted novel safety concerns 
regarding its overuse (Aminoshariae and Khan, 2015). In addition to 
serendipitous discoveries, a phenotypic drug discovery approach has long 
dominated the pharmaceutical industry (Swinney, 2013). In phenotypic assays 
crude extracts or compound libraries are tested for their activity in cellular 
and/or animal models relevant to the respective disease background to identify 
new drug candidates. Only after compound efficacy in disease-relevant assay 
systems has been demonstrated, is effort invested into identifying its target and 
mechanism of action. The quality and translational value of the selected assay 
systems are absolutely imperative, as they need to reflect the condition to be 
treated as closely as possible and allow measurement of an appropriate 
biomarker to track treatment progress. Although the respective target does not 
necessarily need to be identified for regulatory bodies to allow progression into 
clinical trials, an extensive body of evidence is required to demonstrate the 
therapeutic benefit of the candidate drug and moving forward without a defined 
mechanism of action can be very challenging. Furthermore, with structure-based 
investigations playing an important role in the compound optimisation progress, 
the lack of a known target can also hinder progress. 
In contrast, a more recent approach to drug development follows a reverse 
methodology by starting with the search for an appropriate protein target that 
has a clear implication in the disease mechanism (Eder et al., 2014). Target 
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identification and validation follows on to development of compounds with the 
desired pharmacological action. Disease-relevant model systems to confirm 
compound efficacy are then employed during the optimisation process of 
identified candidate drugs. The concept of target-based (or rational) drug 
discovery is deeply rooted in our significantly improved understanding of the 
underlying molecular mechanisms of disease origin and progression. By utilising 
rational drug development important therapeutic needs have been addressed, 
including the identification of tyrosine kinase inhibitors as novel cancer 
treatments (Arora and Scholar, 2005) and antivirals to treat HIV infection 
(Pommier et al., 2005). However, despite our increased knowledge base, some 
conditions are governed by complex interlinked processes that are not fully 
understood and targeting only one component may not be sufficient to exert a 
therapeutically beneficial effect. Therefore, it is important to ensure that 
sufficient evidence is present to demonstrate the therapeutic potential of the 
selected target, with studies in disease-relevant animal models that employ tool 
compounds being particularly important. 
The informed nature of target-based drug development was initially thought to 
be superior to phenotypic screening, but recently phenotypic approaches have 
once more attracted industrial attention. Pharmaceutical companies including 
Novartis AG and GlaxoSmithKline plc are investing in the development of novel 
phenotypic screening methodologies (Kotz, 2012). This may in part be due to the 
results of an analysis of new molecular entities approved between 1999 and 
2008, which revealed that the majority (37%) of first-in-class drugs were 
identified by phenotypic screening rather than rational development (23%) 
(Swinney, 2013). The report suggested that target-based screening is likely to 
play a more important role in the development of follower drugs, of which half 
were identified following such an approach, while only a fifth were identified by 
phenotypic screening. However, a more recent study encompassing data up to 
2013 came to a different conclusion with 70% of first-in-class drugs resulting 
from target-based development and phenotypic screening contributing to only 
30% (Eder et al., 2014). In 2011 and 2012 alone, 22 new approved first-in-class 
drugs were developed in a target-based fashion, while only 4 were initially 
identified by phenotypic screening. The relevance of rational drug discovery has 
potentially only become apparent recently due to the long time-frame between 
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target selection and drug approval. However, scientific advances have not only 
affected rational drug discovery in a positive fashion (Kotz, 2012). Most recent 
phenotypic screening efforts employ elaborate assay systems, such as the use of 
organotypic multicellular cultures that aim to mimic the responses of organs in 
vivo, and the means of drug target identification have also drastically improved 
with chemical proteomics being particularly successful. These use a mass 
spectrometry–based affinity chromatography approach to identify small 
molecule-protein interactions. With these developments in mind, the choice of 
drug discovery approach will perhaps become dependent on the available 
knowledge base and screening methodologies in the respective disease context. 
1.1.2 Principles of rational target-based drug discovery 
While phenotypic screening is commonly executed by pharmaceutical companies 
with large compound libraries and high-throughput equipment, the initial stages 
in rational drug discovery are often performed in an academic setting or in 
collaborations between academia and industry (Vallance, 2016). In the rational 
drug discovery pipeline such preclinical studies can progress from target 
identification all the way to selection of a candidate lead compound to proceed 
into clinical trials and regulatory approval (Figure 1.1). 
 
Figure 1.1 The pipeline of target-based drug discovery Development of novel therapeutics is a 
long and cost-intensive process. The initial identification of an appropriate target is often based on 
work generated by academia, as it requires a substantial amount of basic science research. Once 
a target has been selected, a high-throughput screening system must be developed in which large 
libraries of potential ligands can be tested. Any compounds that are identified in this fashion likely 
require further optimisation, which includes extensive medicinal chemistry to develop a lead 
compound appropriate for clinical testing. At this stage the ligands are commonly also employed in 
animal models to validate the chosen target and define properties such as bioavailability, toxicity 
and potential metabolism. Clinical trials initially evaluate the safety of the lead drug in healthy 
subjects (Phase I) and then assess both safety and efficacy in a small cohort of patients with the 
condition to be treated (Phase II). If sufficient efficacy is observed, the trial is performed in a larger 
group with a focus on avoidable adverse effects that may only become apparent in a larger test 
population (Phase III). The last hurdle that needs to be overcome is the approval process, which 
may have to be repeated for different regions of the world depending on the target market. Figure 
modified from (Roses, 2008) and cost estimations obtained from (DiMasi et al., 2016). 
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The key features of a good drug target are its ability to be modulated by a drug 
molecule to exert a therapeutic benefit without causing side effects (Hughes et 
al., 2011). The term drug target itself is relatively broad and includes classical 
protein targets, but also genes and non-coding RNAs. A range of different 
methodologies and sources can be employed to identify such targets, but 
essentially these all come down to data mining of published information such as 
gene expression, proteomics and transgenic phenotyping (Yang et al., 2012). 
Correlating such data with risk of disease and its incidence can highlight genes 
and proteins that may be involved in the mechanism of disease, for example by 
identifying relevant genetic polymorphisms, as in case of the amyloid precursor 
protein in Alzheimer’s Disease (Bertram and Tanzi, 2008). Any potential target 
identified in this fashion is subjected to a detailed validation process in which 
multiple techniques are combined to confirm its therapeutic potential (Hughes 
et al., 2011). Common methods include manipulation of target expression by use 
of RNA-based antisense technology to block protein synthesis and transgenic 
knock-out animals, or studies employing available tool compounds in cell-based 
and in vivo disease models. The more evidence is available on the role of the 
identified target in the disease of interest and the exact mechanism by which it 
modulates disease progression, the higher is the likelihood of a successful drug 
discovery project. 
Once the drug target has been selected and thoroughly validated, the screening 
process begins. Selection of an appropriate assay format is a deciding factor in 
the drug discovery process. In the case of signalling proteins that alter the 
concentration of secondary messengers, such as calcium ions, in the cell or 
affect expression of downstream reporter genes, this can be relatively 
straightforward. Important considerations, in particular for high-throughput 
screens commonly employed by the pharmaceutical industry, include 
reproducibility and quality of the assay, but also the associated costs (Hughes et 
al., 2011). A good example for G protein-coupled receptors (GPCRs) (see section 
1.2) is the aequorin-based assay (Stables et al., 2000). Some active GPCRs signal 
by coupling to the Gq/11 subfamily of G proteins, which results in an increase of 
intracellular levels of calcium ions. This can be quantified in presence of 
aequorin, which is a natural calcium-sensitive protein that produces 
bioluminescence by oxidising its substrate coelenterazine in presence of calcium 
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ions. Alternative approaches to high-throughput screening include informed 
focussed screening, in which a smaller number of compounds to be screened is 
selected based on known ligands or molecular modelling (Valler and Green, 
2000), or fragment screening, which aims to identify small molecules with a low 
molecular weight to be used as building blocks for larger compounds (Erlanson et 
al., 2016). If sufficient structural information of good quality is available, virtual 
screening can also be employed, in which putative ligands are docked 
computationally into potential binding sites (Congreve et al., 2011). 
When developing a clinical candidate from compounds identified in initial 
screens, medicinal chemistry projects run in parallel with screening efforts to 
generate the best possible compound. In addition to the ability of the compound 
to modulate the desired target, other factors are also assessed that are crucial 
for clinical testing. Studies need to be performed to define in vivo properties 
such as compound absorption, distribution, metabolism and excretion; and 
pharmacokinetics. In some cases, compound activity needs to be sacrificed for 
optimisation of such in vivo parameters to reduce the likelihood of side effects. 
At earlier stages it can be beneficial to confirm whether the compound can be 
classified as drug-like according to the Lipinski Rule of Five (Lipinski et al., 
2001), which includes assessment of the molecular weight (<400 kDa) and 
lipophilicity in terms of clogP (<4). Furthermore, initial toxicity tests in 
hepatocytes and other cell lines can provide an indication of the likelihood of in 
vivo toxicity (Gomez-Lechon et al., 2010). Failure of a potential drug can occur 
at any of the stages described above, from the inability to develop an 
appropriate assay system to lack of compound efficacy in disease-relevant tests 
or off-target toxicity. Only approximately 10% of industrial drug discovery 
projects result in a clinical candidate, of which again only 10% reach the market 
(Hughes et al., 2011). The further along the pipeline the failure takes place, the 
costlier the drug discovery project becomes, hence careful target selection and 
validation are one of the most important factors in the drug discovery process. 
Therefore, academic research also plays an important role in rational drug 
development with exploratory drug discovery projects contributing significantly 
to validation of drug targets and their therapeutic potential. 
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1.1.3 Significance of G protein-coupled receptors as drug targets 
Looking back at the past to analyse successfully targeted protein families can 
provide us with valuable information for informed drug target selection. Perhaps 
it is to be expected that the class including the most successfully utilised drug 
targets are GPCRs, followed by ion channels, nuclear receptors and kinases 
(Santos et al., 2017). These protein families all act in response to a stimulus 
provided directly (GPCRs and ion channels) or indirectly (nuclear receptors and 
kinases) by the cellular surroundings; they are a component of the cellular 
machinery that senses the extracellular environment and induces a 
corresponding response by activating a specific intracellular signalling cascade. 
GPCRs seem to play a particularly important role, with roughly a third of all 
small-molecule drugs exerting their effects by acting on these receptors (Santos 
et al., 2017). Interestingly, the contribution of GPCRs to the pool of drug targets 
has not changed significantly over the last six years as a similar analysis in 2011 
came to the same conclusion (Rask-Andersen et al., 2011). Although the bulk of 
drugs targeting GPCRs has been approved before 1990, innovation in drug 
development has been ongoing with 4-5 new drugs, including small molecules 
and biologics, being approved per year (Santos et al., 2017). 
But what are GPCRs and what makes them such superior drug targets? GPCRs are 
the largest family of transmembrane receptors in the human genome with 
approximately 800 members (Fredriksson et al., 2003) and they are 
complemented by a strikingly diverse selection of ligands, ranging from small 
organic compounds and lipid-like molecules to peptides and even proteins. In 
response to their respective stimulus GPCRs can induce signalling cascades by 
coupling to different G protein subtypes and arrestins, which can exert a variety 
of downstream effects. From a drug discovery perspective, being involved in 
virtually every physiological process and having a readily druggable binding site 
makes GPCRs very suitable target candidates. By designing synthetic molecules 
with different pharmacological properties, one could conceptually be able to 
manipulate any disease-relevant cellular process in the desired fashion by 
inducing, blocking or modulating the response of different GPCRs. Indeed, drugs 
that target GPCRs are in use in the majority of officially classified therapeutic 
areas, highlighting their universal drug target potential (Santos et al., 2017). 
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1.2 G protein-coupled receptors 
1.2.1 Overview of GPCRs and their subfamilies 
The number of GPCRs in the human genome and the variety of their ligands 
highlight the functional diversity of this superfamily, however certain properties 
that designate them as GPCRs are shared by all members. In addition to the 
common nature of their signalling, the most notable defining characteristics are 
their structural features. All GPCRs are composed of seven transmembrane 
domain helices (termed TM1-7), linked by three intracellular (ICL1-3) and three 
extracellular (ECL1-3) loops with the N terminus facing the extracellular 
environment and the C terminus being intracellular. The N terminus and, in 
some cases the ECLs, show high structural diversity as they often play a key role 
in receptor functionality and ligand binding, especially as for some GPCR classes 
it is the main point of ligand-receptor interaction. 
The structural variation among GPCRs is reflected in their phylogenetic 
relationship and led to the first classification of the receptor family into class A-
F (also referred to as class 1-6) (Kolakowski, 1994). This nomenclature system 
has been modified over the years and was also adapted by the International 
Union of Pharmacology (Foord et al., 2005). The sequencing of the human 
genome in 2001 allowed for a more comprehensive investigation of the GPCR 
repertoire and resulted in the now commonly accepted classification system 
(Fredriksson et al., 2003), which retains most of the characteristics of the 
initially defined classes. GPCRs cluster into five main groups referred to as 
Rhodopsin (class A), Secretin (class B), Adhesion (class B), Glutamate (class C) 
and Frizzled/Taste2 families (Figure 1.2). 
The Rhodopsin family is the largest subfamily of GPCRs with approximately 670 
members and is also the most diverse in its ligands (Fredriksson et al., 2003), 
which undoubtedly contributes to the fact that it also contains the largest 
number of therapeutic targets. Examples include muscarinic receptors that bind 
the neurotransmitter acetylcholine (Wess, 1993); receptors activated by 
chemokines, which are small signalling proteins (Gershengorn et al., 1998); 
protease-activated receptors that bind a peptide cleaved from their N terminus 
(Vu et al., 1991); and fatty acid receptors (Milligan et al., 2017). In contrast to 
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Figure 1.2 Structural features of the GPCR families All G protein-coupled receptors (GPCRs) 
share a 7-transmembrane helix arrangement with an extracellular N terminus and an intracellular C 
terminus. While the intracellular portions are relatively conserved between different families, the 
extracellular region is highly diverse. Red shapes represent the different modes of ligand 
interaction with respective GPCR families. Conserved cysteines that stabilise the N terminus to 
allow for ligand binding are shown in green. Properties of common GPCR subfamily ligands are 
listed below corresponding subclasses. The N terminus of the Adhesion family is composed of a 
GPCR autoproteolysis-inducing (GAIN) domain that catalyses the cleavage of the N terminus such 
that the adhesion domains, which contain a range of glycosylation sites, are non-covalently 
associated with the receptor. Most members of the Glutamate family exist in dimeric form and bind 
ligands by employing their venus fly trap domain (VFD). Protein ligands associate with the 
cysteine-rich domain (CRD) of Frizzled family receptors with help of their palmitoyl group (red line). 
The family of Taste2 receptors is not shown as its structural features are less understood and they 
do not show distinctive N terminal modifications. Their transmembrane domains show highest 
similarity to the Frizzled family. 
 
all other families, the majority of endogenous ligand binding sites lie within the 
TM region, which therefore varies more significantly between members of this 
family compared to others. Additionally, the TM region also contains the highly 
conserved DRY (Rovati et al., 2007) and NPxxY (Urizar et al., 2005) motifs that 
Chapter 1  9 
 
are thought to stabilise different conformational states of the receptor. The 
Secretin family is relatively small with only 15 members and is characterised by 
an extracellular peptide hormone-binding domain that is also the most varied 
region within the family (Bazarsuren et al., 2002). However, as in case of the TM 
domains of the Rhodopsin family, this domain also contains conserved features, 
namely cysteine residues that are thought to stabilise the N terminus to allow 
for ligand binding. The Adhesion family and its 33 members were initially classed 
with the Secretin family due to the similarity of their TM domains, however their 
N termini have a long and rigid structure with extensive glycosylation sites 
allowing them to bind extracellular matrix proteins (Fredriksson et al., 2003). 
The most distinguishing feature of the Glutamate family is the dimeric 
quaternary structure adopted by most of its members that bind glutamate by 
employing a Venus flytrap mechanism using their large N terminal lobes 
(Kunishima et al., 2000). The GABA-binding members of the family use a similar 
mechanism to facilitate ligand binding. The Frizzled family is activated by Wnt 
glycoproteins that bind to a cysteine-rich region within their N terminus and may 
also engage the extracellular loops (Dann et al., 2001). The Taste2 receptors are 
the most recently identified GPCR subfamily and are thought to translate the 
bitter taste of certain molecules that bind to the extracellular loops of the 
receptor (Pronin et al., 2004), however the ligands for most of their members 
remain to be identified (Chandrashekar et al., 2000). Furthermore, the family 
also shows a relatively high sequence diversity (Conte et al., 2002) with few 
conserved residues, which may be related to the fact that only 25 putative 
members are able to recognise more than a thousand different bitter 
compounds. 
This overview of the different GPCR subfamilies exemplifies the link between 
the structural diversity and universal role that these receptors play in the 
functioning of the human body (Lagerstrom and Schioth, 2008). However, it also 
highlights that not all 800 members have equal therapeutic potential as sensory 
receptors are traditionally not thought to play a role in disease-related 
processes, leaving approximately 400 potential drug targets. Targeting different 
classes of GPCRs requires distinct approaches to ligand development, as the 
druggability of binding sites needs to be considered and the nature of the 
endogenous binding pocket plays a crucial role. For example, it is difficult to 
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design small-molecule ligands that bind with high affinity to the often shallow 
sites that are targeted by peptides, whose nature of binding to a receptor 
resembles interactions between proteins. 
1.2.2 Canonical GPCR signalling pathways 
The ability of GPCRs to transduce signals by activation of associated guanine 
nucleotide-binding proteins, or G proteins, is what gives the receptors their 
name and is the most studied component of the GPCR signalling cascade. G 
proteins are heterotrimeric proteins that are composed of three subunits: α, β 
and γ (Lambright et al., 1996). Gα contains distinct structural features including 
a Ras-like GTPase domain, an α helical domain and an N-terminal α helix. Gβ 
consists of β sheets that form a propeller-like structure and an α helix, while Gγ 
is largely unstructured with two α helices that form a multitude of interactions 
with the α helix and β sheets of Gβ. GPCR ligand binding and activation triggers 
the exchange of GDP for GTP in the cleft between the GTPase and α-helical 
domain of Gα (Dror et al., 2015). This induces a conformational change in Gα 
that facilitates its dissociation from the Gβγ heterodimer and allows for Gα and 
Gβγ to independently interact with different downstream effectors. This 
signalling cascade is inactivated by the hydrolysis of GTP to GDP by the Ras-like 
GTPase domain of Gα, whose activity is augmented by the binding of regulators 
of G protein signalling, and promotes the reassociation of the heterotrimeric 
Gαβγ complex (Mann et al., 2016). A single activated GPCR can turn over 
multiple G proteins and thereby constitutes the first amplifying step of the 
signalling cascade. Although the principle of G protein-dependent signalling is 
relatively straightforward, it is complicated significantly by the presence of 16 
Gα, 5 Gβ and 12 Gγ proteins in the human genome that all have the capacity to 
promote different signalling pathways (Hewavitharana and Wedegaertner, 2012). 
Association of a GPCR with differently composed heterotrimers can therefore 
induce highly diverse downstream effects, however traditionally the Gα subunit 
was thought to be the deciding factor. Gα proteins can be categorised into four 
families based on preferential downstream signalling and sequence similarity: 
Gαs (includes Gαs(S), Gαs(L) and Gαs(olf)), Gαi (includes GαoA, GαoB, Gαi1-3, Gαz, Gαt1-
2 and Gαgust), Gαq (includes Gαq, Gα11 and Gα14-16) and Gα12 (includes Gα12 and 
Gα13) (for detailed signalling pathways see figure 1.3). Additionally, different 
combinations of Gβγ heterodimers facilitate the activation of a variety of 
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downstream effectors. From a translational perspective it is therefore not only 
important to consider which G proteins are activated by a specific GPCR, but 
also the expression of the respective subunits in the disease-relevant tissue. 
Figure 1.3 Signalling cascades induced by GPCR activation Association of a G protein-coupled 
receptor (GPCR) with its ligand promotes an active conformational state (A). This conformational 
rearrangement results in recruitment of a heterotrimeric G protein and facilitates guanosine 
nucleotide exchange in the Gα subunit, which induces dissociation of Gα from the Gβγ subunits. 
Depending on the Gα subtype, different downstream signalling pathways are engaged with pink 
boxes showing direct protein targets and orange boxes representing proteins activated further 
downstream. The Gβγ subunits are also able to engage a range of different signalling cascades 
that depend on Gβγ subtypes and cell system. Actively signalling GPCRs are targeted by G 
protein-coupled receptor kinases (GRKs) that phosphorylate the C-terminal tail of GPCRs (B). 
Arrestins show high affinity for the phosphorylated C terminus of GPCRs and induce internalisation 
of the receptor upon association (C). Once internalised, the GPCR is either directly targeted for 
degradation or recycling pathways, or it induces arrestin-dependent signalling such as activation of 
mitogen-activated protein (MAP) kinases. 
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While actively signalling G proteins have an inherent inactivation mechanism, 
downregulation of activated GPCRs is a more complex process. G protein-
coupled receptor kinases (GRKs) induce the first step in this cascade by 
phosphorylating multiple serine and threonine residues in the C terminal tail 
and/or intracellular loops (Tobin et al., 2008). These changes in the intracellular 
surface of the receptor increase the affinity of the receptor for binding of the 
arrestin adaptor proteins. The arrestin protein family includes only four 
members: arrestin 1 (or visual arrestin), arrestin 2 (or β-arrestin 1), arrestin 3 
(or β-arrestin 2) and arrestin 4 (or cone arrestin). While arrestins 1 and 4 have a 
sensory function in photoreceptors, the β-arrestins were initially identified as 
regulators of the β2 adrenergic receptor (β2AR), hence termed β-arrestins (Lohse 
et al., 1990), and are now known to be expressed ubiquitously to regulate non-
photoreceptor GPCR desensitisation (DeWire et al., 2007). Upon association with 
a GPCR, β-arrestins facilitate clathrin-mediated endocytosis, which facilitates 
internalisation of the receptor and targeting of resulting intracellular vesicles for 
recycling to the cell membrane or degradation (Goodman et al., 1996). It is now 
universally accepted that β-arrestins are also able to induce specific signalling 
cascades by activating, among others, specific mitogen-activated protein kinases 
(MAPKs) (Daaka et al., 1998), making them an integral component of GPCR 
signalling (Figure 1.3). However, β-arrestin signalling does not seem to be 
triggered by activation of every GPCR, which may be regulated by the 
conformational changes induced in β-arrestins upon interaction with a GPCR, or 
the fashion in which it associates with the receptor (Cahill et al., 2017). 
1.2.3 Structural investigations of GPCR activation 
Deciphering how a GPCR translates the extracellular binding of a ligand into 
conformational rearrangements of its intracellular portion to facilitate the highly 
specific activation of interacting proteins is not only of fundamental research 
interest, but also has translational relevance due to its impact on future ligand 
development and rational targeting of specific GPCR signalling pathways. A key 
scientific advance that has undoubtedly played a critical role in understanding 
this process is the availability of high-resolution structures. The award of the 
Nobel Prize in Chemistry for solving the crystal structure of the β2AR in complex 
with its signalling partner, the G protein Gs, clearly highlights the impact of this 
work (Rasmussen et al., 2011). The flexible nature of GPCRs hinders the 
Chapter 1  13 
 
formation of rigid crystals that are required for structure determination by X-ray 
diffraction, therefore recent approaches commonly induce artificial stabilisation 
of the GPCR. These include the fusion of easy-to-crystallise proteins such as T4 
lysozyme to the receptor (Rosenbaum et al., 2007); conformational stabilisation 
by introduction of thermostabilising mutations (Magnani et al., 2016); and co-
crystallisation with engineered interaction partners such as nanobodies (Pardon 
et al., 2014) or peptides of naturally interacting proteins such as G proteins 
(Carpenter and Tate, 2016) and arrestins (Szczepek et al., 2014) to stabilise 
specific GPCR conformations. Availability of these and other methodologies has 
led to an explosion in the number of GPCR crystal structures. While 59 crystal 
structures were available in total in 2011, in 2016 alone 32 new crystal 
structures were published (Isberg et al., 2016). The GPCRdb database now lists a 
total of 203 crystal structures with the majority belonging to the Rhodopsin 
family. In addition to X-ray crystallography, other approaches to structure 
investigation have also become more advanced, including nuclear magnetic 
resonance (NMR), which has been used to visualise entire unmodified GPCRs in a 
lipid bilayer (Park et al., 2012) or to assess structural changes in localised areas 
by selectively labelling residues of interest (Manglik et al., 2015); and single-
particle cryo-electron microscopy that enables visualisation of more flexible 
GPCR complexes (Liang et al., 2017). Finally, computational methods have also 
advanced substantially and simulation of the molecular dynamics of GPCR 
activation and ligand binding now play a crucial role in defining the link between 
structure and function (Latorraca et al., 2017).  
Considering the invaluable information provided by crystal structures of 
receptors in different conformations, it is easy to overlook that the dynamic 
movement of GPCRs is what lies at the heart of the molecular basis of GPCR 
signalling (Latorraca et al., 2017). To truly appreciate this process, it is 
important to consider that common schematics that show signalling cascades as 
sequential mechanisms (Figure 1.3) do not reflect what occurs in cells. In reality 
GPCRs are highly flexible and molecular dynamics simulations indicate that 
GPCRs spontaneously adopt multiple conformations including inactive, active 
and intermediate states (Dror et al., 2011). Rather than switching all receptors 
into an active state, ligand binding seems to affect both the transition speed and 
resting time of a GPCR in certain conformations and thereby changes the 
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probability to detect the receptor in its active or inactive form. Association of G 
proteins and arrestins also plays a role in such conformational transitions and 
stabilisation of active-state structures, which may explain why many ligand-
bound structures appear to be in an intermediate conformation between 
canonical inactive and active states (Lebon et al., 2012). 
This complexity may suggest that GPCRs undergo different conformational 
changes upon activation, depending on the bound ligand and activated signalling 
pathways. However, structures of GPCRs in their active state appear to share 
certain structural rearrangements when compared to their inactive-state 
structures (Figure 1.4). In essentially all putative active-state crystal structures 
of Rhodopsin family GPCRs the TM6 is rotated and displaced by 6-14 Å away from 
the helical bundle (Rasmussen et al., 2011, Kruse et al., 2013, Huang et al., 
2015). In some cases, this movement is also accompanied by an outward 
movement of TM5. This intracellular helix rearrangement is responsible for the 
formation of a crevice flanked by TM3, TM5 and TM7 that serves as the G protein 
(and likely also β-arrestin) binding site. Interestingly, this movement was also 
conserved in the cryo-EM structure of the Secretin family calcitonin receptor 
(Liang et al., 2017), suggesting that this may be conserved throughout the entire  
Figure 1.4 Structural changes induced by GPCR activation Inactive (grey) and active 
(coloured) state structures of three different receptors are aligned and the outward shift of the TM6 
is illustrated in red. The rearrangement of arginine (R) and tyrosine (Y) residues within the 
conserved DRY and NPXXY motifs is highlighted. The PDB IDs of the respective structures are 
2RH1 and 3SN6 (inactive and active β2AR); 3UON and 4MQS (inactive and active M2R); 4DKL and 
5C1M (inactive and active µOR). 
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GPCR family. Other helices such as TM3 and TM7 undergo more subtle rotations. 
Defining the exact mechanism of G protein and β-arrestin association with GPCRs 
comprises a field of research that is continuously evolving due to new 
developments. In the case of G proteins, structures of rhodopsin with a 
G protein peptide (Choe et al., 2011) and the β2AR-Gs complex structure 
(Rasmussen et al., 2011) both suggested that the C terminal α5 helix of the Ras-
like domain inserts into the intracellular crevice, while the α-helical domain 
shows increased mobility and thereby potentially facilitates GDP release. 
Interaction of β-arrestin with the receptor is less understood, however the 
phosphorylated C terminal tail of GPCRs appears to act as the defining 
recruitment site. Some studies also suggest that a finger loop within one of the 
immunoglobulin-like domains of β-arrestin may occupy the same region as the α5 
helix of G proteins, thereby making association of G proteins and β-arrestins 
mutually exclusive (Szczepek et al., 2014, Kang et al., 2015). The potential of 
β-arrestins to mediate either desensitisation or further downstream signalling 
seems to relate to different β-arrestin conformations that occupy either just the 
C terminal tail or engage with the transmembrane core of the receptor (Cahill et 
al., 2017, Shukla et al., 2014). 
In some structures helical rearrangements also correlate with the role of 
conserved Rhodopsin family motifs, including the breaking of the ionic lock 
within the DRY motif upon ligand binding and the formation of interactions 
within the NPxxY motif once the receptor is in an active confirmation (Figure 
1.4) (Rasmussen et al., 2011, Kruse et al., 2013, Huang et al., 2015). But how 
does agonist binding facilitate these observations? This is a question that is more 
difficult to answer. While on the cytoplasmic side movements are relatively 
conserved between different GPCRs of one family, conformational 
rearrangements at the extracellular side differ substantially between receptors. 
The β2AR active-state structure and molecular dynamics simulations suggest that 
a central network of TM3, TM5, TM6 and TM7 residues located within the helical 
bundle may be responsible for transmitting the signal of ligand binding into the 
conserved intracellular rearrangements (Latorraca et al., 2017). It is likely that 
other receptors will also have such a “transmission network”, however residues 
and conformational changes induced may differ between receptors and depend 
on the pharmacology of employed ligands. It is also important to consider that it 
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is still challenging to obtain true active-state structures of GPCRs. 
Crystallisation-assisting techniques such as thermostabilising mutations induce 
an artificially stabilised conformational state of the receptor, in which agonist 
binding is often uncoupled from the structural rearrangement of the intracellular 
surface. 
1.2.4 Pharmacology of GPCR ligands 
The inherent pharmacological parameters that define the action of a ligand at a 
receptor are affinity and efficacy (or intrinsic activity).  Affinity represents the 
strength of interaction between a compound and its binding site. To determine 
affinity values experimentally, a means of measuring ligand binding to the 
receptor is required, for example using a radioactively or fluorescently labelled 
probe. Should a suitable probe not be available, ligand potency in functional 
assays can be used as a surrogate measure of ligand affinity (Rosenkilde and 
Schwartz, 2000). However, functional potency may be dependent on both 
affinity and efficacy in assay systems with a significant receptor reserve present, 
and therefore care must be taken in selecting a suitable functional assay to use 
as a surrogate for agonist affinity (Kenakin, 2001). Defining efficacy can be more 
challenging; it essentially reflects the ability of a ligand to promote specific 
receptor conformations that change its basal behaviour by, for example, 
activating downstream effectors (Kenakin, 2002). Although the conformational 
changes in a receptor induced by a ligand are conceptually independent of the 
respective assay system, it is commonly assessed in a system-dependent fashion 
by measuring the maximum response achievable by a ligand in a functional 
assay. Efficacy measurements are also governed by the receptor reserve of the 
employed system, which is related to the number of receptors that need to be 
occupied by a specific ligand to induce a maximal response. Depending on the 
properties described above, ligands can be broadly separated into the following 
four classes: Full, partial or inverse agonists and neutral antagonists (for 
detailed description see figure 1.5A). 
Although this classification is sufficient to describe orthosteric ligands that are 
defined by their interaction with the endogenous ligand binding site, advances in 
understanding GPCR ligand binding in the past decade have resulted in an 
emerging interest in allosteric ligands that can alter receptor activity by  
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Figure 1.5 Pharmacology of GPCR ligands The pharmacology of orthosteric (A) and allosteric 
(B) ligands is illustrated. (A) Binding of an agonist (green) to the orthosteric binding site (yellow 
shading) can induce a full or partial recruitment of downstream signalling partners. Association of a 
neutral antagonist (purple) with the orthosteric site does not affect the basal activity level of 
receptor, while an inverse agonist is able to inhibit basal activity by promoting an inactive 
conformational state. (B) Allosteric ligands associate with a distinct binding site (orange shading) 
and can act as agonists (green) or antagonists (purple) independently of an orthosteric ligand. 
However, allosteric ligands often act as positive (PAM) or negative allosteric modulators (NAM) of 
agonist action by modulating agonist affinity (top arrow) and/or efficacy (bottom arrow). It is 
assumed that the ligands presented recruit G proteins and arrestins consecutively, but at equal 
measure. 
 
associating with sites distinct from the orthosteric pocket (Wootten et al., 
2013). Effects exerted by allosteric ligands add a significant level of diversity to 
GPCR ligand pharmacology (Figure 1.5B). Similarly to orthosteric ligands, they 
can show intrinsic agonism; ligands that act exclusively in this fashion are usually 
referred to as allosteric agonists. However, allosteric compounds often also have 
the ability to modulate the affinity and/or efficacy of ligands bound to the 
orthosteric site, making them positive or negative allosteric modulators (PAMs or 
NAMs) (Hudson et al., 2014). Such modulatory effects are highly dependent on 
the bound orthosteric ligand and the assessed pathway, and therefore they 
should always be considered in this context (Watson et al., 2005). Development 
of allosteric ligands for GPCRs has attracted much attention in recent years, in 
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particular due to potential therapeutic advantages. Compounds that are pure 
allosteric modulators and do not show intrinsic agonism have a saturable 
modulatory effect, which is restricted by the temporal and spatial properties of 
the respective endogenous ligand, thereby preventing possible side effects and 
overdose (Kenakin and Miller, 2010). Furthermore, when targeting highly 
conserved receptor subclasses allosteric sites can provide increased selectivity, 
for example to target muscarinic receptor subtypes in neurological disorders 
(Chan et al., 2008, Bradley et al., 2017), and for GPCRs with endogenous peptide 
ligands such as the chemokine (Dragic et al., 2000) or glucagon (Koole et al., 
2010) receptor the targeting of allosteric sites may be the only feasible option 
for small-molecule drug development. 
To complicate the matter even further, some molecules can simultaneously 
engage both orthosteric and allosteric sites and are therefore referred to as 
bitopic ligands (Valant et al., 2012). Therapeutically such compounds are 
attractive as they may show added affinity and selectivity over orthosteric 
ligands since they interact with additional sites. The majority of bitopic ligand 
examples were initially designated as orthosteric or allosteric ligands and only 
continuing pharmacological investigation revealed their bitopic mode of binding 
(Valant et al., 2008, Lane et al., 2014). Designing such ligands is theoretically 
straightforward as a combination of orthosteric and allosteric pharmacophores 
with a suitable linker should theoretically yield a ligand that occupies both sites. 
In practice this is more complicated and recent efforts often include in-depth 
medicinal chemistry efforts to define, for example, the contribution of primary 
and secondary compound pharmacophores and their linker to dopamine receptor 
subtype selectivity of bitopic ligands (Kumar et al., 2017). However, in the case 
of the M2 muscarinic receptor the rational design of a bitopic agonist has been 
achieved by linking an orthosteric agonist compound to an allosteric fragment 
(Antony et al., 2009). 
1.2.5 Impact of diverse ligand binding sites on GPCR signalling 
The main determinant that defines GPCR ligand pharmacology is the mechanism 
by which the compound engages the receptor. Understanding how the mode of 
ligand binding translates into pharmacological action is one of the most 
important guides for rational drug design. Although a combination of receptor 
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mutagenesis and signalling studies has provided important information on ligand 
binding sites, GPCR structures in complex with different ligands are undoubtedly 
crucial. Recently solved crystal structures illustrate unexpected modes of ligand 
binding that, however, clearly correlate with ligand pharmacology (Figure 1.6). 
The structure of the glucagon receptor bound to the allosteric antagonist 
MK-0893 revealed that the ligand exerts its negative allosteric modulation by 
associating with an extra-helical binding site between TM6 and TM7 and may 
thereby restrict the outward movement of TM6 necessary for the glucagon 
receptor to adopt an active conformation (Jazayeri et al., 2016). A further 
example of an extra-helical binding site is the binding of protease-activated 
receptor 2 (PAR2) antagonist AZ3451, which is highly lipophilic and likely 
prohibits active-state conformational rearrangements by limiting movements of 
TM2-4 (Cheng et al., 2017). The recent structure of the CCR9 chemokine 
receptor in complex with the allosteric antagonist vercirnon demonstrated a 
further unexpected binding site: The intracellular side of the receptor (Oswald 
et al., 2016). In this way vercirnon locks the CCR9 receptor in a conformation 
that results in a steric clash with G protein or β-arrestin binding. These studies 
highlight that allosteric ligands can also exert their action through modulating 
receptor conformation independently of the orthosteric binding site by 
preventing helical movement or association of signalling partners. Such modes of 
action are difficult to identify without structural data and highlight that there 
may be much that we still do not know regarding GPCR ligand binding sites. 
Figure 1.6 Unusual mechanisms of GPCR ligand binding Structures of the glucagon receptor 
(GCGR), protease-activated receptor 2 (PAR2) and C-C chemokine receptor type 9 (CCR9) are 
shown in complex with different allosteric ligands as indicated in brackets. The PDB IDs of the 
respective structures are 5EE7 (GCGR), 5NDZ (PAR2) and 5LWE (CCR9). 
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One pharmacological concept that lies on the interface between GPCR 
activation, signalling and ligand binding is that of biased ligands. These display 
functional selectivity and modulate the output of GPCR activation in a fashion 
that results in a different signalling profile compared to the receptor liganded 
with its endogenous agonist (Figure 1.7). Commonly such altered signalling 
behaviour refers to preferential ligand-induced activation of G protein or β-
arrestin signalling by a receptor that can engage both pathways simultaneously. 
As in the case of the concept of bitopic binding modes, such pharmacological 
behaviour was first discovered retrospectively with a study suggesting that the 
well-established beta-blocker propranolol acts in a biased fashion by promoting 
MAPK activation via β-arrestin signalling, while suppressing Gs-coupled signalling 
(Baker et al., 2003). Considering recent advances in understanding the dynamic 
nature of GPCR conformations, it is not unexpected that distinct agonist ligands 
may promote different conformational states of the receptor that induce diverse 
downstream signalling. 
Although allosterism and signalling bias are not directly connected, ligands that 
engage allosteric binding sites have a high potential to (a) induce distinct 
conformational changes and signalling compared to an orthosteric agonist if they 
show intrinsic agonism (Bolognini et al., 2016a) and/or (b) modulate the 
response of the receptor to the orthosteric ligand in a biased fashion (Goupil et 
al., 2010). Both of these studies also demonstrated that biased signalling does 
not only encompass the selection between G protein and β-arrestin signalling but 
can also include selective coupling to different G protein subtypes. In addition, 
Figure 1.7 Biased signalling by GPCR ligands Both orthosteric (A) and allosteric (B) ligands can 
show biased signalling behaviour. Orthosteric ligand binding can preferentially induce recruitment 
of G proteins or arrestins (A). Some allosteric ligands have the capability to bias the signalling of a 
non-biased orthosteric ligand by promoting conformational states that preferentially associate with 
G proteins or arrestins (B). 
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it is also important to assess signalling bias by measuring the receptor response 
to the biased ligand at different levels of the signal transduction cascade, as two 
β-arrestin-biased ligands for the angiotensin II receptor induced distinct kinase 
substrate phosphorylation patterns (Santos et al., 2015). This may suggest that 
ligands inducing β-arrestin signalling have a means of promoting selective 
activation of downstream kinases, potentially in part by promoting differential 
phosphorylation patterns of the GPCR C terminus by GRKs (Nobles et al., 2011). 
1.3 Identification of the free fatty acid receptor family 
1.3.1 Relevance of metabolites as signalling molecules 
The role of metabolites in regulating physiological processes is well established; 
they serve as crucial energy sources and intracellular signalling molecules that 
act on enzymes such as histone deacetylases (HDACs) (Shimazu et al., 2013) and 
nuclear hormone receptors including peroxisome proliferator-activated receptors 
(PPARs) (Ahmadian et al., 2013). However, recent research efforts revealed that 
metabolites also have the capability to act as extracellular signalling molecules 
by targeting a group of metabolite-sensing GPCRs on the cell surface of 
accessible tissues such as the gastrointestinal (GI) tract (Husted et al., 2017). 
One group of signalling metabolites that has recently attracted much attention 
as GPCR ligands are free fatty acids, which are composed of a carboxylic acid 
moiety linked to an aliphatic chain (Milligan et al., 2017). Fatty acids are 
typically grouped into classes defined by the length of their carbon chain 
including short chain fatty acids (SCFAs) with 6 or less carbons, medium chain 
fatty acids (MCFAs) with 7-12 carbons and long chain fatty acids (LCFAs) with 
more than 12 carbons. Furthermore, the number and position of unsaturations in 
the aliphatic chain is also highly relevant, in particular for LCFAs. With the 
global effort to educate the public on nutrition that promotes good health, use 
of polyunsaturated fats such as omega-3 fatty acids has been promoted due to 
their metabolic and inflammatory health benefits (Oh et al., 2010), while 
excessive consumption of specific saturated fats is thought to increase the risk 
of cardiovascular disease (Wang and Hu, 2017). A factor that further 
distinguishes SCFAs from MCFAs and LCFAs is their source. MCFAs and LCFAs are 
obtained primarily from dietary fats or synthesised de novo in the liver. In 
contrast, SCFAs are produced through fermentation of dietary fibre by the gut 
Chapter 1  22 
 
microbiome and in response to alcohol consumption through ethanol metabolism 
in the liver. Therefore, their production is not only dependent on the level of 
fibre consumption, but also on the composition of the gut microbiota with some 
species preferentially producing different SCFAs that may exert distinct effects 
(den Besten et al., 2013). Targeting gut microbiome composition and signalling 
in general has been highlighted as a novel approach to treat metabolic and 
inflammatory disorders and using drugs to modulate SCFA effects presents a 
potential strategy (Jia et al., 2008). 
1.3.2 Deorphanisation of FFA receptors 
Understanding how free fatty acids (FFAs) exert their physiological effects is key 
to developing successful therapeutics targeting these processes. The 
deorphanisation of GPCRs activated by FFAs approximately 15 years ago revealed 
the role of FFAs as extracellular signalling molecules and has put the FFA 
receptor family on the map as potential drug targets. The family of FFA 
receptors is composed of four members: FFA1 (or GPR40), FFA2 (or GPR43), FFA3 
(or GPR41) and FFA4 (or GPR120). FFA1-3 were the first FFA receptors to be 
deorphanised in 2003 in multiple independent studies with FFA1 responding to 
MCFAs and LCFAs, and FFA2-3 responding to SCFAs. These three receptors share 
a relatively high sequence identity of 30-40% and are encoded in tandem at 
chromosomal location 19q13.1 in humans (Sawzdargo et al., 1997). Interestingly, 
this genomic location also encodes GPR42, which shows six amino acid 
differences compared to FFA3 and whose function remains largely unexplored. 
Although it has long been considered simply a pseudogene, one study 
demonstrated that GPR42 could indeed be expressed in humans and might even 
show a different pharmacological profile in terms of SCFA potencies (Puhl et al., 
2015). Therefore, GPR42 may play a physiological role, but due to lack of further 
investigations this remains to be confirmed. 
The majority of deorphanisation studies employed a high-throughput screening 
approach to identify putative endogenous ligands. In particular pharmaceutical 
companies often have large compound libraries and the appropriate equipment 
to perform ligand screening on a large scale. In the case of FFA1 two 
independent groups found that MCFAs and LCFAs were able to induce a Gq-
dependent calcium response in different immortalised cell line models 
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transiently expressing FFA1 (Briscoe et al., 2003, Itoh et al., 2003), while a 
further study took a more rational approach by testing FFAs on a range of orphan 
GPCRs based on the hypothesis that fatty acids could act as receptor ligands 
(Kotarsky et al., 2003). FFA2 was also deorphanised by three independent 
groups. Two studies performed high-throughput screening using either a yeast-
based reporter assay with G protein chimeras (Brown et al., 2003) or a calcium-
based approach (Le Poul et al., 2003). These screens yielded responses from a 
range of structurally unrelated compounds with the only common feature being 
their acetate (C2) counterion, leading to the unexpected conclusion that FFA2 
was actually activated by SCFAs. As FFA3 shows relatively high sequence 
similarity to FFA2, its response to SCFAs was also assessed, thereby confirming 
the existence of two SCFA receptors. In contrast, the third study screened 
different FFAs at FFA2 based on the close phylogenetic relationship to FFA1, but 
came to the same conclusion (Nilsson et al., 2003). 
Although FFA4 is clearly confirmed to be an LCFA receptor and thereby belongs 
to the FFA receptor family, it was deorphanised separately in 2005 and does not 
cluster with the other FFA receptors phylogenetically (Fredriksson et al., 2003). 
Its deorphanisation was also based on high-throughput screening, initially by 
assessing the internalisation response of the receptor tagged with enhanced 
green fluorescent protein (Hirasawa et al., 2005). Upon observation of its 
response to LCFAs, this was verified in a system detecting the calcium response 
of FFA4 fused to the promiscuous G16 Gα protein. In particular polyunsaturated 
fatty acids tended to show the highest activity at FFA4 (Christiansen et al., 
2015) and a later study established the therapeutic relevance of this 
observation, by demonstrating that FFA4 may be responsible for mediating the 
anti-inflammatory effects of omega-3 fatty acids through β-arrestin-dependent 
signalling (Oh et al., 2010). 
In addition to the FFA receptor family, three other GPCRs have also been 
demonstrated to respond to fatty acids: GPR84, OR51E2 and GPR109A (Milligan 
et al., 2017). The endogenous ligand of GPR84 has not yet been officially 
identified, therefore it remains a so-called orphan GPCR. Studies aiming to 
deorphanise GPR84 demonstrated that it is able to respond to fatty acids with a 
carbon chain length of 9-14 with C10 and C11 being the most potent (Wang et 
Chapter 1  24 
 
al., 2006). The expression profile of GPR84 in a range of immune cells such as 
neutrophils and eosinophils (Yousefi et al., 2001) and its suggested role as a pro-
inflammatory receptor (Suzuki et al., 2013) has highlighted its potential as a 
drug target and future studies will likely explore this aspect further. Olfr78 is a 
murine olfactory receptor (OR51E2 in human) expressed in the kidney (Pluznick 
et al., 2009) and on peptide YY (PYY)-secreting enteroendocrine cells (Fleischer 
et al., 2015). Although olfactory receptors are traditionally not considered as 
drug targets, an increasing body of evidence suggests their involvement beyond 
sensory functions (Griffin et al., 2009, Busse et al., 2014) and Olfr78 has been 
shown to modulate physiological processes such as blood pressure in response to 
SCFAs (Pluznick et al., 2013). Although additional research is certainly required 
to dissect the function of this receptor, it is highly interesting that an olfactory 
receptor potentially regulates bodily functions in response to fatty acids. 
GPR109A has now been deorphanised as a receptor for hydroxycarboxylic acids 
and is hence also referred to as HCA2 receptor (Taggart et al., 2005). However, 
it also appears to respond to C4-C8 fatty acids, albeit with a lower potency than 
to endogenous agonist β-hydroxybutyrate. GPR109A modulates lipolysis in 
adipocytes (Offermanns et al., 2011) and appears to mediate anti-inflammatory 
effects in immune cells and the colon (Graff et al., 2016). Although the 
physiological function of this distinct set of receptors is far from being fully 
understood, their expression across tissues involved in metabolic regulation such 
as the GI system and immune cells makes them an attractive target for further 
studies. 
1.4 Short chain fatty acid receptors as novel drug targets 
1.4.1 SCFAs as endogenous GPCR ligands 
Although all members of the FFA receptor family have received significant 
attention as potential drug targets, SCFA receptors are of particular interest due 
to their link to gut microbiome activity. To fully appreciate the therapeutic 
potential of FFA2 and FFA3 it is crucial to understand the unique properties of 
their ligands. Some physiological roles of SCFAs have already been demonstrated 
prior to identification of their receptors, particularly in context of the health 
benefits of fibre consumption that provides the basis for SCFA production by 
microbes in the gut (Cook and Sellin, 1998). The main SCFAs that are produced 
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during the fermentation process are acetate (C2), propionate (C3) and butyrate 
(C4). As the gut microbiota resides in the intestinal lumen, the concentration of 
SCFAs can reach up to 50-100 mM with C2 being the most prevalent (Cummings 
et al., 1987). SCFAs exert many of their actions on enterocytes and 
enteroendocrine cells, but also on resident immune cells such as macrophages 
and neutrophils after crossing the intestinal barrier into the lamina propria 
(Husted et al., 2017). Through the lamina propria SCFAs also have access to the 
liver via the portal vein and are further diluted, such that circulating plasma 
concentrations are reduced by approximately 1000-fold compared to the gut 
lumen (Akanji et al., 1989, Cummings et al., 1987). In target tissues several cell 
types such as pancreatic β cells, and likely also adipocytes, appear to have the 
capacity to produce C2 in an autocrine and paracrine manner from glucose 
metabolism, thereby increasing SCFA concentrations locally (Tang et al., 2015). 
In cases of obesity and diets rich in processed foods, not only the composition of 
the microbiome can be affected in a detrimental fashion (Sweeney and Morton, 
2013), but also intestinal barrier function is often impaired, allowing for 
increased leakage of metabolites and bacterial by-products (Raybould, 2012), 
which can modulate circulating concentrations of SCFAs. The beneficial effects 
of SCFAs and their receptors is a carefully balanced process and drastic changes 
in circulating and tissue concentrations are likely to result in disruption of 
metabolic regulation, which will also become apparent the discussion of the 
therapeutic implications of SCFA receptors (see section 1.4.2). 
To investigate the link between gut microbiome activity and SCFA receptors, 
mice with modified gut microbiota composition are often employed in 
combination with transgenic knock-out (KO) mice of SCFA receptors (Milligan et 
al., 2017). Animals that lack a gut microbiome, achieved by germ-free (GF) 
raising or treatment with antibiotics, can be treated with SCFAs to provide 
information on the function of SCFA receptors. The majority of studies on FFA2 
have investigated its role in regulating inflammatory responses. Dysregulated 
immune responses were observed in GF mice with induced colitis, which was also 
the case in FFA2 KO mice, and C2 treatment was able to improve the condition 
of GF mice (Maslowski et al., 2009). Furthermore, it was shown that the 
population of regulatory T cells in the intestine was reduced in GF mice 
compared to regular animals and SCFA treatment was able to recover this 
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population in an FFA2-dependent fashion, while this effect was not observed in 
GF mice with FFA2 KO (Smith et al., 2013). In a mouse model of gout, gut 
microbiome-lacking and FFA2 KO mice both showed reduced production of pro-
inflammatory IL1-β, and administration of SCFAs was able to restore IL1-β levels 
(Vieira et al., 2015). In addition, the role of SCFAs and FFA2 in adiposity was also 
explored by comparing the body weight of WT and FFA2 KO mice raised under 
conventional and GF conditions. Interestingly, FFA2 KO induced obesity in the 
animals, but was only observed in conventionally raised mice and not GF animals 
(Kimura et al., 2013). In contrast, when performing an equivalent experiment 
with FFA3 KO mice, decreased adiposity was found in FFA3 KO mice compared to 
wild type, which was not the case in GF animals (Samuel et al., 2008). 
Interestingly, FFA3 has also been demonstrated to play a protective role in 
allergic airway disease with mice on a diet with high fibre content, which led to 
a higher level of circulating SCFAs, showing reduced lung inflammation 
compared to chow-fed animals (Trompette et al., 2014). More detailed 
investigation of the effect of exogenous C3 administration revealed that this 
was, at least in part, due to impaired ability of dendritic cells in the lung to 
induce pro-inflammatory T helper type 2 cell function. These studies clearly 
demonstrate that there is a causative link between gut microbiome-mediated 
SCFA production and the function of SCFA receptors. Although information 
obtained from work in GF mice is already very informative, a closer investigation 
of the specific beneficial bacteria that contribute to SCFA production and how 
they depend on diet, in particular in humans, could be of interest to the 
probiotic industry.  
Although SCFAs can act on both FFA2 and FFA3, they do so with different 
potencies depending on their carbon chain length. While FFA2 preferentially 
binds C2 ≈ C3 > C4 > C5 ≈ C1, FFA3 has a rank order of C3 ≈ C4 ≈ C5 > C2 > C1 
(Hudson et al., 2011). In terms of signalling the SCFA receptors also differ 
substantially (Figure 1.8). FFA2 is a relatively promiscuous receptor and the 
deorphanisation study that employed a range of G protein subtype chimeras 
demonstrated that FFA2 was able to couple to multiple members of the Gq/11, 
Gi/o and G12/13 G protein families (Brown et al., 2003). Nowadays SCFA-mediated  
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Figure 1.8 SCFA receptor signalling Fatty acids with a range of carbon chain length from 1 to 5 
(A) can bind to FFA2 (B) and FFA3 (C) to induce GPCR signalling. Chemical structures of short 
chain fatty acids (SCFAs) are illustrated (A). Activation of FFA2 results in signalling through Gi and 
Gq G proteins (B). Only selected studies suggest that FFA2 can also stimulate G12- and β-arrestin-
dependent signalling, therefore dashed lines are shown. In contrast to FFA2, FFA3 only signals 
through Gi G proteins (C). 
 
FFA2 coupling to both Gq and Gi is well established and functional assays 
measuring, for example, Gq-dependent Ca2+ release or Gi-coupled [35S]-GTPγS 
incorporation are routinely employed (Hudson et al., 2013a). Furthermore, FFA2 
activation also induces β-arrestin 2 recruitment, albeit it is not fully confirmed 
whether this only leads to receptor desensitisation or if FFA2-bound β-arrestin 2 
also activates G protein-independent signalling pathways. Activation of FFA2 also 
results in phosphorylation of ERK (Hudson et al., 2012a), which is likely an 
accumulated response from multiple signalling pathways and may also include 
β-arrestin-mediated signalling. In contrast, FFA3 shows a distinct signalling 
profile compared to FFA2, as the only reported G protein-mediated signalling is 
transduced by the Gi/o subtype (Brown et al., 2003). Furthermore, it is not very 
likely that FFA3 signals through arrestins, as siRNA knock-down of β-arrestins in a 
mouse neuroblastoma cell line did not affect the FFA3 response to C3 (Kimura et 
al., 2011). 
The marked difference in C2 potency at FFA2 and FFA3 led to its use as a 
selective ligand for FFA2 (Tolhurst et al., 2012, Zaibi et al., 2010), however the 
approximately 10-fold difference in C2 potency is likely not sufficient to achieve 
selective activation. Furthermore, when employing rodent models, it is 
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important to consider that not only will the inherent microbiome-dependent 
production of SCFAs likely differ, but the rank order of SCFA potencies at FFA2 
and FFA3 is also altered at the rodent orthologues (Hudson et al., 2012b). 
Particularly relevant in mice is the loss of C2 selectivity between the two 
receptors and the increased potency of C3 for FFA3 over FFA2, which appears to 
be related to species-specific residue differences in ECL2. The factors outlined 
above have made it challenging to use SCFAs to dissect the specific physiological 
roles of FFA2 and FFA3, particularly in tissues where the receptors are co-
expressed. Therefore, KO animals are commonly employed to confirm receptor-
specific effects. However, such studies also have limitations. The pharmacology 
of the remaining SCFA receptor may be altered by the loss of the other receptor 
through functional redundancy in some tissues and at least one study has also 
reported altered expression of FFA2 in an FFA3 KO mouse line (Zaibi et al., 
2010). Therefore, the development of selective synthetic ligands with a range of 
pharmacological profiles is crucial to fully understand the function of SCFA 
receptors. 
1.4.2 Therapeutic implications of SCFA receptors 
The relatively broad distribution of SCFAs in the human body upon entering the 
systemic circulation and their capacity to act in an autocrine and paracrine 
manner in tissues involved in metabolic regulation does not make it surprising 
that FFA2 and FFA3 are expressed in a variety of tissues. Both receptors are 
present in the gut epithelium with the highest level in enteroendocrine cells 
(Nohr et al., 2013, Karaki et al., 2006), which also express a range of other 
metabolite-sensing GPCRs and are responsible for secretion of gut hormones that 
affect processes such as satiety and gut motility. Furthermore, FFA2 and FFA3 
are also co-expressed in pancreatic β cells (Priyadarshini et al., 2015) that 
regulate insulin secretion. Some studies also demonstrated expression of both 
receptors in adipose tissue (Xiong et al., 2004), however the consensus is that 
only FFA2 is likely to be expressed (Zaibi et al., 2010). Further cell types that 
primarily express FFA2 belong to the innate immune system and include 
monocytes and granulocytes (Le Poul et al., 2003), highlighting the link between 
metabolic regulation and immune response. In the case of FFA3 exclusive 
expression could only be shown in neurons such as ganglia of the sympathetic 
and enteric nervous system (Nohr et al., 2015). The following paragraphs will 
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highlight the proposed roles of SCFA receptors in these tissues and how they may 
be targeted therapeutically. 
The GI tract shows both high local concentrations of SCFAs and prominent 
expression of FFA2 and FFA3, indicating the involvement of SCFA receptors in 
regulating GI processes. Indeed, SCFA treatment has initially been demonstrated 
to induce satietogenic PYY release in rodents (Darzi et al., 2011) and gut 
motility by promoting peristalsis through serotonin release (Karaki et al., 2006), 
which may be mediated by FFA2 due to its expression in enteroendocrine cells 
and mucosal mast cells (Fukumoto et al., 2003). The direct role of FFA2 in 
regulation of a different gut hormone that regulates blood glucose levels, 
glucagon-like peptide-1 (GLP-1), was demonstrated by the loss of C2- and C3-
induced secretion of GLP-1 from colonic cultures from FFA2 KO mice (Tolhurst et 
al., 2012). In contrast, cultures from FFA3 KO animals retained the ability to 
release GLP-1 upon C2 and C3 treatment, indicating this to be an FFA2-
dependent effect. This was further confirmed in vivo by C3 infusion stimulating 
increase of GLP-1 and PYY in plasma, which was not observed in FFA2 KO mice 
(Psichas et al., 2015). Dietary supplementation with the fermentable 
carbohydrate inulin augmented satiety in mice by expanding the population of 
PYY-producing cells and augmenting PYY release, which was not observed in 
FFA2 KO mice (Brooks et al., 2017). A further peptide involved in satiety 
regulation whose production appears to be in part regulated by FFA2 is appetite-
increasing ghrelin, with one study demonstrating FFA2 expression in ghrelin-
producing cells in the stomach and the ability of C2 and C3 to inhibit its release 
(Engelstoft et al., 2013). The ability to regulate the feeling of satiety would be 
of great value for treatment and prevention of obesity, in particular for 
individuals with genetic predisposition for obesity. 
Developing new and improved treatment approaches for diabetes is a significant 
focus of current drug development programmes. Although obesity, GI health and 
insulin resistance are undoubtedly linked and may suggest a role for the SCFA 
receptors present on pancreatic β cells, the LCFA receptor FFA1 has been the 
main target of such efforts. This may be due to the contradicting results of 
several studies, with SCFA treatment shown to both activate (Priyadarshini et 
al., 2015) and inhibit (Tang et al., 2015) glucose-stimulated insulin secretion. 
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Hypotheses that attempt to explain these observations include the preferential 
activation of FFA2 or FFA3 by treatment with C2 or C3 (Bolognini et al., 2016b) 
and the diverse effect of Gq versus Gi G protein activation in islets enhancing or 
inhibiting insulin secretion, respectively (Milligan et al., 2017).  
A variety of SCFA-mediated processes in adipocytes have also been investigated 
to understand the physiological role of SCFA receptors and while some effects 
are well established, such as the ability of SCFAs to inhibit lipolysis by activating 
FFA2 in immortalised and primary murine adipocytes (Ge et al., 2008), others, 
including influence on adipogenesis and secretion of satietogenic leptin, are less 
well understood. Multiple studies suggest an impact of FFA2 on adipogenesis, 
albeit with opposing effects. Expression of FFA2 was shown to be upregulated 
during differentiation of an adipocyte cell line (Hong et al., 2005) and an in vivo 
study found that FFA2 KO mice on a high fat diet (HFD) show reduced body fat 
compared to wild type animals (Bjursell et al., 2011). A contrasting study 
demonstrated the exact opposite with FFA2 KO resulting in obesity, while in vivo 
adipogenesis was not affected by FFA2 KO, suggesting that FFA2 actually plays 
no role in adipogenesis itself (Kimura et al., 2013). Perhaps most significantly, 
the only study employing human tissue was not able to demonstrate an FFA2-
mediated effect of SCFAs on adipogenesis (Dewulf et al., 2013). The role of SCFA 
receptors in leptin secretion is similarly debated with both FFA2 (Zaibi et al., 
2010) and FFA3 (Xiong et al., 2004) suggested as potential mediators, however it 
is likely that the net input of SCFAs on leptin secretion is positive. A further 
suggested function of SCFAs is their impact on insulin-stimulated glucose uptake. 
Although some studies in immortalised cell lines suggested a role of FFA3 in 
enhancing this process (Han et al., 2014), in vivo evidence demonstrated the 
ability of C2 to suppress insulin signalling in adipose tissue by acting through 
FFA2 (Kimura et al., 2013). 
The best characterised role of SCFA receptors on immune cells is the ability of 
FFA2 activation to induce neutrophil chemotaxis (Maslowski et al., 2009). 
Conversely, SCFAs are traditionally thought to have anti-inflammatory effects 
with in vivo studies demonstrating that SCFAs can reduce production of tumour 
necrosis factor α (TNFα) by mononuclear cells in an FFA2-dependent fashion 
(Masui et al., 2013). However, SCFAs have also been shown to promote release 
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of inflammatory chemokines and cytokines through activation of both FFA2 and 
FFA3 in the colon (Kim et al., 2013). Interestingly, a recent study suggested that 
activation of FFA2 by SCFAs can differentially affect macrophage subtypes by 
inducing TNFα release in anti-inflammatory M2 macrophages, while leaving the 
pro-inflammatory M1 type unaffected (Nakajima et al., 2017). In the context of 
gut inflammation and potential targeting of FFA2 to treat inflammatory bowel 
disease, the best approach is also not clear as separate studies have shown both 
increased (Maslowski et al., 2009) and decreased (Sina et al., 2009) 
inflammation and mortality upon FFA2 KO in a murine model of colitis. 
Therefore, the role of SCFA receptors in inflammation is a further physiological 
process which requires additional investigation. 
Although there is a large body of evidence that SCFA receptors do play a role in 
a variety of tissues that regulate metabolic processes, an overview of published 
studies makes clear that we are still far from a consensus regarding the 
underlying mechanisms (Ang and Ding, 2016). The only physiological impact 
whose investigation has not yielded contradictory results is the promotion of gut 
hormone release, therefore it is not clear whether SCFA receptors are indeed 
good therapeutic targets and if so, then which pharmacological targeting 
approach would be best. Figure 1.9 summarises the diverse hypotheses for the 
physiological role of SCFA receptors and the signalling pathways that are thought 
to mediate the respective processes. As FFA2 and FFA3 have different 
downstream signalling profiles, treatment with pertussis toxin (PTX) that 
specifically inhibits Gi G proteins can provide some indication of which receptor 
is responsible for observed responses. However, PTX will also block Gi-mediated 
effects of FFA2 and therefore only allows differentiation between FFA3 effects 
and Gq-mediated FFA2 responses. Furthermore, PTX treatment can also have 
secondary effects including the induction of cytokine release and activation of 
tyrosine kinases (Mangmool and Kurose, 2011). This is important to consider, in 
particular for studies on immune cells. One additional factor that is easy to 
overlook when assessing studies of SCFA receptor physiology is the nature of the 
selected model animal. In rodents, the most commonly used animal for such 
studies, the gut microbiome can differ significantly between different strains 
and environmental conditions, which may have a drastic impact on SCFA 
receptor studies and potentially lead to contradictory results. Furthermore,  
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Figure 1.9 Potential physiological role of SCFA receptors The composition of the human gut 
microbiota is dependent on a range of different factors including genetics, diet and environment, 
which in turn influences the production of short chain fatty acids (SCFAs) that activate FFA2 and 
FFA3. The roles the receptors play can be broadly divided into glucose homeostasis (blue), 
satiety/gut health (orange) and inflammation (green). Known contribution of FFA2 and FFA3 to the 
observed physiological effects are written in blue and purple, respectively, and the G protein 
subtype that is thought to mediate respective effects is also shown. 
 
dissecting the specific roles of FFA2 and FFA3 using SCFA treatments is 
challenging and highlights the need for specific high-potency ligands with good 
bioavailability. An alternative, chemogenetic approach is the generation of a 
transgenic animal expressing FFA2 modified to be a designer receptor exclusively 
activated by designer drugs (DREADD). As the name suggests, such a receptor has 
been modified, usually by introduction of amino acid sequence mutations, to 
lose responsiveness to intrinsic endogenous ligands and is instead activated 
solely by synthetic ligands that need to be administered externally (Lee et al., 
2014). DREADD receptors play an increasingly important role in drug discovery, 
as they allow for dissection of specific signalling pathways and distinguishing 
between e.g. different receptor subtypes if selective ligands are not available. 
In the case of FFA2, by exploiting species differences between the human and 
bovine receptor, a FFA2 DREADD receptor that responds to the small molecule 
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sorbic acid, but not SCFAs, has been developed (Hudson et al., 2012a). Future 
studies that aim to employ a transgenic mouse line expressing FFA2 DREADD 
instead of wild type FFA2 are likely to provide a valuable insight into FFA2 and 
FFA3 physiology and may help to resolve some of the outstanding questions. 
1.5 Drug development for SCFA receptors 
1.5.1 Homology modelling as a tool to predict structural features 
As highlighted in chapter 1.2, understanding receptor structure and function can 
provide an important contribution for successful drug discovery. However, FFA 
receptors were only deorphanised relatively recently and compared to the β2AR 
or adenosine A2A receptor there are limited high-affinity pharmacological tools 
available for them. Crystallising a receptor and solving its structure can be time-
consuming and typically requires a high-affinity ligand to stabilise the receptor 
for crystallisation, therefore GPCR structural projects tend to focus on more 
established GPCRs with richly described pharmacology. For receptors without 
crystallographic information, homology modelling is commonly employed as a 
method to gain some structural insight (Costanzi, 2013). Homology modelling 
refers to the use of a known structure as a template to computationally predict 
that of a related receptor. In the case of GPCRs this is possible due to the high 
extent of evolutionary conservation of their three-dimensional structure. The 
predictability of homology models was tested in the community-wide GPCR Dock 
2010 Assessment in which 35 groups submitted homology models of the 
dopamine D3 and CXCR4 receptor without knowledge of the crystal structures 
about to be published (Kufareva et al., 2011). This study highlighted that 
homology models based on templates with 35-40% sequence identity can predict 
structural features and even ligand binding sites with high accuracy. However, a 
sequence identity of less than 30% is insufficient for complete structural 
predictions, making accurate docking of ligands and structure-based drug design 
close to impossible. Therefore, homology models need to be considered in the 
context of the GPCR providing the template structure and high-quality data on 
ligand binding and function is necessary to guide its construction. As high 
sequence identity is the deciding factor for selecting an appropriate template 
structure, it is convenient for the generation of a homology model for SCFA 
receptors that multiple crystal structures of FFA1 are available. 
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Although the close phylogenetic relationship between FFA1 and the SCFA 
receptors suggests that FFA1 is an appropriate template structure for FFA2 and 
FFA3, it is important to consider the state in which the receptor was crystallised 
and FFA1-specific structural features that may be erroneously translated into 
homology models. The understanding of the physiological role of FFA1 may be 
more advanced than that of SCFA receptors, but regarding ligand binding and 
pharmacology FFA1 comes with its own set of challenges. None of the available 
structures are crystallised in complex with an endogenous ligand, so the 
endogenous binding site of FFA1 remains to be fully defined and this makes it 
difficult to define orthosteric, allosteric or indeed bitopic binding sites with 
certainty (Figure 1.10). However, a pair of arginine residues conserved between 
FFA1, FFA2 and FFA3 is considered as a point of interaction for the fatty acid 
carboxylate (Figure 1.11). This has been confirmed in a range of functional 
studies in which mutation to alanine resulted in loss of agonist action (Stoddart 
et al., 2008, Sum et al., 2007). The first crystal structure of FFA1 was complexed 
with the partial agonist TAK-875, which is defined as an allosteric ligand, as it 
can modulate LCFA response in functional assays (Srivastava et al., 2014) and  
Figure 1.10 Crystal structure of the FFA1 receptor Published crystal structures of FFA1 in 
complex with TAK-875 (A) and MK-866 and AP8 (B) are shown. Agonists are shown in green and 
allosteric modulators in blue. PDB IDs of respective structures are 4PHU for the structure in 
complex with TAK-875 (Srivastava et al., 2014) and 5TZY for MK-8666 and AP8 (Lu et al., 2017). 
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Figure 1.11 FFA receptor amino acid sequences and important residues The NCBI Basic 
Local Alignment Search Tool (BLAST) was employed to align sequences of human FFA1, FFA2 
and FFA3 (A). Residues that are thought to interact with the endogenous fatty acid carboxylate are 
highlighted in colour. A snake plot of the FFA2 amino acid sequence is shown; residues that 
comprise the putative orthosteric binding site shown in red or blue (B). 
 
was competitive in direct binding studies with an allosteric fluorescent tracer of 
FFA1 (Christiansen et al., 2016). Interestingly, in the crystal structure TAK-875 
occupies a site that reaches from the proposed orthosteric binding site to the 
lipid bilayer via a gap between TM3 and TM4. In a further study the structurally 
related partial agonist MK-8666 occupies a similar binding pose (Lu et al., 2017). 
Interestingly, MK-8666-bound FFA1 was also crystallised in complex with a 
second ligand, the positive allosteric modulator AP8. Comparison between 
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structures revealed the mechanism by which AP8 exerts its PAM effect on 
MK-8666 potency through facilitation of a ligand-induced fit that involved 
conformational changes in TM4, TM5 and ICL2. The TM architecture does seem to 
share some characteristics with published GPCR structures in their active-state, 
but the typical outward movement of TM6 cannot be observed, indicating that 
FFA1 is in an artificial or intermediate “inactive-like” state, which is likely due 
to the introduction of thermostabilising mutations to stabilise the receptor for 
crystallisation. Although these data are certainly of great interest to understand 
the structural basis for allosteric modulation and future development of FFA1 
ligands, it is of limited use as a homology modelling template. In particular the 
gap between TM3 and TM4 may not be present in SCFA receptors, because they 
are unable to bind longer chain fatty acids. However, the conformation of the 
orthosteric binding site may be comparable between FFA1, FFA2 and FFA3 due to 
its conserved nature. 
Much of the understanding of SCFA receptor structure and function was initially 
based on functional studies. In the effort to define the anchorage point of the 
negatively charged SCFA carboxylate an investigation of all ligand-accessible 
positively charged residues and the effect of their replacement with alanine on 
agonist action led to the identification of two arginine residues at positions 5.39 
and 7.35 (Ballesteros and Weinstein, 1995), which were mentioned previously to 
be conserved between FFA1, FFA2 and FFA3 (Stoddart et al., 2008). 
Furthermore, mutation of a histidine residue at position 6.55 was also 
detrimental for FFA2 and FFA3 activation by SCFAs. While FFA1 binds longer 
chain fatty acids that likely require further anchoring residues to allow for 
sufficient binding affinity, for binding of SCFAs to FFA2 and FFA3 this Arg-His-Arg 
triad may indeed represent the only point of interaction, thereby defining these 
residues as the orthosteric binding site. A more comprehensive analysis of 
homology models based on the FFA1 structure revealed that both SCFA receptors 
show a more interlinked network of residues around the orthosteric binding site, 
particularly in the case of FFA2 (Tikhonova and Poerio, 2015). This includes the 
presence of additional hydrogen bonds and hydrophobic interactions. 
Furthermore, as expected by the smaller nature of their ligands, the accessible 
SCFA binding cavity is also significantly smaller. It would also be of value to be 
able to investigate the conformation of ECL2, which plays a significant role in 
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regulating constitutive activity and species differences, but the low similarity of 
the ECL2 of FFA1 makes it difficult to construct a precise model. Homology 
modelling of variable and flexible regions such as ECL2 are very challenging in 
general and even a sequence similarity as high as 40% between model and 
template receptor in the GPCR Dock 2010 Assessment did not result in accurate 
ECL2 predictions (Kufareva et al., 2011). 
1.5.2 Overview of FFA2 and FFA3 drug development efforts 
Developing novel treatment approaches for obesity-related disorders and 
inflammatory conditions of the gut is one of the key aims of the pharmaceutical 
industry due to an increasing demand for improved therapeutics in these areas. 
The apparent involvement of SCFA receptors in related processes has attracted 
attention of both academia and industry to target these receptors 
therapeutically. However, at this stage it is also important to consider that 
identification of novel FFA2- and FFA3-specific compounds does not only serve a 
therapeutic purpose, but it is also essential for understanding the pharmacology 
and physiological function of SCFA receptors. In particular considering the poor 
properties of endogenous SCFAs as ligands and their lack of selectivity between 
FFA2 and FFA3, specific synthetic ligands are required to answer the outstanding 
questions regarding SCFA receptor function. 
As SCFAs are relatively small and defined by their carboxylic acid moiety, first 
efforts to develop orthosteric agonists were based on modifying the aliphatic tail 
of SCFAs (Schmidt et al., 2011). Although none of these analogues exceeded the 
potency of SCFAs, it revealed that the hybridisation state of the α carbon 
defines selectivity between SCFA receptors with FFA2 preferring sp- or sp2-
hybridisation, such as in case of propiolic and angelic acid, while substituted sp3-
hybridised carbons, including 2-methylbutyric acid, show higher selectivity for 
FFA3. Despite their low potency, two selected FFA2-specific carboxylic acids 
were able to induce glucose-stimulated insulin secretion in isolated mouse islets, 
which was lost upon KO of FFA2 (Priyadarshini et al., 2015). Following on from 
this initial characterisation, a variety of patents for specific synthetic ligands 
have been filed that have likely been identified by high-throughput screening 
and served as the basis for tool compounds currently in use (Figure 1.12). In this 
context FFA2 has received significantly more attention than FFA3, although it is 
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unclear whether this is due to an increased therapeutic interest in FFA2 or if 
ligand development for FFA3 is inherently more difficult. 
The only published FFA3 compound series is derived from a patent filed by Arena 
Pharmaceuticals (Leonard et al., 2016). Although the potential of compounds 
from this series for ex vivo use was demonstrated by the ability of 
representative ligand AR420626 to induce GLP-1 release from murine colonic 
crypt cultures (Nohr et al., 2013), the pharmacology of this series appears to be 
highly complicated (Hudson et al., 2014). Firstly, the ligands were able to 
activate FFA3 after alanine replacement of Arg1855.39 and Arg2587.35, suggesting 
 
Figure 1.12 Chemical structures of SCFA receptor ligands The structures of different ligand 
classes for FFA3 and FFA2 are shown. 
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that they were binding to a different site than SCFAs and are therefore 
allosteric. Secondly, even minor modifications to the compound scaffold were 
able switch compound pharmacology from agonism to antagonism and between 
PAM and NAM behaviour. One analogue even displayed divergent allosteric 
behaviour by having NAM effect on C3 efficacy and a PAM effect on C3 potency. 
The complicated pharmacology of this compound series combined with a lack of 
binding site information and relatively low potency (low µM range) make 
compounds of this series sub-optimal tools, hence novel selective ligands are 
required to fully explore the function of FFA3. 
Considering the complex pharmacology of available FFA3 tool compounds and 
the lack of a selection of ligands with distinct pharmacology, FFA2 presents a 
more attractive and accessible target for drug discovery. Furthermore, 
contributing to the development of selective FFA2 ligands will also provide 
information on the physiological role of FFA3, as it will allow dissection of their 
respective roles in tissues in which they are co-expressed. Therefore, the work 
presented in this thesis is focussed on FFA2 and an outline of available tool 
compounds and their proposed modes of binding is described in the following 
sections. 
1.5.3 Orthosteric FFA2 agonists 
The structure of the first synthetic agonist series for FFA2 was based on a 
backbone patented by the clinical-stage drug discovery company Euroscreen 
(now Ogeda) (Hoveyda et al., 2010). The pharmacology of two representative 
compounds, here referred to as compounds 1 and 1-2, has been characterised in 
detail (Hudson et al., 2013a). Both compounds were able to activate human and 
murine FFA2 (mFFA2) with potency in the high nM range, while inducing no 
response at other FFA receptors including FFA3. Their action was dependent on 
Arg1805.39, Arg2557.35 and His2426.55 in a similar manner to SCFAs, indicating an 
orthosteric mode of binding. As the carboxylate moiety of SCFAs is crucial for 
their function, it was of interest to see that the patented compound 1 series also 
contained such a moiety. Indeed, replacement of the carboxylate with an ester 
moiety rendered compound 1-2 inactive, indicating that this structural feature is 
essential for orthosteric agonist function (Hudson et al., 2013a). Although 
compound 1 induced a similar signalling profile to C3, as may be anticipated for 
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an orthosteric agonist, further structural modifications yielded diverse responses 
in a variety of Gi-coupled assays (Brown et al., 2015). While all compounds 
retained the ability to activate FFA2 in [35S]-GTPγS assays, only selected 
analogues were able to inhibit cAMP production and when assessed in a yeast-
based Gi coupling assay some compounds even acted as inverse agonists. As a 
synthetic ligand will likely interact with more residues than SCFAs to reach 
sufficient affinity, it is perhaps not surprising that some structural modifications 
yield ligands with diverse signalling profiles. However, all the assessed assay 
systems were employed to measure coupling through Gi, so it is not clear how 
far the observed bias was down to assay artifacts that may, for example, be 
caused by distinct binding kinetics of specific analogues. From a physiological 
perspective various FFA2-dependent effects could be demonstrated using this 
ligand series, including GLP-1 secretion, inhibition of lipolysis and the ability to 
induce a Ca2+ release in neutrophils (Hudson et al., 2013a, Brown et al., 2015). 
However, it is important to consider that the potency of compounds 1 and 1-2 
was markedly species-specific and assay dependent. While compound 1 showed a 
potency reduction of up to 14-fold at murine compared to human FFA2 in Ca2+ 
release assays, compound 1-2 showed a significantly greater reduction of 420-
fold (Hudson et al., 2013a). Therefore, compound 1 would likely be of most use 
for in vivo studies. 
A further agonist series patented by Euroscreen that has only been investigated 
recently is based on the structure of compound 2 (Hoveyda et al., 2011). 
Although the study employing compound 2 was focussed on its physiological role, 
the presence of a carboxylate moiety and lack of allosteric modulation by C2 
suggested an orthosteric mode of action (Forbes et al., 2015). Interestingly, 
compound 2 appeared to have diverse effects on metabolic regulation in FFA2 
KO studies with a beneficial effect on gut transit and food intake, but no 
improvement of the impaired glucose tolerance displayed by FFA2 KO mice. 
Furthermore, the observed effects were mostly mediated through release of PYY 
rather than GLP-1, as in vivo release of GLP-1 was only observed when a 
dipeptidyl peptidase-4 inhibitor that prevents GLP-1 degradation was co-
administered. This study provided further evidence of the role and therapeutic 
potential of FFA2 in obesity and satiety regulation, but more work is required to 
truly assess the therapeutic potential of this compound series. 
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1.5.4 Orthosteric FFA2 antagonists 
Although the health benefits of SCFAs suggest that FFA2 agonists rather than 
antagonists would be of therapeutic value, the ability of FFA2 activation to 
promote immune cell recruitment indicates that treatment with antagonists may 
have an anti-inflammatory effect. The physiological function of FFA2 appears to 
be a delicately balanced process, therefore the desired pharmacological action 
of drugs targeting FFA2 likely depends on the condition to be treated. The first 
antagonist to be reported was based on a patent from Euroscreen (Brantis et al., 
2011) and is commonly referred to as CATPB (Hudson et al., 2013a). Although 
structurally very distinct from FFA2 agonists, CATPB does contain a carboxylate 
moiety typical of orthosteric FFA2 ligands. It is able to inhibit the response of 
FFA2 to C3 and also reduces the constitutive activity of the receptor in 
[35S]-GTPγS binding assays, indicating inverse agonist behaviour (Hudson et al., 
2012b). However, it only acts as an antagonist at human FFA2 and does not 
inhibit SCFA responses at rodent forms of the receptor. When co-added with 
orthosteric agonists, CATPB induces a concentration-dependent, surmountable 
right-shift of their concentration-response curves, consistent with binding to the 
orthosteric site (Hudson et al., 2013a). Functionally CATPB has been employed 
to confirm FFA2 mediated inhibition of lipolysis in a human adipocyte cell line 
(Hudson et al., 2013a). 
In addition to CATPB, a further FFA2 antagonist series was developed by 
Galapagos, a clinical-stage biotechnology company, with its lead compound 
referred to as GLPG0974 (Pizzonero et al., 2014). Although this ligand series has 
a different structure compared to CATPB, both antagonists share some features 
including the carboxylic acid and a chlorobenzene ring. The therapeutic 
potential of GLPG0974 was based on its ability to block both C2-induced 
migration of human neutrophils and expression of neutrophil activation marker 
CD11b in human blood, which served as an appropriate biomarker for target 
engagement (Pizzonero et al., 2014). As in the case of CATPB, GLPG0974 does 
not inhibit SCFA responses at rodent orthologues of FFA2. However, the 
convincing data of target engagement in human blood led to GLPG0974 being the 
first FFA2 ligand to enter clinical trials for treatment of ulcerative colitis, albeit 
no proof-of-principle studies in animal models were performed. Despite being 
well-tolerated and showing a good safety profile, treatment of patients showing 
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mild to moderate ulcerative colitis symptoms with GLPG0974 for four weeks did 
not yield a measurable health improvement compared to the placebo-treated 
control group (Vermeire et al., 2015). Nevertheless, it was demonstrated that 
GLPG0974 was indeed capable of reducing neutrophil activation and influx in 
patients, indicating that targeting only neutrophil migration in ulcerative colitis 
may not be sufficient to yield a measurable patient improvement within a short 
period of time. This highlights that a deeper understanding of the physiological 
functions of FFA2 is required to develop effective therapeutics. The 
characterisation of GLPG0974 binding and pharmacology will be the focus of the 
work discussed in chapter 4. 
A more recent study has identified a third series of FFA2 antagonists, discovered 
through high-throughput screening (Park et al., 2016). Interestingly, although 
this compound series lacks a carboxylate, initial characterisation of two 
representative ligands, BTI-A-404 and BTI-A-292, indicates competitive 
behaviour with C2 and C3. Furthermore, this compound series also appears to be 
species-selective for the human receptor. Unexpectedly the compounds 
appeared to promote GLP-1 secretion in a human colorectal adenocarcinoma cell 
line, however due to the high concentrations employed this may be due to off-
target effects. Therefore, although this compound series provides further 
information on possible structural features of FFA2 antagonists, their relatively 
low potency compared to other antagonists and potential to cause off-target 
effects, as potentially observed in the GLP-1 secretion assay, indicates limited 
potential for in vivo use. 
The selectivity of FFA2 antagonists for the human receptor represents one of the 
key limitations for in vivo studies in rodents and has hindered progress in 
understanding the physiological roles of FFA2. The lack of active rodent FFA2 
antagonists prohibits specific inhibition of the receptor, which is necessary to 
confirm that agonist-induced responses are mediated by FFA2 and would provide 
crucial information on the roles of FFA2 versus FFA3. Therefore, most in vivo 
studies have employed KO animals to overcome this limitation. These are also 
not an optimal system due to the potential for altered expression of FFA3. The 
molecular mechanism of the antagonist species selectivity is poorly understood 
to date but will be discussed in chapter 6. 
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1.5.5 Allosteric FFA2 regulators 
The first selective FFA2 agonist was identified by the biopharmaceutical 
company Amgen in a high-throughput screen assessing Gi- and Gq-coupled 
signalling in cAMP inhibition and calcium release assays, respectively (Lee et al., 
2008). The lead compound within the series, AMG7703 (here referred to as 
4-CMTB), showed modest potency at human and rodent FFA2 with respective 
potencies of approximately 500 nM and 1 µM in a cAMP inhibition assay (Lee et 
al., 2008). However, it has been used in a range of studies that are described 
below, due to its commercial availability. The structure of 4-CMTB does not 
contain a carboxylate moiety and it retained the ability to activate FFA2 upon 
mutation of binding site residues Arg1805.39, Arg2557.35 and His2426.55, indicating 
that it binds to an allosteric site (Smith et al., 2011). Further investigation of 
the effect of 4-CMTB on SCFA concentration responses revealed that it acts as a 
PAM of SCFA potency. Interestingly, 4-CMTB does not have a modulatory effect 
on the response to synthetic agonist compound 1 (Hudson et al., 2013a), making 
it a typical example of the “probe dependence” that is common among allosteric 
ligands. Efforts to improve 4-CMTB potency using medicinal chemistry had 
limited success (Wang et al., 2010, Smith et al., 2011). None of the explored 
4-CMTB analogues showed improved potency over the parent compound. 
However, in functional studies some of these analogues have been employed, 
potentially due to the poor pharmacokinetic profile of 4-CMTB (Wang et al., 
2010). Other attempts to identify the binding site of 4-CMTB that did not initially 
yield any outcomes, were able to demonstrate that ECL2 appears to play a key 
role in the allosteric modulation of SCFA potency as its replacement with the 
ECL2 of FFA3 led to a loss of allosterism with C3 (Smith et al., 2011). A recent 
kinetic analysis of 4-CMTB binding, measuring both dynamic mass redistribution 
over time and inositol monophosphate (IP1) accumulation at different time 
points, suggested that 4-CMTB associates with the receptor in a distinct fashion 
by initially binding to the orthosteric site and activating the receptor, followed 
by a transition to the allosteric site through which its modulatory effects on 
SCFAs were mediated (Grundmann et al., 2016). Although more work is needed 
to confirm this mode of binding, it led to the identification of proposed 
allosteric residue Lys652.60, whose involvement in FFA2 ligand binding and 
signalling will be discussed in chapter 6. Functionally 4-CMTB has been shown to 
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mimic the effects of SCFAs at FFA2; it was able to inhibit lipolysis in a rat 
adipocyte cell line (Lee et al., 2008) and has been shown to mediate FFA2-
dependent migration of neutrophils in conjunction with SCFAs (Vinolo et al., 
2011). A close analogue of 4-CMTB has also been employed to demonstrate that 
SCFA treatment promoted GLP-1 release in mouse colonic crypts in an FFA2-
dependent fashion (Nohr et al., 2013) and that FFA2 activation specifically had 
an inhibitory effect on ghrelin secretion in primary gastric mucosal cells 
(Engelstoft et al., 2013). 4-CMTB has certainly been a useful tool compound in 
functional studies, however its modest potency, allosteric nature and potentially 
complex mode of binding highlights that it is not equivalent to a high-affinity 
orthosteric agonist. 
Much more recently the pharmacology of a novel allosteric ligand for FFA2, 
AZ1729, has been described (Bolognini et al., 2016a). As in the case of 4-CMTB, 
AZ1729 lacks a carboxylate moiety and was able to activate orthosteric binding 
site mutants of FFA2. Closer investigation of the signalling profile of AZ1729 
revealed strongly biased behaviour as it was able to activate FFA2 in Gi-coupled 
cAMP inhibition and [35S]-GTPγS assays but was unable to promote Gq-dependent 
accumulation of IP1. Furthermore, AZ1729 was also able to allosterically 
modulate C3 and compound 1 concentration response curves, however also in a 
biased fashion. In Gi-coupled systems AZ1729 acted as a PAM of agonist potency, 
but when measuring Gq signalling in the same manner a NAM effect on agonist 
efficacy could be observed. Assessment of its direct effect on binding of C3 
revealed that increasing concentrations of AZ1729 increase C3 affinity, which 
likely results in the PAM effect in Gi-coupled assays. However, more detailed 
investigations of AZ1729 pharmacology may be required to define the molecular 
basis for its NAM effect on responses through Gq. At the murine orthologue 
AZ1729 retains its biased agonist behaviour, however its negative allosterism in 
Gq-coupled assays at the human receptor appears to have switched to a PAM 
effect on C3 potency and efficacy. Despite its distinct allosterism at mFFA2, 
AZ1729 could still be employed to define the contribution of Gi and/or Gq 
pathways to different physiological outputs of FFA2 activation. AZ1729 was able 
to inhibit lipolysis in primary mouse adipocytes and induce human neutrophil 
migration, and potentiated the response to C3 in both assay systems, suggesting 
that these effects are primarily mediated through Gi. On the other hand, AZ1729 
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did not regulate release of GLP-1 from mouse colonic crypts, suggesting an 
underlying Gq-coupled mechanism. These observations confirm that the various 
physiological functions of FFA2 may be mediated by different signalling pathways 
and that it is possible to develop an FFA2 ligand that can induce downstream 
responses in a selective fashion. In particular for a receptor with a complex 
physiological role and promiscuous signalling behaviour as observed for FFA2, a 
biased tool compound could be of great translational value, especially 
considering that some biological outputs that are mediated by Gi versus Gq have 
been suggested to have contradictory effects (Priyadarshini et al., 2015, Tang et 
al., 2015). The species-specific pharmacology of AZ1729 limits its use in 
dissecting the physiological relevance of respective G proteins coupling to FFA2 
in murine models, as AZ1729 will equally potentiate Gi and Gq responses of 
murine FFA2 to SCFAs. However, AZ1729 can still be employed in ex vivo or in 
vivo studies in absence of SCFAs to understand the contribution of Gi versus Gq 
signalling to individual physiological outputs, as it remains a biased agonist at 
mFFA2. 
1.6 Aims 
The SCFA receptor FFA2 is a fascinating GPCR that is deeply involved in the link 
between gut microbiome activity and metabolic regulation. Although FFA2 has 
been suggested as a potential therapeutic target in a range of conditions, a 
variety of factors have limited the progression of drug development. The work 
presented in this thesis aims to employ and develop pharmacological tool 
compounds and assay systems to provide a better understanding of FFA2 ligand 
binding and signal transduction. An initial characterisation of systems available 
to measure ligand action and binding will be followed by a detailed analysis of 
the structure-activity relationship of an agonist series recently investigated in a 
functional study (Forbes et al., 2015) at human and murine FFA2 (Chapter 3). 
The pharmacology and binding mode of FFA2 antagonists remains largely 
unexplored, therefore considerable effort has been invested herein to define the 
pharmacology of the GLPG0974 (Pizzonero et al., 2014) and CATPB (Hudson et 
al., 2012b) antagonist series. Although the use of signalling assays in 
combination with medicinal chemistry and mutagenesis can provide crucial 
information on ligand pharmacology and binding (Chapter 3), the lack of a 
means to directly assess binding to the receptor can limit investigation of 
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antagonists at FFA2 mutations that prohibit activation by agonists. Therefore, a 
radioligand based on GLPG0974 was employed to define the binding site and 
mechanism of FFA2 antagonists, particularly in the context of the known 
orthosteric binding pocket residues and in comparison to FFA2 agonists 
(Chapter 4). Fluorescence-based methodology has recently been proposed as an 
alternative to radioactive labelling, as it allows for real-time monitoring of 
ligand binding and is safe to use in live animals (Ma et al., 2014). To assess the 
feasibility and usefulness of fluorescence-based binding assays for FFA2, a novel 
binding assay based on bioluminescence resonance energy transfer between a 
fluorescently labelled ligand and nanoluciferase-tagged receptor was developed 
(Chapter 5). Another factor that has greatly hindered functional studies at FFA2 
is the lack of antagonists active at rodent orthologues. Using a homology model 
based on direct binding studies at different FFA2 mutants the molecular basis of 
species selectivity was identified (Chapter 6). Finally, the mechanistic basis of 
the promiscuous signalling behaviour of FFA2 was explored to develop a biased 
receptor (Chapter 6). The findings discussed will shine some light on the 
complex pharmacology of synthetic FFA2 ligands and the mechanisms that 
produce their function. This will contribute to future drug development efforts.
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2 Materials and methods 
2.1 Pharmacological reagents 
Sodium propionate: Sigma-Aldrich 
AZ1729 (N-[3-(2-Carbamimidamido-4-methyl-1,3-thiazol-5-yl)phenyl]-4-
fluorobenzamide): Synthesised in collaboration with AstraZeneca. 
[3H]-GLPG0974 (([3H]-4-[[1-(benzo[b]thiophene-3-carbonyl)-2-
methylazetidine-2-carbonyl]-(3-chlorobenzyl)amino]butyric acid): Provided as 
a gift by AstraZeneca. 
[35S]-GTPγS ([35S]-guanosine-5′-O-(3-thio)triphosphate): PerkinElmer 
The following test compounds were all synthesised in collaboration with 
University of Southern Denmark. The identity and >95% purity of each compound 
was confirmed by nuclear magnetic resonance, mass spectrometry and liquid 
chromatography. 
Compound 1 (3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-
yl)amino)-4-oxobutanoic acid) 
Compound 2 ((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-
carbonyl)pyrrolidine-2-carboxylic acid) 
Compound 2 analogues 1-28 (Chemical structures are related to compound 2 
and will be described in chapter 3) 
GLPG0974 (4-[[1-(benzo[b]thiophene-3-carbonyl)-2-methylazetidine-2-
carbonyl]-(3-chlorobenzyl)amino]butyric acid) 
GLPG-1 ((4-(1-(benzo[b]thiophene-3-carbonyl)-2-methyl-N-(4-
trifluoromethylbenzyl)azetidine-2-carboxamido)butanoic acid) 
MeGLPG-1 (methyl 4-(1-(benzo[b]thiophene-3-carbonyl)-2-methyl-N-(4-
trifluoromethylbenzyl)azetidine-2-carboxamido)butanoate) 
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GLPG-2 (4-(1-(2-(benzo[b]thiophen-3-yl)acetyl)-N-(4-chlorobenzyl)-2-
methylazetidine-2-carboxamido)butanoic acid) 
MeGLPG-2 (methyl 4-(1-(2-(benzo[b]-thiophen-3-yl)acetyl)-N-(4-
chlorobenzyl)-2-methylazetidine-2-carboxamido)butanoate) 
MoGLPG-2 (1-(2-(benzo[b]thiophen-3-yl)acetyl)-N-(4-chlorobenzyl)-2-methyl-
N-(4-morpholino-4-oxobutyl)azetidine-2-carboxamide) 
GLPG-3 (4-(1-(2-(benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-
(trifluoromethyl)benzyl)azetidine-2-carboxamido)butanoic acid) 
MeGLPG-3 (methyl 4-(1-(2-(benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-
(trifluoromethyl)benzyl)azetidine-2-carboxamido)butanoate) 
LinkGLPG-3 (tert-butyl (3-(4-(1-(2-(benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-
(4-(trifluoromethyl)benzyl)azetidine-2-carboxamido)butanamido) 
propyl)carbamate) 
CATPB ((S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl) 
phenyl)butanoic acid) 
MeCATPB (methyl (S)-3-(2-(3-chlorophenyl)-acetamido)-4-(4-
trifluoromethylphenyl)butanoate) 
LinkCATPB (tert-butyl (S)-(3-(3-(2-(3-chlorophenyl)acetamido)-4-(4-
(trifluoromethyl)phenyl)butanamido)propyl)carbamate) 
F-1 (1-(2-(benzo[b]thiophen-3-yl)acetyl)-2-methyl-N-(4-((3-((7-
nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propyl)amino)-4-oxobutyl)-N-(4-
(trifluoromethyl)benzyl)azetidine-2-carboxamide) 
F-2 ((S)-3-(2-(3-chlorophenyl)acetamido)-N-(3-((7-nitrobenzo[c] 
[1,2,5]oxadiazol-4-yl)amino)propyl)-4-(4-(trifluoromethyl)phenyl)butanamide) 
F-3 ((2R,4R)-2-(2-chlorophenyl)-3-(4-(((7-nitrobenzo[c][1,2,5]oxadiazol-4-
yl)amino)methyl)benzoyl)thiazolidine-4-carboxylic acid) 
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2.2 Molecular Biology 
2.2.1 DNA constructs 
For the work described in this thesis a range of different DNA constructs were 
employed to generate both transiently transfected and stably expressing cell 
lines. While most constructs were generated as part of this PhD project and will 
be described in later sections, several plasmids have been engineered 
previously. The vectors used to construct the plasmids include pcDNA3.1 
(Thermo Fisher), pcDNA5/FRT/TO (Thermo Fisher) and pCAGGS (obtained in 
collaboration with Tohoku University), which all encode an ampicillin resistance 
gene for selection. Initially plasmids encoding human (h)FFA2, hFFA3 and murine 
(m)FFA2 were generated in the pcDNA3.1 vector with enhanced yellow 
fluorescent protein (eYFP) fused to the receptor C terminus (Stoddart et al., 
2008), which was followed by a sub-cloning into the pcDNA5/FRT/TO vector 
(Hudson et al., 2012b). Orthosteric binding site mutations R180A, R255A and 
H242A were also introduced into pcDNA5/FRT/TO-hFFA2-eYFP previously 
(Hudson et al., 2012b). For the BRET-based β-arrestin recruitment assay, a 
pcDNA3 vector encoding Renilla luciferase (RLuc)-tagged β-arrestin 2 was 
generated in previous studies (Hudson et al., 2013a). For the transforming 
growth factor α (TGFα) shedding assay, pCAGGS vectors encoding alkaline 
phosphatase (AP)- tagged TGFα, FLAG epitope-tagged histamine H1 receptor, 
native Gα proteins and Gα chimeras were obtained in collaboration with Tohoku 
University (Inoue et al., 2012). 
2.2.2 Preparation of competent bacteria 
The chemically competent Escherichia coli strain XL1-Blue was utilised for 
chemical transformation of plasmid DNA. To prevent contamination with 
environmental bacteria, sterile technique was applied throughout and all culture 
media and reagents were autoclaved or filter-sterilised. A stock of XL-1 Blue 
cells stored at -80°C was defrosted on ice and streaked onto LB agar (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl and 15 g/L agar at pH 7). Streaked 
plates were incubated for 16 h at 37°C and a single colony was used to inoculate 
5 mL of LB broth (10 g/L tryptone, 5 g/L yeast extract and 10 g/L NaCl at pH 7), 
which was grown for a further 16 h at 37°C in a shaking incubator. The bacterial 
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culture was then transferred into a conical flask with 100 mL LB broth and grown 
at 37°C in a shaking incubator until an optical density of 0.48 was reached at a 
wavelength of 600 nm. To halt bacterial growth the flask was incubated on ice 
for 5 min, then transferred into two 50 mL falcon tubes and centrifuged at 
1,800 x g for 10 min at 4°C. The resulting pellet was resuspended in 20 mL of 
solution A (30 mM CH3CO2K, 10 mM RBCl2, 10 mM CaCl2, 50 mM MnCl2 and 15% 
(v/v) glycerol at pH 5.8 with acetic acid), incubated on ice for 5 min and 
centrifuged as before. The pellet generated by this second centrifugation was 
resuspended in 2 mL of solution B (10 mM 3-morpholinopropane-1-sulfonic acid 
(MOPS), 10 mM RbCl2, 75 mM CaCl2 and 15% (v/v) glycerol at pH 6.5 with HCl) 
and incubated on ice for 15 min. The resulting competent XL1-Blue bacteria 
were aliquoted into pre-chilled microcentrifuge tubes and stored at -80°C. 
2.2.3 Bacterial transformation 
Chemically competent XL-1 Blue cells prepared as described above were 
defrosted on ice and 100-500 ng DNA was added to 50 µL bacteria in pre-chilled 
microcentrifuge tubes and incubated on ice for 15 min. Samples were then 
transformed at 42°C for 90 s, followed by immediate incubation on ice for 
2 min. To allow for recovery and expression of the ampicillin resistance gene in 
successfully transformed bacteria, 450 µL LB broth were added and samples 
were placed in a shaking incubator for 1 h at 37°C. LB agar plates containing 
50 µg/mL ampicillin were prepared in advance and were used to plate 100-
250 µL of recovered bacterial culture. Resulting plates were incubated for 16 h 
at 37°C and cultures for preparation of plasmid DNA were inoculated with single 
colonies. 
2.2.4 Plasmid DNA purification 
Different kits were employed for purification of plasmid DNA, depending on the 
amount of DNA required for respective applications. A MiniPrep purification is 
commonly used when only small yield in the µg range is required, for example 
for initial screening of newly engineered plasmids. In contrast, MaxiPrep 
purification is appropriate when a larger yield in the mg range is necessary for 
downstream applications. Although the underlying mechanism of DNA isolation is 
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equivalent and manufacturer’s instructions were followed, both procedures are 
briefly described below. 
For MiniPrep purifications the Wizard® Plus SV Minipreps DNA Purification System 
(Promega) was employed. A 16 h bacterial culture of 5 mL was harvested by 
centrifugation at 9,300 x g for 5 min. The resulting bacterial pellet was 
resuspended in 250 µL resuspension solution and lysed by addition of 250 µL 
SDS-containing lysis solution. Additionally, 10 µL alkaline protease solution was 
added to inactivate endonucleases and other proteins. Lysates were incubated 
for 10 min at room temperature (RT) and 350 µL neutralisation buffer was added 
to induce precipitation of denatured proteins, cellular debris and chromosomal 
DNA, with plasmid DNA remaining in solution. The treated lysate was centrifuged 
at 16,000 x g for 10 min and the resulting supernatant was applied to a provided 
spin column, followed by a centrifugation at 16,000 x g for 1 min to allow the 
DNA to bind to the column. The flow-through was discarded and the column was 
washed two times with ethanol-containing buffer including centrifugations at 
16,000 x g for 1 min each time. To remove remaining ethanol the column was 
centrifuged at 16,000 x g for a further 2 min and DNA was eluted in 100 µL 
nuclease-free water into a sterile microcentrifuge tube. 
For MaxiPrep purifications the QIAGEN® Plasmid Maxi Kit (QIAGEN) was used. A 
16 h bacterial culture of 100 mL was centrifuged at 3,200 x g for 30 min at 4°C 
and the resulting pellet was resuspended in 10 mL RNase A-containing 
resuspension buffer at 4°C. Bacteria were lysed by addition of 10 mL 
SDS-containing lysis buffer and incubation for 5 min at RT. To neutralise the 
solution, 10 mL of pre-chilled neutralisation buffer were added, followed by 
incubation for 20 min on ice and centrifugation at 3,200 x g for 20 min at 4°C. A 
QIAGEN-tip 100 column was equilibrated with 10 mL equilibration buffer and the 
plasmid DNA-containing supernatant was carefully decanted into the column. 
After passing of the solution through the column by gravity flow, the column was 
washed twice with 30 mL of ethanol-containing wash buffer. Next, 15 mL elution 
buffer were applied to elute the DNA and by adding 10.5 mL isopropanol the DNA 
was precipitated, followed by a centrifugation at 3,200 x g for 30 min at 4°C. 
The pellet was air-dried, desalted by washing with 2 mL of 70% (v/v) ethanol and 
transferred into a sterile microcentrifuge tube. The precipitated DNA was then 
Chapter 2  52 
 
centrifuged at 20,000 x g for 10 min. The supernatant was aspirated and once 
the resulting pellet of purified DNA air-dried, it was dissolved in 600 µL 
nuclease-free water. 
Concentration and purity of purified plasmid DNA was assessed using a UV 
spectrophotometer to measure the absorbance of a sample diluted at 1:1000 at 
wavelengths of 260 and 280 nm. The absorbance at 260 nm (A260) corresponds to 
the maximal absorbance wavelength of nucleic acids and therefore allows 
quantification of DNA concentration. In a cuvette with a path length of 1 cm the 
A260 value equals unity for a 50 µg/mL solution of double-stranded DNA (Barbas 
et al., 2007). Proteins absorb at 280 nm and an absorbance ratio (A260/A280) 
between 1.8 and 2.0 is considered to be pure nucleic acid. After DNA 
quantification samples were stored at -20°C. 
2.2.5 Sequencing 
Completed cloning and mutagenesis products were sequenced to confirm that 
the desired DNA plasmid has indeed been produced and the sequence of 
plasmids obtained in collaboration was also confirmed in this fashion. DNA 
sequencing was performed by DNA Sequencing & Services (MRC I PPU, College of 
Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA sequencer. DNA sequences were assessed for quality 
using SnapGene software, translated with the ExPASy Translate Tool 
(web.expasy.org/translate/) and analysed with the NCBI Basic Local Alignment 
Search Tool (www.blast.ncbi.nlm.nih.gov). 
2.2.6 Cloning strategy 
Polymerase chain reaction (PCR) is an essential tool for molecular biology to 
amplify specific fragments of DNA. By designing specific primers desired 
restriction sites and epitope tags can be introduced in the sequence. For 
amplification of DNA fragments, reactions were set up in nuclease-free water in 
sterile 500 µL PCR tubes in a final volume of 50 µL with the following final 
amounts of reagents: 
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• 1 x Pfx Amplification Buffer (Invitrogen) 
• 1 mM MgSO4 (Invitrogen) 
• 250 µM deoxyribonucleotide (dNTP) mixture including deoxyadenosine 
triphosphate (dATP), deoxycytidine trisphosphate (dCTP), deoxyguanosine 
trisphosphate (dGTP) and deoxythymidine trisphosphate (dTTP) (Promega) 
• 2.5 units PlatinumTM Pfx DNA Polymerase (Invitrogen) 
• 400 nM each forward and reverse primers 
• 50 ng template DNA 
Reaction mixtures were then transferred into a thermal cycler and subjected to 
the following cycling programme: 
1. Preheating  94°C  3 min  
2. Denaturing  94°C  30 s 
3. Annealing  55-60°C 30 s 
4. Extension  68°C  1 min 
5. Repeat steps 2-4 for 30 cycles 
6. Final extension 68°C  5 min 
The annealing temperature can be adjusted to optimise the PCR reaction and 
depends on the melting temperature (Tm) of respective primers with a 
temperature of approximately 5-10°C lower than Tm being optimal. After the 
reaction samples are held at 4°C and then transferred to -20°C for long-term 
storage. 
The QIAquick® PCR Purification Kit (QIAGEN) was used to purify PCR products 
after cycling and was employed as per manufacturer’s instructions. Completed 
PCR reactions were diluted in five volumes of binding buffer, applied to a 
QIAquick spin column and centrifuged at 16,000 x g for 1 min. The flow-through 
was discarded and the column was washed with an ethanol-containing buffer, 
followed by a centrifugation as before. After the wash the column was 
centrifuged once more to remove residual ethanol and 50 μL of nuclease-free 
water were applied to the column for 1 min. DNA fragments were then eluted 
into a sterile microcentrifuge tube by centrifugation. Samples were either 
processed directly or stored at -20°C. 
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Cloning of a novel DNA plasmid usually includes the insertion of a DNA fragment 
into an empty vector. To achieve this, both components need to be digested 
with restriction endonuclease enzymes to generate sticky-end DNA fragments 
optimal for ligation. Digestion reactions were performed in a volume of 
50-100 µL and incubated for 16 h at 37°C with following reagents: 
• 1 x CutSmart® Buffer (New England Biolabs) 
• 10-50 µg vector DNA or 50 µL PCR product 
• 1-10 units of High Fidelity (HF®) restriction endonucleases (New England 
Biolabs) with units used dependent on manufacturer’s instructions 
To purify digested DNA insert and vector fragments, they were first separated by 
agarose gel electrophoresis. Agarose gels were prepared by dissolving 1% (w/v) 
agarose in TAE buffer (40 mM Tris, 1 mM EDTA (at pH 8) and 20 mM acetic acid) 
and adding 1 x SYBR® Safe DNA Stain (Life Technologies) to allow visualisation of 
DNA. Samples were prepared by adding the respective volume of 6 x DNA loading 
buffer (0.4 mg/mL sucrose and 0.25% (w/v) bromophenol blue) and 5-50 µL were 
loaded per well onto the set gel immersed in TAE buffer. In addition to the 
samples, 5 µL HyperladderTM 1kb (Bioline) was loaded into one well to allow 
quantification of DNA fragment size and concentration. The gel was then 
objected to an electric current of 125 V for 20-30 min. 
To extract the digested DNA fragments from the agarose gel the QIAquick Gel 
Extraction Kit (QIAGEN) was used as per manufacturer’s instructions. The 
agarose gel bands that contain the DNA fragments of interest were visualised 
with a UV transilluminator and carefully excised with a razor blade. The gel 
pieces were weighed in sterile microcentrifuge tubes and three gel volumes of 
solubilisation buffer were added, followed by an incubation for 10 min at 50°C, 
vortexing every 2-3 min, to dissolve the gel pieces. One gel volume of 
isopropanol was added to the resulting solution and applied to a QIAquick spin 
column. The column was centrifuged at 16,000 x g for 1 min and after discarding 
the flow-through, the column was washed including a centrifugation as before. 
The wash was followed by a further centrifugation to remove residual ethanol 
and 30-50 µL nuclease-free water were added to the column, which was 
incubated for 1 min. DNA was then eluted into a sterile microcentrifuge tube by 
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means of a further centrifugation. When not processed immediately, samples 
were stored at -20°C. 
To select appropriate concentrations of gel-extracted DNA vector and insert, a 
further agarose gel electrophoresis was performed, and the DNA concentration 
was estimated with the HyperladderTM 1kb. After determination of vector and 
insert concentrations, the required amount of insert and vector DNA to reach 
molar ratios of 1:3 and 1:5 were calculated with the following formula: 
𝑀𝑎𝑠𝑠𝑖𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔) = 𝑀𝑜𝑙𝑎𝑟 𝑅𝑎𝑡𝑖𝑜 × 𝑀𝑎𝑠𝑠𝑣𝑒𝑐𝑡𝑜𝑟 (𝑛𝑔) ×
𝑆𝑖𝑧𝑒𝑖𝑛𝑠𝑒𝑟𝑡 (𝑘𝑏)
𝑆𝑖𝑧𝑒𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏)
 
Sticky-end ligation reactions were set up in a volume of 20 µL with the following 
reagents: 
• 1 x T4 DNA Ligase Reaction Buffer (New England Biolabs) 
• 75 ng vector DNA 
• insert DNA (calculated in ng as above) 
• 400 units T4 DNA Ligase (New England Biolabs) 
Reactions were incubated for 2 h at RT and 5-10 µL of ligated product was 
transformed into XL1-Blue competent bacteria as described in section 2.2.3. 
2.2.7 Generation of hemagglutinin (HA)-tagged FFA2 constructs 
Plasmids encoding hFFA2 with a C-terminal HA tag (amino acid sequence 
YPYDVPDYA) were generated by using pcDNA5/FRT/TO-hFFA2-eYFP (see section 
1.2.1) as a template. Forward primers were designed to add a HindIII restriction 
site followed by a Kozak sequence (double line), which facilitates initiation of 
translation, and the hFFA2 start codon (grey). Reverse primers were designed to 
fuse the HA tag (broken line) to the hFFA2 C terminus followed by a stop codon 
(grey) and an XhoI restriction site (full line).  
HindIII hFFA2 Forward Primer 
5’ TTTTAAGCTTGCCACCATGCTGCCGGACTGGAAG 3’ 
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hFFA2-HA XhoI Reverse Primer 
5’ TTTTCTCGAGCTAAGCGTAATCTGGAACATCGTATGGGTACTCTGTAGTGAAGTCCG
AACTTGG 3’ 
PCR products were cloned into the pcDNA5/FRT/TO vector as described in 
previous sections for subsequent use in the Flp-InTM T-RExTM system. 
2.2.8 Generation of Nanoluciferase-tagged FFA2 constructs 
Development of the BRET-based binding assay (see section 2.4.5) required the 
generation of an hFFA2 construct N terminally tagged with Nanoluciferase (NLuc) 
in the pcDNA5/FRT/TO vector. For this purpose, the pcDNA5/FRT/TO-NLuc-
hFFA4 plasmid developed for a previous BRET-based binding study was employed 
as an NLuc template (Christiansen et al., 2016) and pcDNA5/FRT/TO-hFFA2-eYPF 
as an hFFA2 template. The NLuc sequence was previously fused to an mGLUR 
signal at the N terminus to ensure correct insertion of the NLuc-tagged receptor 
into the plasma membrane. To amplify the NLuc insert a forward primer 
upstream of the multiple cloning site of the pcDNA5/FRT/TO vector was 
employed and a reverse primer was designed to introduce an XmaI restriction 
site downstream of the NLuc sequence. The hFFA2 sequence was amplified using 
a forward primer that introduced an XmaI restriction site upstream, to allow for 
ligation with the NLuc insert, and a reverse primer that introduced an XhoI 
restriction site downstream of the hFFA2 sequence. 
pcDNA5/FRT/TO-MCS Forward Primer 
5’ CCACGCTGTTTTGACCTCCAT 3’ 
NLUC-XmaI Reverse Primer 
5’ ACTGACTGCCCGGGCGCCAGAATGCGTTCGCACAG 3’ 
XmaI-hFFA2 Forward Primer 
5’ ACTGACTGCCCGGGATGCTGCCGGACTGGAAGAGC 3’ 
hFFA2-XhoI Reverse Primer 
5’ TTTTCTCGAGCTACTCTGTAGTGAAGTCCGAACTTG 3’ 
The empty pcDNA5/FRT/TO vector was digested with HindIII and XhoI to 
generate sticky-end DNA necessary for ligation, while the amplified Nluc insert 
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was digested with HindIII and XmaI, and the amplified hFFA2 insert with XmaI 
and XhoI. The cloning procedure was followed as described in sections above and 
the resulting pcDNA5/FRT/TO-NLuc-hFFA2 plasmid was used in the Flp-InTM 
T-RExTM system. 
2.2.9 Site-directed mutagenesis 
To alter the wild type sequence of receptors by introducing point mutations, the 
Stratagene QuikChange® System was employed. Although the general procedure 
is akin to standard PCR described in section 2.2.6, it is actually a linear 
amplification technique as the reaction product is never used as a template. 
Oligonucleotide primers that contain the desired base substitution were 
designed using the online software PrimerX (www.bioinformatics.org/primerx), 
which screens for primers that are between 20-40 bp in length with a low GC 
content of ≤60%, when possible, and a Tm ≥75°C. The reactions were performed 
in a volume of 50 µL and set up in 500 µL PCR tubes with following final reagent 
concentrations: 
• 1 x Pfu DNA Polymerase Buffer with MgSO4 (Promega) 
• 250 µM dNTP mixture 
• 1 µM each forward and reverse primers 
• 20 ng template DNA 
• 2.5 units Pfu DNA Polymerase (Promega) 
A thermal cycler was employed to subject the reaction mixtures to the following 
cycling programme: 
1. Preheating  95°C  5 min  
2. Denaturing  95°C  30 s 
3. Annealing  42-65°C 30 s 
4. Extension  72°C  ≥2 min 
5. Repeat steps 2-4 for 30 cycles 
6. Final extension 72°C 5 min 
As in the case of PCR described in section 2.2.6, the annealing temperature 
needs to be adjusted to the Tm of respective primers. For the extension time it 
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is recommended to allow approximately 2 min per 1 kb that need to be 
amplified. Following the reaction, the methylated parental template DNA was 
digested by adding 10 units of the DpnI restriction enzyme (Promega) to the 
reaction product and incubating the samples for 16 h at 37°C. To express and 
purify the desired plasmid DNA, 1 µL of digested product was used to transform 
XL1-Blue competent bacteria following the protocol described in section 2.2.3. 
2.2.10 Generation of FFA2 point mutant constructs 
The generation of hFFA2 and mFFA2 constructs that contain point mutations of 
interest was performed by site-directed mutagenesis. Depending on the 
application, different templates were used for generation of mutations, 
including pcDNA5/FRT/TO-hFFA2-eYFP, pcDNA5/FRT/TO-hFFA2-HA, 
pcDNA5/FRT/TO-NLuc-hFFA2 and pcDNA5/FRT/TO-mFFA2-eYFP. For generation 
of the same mutations in different plasmids, the same mutagenic primers were 
employed. 
R180A (in pcDNA5/FRT/TO-NLuc-hFFA2) 
Forward Primer: 5’ GTGCTGCCCGTGGCGCTGGAGCTGTG 3’ 
Reverse Primer: 5’ CACAGCTCCAGCGCCACGGGCAGCAC 3’ 
R255A (in pcDNA5/FRT/TO-NLuc-hFFA2) 
Forward Primer: 5’ GAAAAAGCCCCTGGTGGGCGTCAATAGCCGTGGTG 3’ 
Reverse Primer: 5’ CACCACGGCTATTGACGCCCACCAGGGGCTTTTTC 3’ 
H242A (in pcDNA5/FRT/TO-NLuc-hFFA2) 
Forward Primer: 5’ CTTACAACGTGTCCGCGCTGGTGGGGTATCAC 3’ 
Reverse Primer: 5’ GTGATACCCCACCAGCGCGGACACGTTGTAAG 3’ 
K65A (in pcDNA5/FRT/TO-NLuc-hFFA2 and –hFFA2-HA) 
Forward Primer: 5’ CTGCTGCCCTTCGCGATCATCGAGG 3’ 
Reverse Primer: 5’ CCTCGATGATCGCGAAGGGCAGCAG 3’ 
K65R (in pcDNA5/FRT/TO-NLuc-hFFA2 and –hFFA2-HA) 
Forward Primer: 5’ GCTGCTGCCCTTCCGTATCATCGAGGCTGC 3’ 
Reverse Primer: 5’ GCAGCCTCGATGATACGGAAGGGCAGCAGC 3’ 
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K65E (in pcDNA5/FRT/TO-NLuc-hFFA2 and –hFFA2-HA) 
Forward Primer: 5’ CTGCTGCTGCCCTTCGAAATCATCGAGGCTGC 3’ 
Reverse Primer: 5’ GCAGCCTCGATGATTTCGAAGGGCAGCAGCAG 3’ 
R65K (in pcDNA5/FRT/TO-mFFA2-eYFP) 
Forward Primer: 5’ GCTGCTGCTGCCCTTCAAAATCGTGGAAGCAGCATC 3’ 
Reverse Primer: 5’ GATGCTGCTTCCACGATTTTGAAGGGCAGCAGCAGC 3’ 
To generate the dual R180A-R255A mutant two sequential site-directed 
mutagenesis reactions were performed. After confirming by DNA sequencing that 
correct base replacements have been introduced, the plasmids were either 
employed for transient transfection or generation of stable cell lines using the 
Flp-InTM T-RExTM system. 
2.3 Mammalian cell culture 
2.3.1 Cell line maintenance 
All cell culture procedures were performed under sterile conditions in a class II 
laminar flow biosafety cabinet with culture medium and reagents pre-warmed in 
a water bath at 37°C, when possible. 
Two variants of the human embryonic kidney 293 cells were employed, namely 
HEK293T cells, which stably express large T antigen that can enhance protein 
production by binding to SV40 enhancers of expression vectors, and HEK293A 
cells, which stably express E1 proteins required to generate recombinant 
adenovirus. Both cell lines were maintained in Dulbecco’s Modified Eagle’s 
Medium supplemented with 10% (v/v) heat-inactivated foetal calf serum (FCS), 
2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin (Sigma) 
at 37°C and 5% CO2 in a humidified atmosphere. 
Before stable transfection of receptors of interest, parental Flp-InTM T-RexTM 293 
cells (Life Technologies) were maintained in Dulbecco’s Modified Eagle’s Medium 
with high glucose and without sodium pyruvate supplemented with 10% (v/v) 
heat-inactivated FCS, 100 units/mL penicillin, 100 µg/mL streptomycin and 
5 μg/mL blasticidin at 37°C and 5% CO2 in a humidified atmosphere. 
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To passage cell lines, the respective culture medium was aspirated and cells 
were washed with sterile PBS (137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4 and 10 
mM Na2HPO4 at pH 7.4), followed by incubation with 0.25% trypsin-EDTA for a 
maximum of 5 min at RT. Upon detachment of cells from the culture vessel, 
proteolytic cleavage was inhibited by addition of culture medium and the 
volume of cell suspension required to achieve the desired dilution for cell 
passaging was transferred into a sterile culture vessel with an appropriate 
volume of fresh culture medium added. 
For long-term storage cell lines were cryopreserved and stored in liquid 
nitrogen. After detachment of cells as described above, cells were centrifuged 
at 300 x g for 5 min and the resulting pellet was resuspended in 2 mL FCS with 
10% (v/v) DMSO (for a confluent 75 cm2 flask of HEK293 cells). Aliquots of 1 mL 
were frozen at -80°C for 24 h prior to transfer into liquid nitrogen storage. To 
revive cryopreserved cells, aliquots were rapidly thawed in a water bath at 37°C 
and transferred into a flask with 10 mL fresh culture medium. Cells were 
allowed to attach for 1-2 h and medium was replaced to remove DMSO. 
2.3.2 Transient transfection 
Transient transfection of cells was executed with polyethyleimine (PEI) as a 
transfection reagent and commonly performed in 10 cm dishes. To transfect 
respective DNA plasmids, 5 µg of DNA was diluted in 250 µL of 150 mM NaCl and 
mixed with 250 µL of 150 mM NaCl containing 30 µg PEI. The mixture was 
vortexed and incubated for 10 min at RT, followed by dropwise addition to the 
dish. To transfect cells grown in smaller culture vessels, the procedure was 
scaled down accordingly. Cells were incubated with PEI for 24 h at 37°C and 
5% CO2 in a humidified atmosphere and depending on the downstream 
application either employed for assays directly, or the medium was replaced and 
cells were used after passage into appropriate culture vessels and a further 24 h 
incubation. 
2.3.3 Generation of stably transfected Flp-InTM T-RExTM 293 cell 
lines 
Most assays made use of Flp-InTM T-RExTM 293 cells, which contain a doxycycline-
controlled flippase recognition target (FRT) site that allows stable integration of 
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DNA plasmids in the pcDNA5/FRT/TO vector when co-transfected with the 
Flp recombinase-encoding pOG44 vector. In addition to the receptor of interest, 
the pcDNA5/FRT/TO plasmid also confers hygromycin resistance to positively 
transfected cells, which serves as a means of selection. Parental cells were 
cultured to reach 50-60% confluency in a 10 cm dish and co-transfected with 
8 µg of DNA, including the receptor of interest in the pcDNA5/FRT/TO vector 
and pOG44 at a ratio of 1:8, using PEI. The medium was changed after 24 h and 
following a further 24 h incubation cells were subcultured at ratios of 1:10, 1:25 
and 1:50. Selection of positively transfected cells was initiated by addition of 
200 µg/mL hygromycin to the basal Flp-InTM T-RExTM 293 medium, which was 
maintained upon positive clonal selection. The culture medium was changed 
every 2-3 days until cell colonies could be detected by eye (14-28 days). Cells 
were detached as described previously and colonies were combined to yield 
polyclonal cell lines in which expression of the integrated gene could be 
stimulated by incubation with 100 ng/mL doxycycline for 16 h. 
To confirm successful clonal selection, different approaches were employed 
depending on the fusion tag of the respective receptor. For eYFP-tagged 
constructs, cells were visualised under the epifluorescent Nikon ECLIPSE Ti 
microscope with a mercury light source and an eYFP filter set situated above the 
objective lens. The employed filter consists of an exciter with 500 nm peak and 
20 nm bandwidth, a dichroic Q515LP mirror that allows passing of wavelengths 
above 515 nm and an emitter with 535 nm peak and 30 nm bandwidth. 
Alternatively, expression levels were assessed by determining eYFP fluorescence 
by excitation of doxycyline-induced cells with light at 500 nm and measuring 
emission at 530 nm using a POLARstar Omega Plate Reader (BMG LABTECH). As 
NLuc is capable of bioluminescence upon addition of the Nano-Glo® Luciferase 
Assay Substrate (Promega), NLuc-tagged receptor expression was assessed by 
measuring NLuc luminescence at 470 nm using a PHERAStar FS Plate Reader 
(BMG LABTECH). Although measurement of eYFP fluorescence and NLuc 
luminescence is not quantitative, it provides qualitative information on the 
comparability of expression levels in different cell lines. Receptor functionality 
and expression in HA-tagged receptor cell lines was confirmed in functional 
assays and directly quantified in radioligand binding studies. 
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2.4 Biochemical assays 
2.4.1 Preparation of cellular membranes 
Membranes required for biochemical assays were generated from Flp-InTM 
T-RExTM 293 cells treated in confluent 10 cm dishes with 100 ng/mL doxycycline 
for 16 h under sterile conditions to induce expression of the receptor of interest. 
Cells were washed once with non-sterile ice cold PBS, detached from the dish in 
3 mL PBS by scraping, and centrifuged at 1,800 x g for 5 min at 4°C. Pellets were 
incubated at -80°C for a minimum of 30 min and then resuspended in TE buffer 
(10 mM Tris and 0.1 mM EDTA at pH 7.4) containing cOmplete™ EDTA-free 
Protease Inhibitor Cocktail (Roche), followed by homogenisation by passing the 
cell suspension through a 5 mL hand-held Dounce homogeniser 50 times. The cell 
lysate was then passed 5 times through a 25-gauge needle and centrifuged at 
450 x g for 5 min at 4°C to pellet cell debris. The plasma membrane-containing 
supernatant was then transferred to ultracentrifuge tubes and subjected to a 
centrifugation at 90,000 x g for 30 min at 4°C. The pellet was resuspended in TE 
buffer with protease inhibitor and passed 5 times through a 25-gauge needle. 
Membrane preparations were either used immediately or aliquoted and stored at 
-80°C. 
2.4.2 Determination of membrane protein concentration 
After membrane preparation, the concentration of protein was quantified to 
allow appropriate dilution for downstream applications. The bicinchoninic acid 
(BCA) assay was employed for protein quantification, using a standard curve of 
0.25–3 μg/μL bovine serum albumin (BSA). Samples were diluted 1:2 and 10 μL of 
diluted sample or undiluted standard was added to a clear 96-well plate. 
Proteoquant BCA Reagent B (Expedeon) was diluted 1:50 in Proteoquant BCA 
Reagent A (Expedeon) and 200 μL/well were added to the samples and 
standards. The plate was incubated at 37°C for 20 min and absorbance at 
562 nm was measured on a POLARStar Omega Plate Reader (BMG Labtech). 
Diluted sample concentrations were interpolated from the linear BSA standard 
curve and multiplied by 2 to determine protein concentrations. 
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2.4.3 [35S]-GTPγS binding assay 
To assess coupling of Gi subtype G proteins to FFA2, the [35S]-GTPγS binding 
assay was employed. GTPγS is a non-hydrolysable analogue of GTP and remains 
bound to Gαi upon nucleotide exchange induced by an actively signalling GPCR. 
By radiolabelling GTPγS with [35S], the extent of Gαi protein activation can be 
quantified with an approach comparable to radioligand binding. Assays were 
performed in glass tubes in a total volume of 250 µL using a water bath at 25°C. 
Initially, 10 μg of membrane protein were pre-incubated for 15 min in assay 
buffer (50 mM Tris, 10 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 1 μM GDP, 30 µg/ml 
saponin and 0.1% (w/v) fatty acid-free BSA at pH 7.4) containing the indicated 
ligand concentrations. The reaction was then initiated by addition of [35S]-GTPγS 
at 50 nCi per tube, and the reaction was terminated after a further 45 min 
incubation by rapid filtration through GF/C glass filters (Alpha Biotech), which 
were pre-soaked in ice-cold wash buffer (50 mM Tris and 10 mM MgCl2 at pH 
7.4), using a 24-well Brandel cell harvester (Alpha Biotech). This filtration allows 
separation of free [35S]-GTPγS and Gi-bound [35S]-GTPγS, which will be unable to 
pass through the glass filter. Unbound radioligand was removed from filters by 
washing 3 times with ice-cold wash buffer and filters were dried for a minimum 
of 30 min at RT. Dried filters were transferred to 6 mL polyethylene (PE) Pony 
Vials (PerkinElmer) and 3 mL of Ultima GoldTM XR liquid scintillation cocktail 
(PerkinElmer) were added per vial. To quantify [35S]-GTPγS binding, a Tri-Carb® 
liquid scintillation counter was employed to measure [35S] counts per minute 
(CPM) with a maximum quantification time of 5 min. For data analysis, CPM was 
plotted against ligand concentrations on a logarithmic scale. 
2.4.4 Radioligand binding assay 
All radioligand binding assays using [3H]-GLPG0974 were conducted in binding 
buffer (50 mM Tris, 100 mM NaCl, 10 mM MgCl2 and 1 mM EDTA at pH 7.4) in 
glass tubes at a total volume of 200 µL and using a water bath at 25°C. 
Nonspecific binding of the radioligand was determined in the presence of 10 µM 
unlabelled GLPG0974 or CATPB, as stated in respective figure legends. The 
indicated incubation time of radioligand with membrane protein, generated 
from doxycycline-induced Flp-InTM T-RExTM cells, and other experiment-specific 
additions was followed by separation of receptor-bound and free [3H]-GLPG0974 
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by rapid vacuum filtration through PBS-soaked GF/C glass filters (Alpha Biotech) 
using a 24-well Brandel cell harvester (Alpha Biotech). As in case of [35S]-GTPγS 
assays, receptor-bound radioligand will be unable to pass through the glass 
filter. To remove remaining unbound radioligand, the filter was washed 3 times 
with ice-cold PBS. After drying for a minimum of 30 min, cut filters were 
transferred to 6 mL PE Pony Vials (PerkinElmer) and 3 ml of Ultima GoldTM XR 
liquid scintillation cocktail (PerkinElmer) were added to each sample vial. 
Radioactivity of receptor-bound [3H]-GLPG0974 was quantified by using the Tri-
Carb® liquid scintillation counter to measure [3H] disintegrations per minute 
(DPM) with a maximum quantification time of 3 min. Corresponding standards of 
[3H]-GLPG0974 concentrations used in respective assays were also quantified to 
define the concentration of [3H]-GLPG0974 added per tube: 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 (𝐷𝑃𝑀)
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (
𝐷𝑃𝑀
𝑓𝑚𝑜𝑙)
×
1
200 (𝐴𝑠𝑠𝑎𝑦 𝑣𝑜𝑙𝑢𝑚𝑒)
=
𝑓𝑚𝑜𝑙
𝜇𝐿
=
𝑛𝑚𝑜𝑙
𝐿
= 𝑛𝑀 
Radioligand binding data analysis usually includes the calculation of specific 
binding by subtracting nonspecific binding from total binding, which is 
appropriate as total radioligand binding never exceeded more than 10% of that 
added, thereby avoiding complications associated with free radioligand 
depletion (Hulme and Birdsall, 1992). To quantify specifically bound 
[3H]-GLPG0974 in context of the protein concentration the following formula was 
used: 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (𝐷𝑃𝑀)
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (
𝐷𝑃𝑀
𝑓𝑚𝑜𝑙)
×
1000
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 (
𝜇𝑔
𝑡𝑢𝑏𝑒) 
= 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (
𝑓𝑚𝑜𝑙
𝑚𝑔
) 
Availability of a radioligand allows for various different approaches to 
radioligand binding including assessment of saturation and competition binding 
or kinetic studies. The methods described above apply for all radioligand binding 
assays, while experiment-specific procedures will be described in the following 
paragraphs. Detailed data analysis and calculations of respective parameters are 
described in section 2.7.3. 
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To construct saturation binding isotherms, which allow calculation of 
radioligand affinity in terms of the dissociation constant (Kd), increasing 
concentrations of [3H]-GLPG0974 were incubated with 5 µg of membrane protein 
for 2 h followed by filtration and quantification. For data analysis, specific 
binding was plotted against quantified [3H]-GLPG0974 concentrations. 
Competition binding assays are a valuable tool for calculation of unlabelled 
ligand affinity in terms of Ki by assessing their ability to displace the radioligand 
from the receptor. To perform such an assay, [3H]-GLPG0974 at Kd concentration 
and increasing concentrations of unlabelled ligand of choice were co-added to 
5 µg of membrane protein. The reactions were incubated for 2 h and processed 
following standard protocol. To analyse the resulting data, specific binding was 
plotted against unlabelled ligand concentrations and [3H]-GLPG0974 
concentration to be displaced was quantified. 
Dissociation and association kinetic binding assays were performed using a 
reverse time protocol. To measure radioligand dissociation [3H]-GLPG0974 at Kd 
concentration was incubated with 5 µg of membrane protein for 1 h to allow 
pre-association of the radioligand with the receptor. To induce radioligand 
dissociation two different approaches were employed. Either 10 µM CATPB was 
added to monitor displacement of [3H]-GLPG0974 by competition (standard 
procedure) or an “infinite dilution” approach was used, in which the reaction 
mixture was scaled down to 100 µL and diluted 70-fold. This was performed in a 
time-staggered fashion to capture time points between 5 and 240 min. For 
determination of association kinetics, [3H]-GLPG0974 was added to 5 µg 
membrane protein in a time-staggered protocol to measure 5–240 min time 
points. For both kinetic binding assays filters were processed simultaneously, 
while measuring the time required per filter to correct for increased incubation 
time, and processed according to standard protocol. Before data analysis, 
specific binding was plotted against time and for association kinetics 
calculations, the employed [3H]-GLPG0974 concentration was quantified. 
Competitive kinetic binding assays can be employed to determine the kinetic 
binding parameters of unlabelled ligands by assessing radioligand association in 
presence of different concentration of competing ligands (Dowling and Charlton, 
2006). Three concentrations of competing ligand at 1-, 3-, and 10-fold Ki were 
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co-added with a Kd concentration of [3H]-GLPG0974 and 5 µg of membrane 
protein was added at indicated time points. As in the case of regular kinetic 
binding assays, specific radioligand binding was plotted against time for data 
analysis. 
2.4.5 BRET-based binding assay 
The BRET-based binding assay was developed to measure binding of fluorescent 
ligands to FFA2 tagged N-terminally with NLuc. This approach has already been 
successfully applied previously (Christiansen et al., 2016) and the described 
approach has been followed. This technique combines features of radioligand 
binding assays (see section 2.4.4) with BRET-based methodology (see section 
2.5.4). The underlying mechanism of the binding assay itself will be described in 
detail in chapter 5 and this section aims to outline the experimental procedures. 
For data analysis the BRET ratio was calculated, which corresponds to division of 
emission at 545 nm (substrate emission wavelength) by 460 nm (NLuc emission 
wavelength). Apart from the data processing, the underlying approach to 
measuring saturation, competition and kinetic binding is identical to the 
radioligand binding, therefore the following paragraphs will briefly highlight 
differences in experimental setup and detection. 
For equilibrium BRET binding assays, which include saturation and competition 
binding, membrane protein was suspended in binding buffer and transferred into 
a white 96-well plate at 2.5 μg membrane protein/well. The reaction was 
performed in a total volume of 100 µL and respective reagents were added at 
10 µL/well. Fluorescent ligand was added at increasing concentrations for 
saturation binding, or Kd concentration for competition binding in presence of 
increasing concentrations of unlabelled ligand. Nonspecific binding was 
determined by addition of an appropriate competitive unlabelled ligand, in an 
optimal case a fluorescent ligand analogue without attached fluorophore, at 
fully displacing concentration. Incubations were performed at 30°C for 2 h in a 
gently shaking incubator at 50 rpm. Following incubation, the Nano-Glo® 
Luciferase Assay Substrate (Promega) was added at a final dilution of 1:800 and 
after a further 5 min incubation bioluminescent emission at 460 and 545 nm was 
measured using a CLARIOstar Plate Reader (BMG LABTECH). The resulting 
specific BRET ratio (nonspecific signal subtracted from total signal) was plotted 
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against fluorescent ligand concentration or displacing unlabelled ligand 
concentration. 
For kinetic BRET binding assays, cell membranes were distributed in white 96-
well microplates at 2.5 μg membrane protein/well, as before. The substrate was 
then added (1:800 final dilution) and after incubation for 5 min at 30°C, plates 
were inserted into a CLARIOstar Plate Reader, with temperature set to 30 °C. 
Emission at 460 and 545 nm was then measured at 90 s intervals. For association 
experiments, fluorescent ligand was added manually to the plate after 60 s of 
measurement to a final concentration of 100, 300, 500, or 1000 nM. 
Measurement was resumed and continued at 90 s intervals for the indicated time 
period. For dissociation experiments, the reaction was incubated for 2 h at 30°C 
followed by two washes with binding buffer, including centrifugation at 
20,000 x g at 4°C for 15 min, to induce fluorescent ligand dissociation. The 
membrane pellet was then resuspended in binding buffer pre-warmed to 37°C, 
transferred into a white 96-well microplate at 90 μL/well and after pre-
incubation with substrate for 5 min at 30°C, emission at 460 and 545 nm was 
measured as before at 90 s intervals. In all kinetic experiments, nonspecific 
binding was assessed in parallel by preparing wells with pre-added competing 
unlabelled ligand at fully displacing concentration. Kinetic binding data were 
then plotted as specific BRET ratio against time. 
Competitive kinetic binding assays were also performed using the BRET-based 
binding system. Membrane protein was pre-incubated for 5 min with substrate, 
in this case coelenterazine h (Nanolight Tech), followed by simultaneous 
addition of a Kd concentration of fluorescent ligand and three different 
concentrations of competing unlabelled ligand, namely 1-, 3-, or 10-fold of Ki, 
were added simultaneously. As in the case of other kinetic assays, readings were 
then continued at 90 s intervals for 60 min and the specific BRET ratio was 
plotted against time for data analysis. 
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2.5 Cell-based assays 
2.5.1 IP1 accumulation assay 
To measure Gq G protein-induced production of IP1 an IP-One Tb kit (Cisbio 
Bioassays) was used, which is based on detection of homogeneous time-resolved 
FRET (fluorescence resonance energy transfer) or HTRF, according to 
manufacturer’s instruction. Briefly, Flp-InTM T-RExTM cells were plated in culture 
vessels of appropriate size and treated with 100 ng/mL doxycycline for 16-24 h 
to induce expression of receptor of interest. Test compounds were prepared in 
provided IP1 Stimulation Buffer (10 mM HEPES, 1 mM CaCl2, 0.5 mM MgCl2, 
4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose and 50 mM LiCl 50 mM at pH 7.4), 
which includes LiCl to prevent degradation of IP1, at 2 x final concentration and 
7 µL were added to white low-volume 384-well plates according to the desired 
plate layout. In addition, an IP1 standard curve with final concentrations of 11 to 
11,000 nM was prepared and added at 14 µL/well. Cells were counted in HBSS 
(Hank’s Balanced Salt Solution: 137 mM NaCl, 5.3 mM KCl, 0.34 mM Na2HPO4, 
0.44 mM KH2PO4, 4 mM NaHCO3, 1.26 mM CaCl2, 0.5 mM MgCl2 and 0.4 mM MgSO4 
at pH 7.3) and an appropriate volume was centrifuged at 300 x g for 5 min, 
followed by resuspension in IP1 Stimulation Buffer and addition of 7 µL of cell 
suspension to test compounds resulting in a concentration of 7,500 cells/well. 
For testing of agonists, cells were incubated with test compound for 2 h at 37°C. 
To assess ability of antagonists to inhibit agonist responses, cells were incubated 
with 3.5 µL of test compound per well for 30 min at 37°C prior to addition of an 
EC80 concentration of agonist at 3.5 µL/well, followed by a 2 h incubation at 
37°C. Prepared antagonist and agonist test compound concentrations were 
adjusted accordingly to the increased dilution factor. To terminate the reaction 
and enable measurement of accumulated IP1, synthetic IP1 coupled to dye d2 
and an anti-IP1 antibody labelled with Lumi4TM-Tb cryptate were employed. The 
FRET reaction takes place between Lumi4TM-Tb cryptate and dye d2, therefore 
competition between d2-labelled IP1 and IP1 produced in response to test 
compounds results in reduction of the FRET signal with increasing concentration 
of produced IP1. Both reagents were diluted as instructed (1:20) and added in 
cell lysis buffer at 3 µL/well. As a negative control, lysis buffer instead of 
d2-labelled IP1 was added to a selected triplicate of wells. Plates were 
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incubated for 1 h at RT and then fluorescence at 620 (Lumi4TM-Tb cryptate) and 
665 nm (dye d2) and was quantified using a PHERAstar FS plate reader. 
For data analysis, the ratio of fluorescence at 665 over 620 nm was calculated 
for sample wells and the negative control (Rationeg). To correct for basal 
fluorescence, the Delta F was calculated using the following formula: 
𝐷𝑒𝑙𝑡𝑎 𝐹 =
𝑅𝑎𝑡𝑖𝑜𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑅𝑎𝑡𝑖𝑜𝑛𝑒𝑔
𝑅𝑎𝑡𝑖𝑜𝑛𝑒𝑔
× 100 
The concentration of IP1 in sample wells was then interpolated from the 
sigmoidal IP1 standard curve and plotted as concentration of IP1 in nM against 
tested compound concentrations on a logarithmic scale. 
2.5.2 cAMP inhibition assay 
To measure Gi G protein-mediated inhibition of cyclic adenosine monophosphate 
(cAMP) production, the cAMP Dynamic 2 kit (Cisbio Bioassays) was employed, 
which uses an equivalent technology and approach to the IP-One Tb kit 
described in section 2.5.1, and was performed according to manufacturer’s 
instructions. Due to the similarity to the IP-One TB kit, significant differences in 
procedure are described briefly below. Doxycycline-inducible cells were 
prepared a day prior to the experiment as for the IP1 assay. Test compounds 
were diluted in HBSS with 500 nM IBMX (3-isobutyl-1-methylxanthine), which 
induces cAMP accumulation by inhibiting phosphodiesterase-mediated 
degradation, at 2 x final concentration and added to a white low-volume 384-
well plate at 5 µL/well. Additionally, a cAMP standard curve was also prepared 
with concentrations ranging from 0.17 to 712 nM and added to the plate at 
5 µL/well. Cells were counted in HBSS and diluted to a concentration of 
400,000 cells/mL in HBSS with 2 µM forskolin, which non-specifically activates 
adenylyl cyclase and thereby induces cAMP production. The cell suspension was 
then added to the plate at 5 µL/well, thereby reaching a final concentration of 
2,000 cells/well. For testing of agonists, cells were incubated with test 
compounds for 30 min at RT. As in the case of the IP1 assay, antagonists were 
pre-incubated with stimulated cells at 2.5 µL/well for 30 min at RT prior to 
addition of 2.5 µL agonist per well. Again, agonist and antagonist concentrations 
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were adjusted according to the increased dilution factor. The stimulation was 
terminated by addition of anti-cAMP antibody labelled with Eu3+ cryptate and 
synthetic cAMP conjugated to dye d2 in lysis buffer at 5 µL/well. The assay 
mechanism is equivalent to IP1 detection, with Eu3+ cryptate acting as the FRET 
donor and cAMP-d2 as the acceptor. Plates were incubated for 1 h at RT, 
followed by a fluorescence measurement at 620 (Eu3+ cryptate) and 665 nm (dye 
d2) using the PHERAstar FS plate reader. For data analysis the resulting FRET 
ratio was analysed in the same fashion as described for the IP1 assay to calculate 
the concentration of cAMP per well. As FFA2 is a Gi-coupled receptor and 
therefore has a negative effect on cAMP production, data was plotted as 
inhibition of the basal cAMP level as follows: 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) =
𝑐𝐴𝑀𝑃𝑏𝑎𝑠𝑎𝑙 − 𝑐𝐴𝑀𝑃𝑠𝑎𝑚𝑝𝑙𝑒
𝑐𝐴𝑀𝑃𝑏𝑎𝑠𝑎𝑙
× 100 
The inhibition of the basal cAMP level in percent was then plotted against test 
compound concentrations on a logarithmic scale for further data analysis. 
2.5.3 ERK phosphorylation assay 
To detect the phosphorylation of ERK1/2 a Phospho-ERK1/2 kit (Cisbio Bioassays) 
was used, which uses an equivalent approach to the IP-One Tb (see section 
2.5.1) and cAMP Dynamic 2 (see section 2.5.2) kits and was performed according 
to manufacturer’s instructions. Briefly, Flp-InTM T-RExTM cells were plated in 
culture vessels of appropriate size and treated with 100 ng/mL doxycycline for 
16-24 h to induce expression of the receptor of interest. Antagonist compounds 
were prepared in HBBS at 6 x final concentration and 2 µL were added to white 
low-volume 384-well plates according to the desired plate layout. Cells were 
counted in HBSS and diluted to a concentration of 1,875,000 cells/mL and 
8 µL/well were added to test compounds resulting in a concentration of 
15,000 cells/well. Cells were incubated with antagonist compounds for 1 h at 
37°C, followed by addition of 2 µL of a 6 x final concentration of agonist 
compounds and a further incubation for 30 min at 37°C. Cell lysis buffer was 
prepared by diluting the blocking reagent stock solution 25-fold with 4 x lysis 
buffer. To terminate the reaction, 4 µL of supplemented lysis buffer was added 
per well and the plate was incubated for 30 min at RT under shaking. A 1:1 
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solution of two anti-pERK (phosphorylated ERK) antibodies, one labelled with 
Eu3+ cryptate and the other conjugated to dye d2, was prepared in detection 
buffer and added at 4 µL/well to lysed cells. The antibodies bind to different 
epitopes of pERK and the donor Eu3+ cryptate triggers FRET towards the acceptor 
dye d2 when in close proximity, therefore the FRET signal increases with 
stimulation of ERK phosphorylation. Plates were incubated for 2 h at RT and then 
fluorescence at 620 (Eu3+ cryptate) and 665 nm (dye d2) and was quantified 
using a PHERAstar FS plate reader. For data analysis, the ratio of fluorescence at 
665 over 620 nm was calculated for sample wells and plotted against the 
logarithm of agonist compound concentrations. 
2.5.4 BRET-based β-arrestin recruitment assay 
The BRET-based β-arrestin recruitment assay measures the interaction of 
RLuc-tagged β-arrestin with a receptor fused with eYFP at its C terminus. In 
presence of its substrate, RLuc acts as a BRET donor by emitting light at a 
wavelength that is able to excite the BRET acceptor eYFP, if in close enough 
proximity. HEK293T cells were co-transfected in 10 cm dishes at a 4:1 ratio with 
plasmids encoding an eYFP-tagged receptor and RLuc-tagged β-arrestin 2, using 
PEI as a transfection reagent (see section 2.3.2). For data analysis the BRET 
donor luminescence in absence of its acceptor is required (RLuc only control), 
therefore one 10 cm dish was transfected with RLuc-tagged β-arrestin 2 and 
pcDNA3.1 instead of eYFP-tagged receptor. After incubating transfected cells for 
24 h, they were detached as described in section 2.3.1, resuspended in 20 mL 
media and added at 100 µL/well to white 96-well plates. Prior to addition of 
cells, the plates were coated with poly-D-lysine to facilitate cell attachment by 
preparing a 50 µg/mL solution of poly-D-lysine hydrobromide (Sigma-Aldrich) in 
cell culture medium from a 1 mg/mL stock solution, which was added at 
40 µL/well, and coated plates were incubated at RT for a minimum of 15 min. At 
48 h post-transfection, cells were washed and the culture medium was replaced 
with 70 or 80 µL HBSS depending on further additions to reach a final volume of 
100 µL, allowing cells to equilibrate for a minimum of 30 min at 37°C prior to 
conducting the assay. Test compounds were prepared in HBSS at 10 x final 
concentration and added to the plate at respective time points at 10 µL/well. To 
investigate agonist activation, test compounds were added for 5 min at 37°C 
prior to measurement. For assessment of the inhibitory ability of antagonists, 
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cells were pre-incubated with test compounds for 15 min at 37°C before 
addition of an EC80 concentration of agonist. To measure β-arrestin 2 
recruitment, 10 µL of the RLuc substrate coelenterazine h was added per well to 
a final concentration of 2.5 µM at a time point 15 min prior to measurement. 
The luminescence resulting from BRET between β-arrestin 2-RLuc and FFA2-eYFP 
was assessed by measuring luminescence at 535 (eYFP) and 475 nm (RLuc) using 
a PHERAstar FS plate reader. The BRET ratio was calculated by dividing 
luminescence at 535 nm by luminescence at 475 nm, subtracted by the BRET 
ratio of the RLuc only control and multiplied by 1000 to calculate mBRET values. 
For data analysis, mBRET values were plotted against test compound 
concentrations on a logarithmic scale. 
2.5.5 TGFα shedding assay 
For a standard TGFα shedding assay, a mixture of 250 ng alkaline phosphatase 
(AP)-tagged TGFα and 100 ng receptor of interest plasmids were transfected 
using PEI into one well of HEK293A cells cultured in a 12-well plate. Depending 
on the experimental aim, 50 ng of Gα plasmid was co-transfected with the AP-
TGFα and receptor plasmids. If a larger number of cells was required, quantities 
were increased according to surface of culture vessel. After 24 h incubation 
transfected cells were washed with PBS and detached by adding 200 µL 
0.05% trypsin-EDTA. The proteolytic cleavage was inhibited by addition of 300 µL 
culture medium and cell suspension was centrifuged at 190 x g for 5 min. The 
cell pellet was resuspended in 3.5 mL HBSS+H (HBSS with 5 mM HEPES at pH 7.4) 
and incubated for 15 min at RT to allow for equilibration of cells. After a second 
centrifugation at 190 x g for 5 min, pelleted cells were resuspended in 3.5 mL 
HBSS+H per well (for a 12-well plate). The cell suspensions were plated at 90 μL 
per well in a clear 96-well plate and incubated at 37°C with 5% CO2 for 30 
minutes. During the equilibration period test compounds were prepared at 10 x 
final concentration in HBSS with 0.01% (w/v) fatty acid-free BSA. To stimulate 
TGFα shedding, compounds were added to cells at 10 µL/well and incubated for 
1 h at 37 °C with 5% CO2. Plates were then centrifuged at 190 x g for 2 min and 
80 μL of supernatant was transferred into another clear 96-well plate using a 
multichannel pipette. To quantify the amount of AP-TGFα, a solution containing 
its substrate, p-nitrophenyl phosphate (10 mM p-NPP, 40 mM Tris-HCl (pH 9.5), 
40 mM NaCl and 10 mM MgCl2), was added at 80 μL per well into plates 
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containing only medium or cells. Absorbance at 405 nm of both plates was read 
before and after a 2 h incubation at 37°C using a VersaMax microplate reader 
(Molecular Devices) or a POLARstar Omega plate reader. 
The specific alkaline phosphatase activity was calculated by subtracting the 
absorbance measured at 0 h from the absorbance measured at the 2 h time point 
for conditioned medium and cell plates. To calculate the percentage of total 
AP-TGFα shed into the medium the following formula was employed, which also 
corrects for the different volumes in conditioned medium (CM) and cell (C) 
plates. 
𝑆ℎ𝑒𝑑𝑑𝑖𝑛𝑔𝐶𝑀 (%) =
𝐴𝑃𝐶𝑀
𝐴𝑃𝐶𝑀 + 𝐴𝑃𝐶
× 125 
The data was baseline-corrected by subtracting the basal level of shedding in 
vehicle-treated wells from shedding in compound-treated wells and plotted 
against test compound concentrations on a logarithmic scale. 
2.6 Structural studies 
2.6.1 Homology modelling 
All structural studies were performed by Dr Hansen within Professor Ulven’s 
laboratory group in the Department of Physics, Chemistry and Pharmacy at the 
University of Southern Denmark. The following sections aim to provide a short 
summary of the software and methodology employed to construct homology 
models discussed in this thesis to serve as a reference for future modelling 
efforts. 
The hFFA2 homology model was generated by using the crystal structure of the 
hFFA1 receptor (PDB ID: 4PHU) as a template (Srivastava et al., 2014). Manual 
alignment was performed with the SeaView software (Gouy et al., 2010). 
Initially, the T4 lysozyme fusion protein fused into ICL3 of hFFA1 for enhanced 
crystallisation potential was deleted. The final template was optimized using the 
Protein Preparation Wizard programme (Schrödinger, LLC) in which bond orders 
and partial charges were assigned, hydrogen atoms added, and water molecules 
deleted. Hydrogen bond assignment was generated at pH 7.0 using PROPKA 
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software (Olsson et al., 2011). Restrained minimization until heavy atoms 
converged to a root mean square deviation of 0.3 Å was executed using the 
OPLS-2005 force field (Banks et al., 2005). The homology models of hFFA2, 
mFFA2 and respective mutant receptors were constructed using the homology 
modelling module within the Prime software package (Schrödinger, LLC). Final 
models were subjected to restrained minimization using OPLS-2005 force field in 
Protein Preparation Wizard. 
2.6.2 Ligand docking 
One important function of homology models is the prediction of ligand binding 
modes to the respective receptors. Ligands were prepared for docking by using 
the OPLS-2005 force field in LigPrep (Schrödinger, LLC) and ionization states 
were predicted using Epik at pH 7.0 ± 2.0 (Schrödinger, LLC). Induced-fit docking 
was performed using the IFD 2006 protocol using Glide and Prime software 
(Schrödinger, LLC). Depending on the binding site under investigation, residues 
within 3 Å of each docked ligand were defined as potential interacting residues 
and were initially refined during ligand docking. In certain cases, selected 
residues of interest were not included in the refinement, based on crucial 
interactions observed in the hFFA1 template structure. During ligand 
conformational sampling and docking in Glide, default settings were employed 
and a maximum number of 20 poses per ligand were allowed. The protein-ligand 
complexes were ranked to determine the five models with lowest energy 
complexes, which were then re-docked in standard precision mode, and residue 
refinement was set within 5 Å of each ligand. 
2.7 Data analysis 
All data are presented as mean ± SEM of at least three independent experiments 
unless stated otherwise. For data and statistical analysis, the GraphPad Prism 
software package version 5.02 (GraphPad) was employed. Below, curve fitting 
and calculations for different experimental aims are outlined briefly and include 
models in GraphPad Prism software used for analysis. 
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2.7.1 Analysis of functional agonist and antagonist assays 
Agonist and antagonist response curves both follow sigmoidal functions and data 
are fit accordingly, which allows for calculation of the pharmacological 
parameters of respective ligands. In both cases the slope of the sigmoidal curve 
(Hill slope) was restricted to equal unity, which would be expected when a 
ligand binds to a receptor following the law of mass action. This constrain 
improves the quality of the fit in cases of modest data quality and restricted 
number of data points. In most cases, experiments were designed to test seven 
concentrations of test compounds and one vehicle control, which was plotted 
one log unit lower than the lowest concentration of test compound. 
For agonist ligands, the following formula was employed to fit such a three-
parameter sigmoidal curves by nonlinear regression analysis. It allows calculation 
of the bottom and top asymptotes of the curve with the top asymptote 
representing the maximal response Emax, a means of determining agonist 
efficacy. Most importantly, agonist potency in terms of EC50 can be determined 
from the logEC50, which corresponds to the agonist concentration required to 
induce a half-maximal response. As curves were generated from semi-
logarithmic plots and parametric tests were employed for statistical analysis, 
agonist potency was presented and analysed in terms of pEC50, the negative 
logarithm of the EC50, which is normally distributed. 
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 (𝑌) = 𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10𝐿𝑜𝑔𝐸𝐶50−[𝐿𝑖𝑔𝑎𝑛𝑑] (𝑋)
 
For antagonist ligands, an equivalent formula was employed to fit the inhibition 
curve to calculate IC50 values rather than EC50 values, which equals the 
concentration of antagonist required to reduce the agonist response by half. As 
in case of agonist ligands, data were presented and analysed in terms of pIC50. 
2.7.2 Global Gaddum/Schild analysis 
To investigate whether an antagonist ligand is competitive, and therefore likely 
orthosteric, or non-competitive, and hence likely allosteric, with orthosteric 
agonists, the effect of a constant concentration of antagonist on the agonist 
concentration response was investigated. By performing such an experiment with 
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at least three concentrations of antagonist, the Schild model can be applied to 
the resulting set of curves, if the antagonist behaves in a competitive manner 
(Colquhoun, 2007). The underlying pharmacological principles and possible 
interpretations will be discussed in more detail in chapter 3. The following set of 
formulas is employed by GraphPad Prism to fit a set of antagonist-treated 
agonist response curves. 
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 (𝑌) =
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10(
 
 
(𝐿𝑜𝑔(10𝐿𝑜𝑔𝐸𝐶50×(1+(
[𝐴𝑛𝑡𝑎𝑔𝑜𝑛𝑖𝑠𝑡]
10−1×𝑝𝐴2
)
𝑆𝑐ℎ𝑖𝑙𝑑 𝑠𝑙𝑜𝑝𝑒
)))−𝑋
)
 
 
×𝐻𝑖𝑙𝑙 𝑠𝑙𝑜𝑝𝑒
 
This model generates a global fit of the set of curves to provide top and bottom 
asymptote fits and calculate the EC50 of the agonist in absence of the antagonist. 
The Hill slope is commonly constrained to unity for reasons described in section 
2.7.1, while the Schild slope indicates how well the shift induced by the 
antagonist corresponds to the competitive inhibition model and would equal 
unity in a perfect case. The pA2 corresponds to the negative logarithm of the 
antagonist concentration required to induce a shift of the agonist response curve 
by a factor of 2 and provides a measure of antagonist affinity for the receptor if 
Hill and Schild slope are close to unity. 
2.7.3 Analysis of binding parameters 
Binding studies can provide important pharmacological parameters and allow the 
direct measurement of affinity for labelled and unlabelled ligands. In this thesis 
both radioligand (section 2.4.4) and fluorescent binding (section 2.4.5) studies 
have been employed and despite the different methodology underlying these 
approaches, the data analysis of binding parameters is identical, as the resulting 
data represents ligand binding to the receptor. 
The saturation binding assay assesses the specific binding of a labelled ligand 
(probe) at increasing ligand concentrations. The resulting curve follows a 
rectangular hyperbola, also known as the Michaelis-Menten equation, which was 
initially defined to measure the activity of an enzyme as a function of substrate 
concentration. In the context of radioligand binding, the maximum specific 
binding in terms of Bmax can be calculated and corresponds to receptor 
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expression in membranes if the specific binding is plotted in units such as 
fmol/mg. In the case of BRET binding assays, the Bmax is dependent on the 
nature of the BRET reaction such as the distance between donor and acceptor. 
Furthermore, the equilibrium binding constant Kd is calculated and corresponds 
to the concentration of ligand required to occupy half of all receptor sites, 
which serves as a measure of ligand affinity. The following equation is used to 
determine the described parameters. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (𝑌) =
𝐵𝑚𝑎𝑥 × [𝑃𝑟𝑜𝑏𝑒](𝑋)
𝐾𝑑 + [𝑃𝑟𝑜𝑏𝑒](𝑋)
 
The competition binding assay is an important tool for determining the affinity 
of unlabelled ligands. Essentially, the displacement curve of the radioligand by 
the unlabelled competing ligand is fit to an inverse sigmoidal curve in a similar 
fashion to antagonist inhibition curves from which an IC50 can be calculated. 
However, as the affinity and exact concentration of the displaced labelled ligand 
is known, a model can be applied which allows calculation of unlabelled ligand 
affinity in terms of Ki as described in the formulas below. It is important to 
consider that this value is only an accurate representation of unlabelled ligand 
affinity if the competing and labelled ligand are truly competitive. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (𝑌) = 𝐵𝑜𝑡𝑡𝑜𝑚 +
𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚
1 + 10
[𝐶𝑜𝑚𝑝𝑒𝑡𝑖𝑡𝑜𝑟](𝑋)−𝐿𝑜𝑔(10𝐿𝑜𝑔𝐾𝑖×
1+[𝑃𝑟𝑜𝑏𝑒]
𝐾𝑑
)
 
In kinetic binding assays labelled ligand association and dissociation curves fit a 
simple one phase exponential association or decay, respectively. However, to 
calculate the association rate Kon (M-1 min-1) and dissociation rate Koff (min-1) the 
curves need to be analysed with specific models. In the case of dissociation the 
model is relatively simple, as it can be calculated independently of labelled 
ligand concentration and affinity. The model requires the nonspecific (NS) 
binding, which will be constant throughout the experiment, and the rate 
constant K, which equals the ln of 2 (0.693) divided by the half-life. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (𝑌) = (𝑌0ℎ − 𝑁𝑆) × 𝑒
−𝐾×𝑇𝑖𝑚𝑒(𝑋) + 𝑁𝑆 
Chapter 2  78 
 
The association model is significantly more complicated, as it depends on the 
employed labelled ligand concentration (L), and the ligand Koff must be known. 
Once both dissociation and association constants have been determined, the Kd 
can be calculated by dividing the Koff by the Kon, which provides a further means 
of Kd determination in addition to saturation binding assays. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 (𝑌) =
𝐿
𝐿 + 𝐾𝑑
× 𝐵𝑚𝑎𝑥 × (1 − 𝑒
−1×(𝐾𝑜𝑛×𝐿+𝐾𝑜𝑓𝑓)×𝑇𝑖𝑚𝑒(𝑥)) 
To determine the kinetic parameters of unlabelled ligands by using the 
competitive kinetic binding assay (Dowling and Charlton, 2006), the Kon (K1) and 
Koff (K2) of the labelled ligand must be known as well as the concentration of 
labelled ligand (L) and unlabelled ligand (I). By employing the model outlined 
below the unlabelled ligand Kon (K3) and Koff (K4) can then be calculated. To 
allow for a better overview, the complete model (7) was broken down into 
separate equations (1-6), defining respective factors. 
(𝟏) 𝐾𝐴 = 𝐾1 × 𝐿 + 𝐾2 
(𝟐) 𝐾𝐵 = 𝐾3 × 𝐼 + 𝐾4 
(𝟑) 𝑆 = √((𝐾𝐴 − 𝐾𝐵)2+4×𝐾1×𝐾3×𝐿×𝐼 
(𝟒) 𝐾𝐹 = 0.5 × (𝐾𝐴 + 𝐾𝐵 + 𝑆) 
(𝟓) 𝐾𝑆 = 0.5 × (𝐾𝐴 + 𝐾𝐵 − 𝑆) 
(𝟔) 𝑄 =
𝐵𝑚𝑎𝑥 × 𝐾1 × 𝐿
𝐾𝐹 − 𝐾𝑆
 
(𝟕) 𝑌 = 𝑄 × (
𝐾4 × (𝐾𝐹 − 𝐾𝑆)
𝐾𝐹 × 𝐾𝑆
+
𝐾4 − 𝐾𝐹
𝐾𝐹
× 𝑒−𝐾𝐹×𝑋 −
𝐾4 − 𝐾𝑆
𝐾𝑆
× 𝑒−𝐾𝑆×𝑋) 
2.7.4 Calculation of signalling bias 
Studies described in chapter 6 focus on mutations of hFFA2 that appear to 
induce receptor signalling bias. To quantify this signalling bias the bias factor β 
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was calculated by determining the logarithm of the ratio of relative intrinsic 
activities for a ligand at two different assays (Rajagopal et al., 2011). This 
approach is relatively simple compared to the use of an operational model and 
requires only EC50 and Emax values of the ligands in two pathways to be compared 
at wild type and mutant receptors. The underlying reason for choosing such an 
equiactive comparison over equimolar comparison and the operational model 
will be discussed in section 6.2.5. Typically, such calculations assess signalling of 
a ligand of interest in comparison to a reference endogenous agonist, but in this 
case the response of the agonist at the wild type receptor serves as the 
reference to calculate the effect on the signalling bias induced by respective 
mutations using the following equation. 
𝛽 = Log ((
𝐸max (𝑃1)
𝐸𝐶50 (𝑃1)
𝐸𝐶50 (𝑃2)
𝐸max (𝑃2)
)
𝑊𝑇
× (
𝐸max (𝑃2)
𝐸𝐶50 (𝑃2)
𝐸𝐶50 (𝑃1)
𝐸max (𝑃1)
)
𝑀𝑢𝑡𝑎𝑛𝑡
) 
2.7.5 Statistical analysis 
Graphpad Prism software was employed to perform statistical analyses. As data 
were assumed to be normally distributed, pharmacological parameters of 
different ligands or altered forms of a receptor were compared using 
appropriate parametric tests: Two-tailed unpaired Student’s t test for two 
groups, or one-way analysis of variance (ANOVA) for three or more groups 
followed by a Tukey’s or Dunnett’s post-test, which gives more power to detect 
differences due to consideration of scatter among the analysed groups (McHugh, 
2011). Tukey’s post-test was used to compare all means to one another, while 
Dunnett’s post-test was employed to compare means to a reference mean, such 
as data generated at the wild type receptor. Analyses were performed on data 
with at least three biological replicates, representing independent experiments 
carried out on separate occasions with cells of different passage number, and a 
P value of <0.05 was considered statistically significant. However, due to the 
highlighted limitations of insufficient n numbers and P values (Lew, 2012), 
differences supported by P values above 0.01 were treated with caution and 
scientific conclusions were always drawn in conjunction with data generated by 
alternative means such as homology modelling or by demonstrating the same 
trends in different assay systems that represent the same signalling pathways. 
Furthermore, data were exclusively generated in recombinant cell line systems 
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and no studies using primary cells or animals were performed, which inherently 
display increased variability. Therefore, an n of 3 was deemed sufficient to 
allow statistical analysis and ensure reproducibility of generated data. 
81 
3 Exploring the structure-activity relationships of 
FFA2 agonists and antagonists 
3.1 Introduction 
As discussed in section 1.1.2, selection of an appropriate assay system to test 
ligands for potential therapeutic targets such as GPCRs is an important step in 
the drug discovery process and may play a role in target validation as well as in 
screening for hit and lead compounds. Radioligand binding assays are a popular 
choice, if there is a radioactive probe available for the receptor of interest, as 
these can be performed in a high-throughput, cell-free system with membranes 
isolated from, in the case of ligand screening, cells artificially overexpressing 
the receptor of interest (Bylund and Toews, 1993). While radioligand binding 
assays are invaluable tools for investigation of ligand binding pockets and 
screening for compounds binding to specific sites, they do not provide 
mechanistic information directly, for example whether a ligand is an agonist or 
antagonist. Therefore, functional assays that detect GPCR signalling are usually 
employed either in conjunction with radioligand binding studies or after 
identification of high-affinity ligands (Thomsen et al., 2005). For GPCRs that 
signal by coupling to only one G protein subtype, the selection of an appropriate 
functional screening system is relatively straightforward. Most G proteins affect 
production of specific secondary messengers in a positive or negative fashion, 
which can be detected using a range of approaches. Such platforms utilise 
second messenger-sensitive proteins such as aequorin, which detects Gq/11 
activation by producing bioluminescence in the presence of its substrate in 
response to calcium ions (Stables et al., 2000), or HTRF-based detection of 
downstream products of GPCR activation such as IP1 (Gq/11), cAMP (elevated by 
Gs and inhibited by Gi/o) or phosphorylated ERK1/2 (Norskov-Lauritsen et al., 
2014). Phosphorylation of ERK1/2 can occur in response to activation of multiple 
G protein subtypes, including Gs, Gi/o and Gq/11 (Leroy et al., 2007), and β-
arrestin-mediated signalling (Lefkowitz and Shenoy, 2005). The [35S]-GTPγS 
binding assay is a more direct means of measuring G protein recruitment, in 
particular of the Gi/o subfamily, due to its high rates of basal guanine nucleotide 
exchange (Milligan, 2003). GTPγS is a poorly-hydrolysable analogue of GTP and 
remains bound to the Gα protein after the release of GDP and binding of this 
analogue of GTP has been facilitated by an actively signalling GPCR. Labelling of 
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the GTPγS molecule with the radioactive isotope [35S] allows monitoring of its 
incorporation into G proteins by liquid scintillation spectrometry. Alternatively, 
to achieve a higher throughput and eliminate the filtration step necessary for 
[35S]-GTPγS binding assays, scintillation proximity assays can be performed, in 
which a primary anti-Gα antibody is employed that is captured by anti-IgG 
antibody-coated scintilliant-containing beads (DeLapp, 2004). 
Detection of an interaction between a GPCR and β-arrestin can serve as an 
alternative screening approach to the measurement of G protein-dependent 
signalling. Although β-arrestins play an increasingly important role in mediating 
G protein-independent signalling of a selection of GPCRs, the recruitment of 
β-arrestin itself is an essential component of GPCR desensitisation and the 
majority of GPCRs interact with β-arrestin 1 and/or 2 (DeWire et al., 2007). 
Therefore, β-arrestin recruitment conceptually represents a more universal 
pathway that can be of particular value when developing a screening system for 
poorly characterised receptors, where G protein coupling is not yet fully 
understood (Oakley et al., 2006, Southern et al., 2013). Methods to monitor the 
interaction of β-arrestins with GPCRs have developed significantly over the last 
decade and include proximity-based systems that utilise BRET methodology using 
a Renilla reniformis luciferase (RLuc)-tagged receptor serving as a BRET donor 
and a fluorescent protein-tagged β-arrestin as BRET acceptor (Kocan et al., 
2010). Another example of a commonly employed β-arrestin recruitment assay in 
the drug discovery industry is the PathHunterTM assay developed by DiscoverX 
(Zhao et al., 2008), which is based on an enzyme fragment complementation 
approach. A catalytically inactive N-terminal deletion mutant of the 
β-galactosidase enzyme is fused to β-arrestin and is complemented by a GPCR 
tagged with the respective deleted N-terminal β-galactosidase sequence. Both 
components of the β-galactosidase are brought into proximity by the GPCR-
β-arrestin interaction, thereby regenerating the enzyme and producing a 
chemiluminescent signal upon cleavage of a suitable substrate. 
Considering the variety of different assay systems available for screening of 
ligands at GPCRs, the selection of an appropriate assay for promiscuous 
receptors such as FFA2, which couples to multiple G proteins, can be 
challenging. FFA2 has been shown to couple to Gq/11, Gi/o and G12/13 Gα subtypes 
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(Brown et al., 2003) and recruitment of β-arrestin 2 in response to agonist 
treatment has also been demonstrated (Hudson et al., 2013a). However, due to 
the lack of availability of a labelled probe, the affinity of endogenous and 
synthetic FFA2 ligands remains to be determined. Understanding the structure-
activity relationship (SAR) of synthetic ligands can be an important step in drug 
development, as it provides information on how specific structural modifications 
in a molecule correlate with changes in pharmacological action. However, 
relying on functional potency data alone to define the SAR of compound series 
can be problematic and does not always yield conclusive data. An investigation 
of the SAR of the compound 1 FFA2 agonist series identified analogues which had 
diverse effects in Gi/o-coupled assays, with a selection of ligands showing 
agonism in [35S]-GTPγS binding assays, but inverse agonism in a yeast-based Gi/o 
coupling assay (Brown et al., 2015). As outlined in section 1.2.4, functional 
studies require additional considerations such as the level of receptor reserve in 
the respective systems employed and the extent of signal amplification 
underlying the measurement. 
This chapter aims to assess functional assay systems available for FFA2, including 
Gi/o-coupled [35S]-GTPγS binding and cAMP inhibition, Gq/11-coupled IP1 
accumulation and BRET-based β-arrestin 2 recruitment. To investigate how 
potency values correlate with binding affinity, a direct binding assay was 
developed based on a tritiated form of GLPG0974 recently obtained from a 
collaboration with AstraZeneca. The endogenous SCFA C3, the synthetic agonist 
compound 1 and the two synthetic antagonists CATPB and GLPG0974 served as 
reference ligands for initial characterisation of the respective assays (Figure 
3.1). Following this initial assessment, a detailed SAR analysis of compound 2 
(Figure 3.1), an FFA2 agonist recently used in an in vivo study in mice to 
investigate the role of FFA2 in gut health and obesity (Forbes et al., 2015), was 
performed and employed for a more extensive evaluation of functional versus 
binding assays for ligand screening at FFA2. In addition to the investigation of 
FFA2 agonists, the pharmacology of the antagonist GLPG0974 in comparison to 
CATPB was also explored in selected assay systems. From an SAR perspective, it 
is not clear whether the carboxylate moiety typical of orthosteric FFA2 agonist 
ligands (Figure 3.1) is also required for the action of FFA2 antagonist series. 
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Figure 3.1 FFA2 reference compounds Chemical structures are shown with the carboxyl moiety 
highlighted in red. C3 and compounds 1 and 2 act as agonists at FFA2, while CATPB and 
GLPG0974 are antagonists. 
 
Therefore, the effect of different modifications in this position on the functional 
inhibition of hFFA2 responses to agonists was investigated. The overarching 
purpose of the work described in this chapter is to provide an introductory 
overview of the complex pharmacology of FFA2 and its ligands and serve as a 
guide for future assay selection and development. 
3.2 Results 
3.2.1 Selection of assay systems to screen FFA2 ligands 
To expand the available repertoire of FFA2 ligand screening systems, a 
radioligand binding assay was developed using a tritiated form of GLPG0974. 
Kinetic binding studies in membranes isolated from Flp-InTM T-RExTM 293 cells 
induced to express hFFA2-eYFP were performed to determine the rate of 
association and dissociation of [3H]-GLPG0974, which is necessary to define the 
time required to reach equilibrium binding. To measure radioligand dissociation, 
10 µM of antagonist CATPB, which originates from a distinct chemical series of 
FFA2 antagonists, was added to membranes with 10 nM of pre-associated 
[3H]-GLPG0974. The presence of an excess of competing ligand prevents the 
rebinding of [3H]-GLPG0974 to the receptor and allows monitoring of its 
dissociation. The ability of CATPB to compete with [3H]-GLPG0974 to the same 
level as 10 µM of GLPG0974, which was used to determine levels of nonspecific 
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binding, suggests that these ligands bind to the same site and allows the use of 
CATPB as a competing ligand in dissociation studies (Hulme and Trevethick, 
2010). The determined Koff at 25°C was 0.014 ± 0.001 min-1, which corresponds 
to a half-time of 70 min (Figure 3.2A). The Kon value was then determined from 
an association experiment using the calculated Koff and was equal to 1,730,000 ± 
74,000 M-1 min-1 with a half-time of 40 min for association of 6 nM [3H]-GLPG0974 
(Figure 3.2B). Using the determined rate constants a first estimate of 
[3H]-GLPG0974 affinity could be obtained by division of the Koff by the Kon, 
yielding a predicted Kd of 8.1 ± 0.9 nM. An equilibrium binding assay was then 
performed in which increasing concentrations of [3H]-GLPG0974, which were 
selected based on the Kd derived from the kinetic studies, were incubated with 
membranes containing hFFA2-eYFP to obtain a saturation binding curve (Figure 
3.2C). To allow for full equilibration of radioligand binding, an incubation time 
of 2 h at 25°C was selected, based on the half-time of 6 nM [3H]-GLPG0974 
 
Figure 3.2 Characteristics of [3H]-GLPG0974 binding to wild type hFFA2 Binding of 
[3H]-GLPG0974 to membranes purified from Flp-InTM T-RExTM 293 cells induced to express hFFA2-
eYFP was assessed and data from representative experiments are illustrated. Dissociation (A) and 
association (B) of 6 nM [3H]-GLPG0974 is shown. To monitor [3H]-GLPG0974 dissociation 10 µM 
CATPB were added after 60 min pre-association of the radioligand. The ability of increasing 
concentrations of [3H]-GLPG0974 to bind to hFFA2 was assessed (C). The capacity of varying 
concentrations of C3, compound 1, CATPB and GLPG0974 to compete with 10 nM of [3H]-
GLPG0974 is shown (D). Nonspecific binding was determined in presence of 10 µM GLPG0974 
and subtracted from total binding to calculate specific binding.  
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association, and nonspecific binding was determined by addition of 10 µM 
CATPB. [3H]-GLPG0974 showed a good total to nonspecific binding ratio and the 
resulting specific binding curve fit a one-site, but not a two-site, binding model 
suggesting that [3H]-GLPG0974 binds to a single site on the receptor. The 
radioligand concentration that results in half-maximal occupation of the 
receptor corresponds to the Kd of [3H]-GLPG0974, which was equal to 7.5 ± 
0.4 nM and is hence in agreement with the value derived from the kinetic 
studies. In the context of ligand screening and drug discovery the most relevant 
radioligand-based assay is perhaps the displacement assay, in which the affinity 
of unlabelled ligands can be calculated based on their capacity to compete with 
the radioligand, so long as the unlabelled ligands and radioligand bind to the 
same site (Sweetnam et al., 1993). To assess whether [3H]-GLPG0974 is an 
appropriate radioligand for use in such an assay system, the ability of SCFA C3, 
synthetic agonist compound 1 and the synthetic antagonists CATPB and 
GLPG0974 to compete with the radioligand was determined (Figure 3.2D). All 
unlabelled ligands were able to fully outcompete [3H]-GLPG0974, suggesting that 
they bind to the same site as the radioligand. The SCFA C3 was included in the 
panel of tested ligands to serve as a probe for the endogenous orthosteric 
binding site and its ability to fully displace [3H]-GLPG0974 indicates that the 
radioligand, and the unlabelled ligands able to displace it, also bind in an 
orthosteric fashion. As expected from previous functional studies (Stoddart et 
al., 2008, Schmidt et al., 2011, Hudson et al., 2013a), C3 displayed relatively 
modest affinity with a calculated pKi of 2.96 ± 0.11 (= 1.10 mM), while 
compound 1 showed affinity approximately 9000-fold greater, with a pKi of 6.91 
± 0.12 (= 123 nM) (Table 3.1). The affinities of CATPB and GLPG0974 were 
essentially equivalent to each other with pKi values of 7.87 ± 0.08 and 7.88 ± 
0.08 (= 13 mM), respectively. In addition to providing information on the affinity 
of unlabelled ligands, radioligands can also be employed for more detailed 
investigations of ligand binding and [3H]-GLPG0974 will be used explore the 
binding site and kinetics of FFA2 agonists and antagonists in chapter 4. 
Prior to [3H]-GLPG0974 no labelled FFA2 ligand probes were available. As such, 
functional studies have played a key role in defining the pharmacology of FFA2 
ligands (Stoddart et al., 2008, Hudson et al., 2013a). A selection of different 
assay systems was used to assess FFA2 agonists, which reflect the promiscuity of  
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Table 3.1 Affinity and potency of hFFA2 reference ligands 
Assay 
Agonista Antagonistb 
C3 Compound 1 CATPB GLPG0974 
Binding 
(pKi) 
2.96 ± 0.11 6.81 ± 0.09 7.87 ± 0.08 7.88 ± 0.08 
[35S]-GTPγS 
binding (pE/IC50) 
3.95 ± 0.02$$$ 6.66 ± 0.09 6.60 ± 0.08$$$ 6.70 ± 0.10$$$ 
cAMP inhibition 
(pE/IC50) 
3.97 ± 0.06$$$ 6.66 ± 0.14 6.32 ± 0.13$$$ 6.27 ± 0.03**/$$$ 
IP1 accumulation 
(pE/IC50) 
4.16 ± 0.05*/$$$ 7.16 ± 0.07** 6.71 ± 0.11$$$ 6.94 ± 0.04$$$ 
β-arrestin 2 
(pE/IC50) 
3.35 ± 0.05***/$$$ 5.75 ± 0.07***/$$$ 6.65 ± 0.04$$$ 7.42 ± 0.07**/$$$ 
a Data shown as pKi and pEC50. 
b Data shown as pKi and pIC50. 
* Analysis of pE/IC50 values of one compound in different assays by one-way ANOVA followed by 
Tukey’s test with significant differences denoted as P = * ≤ 0.05 and P = *** ≤ 0.001 
$ Comparison of all pKi and pE/IC50 values of one compound by a one-way ANOVA followed by a 
Dunnett’s test with the pKi as a reference with significant differences denoted as P = $$$ ≤ 0.001. 
 
FFA2 signalling. The [35S]-GTPγS binding assay was performed in membranes 
isolated from Flp-InTM T-RExTM 293 cells, which were induced with doxycycline to 
express stably harboured hFFA2-eYFP. The reactions were set up in single glass 
tubes and bound [35S]-GTPγS was separated from unbound radioligand by 
filtration, therefore this assay system is relatively low-throughput compared to 
other assays employed. The cAMP inhibition and IP1 accumulation assays are 
based on detection of cAMP or IP1 levels by HTRF technology developed by 
Cisbio Bioassays. These assays were performed in 384-well plates and required 
only small amounts of reagents and doxycycline-induced cells, therefore they 
are more suitable for screening of larger numbers of compounds. Increasing 
concentrations of C3 and compound 1 were able to induce FFA2 signalling 
through Gi/o-coupled pathways, as reflected in increasing [35S]-GTPγS 
incorporation (Figure 3.3A) and cAMP inhibition (Figure 3.3B) upon agonist 
treatment. FFA2 is also able to couple to the Gq/11 family of G proteins and 
indeed C3 and compound 1 also promoted accumulation of IP1 in a 
concentration-dependent manner (Figure 3.3C). With an increasing body of 
evidence suggesting that β-arrestin also plays an important role in GPCR 
signalling (Daaka et al., 1998, Cahill et al., 2017), the ability of FFA2 to recruit 
β-arrestin 2 was assessed in a BRET-based system in which β-arrestin-2-RLuc, the 
BRET donor, and hFFA2-eYFP, the BRET acceptor, were transiently co-
transfected into cells, which were seeded in 96-well plates. Activation of 
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Figure 3.3 Assay systems for assessment of hFFA2 agonist signalling The potency of the 
endogenous SCFA C3 and the synthetic agonist compound 1 to activate hFFA2 in [35S]-GTPγS 
binding (A), cAMP inhibition (B), IP1 accumulation (C) and β-arrestin 2 recruitment assays (D) is 
shown. Assays employed membranes (A) or cells (B, C) with a Flp-InTM T-RExTM 293 background 
that stably harbour hFFA2-eYFP and were induced to express the receptor. For β-arrestin 2 
recruitment assays HEK293T cells were transiently co-transfected with hFFA2-eYFP and RLuc-
tagged β-arrestin 2 (D). Results were normalised to the maximal C3 response. All data are means 
pooled from independent experiments (n ≥ 3) that were performed in triplicate (A, B, D) or duplicate 
(C). 
 
hFFA2-eYFP by C3 and compound 1 led to a concentration-dependent increase in 
the BRET signal, indicating recruitment of RLuc-tagged β-arrestin-2 within close 
enough proximity of eYFP to produce BRET (Figure 3.3D). However, while this 
demonstrates that activation of FFA2 results in binding of β-arrestin to the 
receptor, this does not necessarily confirm that FFA2 does induce β-arrestin-
dependent signalling, as recruitment of β-arrestin is also a vital component of 
the GPCR downregulation cascade. As expected from the affinity of the 
respective ligands, compound 1 was consistently more potent than C3 (Table 
3.1). However, across this set of assays some variation in potency could be 
observed. The Gi/o-coupled [35S]-GTPγS binding and cAMP inhibition assays 
yielded almost identical potency values for both C3 and compound 1. In the 
Gq/11-coupled IP1 assay both agonists were more potent, while in the β-arrestin 2 
recruitment assay the lowest potency values were observed. In the case of C3 its 
Chapter 3  89 
 
potency in the β-arrestin 2 recruitment assay came closest to its determined 
affinity, while the measured affinity of compound 1 was more closely 
approximated by G protein-dependent signalling assays. 
The same set of assays were also employed to assess the action of antagonists at 
FFA2. Synthetic antagonists CATPB and GLPG0974 were both able to inhibit the 
response of FFA2 to C3 in [35S]-GTPγS binding, cAMP inhibition, IP1 accumulation 
and β-arrestin 2 recruitment assays in a concentration-dependent fashion 
(Figure 3.4). The concentration of C3 employed was selected to reflect the 
measured EC80 concentration in the respective assay system, which is an 
important consideration as the determined antagonist IC50, the half-maximal 
inhibitory concentration, will depend on the agonist concentration employed. 
 
Figure 3.4 Assay systems for assessment of hFFA2 antagonists The ability of the synthetic 
antagonists CATPB and GLPG0974 to inhibit the response of hFFA2 to indicated C3 
concentrations in [35S]-GTPγS binding (A), cAMP inhibition (B), IP1 accumulation (C) and 
β-arrestin 2 recruitment (D) assays is shown. Assays employed membranes (A) or cells (B, C) with 
a Flp-InTM T-RExTM 293 background that stably harbour hFFA2-eYFP and were induced to express 
the receptor. For β-arrestin 2 recruitment assays, HEK293T cells were transiently co-transfected 
with hFFA2-eYFP and RLuc-tagged β-arrestin 2 (D). Results were normalised with vehicle-treated 
cells set to 0% and response to indicated C3 concentrations set to 100%. All data are means 
pooled from independent experiments (n ≥ 3) that were performed in triplicate (A, B, D) or duplicate 
(C). 
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Some antagonists can act as inverse agonists, which is reflected in an inhibition 
of the basal signalling of the receptor. This appeared to be the case for CATPB in 
the Gi/o-coupled [35S]-GTPγS binding and cAMP inhibition assay (Figures 3.4A 
and B), but not for Gq/11-coupled IP1 accumulation or β-arrestin 2 recruitment 
assays (Figures 3.4C and D). In contrast, inverse agonism of GLPG0974 was only 
observed in the cAMP inhibition and not the [35S]-GTPγS binding assay (Figures 
3.4A and B). When comparing functional IC50 values of antagonists with their 
affinities, the IC50 values were consistently lower than affinity values with at 
least a 10-fold difference (Table 3.1). Furthermore, although CATPB and 
GLPG0974 have essentially equivalent affinity for FFA2, their IC50 values in the 
β-arrestin 2 recruitment assay were almost 6-fold different. 
3.2.2 Screening of a structurally unexplored FFA2 agonist series 
Compound 1 has played an important role in understanding the SAR of FFA2 
agonists (Hudson et al., 2013a), but it has not been employed in any published in 
vivo studies to investigate the physiological role of FFA2, potentially due to its 
reduced potency at mFFA2 and potential concerns regarding the chemical 
stability of the compound. Consequently, there is still need for exploration of 
alternative FFA2-specific agonist series. A recent investigation of the role of 
FFA2 in obesity and diabetes employed a different synthetic FFA2 agonist, here 
referred to as compound 2, in vivo to demonstrate that FFA2 activation induced 
PYY-dependent reduction in gut motility and food intake (Forbes et al., 2015). 
However, this study focussed on a physiological aspect of FFA2 activation and 
did not explore any structural analogues of compound 2. To investigate the SAR 
of this ligand series with the aim to identify compounds with improved potency, 
a range of different analogues with structural modifications in different areas of 
the molecule were tested. The investigation of reference ligands for FFA2 in 
functional assays revealed that agonists tend to show variations in potency in 
different assay systems. Furthermore, screening compounds in multiple assay 
systems allows detection of potential bias in ligand-induced signalling. 
Therefore, the analogues were tested in two different assays to reflect both 
G protein and β-arrestin coupling. Initial replacement of the central pyrroline 
with a thiazolidine and modifications at the eastern part of the molecule did not 
result in improved potencies in the β-arrestin 2 recruitment or cAMP inhibition 
assays (Table 3.2). However, replacement of the northern anisole group of the  
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Table 3.2 Screening of compound 2 analogues with eastern part variations 
 
Compound 
Structure Potency/pEC50 (Efficacy/Emax)a 
CLogPb 
X R β-arrestin 2 recruitment cAMP inhibition 
2 CH2 
 
5.91 ± 0.21 (127) 6.28 ± 0.19 (96) 5.13 
2-1 S 
 
5.60 ± 0.10 (116) 5.61 ± 0.06 (96) 5.13 
2-2 S 
 
4.91 ± 0.29 (93) 5.15 ± 0.19 (106) 5.13 
2-3 S 
 
4.73 ± 0.29 (136) 5.55 ± 0.19 (80) 5.13 
2-4 S 
 
5.65 ± 0.18 (108) 5.45 ± 0.11 (90) 5.28 
2-5 S 
 
5.53 ± 0.16 (116) 6.03 ± 0.15 (88) 4.42 
2-6 S 
 
4.83 ± 0.09 (124) 5.87 ± 0.10 (75) 2.92 
2-7 S 
 
4.74 ± 0.38 (68) 5.66 ± 0.19 (70) 3.60 
2-8 S 
 
< 4 < 4 4.56 
2-9 O 
 
< 4 < 4 4.18 
a Emax values were normalised as percentage of C3 response 
b ClogP values were calculated using ChemBioDraw 
 
thiazolidine-based compound 2-1 with a 3,5-dimethyl-2,3-dihydro-1,2-oxazole 
moiety produced compound 2-23, which showed greatly improved potency in the 
cAMP inhibition assay with an almost 10-fold increase and a more modest 1.5-
fold improvement in the β-arrestin 2 recruitment assay (Table 3.3). The ClogP 
value, which is a computationally determined measure of compound 
hydrophilicity calculated from the logarithm of the ratio of predicted compound 
partition coefficients in octanol and water, was also reduced from 5.13 for 
compound 2 to 3.73 for compound 2-23, suggesting a potentially improved 
pharmacokinetic profile for compound 2-23. Interestingly, a switch of the  
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Table 3.3 Screening of compound 2 analogues with northern part variations 
 
Compound 
Structure Potency/pEC50 (Efficacy/Emax)b 
CLogPc 
ArSa R β-arrestin 2 recruitment cAMP inhibition 
 2-10 (4) 
 
< 4 < 4 3.82 
2-11 (4) 
 
5.09 ± 0.05 (146) 5.00 ± 0.20 (93) 5.71 
2-12 (3) 
 
4.59 ± 0.13 (141) 5.40 ± 0.04 (91) 5.71 
2-13 (4) 
 
5.32 ± 0.23 (122) 5.04 ± 0.18 (82) 5.74 
2-14 (4) 
 
4.66 ± 0.16 (174) 5.35 ± 0.15 (87) 5.69 
2-15 (4) 
 
6.09 ± 0.04 (103) 5.68 ± 0.07 (90) 5.21 
2-16 (4) 
 
5.89 ± 0.08 (95) 5.89 ± 0.13 (95) 5.18 
2-17 (4) 
 
5.14 ± 0.24 (143) 6.04 ± 0.16 (74) 6.19 
2-18 (4) 
 
5.36 ± 0.12 (146) 5.40 ± 0.19 (82) 5.91 
2-19 (4) 
 
5.04 ± 0.17 (212) 5.32 ± 0.15 (89) 6.09 
2-20 (4) 
 
5.22 ± 0.12 (130) 5.68 ± 0.09 (83) 6.46 
2-21 (4) 
 
4.80 ± 0.35 (99) 5.65 ± 0.09 (89) 6.38 
2-22 (4) 
 
6.01 ± 0.04 (103) 6.67 ± 0.12 (77) 4.10 
2-23 (4) 
 
6.10 ± 0.07 (99) 7.11 ± 0.08 (86) 3.73 
a Aromatic substitution at meta (3) or para (4) position 
b Emax values were normalised as percentage of C3 response 
c ClogP values were calculated using ChemBioDraw 
N
O
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thiazolidine core back to a pyrroline in compound 2-24, which is the basis of 
increased potency of compound 2 compared to compound 2-1 (Table 3.2 did 
not result in an improvement in potency and other modifications of the eastern 
region of the molecule also failed to produce a more potent agonist than 
compound 2-23 (Table 3.4). Concentration response curves of a selected set of 
these compounds in the β-arrestin 2 recruitment and cAMP inhibition assays are 
shown in figure 3.5. 
The radioligand competition assay described in section 3.2.1 was then employed 
to determine the affinity of a set of compound 2 analogues, which were selected 
to reflect different types of structural modifications. Compounds 2 and 2-1 
represent the “parent ligands” with pyrroline (2) and thiazolidine (2-1) cores. 
Compounds 2-5 and 2-11 both have thiazolidine cores and a nonpolar benzene 
group in the eastern (2-5) and northern (2-11) part. Thiazolidine-based 
compound 2-23 showed the highest potency across both functional assays, while 
compound 2-24 is the pyrroline core equivalent to compound 2-23. All ligands  
Table 3.4 Screening of compound 2 analogues with isoxazole and eastern part variations 
 
Compound 
Structure Potency/pEC50 (Efficacy/Emax)a 
CLogPb 
X R β-arrestin 2 recruitment cAMP inhibition 
2-24 CH2 
 
5.97 ± 0.08 (90) 6.82 ± 0.07 (85) 3.73 
2-25 S 
 
5.64 ± 0.04 (79) 5.84 ± 0.08 (94) 3.02 
2-26 S 
 
5.99 ± 0.21 (73) 5.46 ± 0.12 (49) 3.29 
2-27 S 
 
5.09 ± 0.11 (79) 5.78 ± 0.04 (83) 2.94 
2-28 S 
 
4.45 ± 0.04 (102) < 4 1.52 
a Emax values were normalised as percentage of C3 response 
b ClogP values were calculated using ChemBioDraw 
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Figure 3.5 Assessment of an hFFA2 agonist series based on compound 2 in functional 
assays The capacity of compound 2 (A) and a selection of analogues (B-F) to activate hFFA2 in 
β-arrestin 2 recruitment and cAMP inhibition assays is shown. To measure cAMP inhibition, 
Flp-InTM T-RExTM 293 cell were induced to express hFFA2-eYFP, while for β-arrestin 2 recruitment 
assays HEK293T cells were transiently co-transfected with hFFA2-eYFP and RLuc-tagged β-
arrestin 2. All data are means pooled from independent experiments (n ≥ 3) that were performed in 
triplicate. RLuc = Renilla luciferase. 
 
were all able to fully displace [3H]-GLPG0974 (Figure 3.6), suggesting an 
orthosteric mode of binding akin to C3 and compound 1. The increased potency 
of compound 2-23 was reflected in a 2.3-fold increase in affinity over “parent” 
compound 2 (Table 3.5). 
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Figure 3.6 Screening of an hFFA2 agonist series based on compound 2 in competition 
binding assays The capacity of compound 2 (A) and a selection of analogues (B-F) to compete 
with [3H]-GLPG0974 for binding to membranes purified from Flp-InTM T-RExTM 293 cells induced to 
express hFFA2-eYFP is shown from representative experiments. To calculate specific binding, 
nonspecific binding was determined in the presence of 10 µM CATPB and subtracted from total 
binding. 
 
Table 3.5 Affinity of compound 2 and representative analogues for hFFA2 
Compound Binding (pKi) 
2 6.32 ± 0.02 
2-1 6.47 ± 0.06 
2-5 5.92 ± 0.08 
2-11 6.01 ± 0.02 
2-23 6.69 ± 0.03 
2-24 6.40 ± 0.06 
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To assess how the potency values between the two assays correlate and compare 
to affinity determined in binding assays, pEC50 and pKi values were shown as 
correlation plots with the r value indicating the correlation coefficient (Figure 
3.7). When considering only the selected set of compounds, the pEC50 values in 
the cAMP inhibition and β-arrestin 2 recruitment assays correlated well with a 
slope steeper than 1 (Figure 3.7A). This suggests that although a corresponding 
increase in potency can be observed in both assays, the spread of values differs.  
 
Figure 3.7 Correlation between hFFA2 agonist potencies and affinities Potency values in 
terms of pEC50 of compound 2 and its analogues in cAMP inhibition and β-arrestin 2 recruitment 
assays are plotted (A). Selected compound numbers are show in full circles and additional 
analogues screened are shown in open circles. Affinity values in terms of pKi calculated from 
[3H]-GLPG0974 competition binding assays are plotted against potency of agonists in β-arrestin 2 
recruitment (B) and cAMP inhibition assays (C). All data are means pooled from independent 
experiments (n ≥ 3) that were performed in triplicate (cAMP inhibition and β-arrestin 2 recruitment 
assays) or duplicate (radioligand displacement assay). Linear regression and correlation coefficient 
r for correlation of potencies and/or affinities of selected compounds (black line) or all analogues 
(broken line) is shown. 
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However, inclusion of the datasets for all analogues yields a comparatively poor 
correlation, perhaps due to the large error of some of the pEC50 values. The 
linear regression of binding affinity and potency in the β-arrestin 2 recruitment 
(Figure 3.7B) or cAMP inhibition assay (Figure 3.7C) yielded respective r values 
of 0.77 and 0.65, which suggested a clear positive correlation. In the case of the 
cAMP inhibition assay the slope of the linear regression is considerably steeper 
compared to the β-arrestin 2 recruitment assay, therefore relative compound 
affinities were more closely approximated by ligand potencies in the β-arrestin 2 
recruitment assay. Overall, it appears that a ligand such as compound 2-23, 
which clearly shows improved potency over the parent compound in two 
different assay systems, is likely to show higher affinity for the receptor. 
However, minor changes in potency between analogues did not necessarily seem 
to correlate between different functional assays and did not always translate 
into equivalent changes in affinity. 
Model animals play an important role at multiple stages of the drug development 
pipeline and can be employed in target validation and lead compound 
optimisation, with rodents being the most commonly used species. To assess 
whether the compound 2 series contains agonists that could be of use in murine 
models of disease, compound 2 analogues were tested at mFFA2 in the cAMP 
inhibition assay. In the case of most ligands, the potency at mFFA2 versus hFFA2 
was not significantly different (Table 3.6). However, selected compounds were 
notably selective for the murine versus the human orthologue and vice versa. 
Compound 2-1 displayed the highest potency at mFFA2 and was selective for the 
murine orthologue. The analogues 2-11, 2-13 and 2-18 also showed significant 
selectivity for the mFFA2, while compounds 2-5, 2-22 and 2-23 had a higher 
potency at hFFA2. Structurally, it appears that the polar modifications of the 
northern region that resulted in an improved potency of compounds 2-22 and 
2-23 at hFFA2, did not correlate with potency values at mFFA2 and indicate 
potential species-specific differences in the SAR of this compound series. 
Although compound 2-23 did not show the highest potency at mFFA2, it was still 
relatively potent and its improved hydrophilicity may suggest a potential 
improvement over compound 2 for use in vivo. 
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Table 3.6 Comparing potency of compound 2 analogues at human and murine FFA2 
Compound 
cAMP inhibition at 
mFFA2 (pEC50) 
Selecta 
2 6.40 ± 0.16 -0.12 
2-1 6.92 ± 0.09 -1.31*** 
2-2 5.64 ± 0.22 -0.49 
2-3 5.63 ± 0.23 -0.08 
2-4 6.24 ± 0.36 -0.79 
2-5 5.13 ± 0.17 0.9* 
2-6 5.51 ± 0.07 0.36* 
2-7 5.35 ± 0.29 0.31 
2-11 5.96 ± 0.09 -0.96* 
2-13 5.95 ± 0.16 -0.91* 
2-14 5.79 ± 0.10 -0.44 
2-15 5.87 ± 0.08 -0.19 
2-16 5.80 ± 0.05 0.09 
2-17 6.50 ± 0.06 -0.46 
2-18 6.32 ± 0.21 -0.92* 
2-19 5.44 ± 0.07 -0.12 
2-20 5.59 ± 0.11 0.09 
2-21 5.67 ± 0.11 -0.02 
2-22 5.89 ± 0.15 0.78* 
2-23 6.44 ± 0.13 0.67* 
a Selectivity represents comparison between species and was calculated by subtracting mFFA2 
EC50 values from hFFA2 EC50 values 
* Comparison of pEC50 values of one compound at murine versus human FFA2 by unpaired t test 
with significant differences denoted as P = * ≤ 0.05 and P = *** ≤ 0.001 
 
3.2.3 Comparing the pharmacology of FFA2 antagonists 
GLPG0974 and CATPB 
The antagonist GLPG0974 is, to date, the only FFA2 compound to reach clinical 
development after preclinical studies in human blood demonstrated its ability to 
inhibit neutrophil migration through blockade of FFA2 (Pizzonero et al., 2014). 
Although GLPG0974 did not show significant efficacy in clinical trials in 
ulcerative colitis patients (Vermeire et al., 2015), it could still be of use as a 
tool compound for investigation of FFA2 function. Many questions remain 
regarding the physiological role of FFA2 (see section 1.4.2), which will likely 
have to be resolved prior to further clinical studies. Understanding the 
pharmacology and mode of action of GLPG0974 can contribute to facilitating its 
use as a tool compound. Therefore, its pharmacological behaviour in regard to 
the SCFA C3 and compound 1 was assessed and compared to CATPB (Figure 3.8). 
Surprisingly, increasing concentrations of C3 were unable to overcome the 
efficacy-reducing effect of increasing GLPG0974 concentrations in the β-arrestin 
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2 recruitment assay (Figure 3.8A), which was not the case for CATPB (Figure 
3.8B). Conceptually insurmountable antagonism indicates a non-competitive 
relationship between agonist and antagonist, but in the case of GLPG0974 this 
would be surprising, as C3 is able to fully compete with the radioligand 
[3H]-GLPG0974 for binding to hFFA2 (Figure 3.2D). Indeed, in an equivalent 
experiment with compound 1 as an agonist ligand, the inhibitory effect of 
GLPG0974 was surmountable (Figure 3.8C) and mirrored the pattern of curves 
observed for CATPB (Figure 3.8D). 
 
Figure 3.8 Effect of hFFA2 antagonists on agonist responses in a β-arrestin 2 recruitment 
assay The capacity of increasing concentrations of C3 (A, B) or compound 1 (C, D) to promote 
recruitment of β-arrestin 2 and how this was altered by the co-addition of the indicated 
concentrations of either GLPG0974 (A, C) or CATPB (B, D) is shown. To measure the interaction 
between receptor and β-arrestin 2, HEK293T cells were transiently co-transfected with hFFA2-
eYFP and RLuc-tagged β-arrestin 2. All data are means pooled from independent experiments 
(n ≥ 3) that were performed in triplicate and are fit using a three-parameter sigmoidal curve (A) or 
global Gaddum/Schild model (B-D). 
 
The insurmountable effect of GLPG0974 on the C3 concentration response in the 
β-arrestin 2 recruitment assay was unexpected and was not observed with the 
synthetic orthosteric agonist compound 1. To confirm whether the same result 
would also be observed in a different assay, the ERK1/2 phosphorylation assay 
was employed as an alternative. Here, C3 and compound 1 had significantly 
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higher potencies than in the β-arrestin 2 recruitment assay with pEC50 values of 
4.83 ± 0.11 and 7.59 ± 0.01, respectively, making it possible to detect a further 
rightward shift of the concentration response curve with increasing antagonist 
concentrations. In this assay system increasing concentrations of C3 were able to 
overcome the inhibitory effect of GLPG0974 (Figure 3.9A), as anticipated for 
competitive antagonism. Fitting of the corresponding Schild plot resulted in a 
linear regression with a slope of 0.98, which is very close to unity and therefore 
a further indication of a competitive relationship between agonist and 
antagonist (Figure 3.9B). Furthermore, the negative x-intercept provides an 
estimation of antagonist affinity in terms of a pA2, which in this case was 8.14 (= 
7.2 nM). These observations were mirrored by an equivalent experiment 
performed with compound 1 showing clearly surmountable effects of GLPG0974  
 
Figure 3.9 Effect of hFFA2 antagonists on agonist response in an ERK1/2 phosphorylation 
assay The ability of increasing concentrations of C3 (A) or compound 1 (C) to induce ERK1/2 
phosphorylation and how this was altered by the co-addition of GLPG0974 is shown. Experiments 
employed Flp-InTM T-RExTM 293 cells induced to express hFFA2-eYFP. All data are means pooled 
from independent experiments (n ≥ 3) that were performed in triplicate and are fit using a global 
Gaddum/Schild model. The Schild plots for GLPG0974 versus C3 (B) and compound 1 (D) are 
shown. The dose ratio (DR) equals A’/A with A representing the agonist EC50 without antagonist 
and A’ the agonist EC50 with antagonist. Values were calculated for each agonist concentration 
response with antagonist present and plotted against the logarithm of antagonist concentration. 
The slope and X-intercept were determined by linear regression. 
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(Figure 3.9C) and a Schild slope of 1.09 with an estimated pA2 of 8.0 (= 10 nM) 
(Figure 3.9D). These pA2 values match very well with the affinity determined in 
the [3H]-GLPG0974 binding assay (Kd = 7.5 ± 0.4 nM), which is a further 
indication of competitive antagonism. 
3.2.4 Effect of carboxylate moiety modifications on FFA2 
antagonists 
Almost all available orthosteric FFA2 ligands contain a carboxylate moiety, 
which is thought to be important for the orthosteric interaction of the SCFA 
carboxylate with a pair of arginines, Arg1805.39 and Arg2557.35, within the core 
orthosteric binding pocket (Stoddart et al., 2008, Hudson et al., 2013a). 
However, the recently published BTI-A series of FFA2 antagonists behave as 
orthosteric ligands despite the lack of a carboxylate group (Park et al., 2016). To 
explore the importance of this structural feature for binding and function of the 
GLPG0974 and CATPB series, the carboxylate moiety of two GLPG0974 
analogues, GLPG-1 and GLPG-2, and of CATPB was replaced with a methyl ester 
(Me) (Table 3.7). In the case of GLPG-2 a further analogue was generated with a  
Table 3.7 Impact of carboxylate moiety modifications on hFFA2 antagonist function 
 
 
GLPG-1a 
 
GLPG-2a 
 
CATPBa 
 
Carboxyl 
6.98 ± 0.03 7.31 ± 0.01 6.65 ± 0.04 
 
Methyl ester (Me) 
5.87 ± 0.08*** 6.08 ± 0.07*** 5.70 ± 0.11*** 
 
Morpholine (Mo) 
 6.23 ± 0.06***  
a Data shown as pIC50 values determined in β-arrestin 2 recruitment assays in presence of an 
approximate EC80 concentration of C3 
* Statistical significance was determined by unpaired t test comparing analogue pIC50 to 
carboxylate pIC50 is denoted as P = *** ≤ 0.001 
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morpholine (Mo) in place of the carboxylate, which features a heterocycle and is 
therefore significantly bulkier than the carboxylate moiety. All methyl ester 
analogues retained the ability to inhibit the C3-induced responses of hFFA2 in a 
concentration-dependent fashion (Figure 3.10), however, with an approximately 
10-fold reduction in pIC50 (Table 3.7). Interestingly, replacement of the 
carboxylate moiety with a morpholine instead of a methyl ester had a similar 
effect (Figure 3.10B) and the pIC50 value of MoGLPG-2 was slightly higher than 
that of MeGLPG-2 (Table 3.7). 
 
Figure 3.10 Importance of carboxylate moiety for hFFA2 antagonist action The capacity of the 
synthetic antagonists GLPG-1 and MeGLPG-1 (A); GLPG-2, MeGLPG-2 and MoGLPG-2 (B); and 
CATPB and MeCATPB (C) to inhibit the response of hFFA2 to C3 in β-arrestin 2 recruitment 
assays is shown. HEK293T cells were transiently co-transfected with hFFA2-eYFP and RLuc-
tagged β-arrestin 2. All data are means pooled from independent experiments (n ≥ 3) that were 
performed in triplicate. Dashed lines indicate that data was shown previously, in this case in figure 
3.4D. Me = methyl ester; Mo = morpholine. 
 
3.3 Discussion 
3.3.1 Use of multiple screening assays is important for 
promiscuous receptors 
The important role of GPCRs in therapeutic development as the largest family of 
drug targets in the human genome (see section 1.1.3) has certainly contributed 
Chapter 3  103 
 
to motivating scientific advances in assay systems that can be employed to 
investigate GPCR signalling and to test compound series. Depending on the aim 
different priorities apply to selection of an assay format (Hughes et al., 2011), 
however likely the most important properties are reproducibility, resulting data 
quality and translational relevance in the context of the disease to be treated, if 
known. For GPCRs that couple to multiple signalling pathways it can be 
particularly important to assess ligands in several assays, however it is not 
always feasible or necessary to perform screening across all available formats. 
As FFA2 is able to couple to multiple G proteins and recruits β-arrestin 2 in 
response to agonists (Stoddart et al., 2008, Hudson et al., 2013a, Brown et al., 
2003), a selection of relevant assays were employed to assess available 
reference ligands: Radioligand competition to measure affinity; and Gi/o-coupled 
[35S]-GTPγS binding and cAMP inhibition, Gq-coupled IP1 accumulation and 
β-arrestin 2 recruitment assays to detect functional responses. [35S]-GTPγS 
binding and cAMP inhibition resulted in equivalent potencies for both C3 and 
compound 1 in these assays, which is in agreement with the ability of both 
assays to detect activation of Gi/o G proteins. This perhaps appears unexpected 
as [35S]-GTPγS assays detect an early event after GPCR activation and were 
therefore thought to be less subject to amplification, which is certainly the case 
for inhibition of cAMP (Zhang and Xie, 2012). However, it has been demonstrated 
that a GPCR is capable of activating more than a single copy of a G protein, 
depending on the respective receptor and G protein subtype (Ross, 2014). 
Therefore, measurement of [35S]-GTPγS incorporation may also be subject to 
amplification. It also appears to be a suitable assay for measurement of 
inhibition of agonist responses by antagonists and in the case of FFA2 it also 
allows detection of inverse agonists. The cAMP inhibition assay measures the 
inhibition of adenylyl cyclase by Gi/o G proteins. Detection of Gs-dependent cAMP 
production is relatively straightforward, but to measure cAMP inhibition it first 
needs to be stimulated, commonly by treatment with forskolin that activates 
adenylyl cyclase (Zhang and Xie, 2012). This does not appear to be an issue for 
assessment of FFA2 agonists, as measured potencies mirrored values in the 
[35S]-GTPγS binding assay, making the cAMP inhibition assay a good alternative 
measure of Gi/o activation that does not require use of radioactivity or a 
filtration step. However, the requirement for pre-stimulation with forskolin 
makes detection of antagonist action more problematic, as it involves the 
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reversal of the inhibition of an artificially stimulated signal. The extreme inverse 
agonism produced by FFA2 antagonists, and the corresponding reduced pIC50 
values compared to the [35S]-GTPγS binding assay, is hence more likely to be an 
assay artifact rather than true pharmacological behaviour, therefore a different 
assay format for assessment of FFA2 antagonists is recommended. 
The IP1 accumulation assay detects the level of inositol monophosphates, which 
reflects degradation of inositol 1,4,5-trisphosphate (IP3) produced by Gq/11-
dependent hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) into IP3 and 
diacylglycerol by phospholipase C (Berridge, 1993). FFA2 agonists showed the 
highest potency in this assay, most likely due to the high level of amplification 
from GPCR activation (Bergsdorf et al., 2008), and it also appears to be an 
appropriate assay for detection of antagonist inhibition. Due to the relatively 
slow binding kinetics of GLPG0974, the IP1 assay is preferable to a Ca2+ release 
assay, which is a more rapid and transient Gq/11-dependent response that allows 
little time for ligand binding equilibration (Zhang and Xie, 2012). Finally, the 
BRET-based β-arrestin 2 recruitment assay measures a G protein-independent 
result of GPCR activation. Each GPCR can only bind one β-arrestin adapter 
protein (Lohse and Hoffmann, 2014), therefore the potency of agonists in a 
β-arrestin recruitment assay should conceptually be a close estimate of their 
affinity. This was indeed the case for C3, with its potency in the β-arrestin 2 
recruitment assay coming closest to its measured affinity. In contrast, compound 
1 showed a significantly lower potency in the β-arrestin 2 recruitment assay 
compared to its affinity. This divergence could perhaps be explained by 
differences in binding kinetics of compound 1 versus C3. SCFAs are small 
compounds and will likely bind the receptor with a diffusion-limited rate. In 
contrast, compound 1 will undoubtedly interact with additional residues within 
the binding pocket, resulting in an increased affinity over C3, but it is likely to 
require more time to fully associate with the receptor. However, more detailed 
studies would be necessary to investigate this hypothesis. For antagonists the 
pIC50 does not serve as an estimate of affinity, as it is dependent on the 
concentration of agonist, and other experimental approaches are usually 
employed to obtain an estimate of affinity in terms of pA2 from functional 
assays, as will be discussed in the following section (Lazareno and Birdsall, 
1993). The pIC50 values of CATPB were not significantly different across the assay 
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systems employed, in contrast GLPG0974 showed more variation. While the low 
pIC50 in the cAMP inhibition assay is likely due to the observed artificial inverse 
agonism, the significantly higher value in the β-arrestin 2 recruitment assay is 
more difficult to explain. However, it may relate to observations that will be 
discussed in the next section. 
Based on the knowledge gained from the screening of reference agonists in 
selected assay systems, the cAMP inhibition and β-arrestin 2 recruitment assays 
were selected to screen a series of ligands based on compound 2, which has 
recently been employed in an in vivo study in mice (Forbes et al., 2015). 
Thereby, the capacity of the tested compounds to activate pathways dependent 
and independent of G protein signalling were assessed. Various modifications of 
different regions of the molecule resulted in the synthesis of compound 2-23, an 
FFA2 agonist with highly improved potency in the cAMP inhibition assay and 
modest potency improvement in the β-arrestin 2 recruitment assay. Introduction 
of a more polar group in the northern part of the molecule resulted in a 
reduction of the compound ClogP to 3.73, suggesting improved hydrophilicity 
and placing compound 2-23 within the Lipinski Rules for drug-like molecules 
(Lipinski et al., 2001). The correlation of compound 2-23 potencies and affinity 
is similar to that of compound 1, with a lower potency in the β-arrestin 2 
recruitment assay compared to the cAMP inhibition assay and its affinity more 
closely approximated by the G protein-dependent assay system. Perhaps this 
may, as proposed for compound 1, be explained by differences in the ligand 
binding kinetics compared to C3. In general, when considering the full selection 
of screened compounds, it is difficult to construct a full SAR of the compound 2 
ligand series as most of the compounds have relatively similar potency with a 
fairly flat SAR and as a result it is difficult to define clear trends. The core 
structure of the compound series consists of one central pyrroline or thiazolidine 
and two northern and one eastern aromatic rings with five or six carbon 
members and different substitutions. Replacement of either of the terminal 
aromatic rings with a hydrogen (compound 2-10) or butyl groups (compounds 2-8 
and 2-9) resulted in loss of agonist action. Furthermore, the variation of 
potencies between the different functional analogues was relatively small and 
considering the, in some cases, high error it is challenging to pinpoint which 
structural changes relate to effects on potency, in particular due to the poor 
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correlation between the two functional assay systems when including all tested 
compounds. 
Although compound 2-23 can be considered an improvement of compound 2, its 
potential use in the physiological characterisation of FFA2 is limited by species-
specific differences. Screening of a selection of compound 2 analogues at the 
murine orthologue of FFA2 demonstrated a different potency rank order 
compared to the human receptor. Perhaps this is not surprising, considering that 
even SCFAs have a different rank order of potency at mFFA2 compared to hFFA2 
and there are clear differences in constitutive receptor activity between the two 
orthologues (Hudson et al., 2012b). Furthermore, an analogue of compound 1 
(here referred to as compound 1-2) also showed a reduced potency at mFFA2 
compared to hFFA2 (Hudson et al., 2013a). 
Based on these results, which assay could be recommended for screening of FFA2 
agonist ligands? As the ability to activate the receptor is an essential feature of 
an agonist, performing an initial screen in a functional assay system seems 
reasonable. The use of an assay further downstream of GPCR activation, such as 
cAMP inhibition, appears to yield a larger spread of potency values due to 
increased amplification, which may facilitate SAR investigations of the tested 
compound series. Although screening of selected compounds in multiple assay 
systems can be of value to obtain more information on compound SAR and aids 
the identification of ligands with a biased signalling profile, conflicting potency 
trends can complicate chemistry decisions. Therefore, it would likely be best to 
base medicinal chemistry optimisation on only one assay system, however 
screening selected key compounds with representative structural modifications 
in an additional assay to confirm whether the SAR is conserved across multiple 
systems would be recommended. Another crucial consideration of ligand 
screening that is easily overlooked is whether the assay end point is close to 
equilibrium binding of the ligands. A recent study on dopamine receptor agonists 
revealed that apparent signalling bias can be heavily dependent on agonist 
kinetics and the time point at which agonist response is measured (Klein 
Herenbrink et al., 2016). Choosing an assay system that allows a long test 
compound incubation time at a reasonably high temperature could circumvent 
bias artifacts due to non-equilibrated ligand binding. 
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3.3.2 Hemi-equilibrium conditions can affect investigations of 
antagonist pharmacology 
Although many questions remain regarding the physiological role of FFA2, its 
ability to promote recruitment of neutrophils to sites of infection seems to be 
generally accepted and has raised interest in FFA2 antagonists as potential 
therapeutics (Pizzonero et al., 2014). GLPG0974 was the first FFA2 antagonist to 
reach clinical trials (Vermeire et al., 2015), however apart from its ability to 
inhibit neutrophil migration and its selectivity for the human over rodent forms 
of FFA2 (Pizzonero et al., 2014), there is little information available on its 
pharmacology. A common means of investigating antagonist pharmacology in the 
context of the employed agonist is to assess the effect of increasing antagonist 
concentrations on the agonist concentration response (Lazareno and Birdsall, 
1993). This provides information not only on whether the antagonist effect is 
surmountable and, therefore, most likely competitive with the tested agonist, 
but also allows estimation of antagonist affinity. Initial radioligand binding 
assays employing a tritiated form of GLPG0974 indicated competitive behaviour 
with SCFA C3 and synthetic orthosteric agonist compound 1, which supports a 
competitive relationship. However, an initial experiment in a β-arrestin 2 
recruitment assay showed that GLPG0974 antagonism was insurmountable by C3 
and that increasing concentrations of GLPG0974 induced a depression in maximal 
response. Such a curve pattern is typical of allosteric non-competitive 
antagonists or competitive antagonists that bind irreversibly (Vauquelin et al., 
2002). This would be highly unexpected for GLPG0974, in particular as this was 
not observed with compound 1. What hypothesis would be able to explain these 
observations? Although GLPG0974 being an allosteric ligand is perhaps the first 
conclusion to be drawn, other pharmacological concepts can also explain such 
observations (Vauquelin et al., 2002). Kinetic binding assays with [3H]-GLPG0974 
showed that GLPG0974 has a slow dissociation rate and perhaps the β-arrestin 2 
recruitment assay does not allow for sufficient equilibration time between 
agonist and antagonist binding, resulting in a measurement at a state of hemi-
equilibrium, as the recruitment of β-arrestin is measured only 5 min after 
agonist addition with a 15 min pre-incubation with antagonist. This is a well-
known problem for calcium release assays, which is usually measured rapidly 
after ligand addition (Charlton and Vauquelin, 2010). Furthermore, a state of 
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hemi-equilibrium could also account for the increased pIC50 value of GLPG0974 
observed in the β-arrestin 2 recruitment assay compared with CATPB. 
To assess whether a state of hemi-equilibrium is indeed the reason for the 
apparent insurmountable antagonism of GLPG0974 on C3, a different assay 
system was employed to perform the experiment, which detects the 
accumulation of phosphorylated ERK1/2 MAP kinases. This assay was selected as 
it allows longer incubation times of agonist and antagonist and in this case, 
antagonist was pre-incubated for 1 h followed by a 30 min incubation with 
agonist. When performing experiments in this fashion, GPLPG0974 induced a 
rightward shift of the C3 concentration response curve and increasing 
concentrations of C3 were able to overcome inhibition by GLPG0974, fully in 
agreement with expectations of competitive antagonism (Colquhoun, 2007). The 
slope of the resulting Schild plot also approximated unity, a further indication of 
competitive antagonism, and the pA2 values from Schild plots against C3 and 
compound 1 matched the affinity of [3H]-GLPG0974 determined in saturation 
binding assays very closely. 
In contrast to GLPG0974, CATPB behaved as a competitive antagonist in the β-
arrestin 2 recruitment assay. If the insurmountable antagonism of GLPG0974 was 
indeed a reflection of slow dissociation kinetics this would imply that the 
dissociation rate of CATPB is faster compared to GLPG0974, despite the 
essentially identical affinity of the two antagonists for the receptor. The 
residence time of ligands at their receptor is an emerging topic in drug discovery 
and is thought to be an increasingly important consideration for successful drug 
development (Hothersall et al., 2016, Hoffmann et al., 2015). Chapter 4 will 
explore this hypothesis further and employ [3H]-GLPG0974 to investigate the 
binding kinetics of different FFA2 ligands. 
3.3.3 Carboxylate moiety contributes to binding of FFA2 
antagonists, but is not essential 
One structural feature shared by most orthosteric FFA2 ligands is a carboxylate 
moiety. SCFAs, whose only functional group is a carboxylate, bind to FFA2 by 
interacting with a pair of arginine residues, Arg1805.39 and Arg 2557.35, and 
histidine residue His2426.55 (Stoddart et al., 2008), whilst activation of FFA2 by 
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synthetic agonist compound 1 is also dependent on the same residues (Hudson et 
al., 2013a). The agonism of the allosteric FFA2 ligands 4-CMTB (Smith et al., 
2011) and AZ1729 (Bolognini et al., 2016a) is, by contrast, not affected by 
alanine replacement of these residues and their structures do not contain a 
carboxylate moiety, therefore this structural feature has been hypothesised to 
be defining for orthosteric FFA2 ligands. However, the lack of agonist action at 
respective alanine replacement mutants prohibited the testing of antagonist 
inhibition, therefore the importance of the carboxylate moiety in antagonist 
ligands remained unexplored. Interestingly, a recently published antagonist 
series lacked a carboxylate moiety and still appeared to behave as competitive 
antagonists of C3 (Park et al., 2016). An exploration of the GLPG0974 and CATPB 
compound series revealed that replacement of the carboxylate with a methyl 
ester moiety resulted in reduced pIC50 values for both antagonist series. 
However, the compounds retained the ability to inhibit the FFA2 response to C3 
in a concentration-dependent manner. Interestingly, larger modifications, i.e. 
introduction of a morpholine in the case of MoGLPG-2, did not significantly 
affect the pIC50 in comparison to the methyl ester analogue MeGLPG-2. 
Nevertheless, the significant reduction in pIC50 upon replacement of the 
carboxylate moiety suggests that the arginine pair potentially serves as an 
important point of antagonist interaction with the receptor that contributes to 
their high affinity but is not required for binding and receptor blockade. 
Interestingly, replacement of the compound 1-2 carboxylate with a methyl and 
tert-butyl ester rendered the ligand non-functional (Hudson et al., 2013a). This 
served as a first indication of potentially different interactions of agonists and 
antagonists with the receptor. Availability of a labelled probe such as [3H]-
GLPG0974 provides a great opportunity to explore the binding of FFA2 
antagonists in more detail and will be discussed in chapter 4. Following this 
investigation, the development of GLPG0974 was published and, interestingly, 
the original hit compound did also not contain a carboxylate moiety, supporting 
that activity of the GLPG0974 compound series is indeed not dependent on the 
presence of a carboxylate (Pizzonero et al., 2014). 
3.3.4 Conclusions 
One of the key questions that needs to be addressed for successful FFA2 drug 
development is whether FFA2 is indeed a realistic therapeutic target and which 
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pharmaceutical action in which disease context would be desirable for 
therapeutic benefit. The physiological roles of FFA2 remain to be fully 
understood (see section 1.4.2) and that makes it difficult to answer this 
question. While studies in KO animals can and have provided important 
information on the function of FFA2, the lack of appropriate tool compounds has 
hindered confirmation of the therapeutic potential of FFA2 in animal models of 
disease. Identification of novel ligands often falls to pharmaceutical companies 
capable of performing high-throughput screening of large compound libraries, 
usually with the aim to identify a hit compound that can be developed into a 
therapeutic candidate. Medicinal chemistry optimisation of compound series 
plays an important role in this process and can lead to development of improved 
ligands, as here demonstrated with compound 2-23. However, cross-screening of 
compound 2 analogues at the murine orthologue of FFA2 has highlighted one 
important issue: Compound SAR can differ between species. This suggests that 
development of a potential therapeutic that acts on human FFA2 does not 
necessarily coincide with an improved ligand that can be employed in rodent 
studies. However, there is a great need for such tool compounds to confirm the 
therapeutic potential of FFA2, therefore it may be of interest to perform an SAR 
study at the murine orthologue with the aim to develop a ligand specifically for 
in vivo use in animal models of disease. Particularly the development of ligands 
biased towards specific pathways such as Gi/o- or Gq/11-mediated signalling could 
provide further information on which pathways mediate which physiological 
effects of FFA2, which could in turn guide the selection of an appropriate 
screening system for the desired signalling profile. Species selectivity of ligands 
is even more relevant for the development of FFA2 antagonists, as all currently 
available antagonists are selective for the human orthologue. The molecular 
basis of this will be considered in chapter 6. 
The screening of FFA2 agonists and pharmacological investigation of the mode of 
action of FFA2 antagonists also revealed that considering the kinetics of ligand 
association and dissociation can be very important. While the aspect of ligand 
kinetics may not play as crucial a role when single concentrations of ligands are 
tested for activity in high-throughput systems, the lack of kinetic considerations 
can lead to skewed potency values upon closer investigation and can even result 
in erroneous conclusions, such as the insurmountable inhibitory effect of 
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GLPG0974 on C3 in the β-arrestin recruitment assay that may be interpreted as 
non-competitive antagonism. Therefore, conditions of hemi-equilibrium should 
be avoided when possible and carefully considered when drawing conclusions 
regarding ligand pharmacology.
112 
4 Defining molecular and kinetic determinants of 
FFA2 ligand binding using [3H]-GLPG0974 
4.1 Introduction 
Mapping the ligand binding sites of GPCRs can play an important role in drug 
discovery, in particular in the process of compound optimisation. Although it is 
not essential to define the entire binding site of a future therapeutic, it can 
greatly contribute to the development of a lead compound and is an important 
component of the structure-based drug design approach. Detailed information on 
ligand-receptor interactions can be obtained from crystal structures of GPCRs 
complexed with respective ligands, however these only exist for a small number 
of GPCRs with a total of only 43 unique receptor-ligand complexes published to 
date (Isberg et al., 2016). Therefore, the majority of efforts to define the 
binding site of GPCR ligands are based on functional and binding data, which 
often include the use of site-directed mutagenesis to generate specific 
mutations in the receptor of interest and the assessment of their effect on 
ligand affinity and efficacy. Due to a lack of structural information on FFA2, such 
an approach has been employed to assess its orthosteric and allosteric binding 
sites (Stoddart et al., 2008, Schmidt et al., 2011, Smith et al., 2011, Hudson et 
al., 2013a, Bolognini et al., 2016a). FFA2 is endogenously activated by SCFAs, 
which can form an electrostatic interaction with positively charged residues 
through their carboxylate moiety. In an effort to identify the point of SCFA 
carboxylate interaction with FFA2, the effect of alanine replacement of 
positively charged residues that were thought to be ligand-accessible was 
investigated and resulted in the identification of two arginine residues, 
Arg1805.39 and Arg2557.35 (Stoddart et al., 2008). Mutation of either of these 
arginines resulted in loss of FFA2 activation by SCFAs (Stoddart et al., 2008) and 
synthetic agonist compound 1 (Hudson et al., 2013a). Furthermore, His2426.55 
was also essential for activation of FFA2 by SCFAs (Stoddart et al., 2008) and 
compound 1 (Hudson et al., 2013a). These observations seemed to define the 
essential importance of the carboxylate moiety for FFA2 agonist activity. 
Replacement of the carboxylate of SCFAs with an amine renders them inactive 
(Schmidt et al., 2011) and methyl and tert-butyl ester analogues of compound 
1-2 lack ability to activate FFA2 (Hudson et al., 2013a). Therefore, there is a 
consensus that orthosteric FFA2 agonists are defined by their ability to form an 
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interaction with Arg1805.39 and Arg2557.35 through their carboxylate moiety. This 
hypothesis is further supported by the fact that allosteric agonists of FFA2, 
4-CMTB (Smith et al., 2011) and AZ1729 (Bolognini et al., 2016a), do not contain 
a carboxylate and retained the capacity to activate R180A and R255A hFFA2. 
While agonist binding to hFFA2 appears to be relatively well understood, there is 
little information on the binding determinants of the FFA2 antagonists GLPG0974 
and CATPB. Defining how antagonists interact with hFFA2 is of high importance, 
as the lack of available antagonists at rodent FFA2 has hindered progress in 
dissecting the physiological role of FFA2 (Hudson et al., 2012b, Pizzonero et al., 
2014, Milligan et al., 2017). Selected studies (Pizzonero et al., 2014, Park et al., 
2016) and data presented in chapter 3 suggested that the carboxylate 
interaction with the orthosteric arginine pair is of lesser importance for FFA2 
antagonists than agonists. Replacement of the carboxylate of GLPG0974 
analogues with a methyl ester or morpholine group only had a modest effect on 
their ability to inhibit the hFFA2 response to C3 (see section 3.2.4) and multiple 
active non-carboxylate analogues were synthesised during the development of 
GLPG0974 (Pizzonero et al., 2014). Furthermore, the recently published BTI-A 
series of FFA2 antagonists also do not contain a carboxylate moiety (Park et al., 
2016). However, it is difficult to assess whether binding of FFA2 antagonists is 
similarly affected by orthosteric arginine mutations as the potency of FFA2 
agonists, because the loss of agonist action at respective mutants prohibits 
assessment of the inhibitory action of antagonists. 
Another aspect of GPCR ligand binding that has recently attracted a lot of 
attention is binding kinetics (Hoffmann et al., 2015). There is a body of evidence 
developing which suggests that in the case of agonists an increased residence 
time at the receptor positively correlates with functional efficacy (Guo et al., 
2012) and that optimising agonist kinetics to achieve a prolonged residence time 
could contribute to improvement of sustained signalling by internalised 
receptors (Hothersall et al., 2016). However, there is also evidence that the 
binding kinetics of antagonists plays an important role in defining their 
therapeutic benefit. There seems to be a clear relationship between antagonist 
residence time and its clinical application (Guo et al., 2014). The muscarinic M3 
receptor antagonist tiotropium, which has a residence time of 35 h, is best-in-
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class for management of chronic obstructive pulmonary disease and provides a 
durable bronchodilatory effect (Casarosa et al., 2009). In contrast, for targeting 
of the dopamine D2 receptor in psychotic disorders with antagonists, a shorter 
residence time is more desirable to prevent on-target side effects. The D2R 
antagonist JNJ-37822681 was specifically developed using a kinetic screening 
assay to optimise for a short residence time and showed a dissociation half-time 
of 6.5 s in kinetic radioligand binding studies (Langlois et al., 2012). In following 
clinical trials an improved tolerability over haloperdidol, which has a half-time 
of 72 s (Schmidt et al., 2012), could be observed. These studies represent only 
some of the examples that suggest that residence time can be an important 
factor in the clinical success of therapeutics (Guo et al., 2014). Although in the 
case of FFA2 it is perhaps not clear whether a short or long drug residence time 
would be therapeutically beneficial, defining the kinetic profile of antagonists is 
undoubtedly important and may contribute to targeted development of a 
potential therapeutic. In addition, furthering the understanding of the kinetic 
profile of FFA2 activation or inhibition that would be desirable in the respective 
disease context could serve as a guide for future drug development. 
This chapter aims to characterise two important aspects of FFA2 ligand binding: 
(1) The determinants of FFA2 agonist and antagonist binding and (2) the kinetic 
profile of FFA2 antagonists. The tritiated FFA2 antagonist [3H]-GLPG0974 played 
a key role in this investigation, as it allowed the assessment of antagonist 
binding to orthosteric binding site mutants R180A, R255A and H242A hFFA2 and 
the effect of respective mutations on the affinity of unlabelled ligands C3, 
compound 1 and CATPB. Furthermore, the contribution of the FFA2 antagonist 
carboxylate moiety to binding affinity was investigated using a selection of 
analogues and served as a support for data from functional studies (see section 
3.2.4). To rationalise observations described in previous chapters and functional 
studies (Stoddart et al., 2008, Hudson et al., 2013a), a homology model of hFFA2 
was constructed using the recently published crystal structure of hFFA1 as a 
template (Srivastava et al., 2014). Various aspects of [3H]-GLPG0974 kinetics 
were also investigated, including the role of the orthosteric arginine pair in 
regulating the kinetics of radioligand binding and how different FFA2 ligands 
impact the dissociation rate of [3H]-GLPG0974. Furthermore, the kinetic profile 
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of the GLPG0974 and CATPB antagonist series was defined in an effort to 
understand previous observations in functional studies (see section 3.2.3). 
4.2 Results 
4.2.1 Binding of [3H]-GLPG0974 to hFFA2 does not require both 
orthosteric arginine residues 
In chapter 3 a hFFA2 binding assay was developed using the tritiated antagonist 
[3H]-GLPG0974 and served as a tool to determine the affinity of compounds in an 
agonist screen (see section 3.2.2). However, in addition to compound screening, 
radioligands can also play a crucial role in the mapping of ligand binding sites. 
While the importance of the orthosteric residues Arg1805.39, Arg2557.35 and 
H2426.55 for hFFA2 activation by agonists has been demonstrated (Stoddart et al., 
2008, Hudson et al., 2013a), to date it is not clear whether antagonist binding 
also relies on electrostatic interaction between the carboxylate moiety and the 
Arg180-Arg255-His242 triad. Therefore, [3H]-GLPG0974 was employed as a 
representative antagonist to examine its binding to membranes purified from 
cells expressing orthosteric binding site mutants of hFFA2. Interestingly, 
[3H]-GLPG0974 retained the ability to bind the single mutants R180A (Figure 
4.1B) and R255A (Figure 4.1C) hFFA2 with a relatively minor decrease in binding 
affinity of 2.9- and 1.7-fold, respectively (Table 4.1). Alanine replacement of 
Arg1805.39 affected binding of [3H]-GLPG0974 to a larger extent, therefore it 
perhaps plays a more important role than Arg2557.35 in anchoring the radioligand. 
In contrast, specific binding of [3H]-GLPG0974 to the dual mutant R180A-R255A 
hFFA2 could not be detected at concentrations of up to 80 nM (Figure 4.1D), 
suggesting that [3H]-GLPG0974 binding requires at least one orthosteric arginine. 
Mutation of His2426.55, a further residue necessary for hFFA2 activation by 
agonists, to alanine did also not negatively impact [3H]-GLPG0974 affinity 
(Figure 4.1E). On the contrary, affinity of the radioligand was increased by 2-
fold compared to wild type hFFA2 (Table 4.1). To confirm that the lack of 
specific binding of [3H]-GLPG0974 to hFFA2-R180A-R255A was not related to a 
lack of expression of this hFFA2 mutant, receptor expression was assessed by 
measuring the fluorescence intensity of the eYFP tag in purified membranes. 
Indeed, all orthosteric binding site mutants of hFFA2 were expressed at a similar 
or even increased level compared to the wild type receptor (Table 4.1).  
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Figure 4.1 Binding characteristics of [3H]-GLPG0974 to orthosteric binding site mutants of 
hFFA2 Binding of [3H]-GLPG0974 to membranes purified from Flp-InTM T-RExTM 293 cells induced 
to express wild type (A) or mutant forms of hFFA2-eYFP with alanine replacement of Arg1805.39 
(B), Arg2557.35 (C) Arg1805.39 and Arg2557.35 (D) or His2426.55 (E) is illustrated from representative 
experiments. No specific binding to hFFA2-R180A-R255A could be measured. Nonspecific binding 
was determined in presence of 10 µM CATPB and subtracted from total binding to calculate 
specific binding. Data in panel A was previously shown in figure 3.2C. 
 
Therefore, loss of specific radioligand binding at hFFA2-R180A-R255A cannot be 
attributed to lack of receptor expression and confirms loss of [3H]-GLPG0973 
binding to this mutant. 
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Table 4.1 Affinity of [3H]-GLPG0974 for orthosteric binding site mutants of hFFA2 
Receptor Kd (nM) Expressiona 
WT 7.5 ± 0.4 373 ± 7 
R180A 21.8 ± 1.3*** 409 ± 11 
R255A 13.0 ± 0.5*** 465 ± 18 
R180A-R255A > 80 405 ± 7 
H242A 3.7 ± 0.3** 794 ± 38 
a Determined by measuring eYFP fluorescence of 5 µg membrane preparation and shown in 
relative fluorescent units. 
* Analysis of Kd values by one-way ANOVA followed by Dunnett’s test with the Kd at WT hFFA2 as 
a reference with significant differences denoted as P = ** ≤ 0.01 and P = *** ≤ 0.001 
 
4.2.2 FFA2 agonists and antagonists have different binding 
determinants 
Because [3H]-GLPG0974 retained the ability to bind to single orthosteric binding 
site mutants of hFFA2, the importance of these residues for binding of other 
hFFA2 ligands could be examined using a radioligand competition binding assay. 
Initially, the capacity of increasing concentrations of the agonists C3 (Figure 
4.2A) and compound 1 (Figure 4.2B) to compete with [3H]-GLPG0974 at each of 
R180A, R255A and H242A hFFA2 was assessed. Only minimal displacement of 
[3H]-GLPG0974 at the orthosteric binding site mutants was observed at the 
highest concentrations of C3 and compound 1 employed, suggesting that the 
affinity of FFA2 agonists was markedly reduced. Therefore, the loss of agonist 
function at each of these mutants described previously (Stoddart et al., 2008, 
Hudson et al., 2013a) resulted from a decrease in agonist affinity and was not 
due to an inability of ligand binding to induce receptor activation. 
In contrast, the hFFA2 antagonist CATPB, which is structurally distinct from 
GLPG0974, retained the ability to displace [3H]-GLPG0974 from mutant forms of 
the receptor (Figure 4.2C). The effects of orthosteric binding site mutations on 
CATPB affinity were much more modest with a 3.5-fold reduction at R180A FFA2 
and a decrease of 7.8-fold at R255A hFFA2, suggesting that CATPB might 
preferentially interact with Arg2557.35 (Table 4.2). Interestingly, this trend is 
opposite to the impact of the respective arginine mutations on [3H]-GLPG0974 
affinity, which was most affected by alanine replacement of Arg1805.39 (Table 
4.1). In the case of the H242A hFFA2 mutant, affinity of CATPB was not 
significantly affected, hence this residue is not likely to play a role in CATPB 
binding (Table 4.2). An equivalent competition experiment was performed with  
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Figure 4.2 Agonists but not antagonists of hFFA2 show reduced ability to compete with [3H]-
GLPG0974 at receptor binding site mutants The capacity of C3 (A), compound 1 (B), CATPB 
(C) and GLPG0974 (D) to compete with [3H]-GLPG0974 for binding to R180A, R255A or H242A 
hFFA2-eYFP is shown from representative experiments. For comparison the displacement of [3H]-
GLPG0974 by respective ligands at WT is also illustrated (- -) with original data shown in figure 3.2 
of chapter 3. Nonspecific binding was determined in presence of 10 µM CATPB and subtracted 
from total binding to calculate specific binding. 
 
GLPG0974 as the displacing ligand (Figure 4.2D). No significant loss in affinity of 
GLPG0974 was observed at R255A or H242A hFFA2, however the R180A mutation 
resulted in a 5.5-fold reduction in affinity (Table 4.2). These observations are in 
agreement with the saturation binding data obtained for [3H]-GLPG0974 and 
although the minor reduction in GLPG0974 affinity at R255A and increase at 
H242A were not statistically significant, the same trend could be observed in the 
[3H]-GLPG0974 saturation binding experiments. The differences in affinity of 
CATPB and GLPG0974 at the orthosteric arginine mutants suggest that although 
both antagonists had the same affinity for the wild type receptor, they might 
adopt different binding poses, with CATPB interacting preferentially with 
Arg2557.35 and GLPG0974 with Arg1805.39. 
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Table 4.2 Affinity of hFFA2 antagonist analogues for wild type and orthosteric binding site 
mutants of hFFA2 
Compound 
Receptora 
WT R180A R255A H242A 
 
GLPG0974 
7.88 ± 0.08 7.14 ± 0.06*** 7.59 ± 0.09 8.04 ± 0.04 
 
CATPB 
7.87 ± 0.08 7.32 ± 0.06*** 6.98 ± 0.06*** 7.63 ± 0.07 
 
MeCATPB 
6.74 ± 0.14$$ 6.52 ± 0.14 7.08 ± 0.10  
 
GLPG-1 
7.39 ± 0.04 7.01 ± 0.10* 7.06 ± 0.09*  
 
MeGLPG-1 
6.22 ± 0.09$$$ 6.89 ± 0.07** 6.80 ± 0.08**  
 
GLPG-2 
7.65 ± 0.08    
 
MeGLPG-2 
7.16 ± 0.06$$$    
 
MoGLPG-2 
7.36 ± 0.08    
a Data shown as pKi values of respective antagonists determined in [3H]-GLPG0974 competition 
assays 
* Analysis of pKi values by one-way ANOVA followed by Dunnett’s test with the pKi at WT hFFA2 as 
a reference with significant differences denoted as P = * ≤ 0.05, P = ** ≤ 0.01 and P = *** ≤ 0.001 
$ Comparison of methyl ester (Me) or morpholine (Mo) analogue pKi values with carboxylate 
compound by unpaired t test with significant differences denoted as P = $$ ≤ 0.01 and P = $$$ ≤ 
0.001 
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4.2.3 Carboxylate moiety present in FFA2 antagonists is not 
necessary for high-affinity binding 
The ability of CATPB and GLPG0974 to bind to single arginine mutants of hFFA2 
supported the hypothesis that the interaction between ligand carboxylate and 
orthosteric binding pocket arginines is of less importance for antagonist than 
agonist binding. Indeed, functional studies in chapter 3 demonstrated that 
CATPB and GLPG0974 analogues with a methyl ester or morpholine in place of 
the carboxylate moiety retained the ability to inhibit the hFFA2 response to C3 
at wild type hFFA2, albeit with a reduced pIC50 (see section 3.2.4). To define 
whether this observation could be explained by a loss of antagonist affinity for 
the receptor, [3H]-GLPG0974 competition binding assays were performed with 
methyl ester (Me) analogues of GLPG0974 analogues GLPG-1 (Figure 4.3A) and 
GLPG-2 (Figure 4.3B), and CATPB (Figure 4.3C). In agreement with functional 
studies, the replacement of the carboxylate moiety led to a loss of affinity  
 
Figure 4.3 Modification of the carboxylate moiety of hFFA2 antagonists results in loss of 
binding affinity The ability of various concentrations of GLPG-1 and MeGLPG-1 (A); GLPG-2, 
MeGLPG-2 and MoGLPG-2 (B); and CATPB and MeCATPB (C) to compete with [3H]-GLPG0974 
for binding to hFFA2-eYFP is shown from representative experiments. Nonspecific binding was 
determined in presence of 10 µM CATPB and subtracted from total binding to calculate specific 
binding. Dashed lines indicate that data was shown previously, in this case in figure 3.2. Me = 
Methyl ester; Mo = Morpholine. 
Chapter 4  121 
 
compared to the carboxylate-containing compound with a 13-fold reduction in Ki 
of MeCATPB, a 15-fold reduction in Ki of MeGLPG-1 and a 3-fold reduction in Ki of 
MeGLPG-2 (Table 4.2). These results show that the affinity of GLPG-2 was least 
affected by modification of the carboxylate moiety. To examine this further, an 
analogue of GLPG-2 with a relatively bulky morpholine (Mo) amide in place of 
the carboxylate was employed (Figure 4.3C). Interestingly, the affinity of 
MoGLPG-2 was higher than that of MeGLPG-2 (Table 4.2), which was also 
observed in functional studies (see section 3.4.2). This might suggest that the 
morpholine moiety of MoGLPG-2 was able to make additional contacts with the 
receptor binding pocket compared to the methyl ester analogue MeGLPG-2. 
Although methyl esters are less electronegative than carboxylates and are not 
negatively charged, they retain the ability to act as hydrogen bond acceptors 
and may still interact with the orthosteric arginine residues. To examine 
whether this is the case, the affinity of MeCATPB and MeGLPG-1 was assessed at 
R180A and R255A hFFA2 (Figure 4.4). Interestingly, the affinity of MeCATPB was 
not significantly affected by these mutations and, although not quite reaching 
statistical significance, a 2.2-fold increase in affinity was observed at R255A 
hFFA2 compared to the wild type receptor (Table 4.2). This positive trend was 
more prominent and significant in the case of MeGLPG-1 with a 4.8-fold increase 
in affinity at R180A hFFA2 and a 3.8-fold increase at R255A hFFA2. These  
 
Figure 4.4 Methyl ester analogues of hFFA2 antagonists display higher affinity at orthosteric 
binding site mutants of hFFA2 The capacity of MeCATPB (A) and MeGLPG-1 (B) to displace 
[3H]-GLPG0974 from R180A and R255A hFFA2-eYFP is shown from representative experiments. 
For comparison the effect of each ligand at WT is also shown (- -) with original data displayed in 
figure 4.3. Me = Methyl ester. 
Chapter 4  122 
 
observations suggest that the presence of two orthosteric arginine residues was 
not required for binding of methyl ester analogues and was instead more likely 
to have a negative impact on binding affinity. 
4.2.4 FFA2 homology model and ligand docking supports diverse 
binding poses of FFA2 agonists and antagonists 
In initial binding studies (see section 4.2.2) clear differences in binding 
determinants of FFA2 agonists and antagonists could be observed with agonists 
requiring both orthosteric arginines and histidine, while antagonists only 
required one arginine residue. Furthermore, distinct antagonist series potentially 
showed differences in arginine preference. These observations provided 
important information on the binding mode of FFA2 ligands, which were applied 
and examined in more detail by generating a homology model of hFFA2. The 
recently published crystal structure of hFFA1 complexed with the allosteric 
partial agonist TAK-875 (Srivastava et al., 2014) was employed as the template, 
which also provides a good opportunity to improve upon currently available 
homology models that were based on the lower-similarity template structure of 
the β2-adrenergic receptor (Schmidt et al., 2011). 
Docking studies of FFA2 agonists C3 (Figure 4.5A) and compound 1 (Figure 4.5B) 
into the constructed hFFA2 homology model resulted in agonist carboxylates 
being positioned in a highly similar fashion, engaging Arg1805.39 and Arg2557.39 
simultaneously in a strong electrostatic interaction that included multiple 
hydrogen bonds. These binding poses were in agreement with the loss of agonist 
binding observed at R180A and R255A hFFA2 mutants. In addition, both agonist 
carboxylates also acted as hydrogen bond donors to Tyr2386.51 (Figures 4.5A and 
B). In previous functional studies mutation of this tyrosine residue resulted in a 
significant loss of C3 and compound 1 potency (Hudson et al., 2013a). 
Interestingly, His2426.55, which is also essential for agonist binding, did not 
directly interact with the agonist carboxylate (Figures 4.5A and B). Instead, 
His2426.55 was hydrogen bonded to Arg2557.39 and may therefore be important for 
positioning Arg2557.39 for interaction with the agonist. While the residues 
described above comprised the binding pocket of C3, compound 1 interacted 
with additional residues, as would be expected from its increased affinity over 
C3 (see section 3.2.1). The binding site of compound 1 also included His1404.56 
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Figure 4.5 Modelling of orthosteric FFA2 agonist binding poses  Docking of C3 (A) or 
compound 1 (B) into a homology model of hFFA2 is illustrated. The carboxylate moiety of C3 and 
compound 1 is anchored by Arg1805.39 and Arg2557.35, which are both required for agonist binding 
and activation of FFA2. His2426.55 appears to play a stabilising role in the binding pocket by 
interacting with and thereby positioning Arg2557.35 for interaction with agonists. In addition to the 
Arg180-Arg255-His242 triad, C3 also interacts with Tyr2386.51. Binding of compound 1 is 
additionally supported by interaction with Tyr903.33, His1404.56, Tyr165ECL2, Val1795.38 and 
Tyr2386.51, whose mutation has been shown to affect activation of hFFA2 by compound 1 (Hudson 
et al., 2013a). The inset in B shows greater detail of electrostatic interactions of the compound 1 
carboxylate with the hFFA2 binding pocket. These figures are the work of Dr Hansen generated in 
collaboration with Professor Ulven’s group at the University of Southern Denmark. 
 
and Val1795.38, which were in close proximity to its phenyl group, as well as 
Tyr903.29, Tyr943.33 and Tyr165ECL2. The importance of Tyr903.29, His1404.56, 
Tyr165ECL2 and Val1795.38 was also demonstrated in previous functional studies, in 
which alanine replacement of these respective residues resulted in a reduction 
of compound 1 potency (Hudson et al., 2013a). 
Docking studies carried out for CATPB and GLPG0974 showed distinct binding 
poses compared to FFA2 agonists (Figure 4.6A). Interestingly, lower-energy 
poses were obtained for CATPB when interacting with Arg2557.35 and for 
GLPG0974 when interacting with Arg1805.39, which is in agreement with the 
effect of the respective mutations observed in binding studies (Table 4.2). The 
hypothesis that CATPB and GLPG0974 prefer to interact with different arginine 
residues was further supported by the observation that mutation of His2426.55, 
which positioned Arg2557.35 in the homology model through a hydrogen bond 
interaction, resulted in a 1.7-fold reduction in CATPB affinity, albeit this was not 
quite statistically significant (Table 4.2). This supporting interaction was 
modelled based on equivalent positioning of corresponding residues in hFFA1, in 
which Asn2556.55 forms a stabilising interaction with Arg2587.35 (Srivastava et al., 
2014). The affinity of CATPB and GLPG0974 was affected by less than 10-fold by 
alanine replacement of either orthosteric arginine (Table 4.2), which may be 
explained by a compensatory interaction of the antagonist carboxylate with the  
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Figure 4.6 Modelling of orthosteric hFFA2 antagonist binding poses Docking of CATPB 
(green) and GLPG0974 (cyan) into hFFA2 demonstrated preferred interaction of GLPG0974 with 
Arg1805.39 and CATPB with Arg2557.35 (A). Representative poses of CATPB and GLPG0974 in 
alanine replacement mutants of Arg2557.35 (B) and Arg1805.39 (C) show that the antagonists are 
able to adapt their binding pose to interact with the respective remaining arginine residue. These 
figures are the work of Dr Hansen generated in collaboration with Professor Ulven’s group at the 
University of Southern Denmark. 
 
remaining, less favourable, arginine. To examine this hypothesis further, the 
effect of R255A (Figure 4.6B) and R180A (Figure 4.6C) mutations on the docking 
of CATPB and GLPG0974 into the hFFA2 binding pocket was investigated. Indeed, 
both antagonists were able to adapt their binding pose to allow for hydrogen 
bond interaction between the carboxylate moiety and the remaining arginine 
residue (Figures 4.6B and C). In the case of CATPB, the favoured binding pose at 
R255A (Figure 4.6B) and R180A (Figure 4.6C) hFFA2 mutants was significantly 
altered compared to wild type hFFA2 (Figure 4.6A) with respective functional 
groups adopting different conformations. In contrast, GLPG0974 favoured a 
similar binding pose to wild type hFFA2 (Figure 4.6A) at the R180A hFFA2 
mutant (Figure 4.6C), while at R255A hFFA2 the conformation of GLPG0974 was 
drastically changed (Figure 4.6B). This may appear to be inconsistent with the 
higher affinity of GLPG0974 for R255A hFFA2, however the length and 
orientation of the hydrogen bond between GLPG0974 and Arg2557.35 seemed to 
be less optimal than that between GLPG0974 and Arg1805.39. As hydrogen bond 
distance and orientation are some of the deciding factors of hydrogen bond 
strength (Hubbard et al., 2016), the interaction between GLPG0974 and R255A 
hFFA2 may be weaker than that between GLPG0974 and R180A, although 
GLPG0974 adopts a similar conformation as at wild type hFFA2. 
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4.2.5 Orthosteric arginine pair may regulate antagonist release 
from the FFA2 binding pocket 
The affinity of a ligand is directly related to the speed at which it associates and 
dissociates from the receptor, with the ratio of Koff and Kon corresponding to the 
Kd. To examine how R180A and R255A mutations affect the kinetics of 
[3H]-GLPG0974, the dissociation (Figure 4.7A) and association (Figure 4.7B) of 
the radioligand was assessed at respective mutants. Although the affinity of 
[3H]-GLPG0974 was only modestly affected at R180A and R255A hFFA2, a drastic 
increase in Koff and Kon rates could be observed at the mutant receptors. The 
dissociation rate of [3H]-GLPG0974 is significantly increased by 15- and 7.6-fold 
at R180A and R255A hFFA2, respectively (Table 4.3). Although the enhancing 
effect of R180A and R255A on radioligand association appears to be very 
pronounced when visually comparing data at mutant and wild type FFA2 (Figure 
4.7B), the impact on the association rate was not quite statistically significant, 
albeit a positive trend was observed with increases of 3.9- and 2-fold at R180A 
and R255A hFFA2, respectively (Table 4.3). The half-time of ligand association is 
dependent on its dissociation rate and binding equilibrium is reached more 
quickly if the ligand has a fast dissociation rate, therefore the impact of R180A 
and R255A mutations on the association curve of [3H]-GLPG0974 does not 
translate into a statistically significant effect on the Kon. These observations 
demonstrated that that orthosteric arginine mutations primarily affected the  
 
Figure 4.7 Alanine replacement of orthosteric arginines increases the speed of [3H]-
GLPG0974 binding kinetics Dissociation (A) and association (B) of 6 nM [3H]-GLPG0974 at WT, 
R180A and R255A hFFA2-eYFP is shown from representative experiments. To induce [3H]-
GLPG0974 dissociation 10 µM CATPB were added after 60 min pre-association of the radioligand. 
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Table 4.3 Kinetic parameters of [3H]-GLPG0974 binding to wild type and orthosteric arginine 
mutants of hFFA2 
Parameter  WT R180A R255A 
Koff (min-1) 0.014 ± 0.001 0.221 ± 0.004*** 0.107 ± 0.009*** 
Kon (M-1 min-1) 1,730,000 ± 74,000 6,794,000 ± 3,388,000 3,480,000 ± 167,000 
Kda (nM) 8.1 ± 0.9 32.5 ± 16.8 30.7 ± 4.1 
a Determined by dividing the Koff by the Kon value of at least three independent kinetic binding 
experiments. 
* Analysis of Koff and Kon values by one-way ANOVA followed by Dunnett’s test with the value at WT 
hFFA2 as a reference with significant differences denoted as P = *** ≤ 0.001 
 
release of [3H]-GLPG0974 from the receptor, which might suggest that Arg1805.39 
and Arg2557.35 play a role in retaining [3H]-GLPG0974 at the binding pocket of 
wild type hFFA2. 
4.2.6 Competitive kinetic binding experiments indicate distinct 
kinetics of GLPG0974 and CATPB despite similar affinity 
The investigation of GLPG0974 and CATPB pharmacology in chapter 3 indicated 
that differences in GLPG0974 and CATPB binding kinetics might account for the 
diverse effects of these antagonists observed in functional assays (see section 
3.2.3). To examine this hypothesis further, a competitive kinetic binding assay 
of [3H]-GLPG0974 was performed in the presence of CATPB (Figure 4.8A) or 
GLPG0974 (Figure 4.8B). Increasing concentrations of the competing ligand 
were added to membranes containing hFFA2-eYFP simultaneously with 
[3H]-GLPG0974 and the association of the radioligand was measured, which will 
be affected in defined ways depending on the binding kinetics of the competing 
ligand (Dowling and Charlton, 2006). Interestingly, CATPB did indeed show 
significantly faster binding kinetics than GLPG0974 with a 4.5-fold increase in 
Koff and a 5.2-fold increase in Kon (Table 4.4), which supports the hypothesis 
that GLPG0974 requires a longer incubation time with the receptor to reach 
equilibrium (see section 3.2.3). This result also exemplified that ligands with 
equal affinities can have relatively different kinetic profiles, which may result in 
different pharmacology. Furthermore, kinetic parameters determined for 
GLPG0974 in the competitive kinetic binding assay (Table 4.4) correlated well 
with association and dissociation rates determined in [3H]-GLPG0974 kinetic 
binding assays (Table 4.3), which suggests that the kinetic binding rates 
calculated from competitive kinetic binding studies are a good representation of 
the true kinetic profile of unlabelled ligands. 
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Figure 4.8 Effects of hFFA2 antagonists on [3H]-GLPG0974 association demonstrate 
different kinetic parameters for the antagonist series The association of 10 nM [3H]-GLPG0974 
to hFFA2-eYFP in absence or presence of indicated concentrations of CATPB (A), GLPG0974 (B), 
GLPG-1 (C) and MeGLPG-1 (D) is shown from representative experiments. A competitive kinetic 
binding model (Dowling and Charlton, 2006) was used to fit shown data to estimate the kinetic 
parameters of unlabelled competing ligands and resulting analysis is shown in table 4.3. 
Respective Ki values of antagonists are shown in table 4.2. Experiments were performed in 
collaboration by Dr Mackenzie in Professor Milligan’s laboratory group. Me = Methyl ester. 
 
As the orthosteric arginine residues seemed to play a role in regulating the 
kinetics of [3H]-GLPG0974, the carboxylate/methyl ester analogue pair 
GLPG-1/MeGLPG-1 was selected to investigate how the potentially weakened 
interaction of MeGLPG-1 with R180A and R255A affected the ligand binding 
kinetics at wild type hFFA2. Therefore, competitive kinetic binding assays were 
performed in the presence of increasing concentrations of GLPG-1 (Figure 4.8C) 
and MeGLPG-1 (Figure 4.8D). Interestingly, the dissociation rate was not 
significantly affected by replacement of the carboxylate moiety with a methyl 
Table 4.4 Kinetic parameters of antagonist binding to wild type hFFA2 
Parameter GLPG0974 CATPB GLPG-1 MeGLPG-1 
Koff (min-1) 0.021 ± 0.002 0.094 ± 0.026* 0.016 ± 0.001 0.011 ± 0.007 
t1/2a (min) 48 11 63 91 
Kon (M-1 min-1) 
1,220,000 ± 
87,000 
6,360,000 ± 
1,540,000* 
398,000 ± 
16,200 
26,900 ± 
9800*** 
Kdb (nM) 17.2 ± 0.6 14.5 ± 0.7 39.9 ± 1.7 638 ± 259 
a Half-time of ligand dissociation calculated by dividing unity by Koff. 
b Determined by dividing the Koff by the Kon value of at least three independent kinetic binding 
experiments. 
* Comparison of Koff and Kon rates of GLPG0974 and CATPB or GLPG-1 and MeGLPG-1 by 
unpaired t test with significant differences denoted as P = * ≤ 0.05 and P = *** ≤ 0.001. 
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ester, while the association rate was significantly reduced by 15-fold (Table 
4.4). This observation might suggest that weakened interaction with orthosteric 
arginines has little effect on the release of ligands from the hFFA2 binding 
pocket, however more time is required for the methyl ester analogue to bind to 
the receptor and adopt its final conformation. In addition, the replacement of 
the chlorobenzene moiety of GLPG0974 with a trifluoromethylbenzene in 
GLPG-1, which led to a reduction in affinity by 3-fold (Table 4.2), primarily 
affected the association and not the dissociation rate with a 3-fold reduction 
compared to GLPG0974. 
4.2.7 Binding of FFA2 agonists appears to have a cooperative 
effect on [3H]-GLPG0974 kinetics 
All functional and competition binding studies shown so far in chapters 3 and 4 
indicate that GLPG0974, CATPB and their respective analogues are orthosteric 
ligands that bind to the same site as the agonists C3 and compound 1. Allosteric 
ligands are defined by their ability to bind to a distinct site on the receptor 
compared to endogenous ligands and usually display a positive or negative 
cooperative effect on the affinity or efficacy of other ligands (Wootten et al., 
2013). The allosteric modulation of probe affinity is rooted in the capacity of 
allosteric ligands to change the association or dissociation rate of the respective 
probe. Therefore, measurement of radioligand dissociation induced by 
competition with an excess of unlabelled compound should serve as a means of 
investigating whether the unlabelled compound has any cooperative effect on 
radioligand dissociation (May et al., 2010). An alternative approach to measuring 
radioligand dissociation is to wash out the radioligand or add an excess of 
binding buffer to the reaction that contains pre-associated radioligand, an 
approach referred to as “infinite dilution” (Guo et al., 2017). 
To measure [3H]-GLPG0974 dissociation independently of the competing ligand, 
an infinite dilution experiment was performed and yielded a similar Koff 
compared to dissociation measured by competition with 10 µM CATPB (Figure 
4.9A). To assess whether this is also the case when employing methyl ester 
analogues, which likely have a distinct mode of binding compared to GLPG0974, 
10 µM of MeCATPB or MeGLPG-1 were employed for competition (Figure 4.9B). 
Indeed, the resulting Koff values were in a similar range compared to values  
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Figure 4.9 FFA2 agonists increase the dissociation rate of [3H]-GLPG0974 The dissociation of 
[3H]-GLPG0974 from hFFA2-eYFP was induced by using an “infinite dilution” approach (70-fold) or 
by competition with 10 µM CATPB (A) or 10 µM methyl ester analogues of hFFA2 antagonists (B). 
The capacity of increasing concentrations of C3 (C) or compound 1 (D) to affect dissociation of 
[3H]-GLPG0974 is illustrated. Data shown is from representative experiments. Me = Methyl ester. 
 
determined by infinite dilution and CATPB competition (Table 4.5). Although the 
dissociation experiments measured by infinite dilution and competition with 
MeCATPB or MeGLPG-1 were only performed once, the radioligand binding assay 
showed good consistency and it is likely that a drastic change in dissociation rate 
would have been detected in a single experiment. Regardless, it is important to 
keep in mind that additional repetitions are required to confirm these results. 
Dissociation of [3H]-GLPG0974 was also measured by competition with agonists 
C3 (Figure 4.9C) and compound 1 (Figure 4.9D). Surprisingly, the use of 
increasing concentrations of C3 (Figure 4.9C) or compound 1 (Figure 4.9D) 
resulted in a concentration-dependent increase in the dissociation rate of 
[3H]-GLPG0974. This effect was most pronounced when 30 µM of compound 1 
was present, which induced a significant 13-fold increase in the Koff of 
[3H]-GLPG0974 (Table 4.5). When adding 250 mM of C3, only a 5.3-fold increase 
was observed, which was not quite statistically significant. These observations 
were unexpected, as increasing concentrations of C3 and compound 1 were both 
able to fully out-compete [3H]-GLPG0974 (see section 3.2.1) and Schild plots  
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Table 4.5 Effect of different ligands on the [3H]-GLPG0974 dissociation rate 
Parameter 
70-fold 
dilutiona 
Antagonistb Agonistb 
CATPB MeCATPBa MeGLPG-1a C3 Compound 1 
Koff 
(min-1) 
0.013 
0.014 ± 
0.001 
0.019 0.020 
0.074 ± 
0.015 
0.187 ±  
0.058* 
a Experiment performed once, therefore no SEM can be determined. 
b [3H]-GLPG0974 dissociation was monitored by addition of 10 µM of respective antagonist, 
250 mM C3 or 30 µM compound 1. 
* Analysis of values by one-way ANOVA followed by Dunnett’s test with the value determined by 
addition of CATPB as a reference with significant differences denoted as P = ** ≤ 0.01 and P = *** ≤ 
0.001. 
 
suggested that GLPG0974 is a competitive, reversible antagonist of C3 and 
compound 1 (see section 3.2.3). Although it is challenging to interpret these 
results, discussion section 4.3.4 will attempt to provide hypotheses that may 
provide an explanation. 
4.3 Discussion 
4.3.1 FFA2 agonists are defined by their interaction with the 
Arg180-His242-Arg255 triad 
The interactions formed between a ligand and its receptor are one of the 
defining factors of ligand pharmacology. Agonists engage the receptor in a 
fashion that causes the receptor conformation to favour an active state. In 
contrast, antagonists bind to the receptor but do not promote conformational 
rearrangements, unless the antagonist has the capacity to act as an inverse 
agonist that shifts the conformational equilibrium towards an inactive state. 
Therefore, although orthosteric agonists and antagonists by definition occupy 
the same endogenous binding pocket of the receptor, the nature of their 
interaction with the receptor must differ to allow for their distinct 
pharmacological actions. In the case of FFA2, the orthosteric arginine pair 
Arg1805.39 and Arg2557.39, as well as His2426.55, are thought to define the 
orthosteric binding site as their replacement with alanine resulted in loss of 
endogenous agonist action (Stoddart et al., 2008, Hudson et al., 2013a). SCFAs 
contain only one functional group, a carboxylate moiety, and its replacement 
with an amide renders SCFAs inactive at FFA2 (Schmidt et al., 2011). Therefore, 
a link between the FFA2 agonist carboxylate and the orthosteric Arg180-His242-
Arg255 triad was established almost a decade ago. Furthermore, the importance 
of the orthosteric arginine pair is exemplified by the fact that it is conserved 
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between the majority of FFA receptor family members including FFA1 (Arg1835.39 
and Arg2587.35) and FFA3 (Arg1855.39 and Arg2587.35). Alanine replacement of 
these arginines in FFA1 (Sum et al., 2007) or FFA3 (Stoddart et al., 2008) also 
affected agonist potency. Therefore, the carboxylate recognition by the 
orthosteric arginine pair does not only appear to be important for binding of 
SCFAs to FFA2 and FFA3, but also for binding of agonists to FFA1. However, all 
previous evidence on FFA2 has been based on investigation of agonist potency in 
functional assays. Although this information undoubtedly demonstrates that the 
Arg180-His242-Arg255 triad is important for agonist action, it does not allow 
differentiation between agonist affinity and efficacy. Therefore, it was not clear 
whether alanine replacement of Arg1805.39, Arg2557.35 or His2426.55 resulted in a 
loss of agonist binding or agonist ability to promote an active receptor state. 
By developing a radioligand competition assay using the tritiated FFA2 antagonist 
[3H]-GLPG0974, data presented in this chapter demonstrated that agonist 
binding is indeed lost at R180A, R255A and H242A hFFA2. Docking of the 
endogenous SCFA C3 and synthetic agonist compound 1 into a homology model of 
hFFA2 revealed that the agonist carboxylate is indeed strictly coordinated by the 
orthosteric arginine pair with His2426.55 potentially playing a coordinating role 
for Arg2557.35. In contrast, antagonist binding poses showed a potentially weaker 
and differently oriented interaction with orthosteric arginines and no 
requirement of a carboxylate moiety for antagonist action, which will be 
discussed in more detail below. What could these observations suggest 
considering the different actions of agonists and antagonists? Potentially the 
engagement of the arginine pair observed in the FFA2 agonist docking represents 
the first step in the cascade of conformational rearrangements that result in an 
equilibrium shift to an active state receptor. In particular, considering that the 
functional groups of SCFAs are limited to a carboxylate, it is likely that this 
interaction with the receptor confers the activation mechanism. Interestingly, 
attempts to understand the molecular basis of differences in constitutive 
activity between FFA2 orthologues revealed that an ionic lock between a 
glutamic acid residue in the ECL2 of mFFA2 and orthosteric arginine residues was 
likely to be responsible for a reduced level of constitutive activity compared to 
hFFA2 (Hudson et al., 2012b). Similar results could be obtained for FFA1 in which 
two ionic locks between glutamic acid residues in ECL2 and the orthosteric 
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arginines limited the constitutive activity of the receptor and were thought to 
be broken by agonist binding (Sum et al., 2007). These studies provide further 
support for a role of Arg1805.39 and Arg2557.35 in FFA2 receptor activation. 
However, as the allosteric ligands 4-CMTB and AZ1729 retain the ability to 
activate R180A and R255A hFFA2, the receptor can still enter an active state 
conformation in the absence of the orthosteric arginine residues, perhaps 
through a different mechanism. 
4.3.2 Key orthosteric binding site residues play limited role in 
hFFA2 antagonist binding 
Multiple antagonists of hFFA2 also contain a carboxylate moiety, which was 
thought to be a defining factor of orthosteric FFA2 ligands. While the presence 
of a carboxylate moiety certainly contributes to increased affinity of 
antagonists, as demonstrated in sections 3.2.4 and 4.2.3, and in the 
development of GLPG0974 (Pizzonero et al., 2014), it is not an absolute 
requirement for antagonist binding. This was exemplified in the ability of 
[3H]-GLPG0974 to bind with comparably high affinity to R180A, R255A and H242A 
hFFA2 and the capacity of CATPB and GLPG0974 to fully out-compete the 
radioligand at respective mutants. The affinity of CATPB and GLPG0974 was only 
modestly affected at the alanine replacement mutants of the orthosteric 
arginines and was unchanged or even increased, in the case of GLPG0974, at 
H242A hFFA2. Furthermore, binding studies at R180A and R255A hFFA2 suggested 
that CATPB and GLPG0974 may prefer to interact with different arginine 
residues, with CATPB affinity being most affected by alanine replacement of 
Arg2557.35 and GLPG0974 by Arg1805.39. This was reflected in binding poses 
obtained for hFFA2 antagonists in which CATPB and GLPG0974 showed lower-
energy poses when interacting with Arg2557.35 and Arg1805.39, respectively. 
However, the lack of specific [3H]-GLPG0974 binding to the dual arginine mutant 
R180A-R255A hFFA2 suggests that at least one arginine residue is required for 
antagonist interaction with the receptor. However, the concentration range of 
radioligand that can be employed in binding assays is limited by the increasing 
nonspecific binding at high radioligand concentrations. Therefore, it may be 
possible that [3H]-GLPG0974 binds to R180A-R255A hFFA2 with an affinity in the 
µM range, which cannot be detected in radioligand binding assays. An alternative 
hypothesis may be that mutation of both Arg1805.39 and Arg2557.35 to alanine 
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leads to a conformational rearrangement of the hFFA2 binding pocket, which 
could result in drastically reduced radioligand affinity. 
To investigate the interaction between the hFFA2 antagonist carboxylate and 
the orthosteric arginines in an alternative fashion, analogues of GLPG0974 and 
CATPB with carboxylate modifications were employed. As anticipated from 
functional studies described in chapter 3 (see section 3.2.4), the affinity of 
methyl ester and morpholine analogues at wild type hFFA2 was indeed reduced 
compared to their carboxylate equivalents. Interestingly, the extent of the 
impact of carboxylate replacement appears to differ between different 
antagonist analogues. While CATPB and GLPG-1 affinities were reduced by over 
10-fold by replacement of carboxylate with a methyl ester, the affinity of 
MeGLPG-2 was only reduced by 3-fold compared to GLPG-2. This indicates that 
GLPG-2 is likely to form additional interactions outside of the orthosteric binding 
pocket. Structurally, GLPG-2 contains one more carbon in the benzothiophene 
linker that may result in a different orientation of the benzothiophene group 
compared to GLPG-1, which could allow MeGLPG-2 to make additional 
interactions compared to MeGLPG-1. Interestingly, R180A and R255A mutations 
had little effect on methyl ester analogue affinity and the affinity of MeGLPG-1 
was actually increased at both mutants. Potentially alanine replacement of one 
orthosteric arginine results in more space in the binding pocket to accommodate 
the methyl ester, which could form a hydrogen bond with the remaining arginine 
residue. This leads to one important question that remains: Do all or some 
methyl ester analogues have the ability to interact with R180A-R255A hFFA2? 
Unfortunately, without a labelled probe that binds the double arginine mutant of 
hFFA2 it is challenging to answer this question, however it will be addressed 
further in chapter 5. 
4.3.3 Relationship between FFA2 antagonist interaction with 
orthosteric arginine residues and binding kinetics 
The residence time of ligands at the receptor binding pocket has become an 
increasingly important factor to consider in drug discovery (Guo et al., 2014). 
Relating specific interactions between ligand and receptor with ligand binding 
kinetics could be a first step in the rational design of compounds with a desired 
kinetic profile. In the case of FFA2, the Arg180-Arg255 pair is one of the defining 
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factors of the orthosteric binding pocket that may translate receptor activation 
and limit the constitutive activity of the murine orthologue by forming an ionic 
lock with a glutamic acid residue in ECL2 (Hudson et al., 2012b). Interestingly, 
although alanine replacement of Arg1805.39 or Arg2557.35 did not have a major 
effect on [3H]-GLPG0974 affinity, its binding kinetics were more significantly 
affected. In particular the dissociation rate of [3H]-GLPG0974 was increased 
drastically compared to wild type hFFA2, suggesting that the orthosteric 
arginines play an important role in prolonging the residence time of 
[3H]-GLPG0974. This observation highlights that it can be of value to not only 
consider the effect of mutations on ligand affinity, but also on its binding 
kinetics as these may be affected even if ligand affinity is unchanged. 
CATPB (Brantis et al., 2011) and GLPG0974 (Pizzonero et al., 2014) are currently 
the highest-affinity published hFFA2 antagonists and originate from different 
compound series. In particular GLPG0974 has attracted much attention as it is 
the first and only hFFA2 ligand that has entered clinical trials (Vermeire et al., 
2015). However, even though the ability of GLPG0974 to inhibit neutrophil 
migration through FFA2 could be demonstrated in patients, it did not lead to 
improvement in ulcerative colitis symptoms. Although functional inhibition of 
the hFFA2 response to C3 (see section 3.2.1) and [3H]-GLPG0974 competition 
assays (see section 4.2.2) suggested that CATPB and GLPG0974 are equivalent in 
affinity for hFFA2, distinct pharmacological behaviour in the BRET-based 
β-arrestin 2 recruitment assay, which has a relatively short incubation time, 
suggested that CATPB and GLPG0974 may have different kinetic profiles. To 
examine this hypothesis further, a competitive kinetic binding assay was 
employed, in which the effect of increasing concentrations of an unlabelled 
ligand on [3H]-GLPG0974 association was assessed. Interestingly, this experiment 
indeed revealed that GLPG0974 and CATPB have different kinetic profiles with 
GLPG0974 associating and dissociating relatively slowly and CATPB showing 
significantly faster kinetics. The dissociation half-time of GLPG0974 equals 
48 min, while the dissociation half-time of CATPB equals 11 min, which 
highlights that the two antagonists spend different amounts of time bound to the 
receptor (Table 4.4). How could this observation be explained structurally? 
When docking both antagonists into the homology model of hFFA2, CATPB and 
GLPG0974 adopted relatively similar poses. Perhaps the preferred interaction 
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with different arginines could result in different kinetic profiles? Alanine 
replacement of Arg1805.39 or Arg2557.35 did affect [3H]-GLPG0974 kinetics, as 
discussed above, so these residues do seem to play a role in regulating binding 
kinetics. However, additional studies are certainly required to dissect the 
determinants of GLPG0974 and CATPB binding kinetics more closely. 
In an effort to understand how the interaction between antagonist carboxylate 
and orthosteric arginines defines binding kinetics, the kinetic profile of GLPG-1 
and MeGLPG-1 was determined and compared. Interestingly, the replacement of 
the carboxylate with a methyl ester primarily affected ligand association such 
that MeGLPG-1 required more time to bind to the receptor than GLPG-1, while 
the association rate was not significantly changed. Therefore, the interaction 
between carboxylate and orthosteric arginines potentially serves as a guide for 
ligand association with the receptor that allows the ligand to adopt its final 
conformation more quickly. 
4.3.4 Cooperative effect of hFFA2 agonists on [3H]-GLPG0974 
kinetics may be rooted in co-binding or cross-dimer 
cooperativity 
Functional studies described in chapter 3 and [3H]-GLPG0974 competition 
binding assays outlined here suggest that GLPG0974 is an orthosteric ligand that 
is a competitive, reversible antagonist at hFFA2. The surmountable right-shifted 
effect of increasing concentrations of GLPG0974 on the C3 and compound 1 
concentration response curves is typical for a competitive antagonist (see 
section 3.2.3). Furthermore, resulting Schild plots had a slope close to unity and 
the pA2 determined from the x-axis intercept of such plots was a good estimate 
of GLPG0974 affinity determined in [3H]-GLPG0974 saturation binding assays, 
which serves as additional support for competitive antagonism. C3 and 
compound 1 were also able to fully out-compete [3H]-GLPG0974 at wild type 
hFFA2, which suggests that they bind to the same orthosteric site on the 
receptor. Therefore, the enhancing effect of agonists on the dissociation rate of 
[3H]-GLPG0974 was surprising, as this is traditionally associated with negative 
cooperative modulation of co-bound ligand affinity by allosteric ligands (Leppik 
et al., 1998) and the majority of evidence supports that GLPG0974 is an 
orthosteric ligand. Of course, conceptually, it could be possible that GLPG0974 is 
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actually an allosteric ligand that has such a strong cooperative effect on C3 
affinity, and vice versa, that it behaves like an orthosteric ligand in functional 
and binding assays (Christopoulos and Kenakin, 2002). However, although the 
dependence of agonist and antagonist binding on orthosteric arginine residues 
differs, mutation of Arg1805.39 or Arg2557.35 does impact antagonist binding 
kinetics and alanine replacement of both arginine residues results in loss of 
detectable [3H]-GLPG0974 binding, therefore it is very likely that GLPG0974 does 
indeed interact with Arg1805.39 or Arg2557.35. Thus, what could serve as a 
feasible explanation for the cooperative effect of C3 and compound 1 on the 
dissociation of [3H]-GLPG0974? 
If C3 or compound 1 and GLPG0974 were able to engage the receptor binding 
pocket simultaneously, this may result in a very strong negative cooperative 
effect and would explain why both agonists and GLPG0974 are affected by 
mutations of the orthosteric arginines. The pKa of the arginine side chain is 12.5, 
which means that arginine will be positively charged at physiological pH and is 
thus able to form five hydrogen bonds through its protonated guanidinium group 
(Borders et al., 1994). Therefore, it could theoretically be possible for C3 and 
GLPG0974 to interact with the orthosteric arginine simultaneously, in particular 
as C3 is a relatively small molecule and could likely accommodate binding of 
GLPG0974. To assess the hypothesis, the effect of Arg1805.39 or Arg2557.35 
alteration to a different positively charged residue such as lysine could be 
investigated, as such a mutation would retain the positive charge but allow less 
hydrogen bonding interactions. However, it is less likely that compound 1 and 
GLPG0974 can bind to the same site simultaneously as both are relatively bulky 
molecules and predicted binding poses in the hFFA2 homology model overlap. 
Furthermore, Schild plots assessing the effect of increasing GLPG0974 
concentrations on the C3 and compound 1 concentration response curve showed 
a Schild slope close to unity and both agonists were able to fully outcompete 
[3H]-GLPG0974 in competition binding assays, which are clear indications of 
competitive antagonism that conceptually contradicts simultaneous binding. 
A different explanation for the enhancing effect of agonists on the 
[3H]-GLPG0974 dissociation rate may be that hFFA2 contains two separate non-
overlapping binding pockets that meet at the orthosteric arginine residues. As 
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both GLPG0974 and CATPB only require one of the two orthosteric arginine 
residues for interaction with the receptor, this would suggest that the remaining 
arginine is at least somewhat available to bind the carboxylate moiety of C3 or 
compound 1. Although both agonists required two arginine residues to fully bind 
to hFFA2, perhaps engagement of the first arginine residue increases the 
dissociation rate of the antagonists, which was observed for [3H]-GLPG0974 upon 
alteration of either Arg1805.39 or Arg2557.35 to alanine. This would allow agonists 
to engage the other arginine residue and fully bind. Thereby the orthosteric 
arginine residues would be required for binding to both pockets and when an 
agonist enters the pocket it could, in a sense, 'pull' the arginine away from the 
already bound antagonist. This would result in competitive behaviour as binding 
of agonists and antagonists is mutually exclusive, but account for the impact of 
agonist binding on antagonist dissociation rate. Molecular dynamics simulations 
may shine some light on this. 
Finally, there is growing evidence that allosteric modulation can also occur 
across GPCR homodimers (Gherbi et al., 2015, Lane et al., 2014, May et al., 
2011). The bitopic allosteric modulator of the dopamine D2 receptor, SB269652, 
lost its allosteric effect when ligand binding to one of the protomers was 
impaired and engagement of the secondary pocket was a requirement for its 
allosteric behaviour (Lane et al., 2014). One could argue that GLPG0974, and 
indeed all synthetic orthosteric ligands of FFA2, are actually bitopic ligands as 
they will undoubtedly occupy a larger area of the binding pocket than SCFAs. 
Furthermore, a recent study demonstrated by utilising a FRET-based approach 
that FFA2 does form homodimers, as well as heterodimers with FFA3 (Ang et al., 
2017). To explore this further, an assessment of the impact of C3 or compound 1 
on [3H]-GLPG0974 dissociation in membranes that co-express wild type and 
R180A-R255A hFFA2 could be performed. The presence of a receptor form that 
cannot bind ligand, such as R180A-R255A hFFA2, should reduce the amount of 
wild type hFFA2 homodimers and would, conceptually, result in a reduction in 
the cooperative effect of C3 and compound 1 on [3H]-GLPG0974 dissociation, if 
this hypothesis is indeed true. An equivalent approach was successfully applied 
previously to confirm that cooperative interactions between two adenosine A3 
receptor ligands occurred across dimers (May et al., 2011). 
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4.4 Conclusions 
Radioligands can be important tools in understanding ligand pharmacology at 
GPCRs and herein [3H]-GLPG0974 did indeed facilitate the analysis of hFFA2 
ligand binding determinants and kinetics. While the Arg180-His242-Arg255 triad 
was essential for agonist binding to hFFA2, antagonist binding was less reliant on 
interaction with these key orthosteric residues, however at least one arginine 
was required to allow radioligand binding. This appears to be linked with the 
importance of the carboxylate moiety present in many orthosteric ligands of 
FFA2, which was crucial for agonist action (Schmidt et al., 2011, Hudson et al., 
2013a) but not antagonist binding. Therefore, in future development of FFA2 
ligands it should be ensured that a carboxylate moiety is set as a requirement 
for orthosteric agonist development, while this area of the molecule could be 
modified further for antagonists. Interestingly, different classes of hFFA2 
antagonists show distinct kinetic profiles, which suggests that it may be possible 
to optimise antagonists for a long or short residence time. It could be of interest 
to relate structural features of antagonists with their kinetics to construct a 
“structure-kinetics relationship” for respective compound series. The use of 
ligands with different kinetic profiles in physiological systems could contribute 
to understanding the desired kinetic properties of ligands that target FFA2. 
However, the use of antagonists in rodent models of disease remains limited by 
the species-selectivity of antagonists for the human orthologue, which will be 
addressed in chapter 6. In conclusion, data presented in this chapter provides 
novel insights into the basis of FFA2 ligand pharmacology and can provide 
guidance for development of novel and improved tool compounds.
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5 Development and characterisation of a 
fluorescent probe for FFA2 
5.1 Introduction 
Radioligand binding studies have played a tremendously important role in 
dissecting the pharmacology and function of GPCRs (Cooper et al., 2017). 
Applications of radioligands range from understanding the mode of ligand 
binding and defining receptor binding pockets (see chapter 4) to studying 
receptor oligomerisation (Ferreira et al., 2015) and tissue distribution (Sharif et 
al., 1999). However, radioligands have inherent limitations such as the safety 
requirements surrounding handling of radioactive materials. With recent 
advances in fluorescence-based methodologies for monitoring of protein-protein 
and protein-small molecule interactions, ligands that incorporate fluorophores 
have become established tools utilised to examine GPCR ligand binding and 
kinetics (Ma et al., 2014). The use of fluorescent probes has several advantages 
over conventional radioligand binding, including the circumvention of safety 
concerns regarding the use of radioactivity and the possibility to monitor ligand 
binding in real-time. Thereby the measurement of ligand binding kinetics can be 
greatly improved (May et al., 2011, Schiele et al., 2015), which is more difficult 
to achieve in a radioligand binding assay, and the interaction between ligand 
and receptor can even be visualised in a living cell (Daly et al., 2010). However, 
despite several advantages, fluorescent probes also have inherent limitations 
(Ma et al., 2014). Depending on the cell or tissue of interest, the emission 
spectrum of the fluorophore can fall into the spectrum of cellular 
autofluorescence, making it difficult to detect specific binding (Sklar et al., 
2002). This limitation is enhanced by the often high level of nonspecific binding 
observed for fluorescent ligands, which can result in an unfavourable signal-to-
noise ratio in applications such as cellular-based imaging (Leopoldo et al., 2009). 
One approach that can overcome issues arising from high nonspecific binding, 
combines fluorescent probes with proximity-based resonance energy transfer 
technology (Stoddart et al., 2015a, Christiansen et al., 2016). However, for 
detection of resonance energy transfer resulting from the fluorescent tracer 
binding to the receptor, the respective GPCR needs to be tagged with an 
appropriate fluorescence or bioluminescence donor such as in the case of 
bioluminescence, a luciferase enzyme. Therefore, such an approach is primarily 
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limited to heterologous expression systems. Taken together the benefits of using 
fluorescence over radioligand binding assay depend on the context of the study 
and the availability of a suitable fluorescent tracer. From a drug discovery 
perspective, fluorescence-based binding assays are attractive screening systems 
as they can, once established and optimised, be scaled up relatively easily to a 
high-throughput plate format and may be more cost-effective than radioligand 
binding assays (Janzen, 2014).  
The investigation of FFA2 ligand binding determinants utilising the tritiated 
radioligand [3H]-GLPG0974 provided crucial information on the orthosteric 
binding pocket of FFA2 and the binding kinetics of distinct compound series (see 
chapter 4). Development of a fluorescent probe would expand the repertoire of 
tools available to examine FFA2 pharmacology and assess its drug target 
potential. A recent study successfully developed a BRET-based binding assay for 
FFA1 using a newly synthesised fluorescent tracer (Christiansen et al., 2016). 
This was achieved by linking an appropriate fluorophore to a FFA1 ligand that 
acted as a BRET acceptor and fusing a luciferase to the receptor N terminus, 
which served as a BRET donor in the presence of a substrate. For BRET-based 
assays that were employed previously to monitor β-arrestin recruitment, a 
luciferase cloned from sea pansy Renilla reniformis was fused to β-arrestin (see 
chapter 3). However, for the purpose of developing a BRET-based ligand binding 
assay, a different luciferase variant was utilised that was recently isolated from 
deep sea shrimp Oplophorus gracilitostris (Hall et al., 2012). The small 
luciferase subunit of the isolated enzyme was heavily engineered to develop the 
Nanoluciferase (NLuc), which has a relatively small size of 19 kDa, shows 
enhanced stability and produces a 150-fold brighter luminescent signal. The 
small size of NLuc and the fact that it has been engineered from a naturally 
secreted protein makes it less likely that N-terminal fusion will disrupt receptor 
trafficking and function (Hall et al., 2012). Indeed, in a study that developed a 
BRET binding assay for the β2AR, a signal representing specific ligand binding 
could only be detected using NLuc and not the Renilla luciferase variant RLuc8 
(Stoddart et al., 2015a). 
The basic requirement for a BRET reaction to take place is the overlap of donor 
emission and acceptor excitation spectra. Furthermore, the acceptor emission 
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spectrum should overlap as little as possible with the emission spectrum of the 
donor to avoid donor bleed-through during detection. These factors usually 
contribute to the selection of an appropriate luciferase and fluorophore pair. In 
the case of the BRET binding assay developed for FFA1, the nitrobenzoxadiazole 
(NBD) fluorophore was selected to complement NLuc-tagged FFA1 (Christiansen 
et al., 2016). How was this decision rationalised? Most importantly, the 
excitation spectrum of NBD matches the NLuc emission spectrum almost exactly, 
while there is little overlap with the NBD emission spectrum (Figure 5.1A). 
Furthermore, NBD is relatively small compared to other commonly employed 
fluorophores and therefore linking of NBD to a high-affinity ligand may be less 
likely to interfere with ligand binding. However, this will depend on the point of 
attachment and can be difficult to predict. Another important property of NBD is 
its solvatochromic behaviour, which refers to the solvent-dependence of NBD 
fluorescence. In a polar environment, such as common aqueous buffer solutions, 
NBD fluorescence is almost fully quenched, while in nonpolar environments, such 
as in organic solvents, or indeed deep ligand binding pockets or cell membranes, 
its fluorescence is high (Lin and Struve, 1991). Therefore, background 
fluorescence of NBD in aqueous environments is almost non-existent.  
 
Figure 5.1 Principle of a BRET binding assay (A) The excitation (Ex) and emission (Em) spectra 
of fluorophore NBD (green) and emission spectrum of NLuc (blue) is shown. The overlap between 
the NBD excitation and NLuc emission spectra is highlighted in light green. (B) The Nanoluciferase 
(NLuc) that is fused to the N terminus of the receptor of interest emits light at 460 nm. When a 
suitable fluorophore such as NBD is in close enough proximity to NLuc, bioluminescence 
resonance energy transfer (BRET) takes place, which results in excitation of the fluorophore and 
emission of light centred at 545 nm. The BRET reaction depends on the distance between donor 
and acceptor, therefore unbound NBD-labelled ligand in the medium is not excited. The 
solvatochromic properties of NBD result in quenching of its fluorescence in an aqueous 
environment, therefore signal from unbound fluorophore should be minimal. 
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Furthermore, NBD has been employed previously for labelling of small molecules 
(Turcatti et al., 1995, Petrov et al., 2011). Therefore, NBD was selected as the 
complementing fluorophore for NLuc to develop a BRET binding assay (Figure 
5.1B). 
This chapter aimed to develop a fluorescent probe for the orthosteric binding 
site of FFA2 to be employed in a BRET binding assay. A selection of potential 
fluorescent tracers was synthesised by linking NBD to different parent molecules 
in collaboration with Dr Hansen in Professor Ulven’s group at the University of 
Southern Denmark. After assessing how fluorophore attachment affected the 
function and binding affinity of resulting fluorescent probes, one candidate was 
selected for further studies. The fluorescent probe F-1 was utilised to develop a 
BRET binding assay, which was employed to measure the binding affinity and 
kinetics of unlabelled orthosteric antagonists for hFFA2. Furthermore, the 
binding site of F-1 was examined by assessing the effect of orthosteric binding 
site mutants of FFA2 on fluorescent probe affinity. Thereby, by following a 
strategy previously successfully applied for FFA1 (Christiansen et al., 2016), a 
BRET binding assay for FFA2 was successfully developed that could find use in a 
variety of applications. Furthermore, work presented in this chapter also 
highlights important considerations for development of fluorescent ligands and 
their suitability to explore ligand binding sites. 
5.2 Results 
5.2.1 Development of a FFA2 fluorescent ligand for BRET binding 
assays 
Although NBD is a relatively small fluorophore, linking it to an existing FFA2 
ligand is highly likely to affect the pharmacology and affinity of the parent 
molecule, hence the point of fluorophore attachment needs to be chosen with 
care. Structural investigations of the GLPG0974 and CATPB hFFA2 antagonist 
series showed that the carboxylate moiety was not necessary for high-affinity 
ligand binding and replacement of the carboxylate with larger functional groups 
was well tolerated, such as the morpholine group in MoGLPG-2 (see section 3.2.4 
and 4.2.3). Therefore, the antagonist carboxylate moiety was selected for 
attachment of the linker and NBD fluorophore. Two potential fluorescent probes 
Chapter 5  143 
 
were generated following this strategy: F-1, based on GLPG0974 analogue 
GLPG-3, which has an additional carbon in the benzothiophene linker and a para-
trifluoromethyl substitution of the benzene ring in place of the meta-
chlorobenzene in GLPG0974; and F-2, which is structurally related to CATPB 
(Figure 5.2A). Among available GLPG0974 analogues GLPG-3 was selected to 
generate a potential fluorescent tracer as its functional groups were least prone 
to secondary reactions during chemical synthesis and attachment of the 
fluorophore, thereby resulting in a higher yield. A further fluorescent probe was 
generated based on the structure of the FFA2 agonist compound 2-23, which 
showed highest potency among screened compound 2 analogues (see section 
3.2.2). Modifications of the northern region were relatively well tolerated; 
therefore, the NBD fluorophore was attached with a short linker to the northern 
 
Figure 5.2 Assessment of function and binding of potential fluorescent tracers for hFFA2 
Structures of potential fluorescent probes F-1, F-2 and F-3 are shown with the nitrobenzoxadiazole 
(NBD) fluorophore highlighted in green and the linker in blue (A). The ability of antagonist-based 
tracers F-1 and F-2 to inhibit the response of hFFA2 to 1 mM C3 in IP1 accumulation assays and 
the ability of the agonist-based tracer F-3 to induce accumulation of IP1 in Flp-InTM T-RExTM 293 
cells induced to express hFFA2-eYFP was assessed (B). The capacity of increasing 
concentrations of F-1, F-2 and F-3 to compete with 10 nM [3H]-GLPG0974 for binding to 
membranes isolated from Flp-InTM T-RExTM 293 cells induced to express hFFA2-eYFP is shown 
from representative experiments (C). IP1 accumulation data was normalised to the response 
induced by 1 mM C3 for F-1 and F-2, and to the maximal response induced by C3 for F-3. Data are 
means pooled from independent experiments (n ≥ 3) that were performed in duplicate (B). 
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Table 5.1 Affinity and potency of potential fluorescent tracers for hFFA2 
Assay F-1a F-2a F-3b 
IP1 accumulation 
(pI/EC50) 
6.57 ± 0.10 < 4.50 < 4.50 
[3H]-GLPG0974 
competition (pKi) 
7.29 ± 0.07 7.26 ± 0.10 < 4.50 
BRET saturation 
binding (Kd) 
65.1 ± 1.8 nM 815 ± 192 nM > 2 µM 
a IP1 accumulation assay data shown as pIC50 
b IP1 accumulation assay data shown as pEC50 
 
benzene ring (Figure 5.2A). Following fluorescent ligand synthesis, the effect of 
the linker and NBD fluorophore addition on the pharmacological function and 
binding affinity of the prospective fluorescent tracers was examined. In IP1 
accumulation assays F-1 and F-2 both retained the ability to inhibit the response 
of hFFA2 to an EC80 concentration of C3 (Figure 5.2B). However, F-1 was at least 
100-fold more potent than F-2 (Table 5.1) and inhibition by F-2 did not reach a 
plateau at concentrations of up to 30 µM (Figure 5.2B). The potency of the 
agonist-based fluorescent probe F-3 was also affected by attachment of the NBD 
fluorophore and F-3 was only able to induce IP1 accumulation at concentrations 
of 10 µM and above (Figure 5.2B). Although the affinity of F-1 and F-2 was not 
significantly different in [3H]-GLPG0974 competition binding assays (Table 5.1), 
F-2 was only able to outcompete approximately 80% of [3H]-GLPG0974 (Figure 
5.2C), which suggested that F-2 may bind to a different site than [3H]-GLPG0974 
and could therefore be acting in an allosteric fashion. Furthermore, the modest 
ability of F-2 to inhibit the response of hFFA2 to C3 in the IP1 accumulation 
assay did not correlate with the high affinity determined in the [3H]-GLPG0974 
competition binding assay (Table 5.1), which also implied that F-2 has a 
complex pharmacology and may allosterically modulate [3H]-GLPG0974 binding 
and/or C3 potency or efficacy. F-3 was also not able to fully outcompete 
[3H]-GLPG0974 when using concentrations of up to 100 µM (Figure 5.2C), 
however, as the competition curve does not reach a plateau, this is most likely 
due to the low affinity of F-3 for hFFA2, which was anticipated from the poor 
potency of F-3 in the IP1 accumulation assay (Figure 5.2B). 
Following this initial assessment, the suitability of F-1, F-2 and F-3 for a BRET 
binding assay was examined. For the purpose of the BRET binding assay, a 
Flp-InTM T-RExTM cell line was generated that stably expressed hFFA2 fused N-
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terminally to NLuc in a doxycycline-inducible fashion. This cell line was 
extensively employed in functional and binding studies described in chapter 6, 
which confirmed expression levels and receptor functionality. As anticipated 
from the good performance in functional and binding assays, F-1 showed the 
highest affinity among the selection of fluorescent ligands (Table 5.1) with a 
good total to nonspecific signal ratio (Figure 5.3A and B). In contrast, the 
affinity of F-2 was 13-fold lower (Table 5.1). To determine the signal resulting 
from nonspecific binding of F-1 and F-2, synthesis intermediates LinkGLPG-3 and  
 
Figure 5.3 Fluorescent tracer F-1 shows highest affinity for hFFA2 in the BRET binding 
assay Binding of increasing concentrations of F-1 (A, B), F-2 (C, D) and F-3 (E, F) to membranes 
isolated from cells induced to express NLuc-hFFA2 is shown from representative experiments. 
Nonspecific binding of F-1 and F-2 was determined in presence of 50 µM LinkGLPG-3 and 100 µM 
LinkCATPB, respectively. The nonspecific signal was subtracted from the total signal to calculate 
the specific signal. To determine nonspecific binding of F-3, 100 µM compound 1 (E) or compound 
2-23 (F) were employed, but no specific signal could be detected. 
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LinkCATPB were employed to compete with respective fluorescent ligands for 
binding to the specific binding pocket. These compounds contain a tert-
butyloxycarbonyl (BOC) group in place of the NBD fluorophore, which served as a 
protecting group of one of the linker amines during linker attachment. As these 
linker intermediates are identical to the fluorescent tracers apart from the 
attached fluorophore, they are likely to occupy the same binding site and can 
therefore be employed to determine the level of nonspecific binding of the 
tracers. For agonist-based fluorophore F-3 such a linker intermediate was not 
available, and it is difficult to predict the binding site of the tracer after 
fluorophore attachment. However, F-3 retained some agonist activity (Figure 
5.2B) and homology modelling studies in chapter 4 suggested that orthosteric 
agonists need to adapt similar binding poses to engage Arg1805.39 and Arg2557.39 
in a specific fashion to induce receptor activation. Therefore, synthetic agonists 
compound 1 (Figure 5.3E) and compound 2-23 (Figure 5.3F) were employed for 
quantification of the nonspecific signal. However, no specific signal representing 
F-3 binding was detected at concentrations of up to 2 µM, which suggested that 
the affinity of F-3 was indeed significantly lower than that of F-1 or F-2. 
The results in the IP1 accumulation, [3H]-GLPG0974 competition and BRET 
binding assay demonstrated that F-1 had the best properties among fluorescent 
ligands tested. This compound showed the highest affinity and seemed to 
associate with the orthosteric site, unlike F-2, which appears to be allosteric. As 
the primary aim of this work was to generate an orthosteric probe, F-1 was 
employed in further investigations. However, more detailed characterisation of 
F-2 may facilitate development of a fluorescent probe for an allosteric binding 
site of FFA2, which could also be of value. 
5.2.2 Real-time tracking of F-1 association and dissociation 
The ability to track the binding kinetics of fluorescent ligands in real-time is one 
key advantage of fluorescent over radioactive ligand binding assays. Filtration-
based kinetic binding assays that employ a radioligand are time-consuming and 
work-intensive because they need to be performed in a time-staggered manner. 
In contrast, light emission of the BRET donor and acceptor can be monitored in 
real-time using an appropriate plate reader. To measure dissociation of F-1 an 
“infinite dilution” approach was employed, which was achieved by 
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centrifugation of membranes expressing NLuc-hFFA2 with pre-associated F-1, 
aspiration of supernatant containing free fluorescent ligand and addition of 
binding buffer to dilute the membrane pellet by at least 100-fold. Measurement 
of the resulting reduction in the specific BRET ratio allowed determination of 
the Koff of F-1 (Figure 5.4A), which was 0.0237 ± 0.0016 min-1. The Kon of F-1 
was determined by monitoring association of four concentrations of F-1 in 
parallel (Figure 5.4B), which resulted in an estimated association rate of 
368,000 ± 29,300 M-1 min-1. In agreement with the law of mass action, the 
association half-time increased with ligand concentration. Using the kinetic rate 
constants determined for F-1 in figure 5.4, the affinity of the fluorescent ligand 
was calculated by dividing the Koff by the Kon, yielding a Kd of 67.7 ± 5.9 nM, 
which is close to the affinity determined in saturation binding (Table 5.1). 
 
Figure 5.4 BRET binding assay can be employed to monitor F-1 binding kinetics in real-time 
Dissociation of 100 nM F-1 from NLuc-hFFA2 was induced by preventing rebinding using an 
“infinite dilution” approach after 2 h pre-association of F-1 and was monitored over time (A). 
Association of varying concentrations of F-1 to NLuc-hFFA2 is shown (B). Nonspecific binding was 
determined in presence of 50 µM LinkGLPG-3 and subtracted from the total signal to obtain the 
specific signal. Data from representative experiments are shown. 
 
5.2.3 Assessment of hFFA2 antagonist binding and kinetics using 
fluorescent ligand F-1 
As the BRET binding assay was, in part, developed with the aim to establish a 
novel compound screening system, the suitability of F-1 for competition binding 
assays was assessed using a selection of hFFA2 antagonists: GLPG0974 (Figure 
5.5A), CATPB (Figure 5.5B) and MeCATPB (Figure 5.5C). All three ligands were 
able to fully outcompete F-1 and with increasing concentrations of F-1 a 
rightward shift of the competition curve could be observed (Figure 5.5), while 
the Ki values determined from competition binding curves with different  
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Figure 5.5 F-1 competition binding assay can be employed to determine unlabelled hFFA2 
antagonist affinity The ability of increasing concentrations of GLPG0974 (A), CATPB (B) and 
MeCATPB (C) to compete with varying concentrations of F-1 for binding to NLuc-hFFA2 is shown 
from representative experiments. Nonspecific binding was determined in presence of 50 µM 
LinkGLPG-3 and subtracted from the total signal to obtain the specific signal. 
 
concentrations of F-1 were consistent. Taken together, these observations 
suggest a competitive relationship between competing and fluorescent ligand. In 
agreement with previous investigations of antagonist analogues (see section 
4.2.3), replacement of the CATPB carboxylate with a methyl ester resulted in a 
26-fold decrease in affinity (Table 5.2). Therefore, the F-1 competition binding 
assay was indeed capable of detecting similar trends as the radioligand 
competition binding assay. However, the estimated affinity of GLPG0974 was 
lower than previously determined in [3H]-GLPG0974 competition binding assays, 
where the Ki of GLPG0974 was estimated at 13 nM (see chapter 4), while binding 
assays utilising F-1 yielded a Ki of approximately 70 nM (Table 5.2). 
Table 5.2 Affinities of hFFA2 antagonists determined in F-1 competition binding assay 
Compound GLPG0974 CATPB MeCATPB 
pKi 7.16 ± 0.03 7.84 ± 0.02 6.42 ± 0.03*** 
* Comparison of MeCATPB pKi values with CATPB by unpaired t test with significant differences 
denoted as P = *** ≤ 0.001 
 
Chapter 5  149 
 
 
Figure 5.6 Use of F-1 competitive kinetic binding assay to determine kinetic parameters of 
hFFA2 antagonists The association of 100 nM F-1 to NLuc-hFFA2 was monitored in the presence 
or absence of GLPG0974 (A) and CATPB (B). A competitive kinetic binding model (Dowling and 
Charlton, 2006) was used to fit shown data to estimate the kinetic parameters of unlabelled 
competing ligands and resulting analysis is shown in table 5.3. Respective Ki values of antagonists 
are shown in table 5.2. Nonspecific binding was determined in the presence of 50 µM LinkGLPG-3 
and subtracted from the total signal to obtain the specific signal. Data from representative 
experiments are shown. 
 
Assessment of GLPG0974 and CATPB binding kinetics in radioligand binding 
assays revealed that GLPG0974 has a significantly slower kinetic profile than 
CATPB (see section 4.2.6). To examine whether an equivalent competitive 
kinetic binding assay can be established using F-1, the effect of increasing 
concentrations of GLPG0974 (Figure 5.6A) and CATPB (Figure 5.6B) on the 
association rate of F-1 was monitored. Indeed, application of a competitive 
kinetic binding model allowed the estimation of association and dissociation 
rates of GLPG0974 and CATPB (Table 5.3). As observed in the radioligand-based 
competition kinetic binding assay, CATPB showed a significantly faster 
association and dissociation rate than GLPG0974 by 5-fold and 2-fold, 
respectively. Resulting Kd values calculated using the estimated rate constants 
(Table 5.3) correlated well with affinities determined in the equilibrium 
competition binding assay (Table 5.2). 
Table 5.3 Kinetics of FFA2 antagonists determined in F-1 competitive kinetic binding assay 
Parameter  GLPG0974 CATPB 
Koff (min-1) 0.0099 ± 0.0014 0.0205 ± 0.0010** 
Kon (M-1 min-1) 211,000 ± 4,780 1,083,000 ± 59,800*** 
Kda (nM) 46.9 ± 6.7 18.9 ± 1.4 
a Determined by dividing the Koff by the Kon value of at least three independent experiments 
* Analysis of Koff and Kon values by unpaired t test with significant differences denoted as P = ** ≤ 
0.01 and P = *** ≤ 0.001 
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5.2.4 FFA2 agonists and allosteric ligands cannot outcompete 
fluorescent ligand F-1 binding 
While the tested hFFA2 antagonists behaved in a competitive fashion with F-1, 
which allowed determination of unlabelled ligand affinity and binding kinetics, 
this does not seem to be the case for FFA2 agonists. Increasing concentrations of 
C3 and compound 1 were unable to fully outcompete F-1 (Figure 5.7A), which 
suggested that F-1 did not bind to the same site as these FFA2 agonists. Perhaps 
this observation was not fully unexpected, as the NBD fluorophore and linker 
were attached at the carboxylate moiety, which is thought to represent the 
main point of interaction with the orthosteric binding site. However, the ability 
of hFFA2 antagonists to fully outcompete F-1 binding suggested that the binding 
site of F-1 should, at least partially, overlap with that of orthosteric hFFA2 
antagonists. To examine whether the binding site of F-1 coincides with that of 
other allosteric FFA2 ligands, the effect of increasing concentrations of 4-CMTB 
and AZ1729 on the binding of F-1 was assessed (Figure 5.7B). Neither 4-CMTB 
nor AZ1729 affected binding of F-1, indicating that the F-1 binding site is distinct 
from that of other allosteric ligands. However, cooperativity between allosteric 
ligand and F-1 binding cannot be ruled out based on these results, as the F-1 
concentration employed may be too high to detect low levels of cooperativity. 
 
Figure 5.7 FFA2 agonists are unable to fully outcompete F-1 The ability of increasing 
concentrations of C3 and compound 1 (A), and 4-CMTB and AZ1729 (B) to compete with 100 nM 
F-1 for binding to NLuc-hFFA2 is shown from representative experiments. Nonspecific binding was 
determined in presence of 50 µM LinkGLPG-3 and subtracted from the total signal to obtain the 
specific signal. 
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5.2.5 Fluorescent ligand F-1 can be used to assess binding to 
R180A-R255A hFFA2 
The inability of FFA2 agonists C3 and compound 1 to fully outcompete F-1 at 
NLuc-hFFA2 suggested that the mode of F-1 binding to hFFA2 might be distinct 
to that of orthosteric ligands. To examine the binding site of F-1 in more detail, 
saturation binding assays were performed at alanine replacement mutants of key 
orthosteric binding site residues. F-1 affinity was increased significantly at single 
orthosteric arginine mutants R180A (Figure 5.8A) and R255A (Figure 5.8B) by 
5.2- and 6.6-fold, respectively. This result was in agreement with the 
observation that other antagonist analogues with modifications at the 
carboxylate moiety, such as methyl ester analogues, showed an increased 
affinity at R180A and R255A hFFA2 (see section 4.2.3). Interestingly, F-1  
 
Figure 5.8 Binding characteristics of F-1 to orthosteric binding site mutants of hFFA2 
Binding of F-1 to membranes isolated from Flp-InTM T-RExTM 293 cells induced to express mutant 
forms of NLuc-hFFA2 with alanine replacement of Arg1805.39 (A), Arg2557.35 (B) Arg1805.39 and 
Arg2557.35 (C) or His2426.55 (D) was assessed and is shown from representative experiments. 
Nonspecific binding was determined in presence of 50 µM (A, B, D) or 100 µM (C) LinkGLPG-3 
and subtracted from the total signal to obtain the specific signal. Kd values shown are means 
pooled from independent experiments (n ≥ 3) that were performed in triplicate. For comparison, 
saturation binding of F-1 to wild type FFA2 is included (broken line) with original data shown in 
figure 5.3. 
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retained the ability to bind the dual mutant R180A-R255A hFFA2 with a relatively 
modest 8-fold loss in affinity (Figure 5.8C). Alanine replacement of His2426.55, 
which is a residue demonstrated to be important for agonist but not antagonist 
binding (see section 4.2.2), did not significantly affect F-1 affinity, suggesting 
that F-1 does not interact with this residue. 
As the radioligand [3H]-GLPG0974 did not display specific binding at the R180A-
R255A mutant of hFFA2 (see section 4.2.1), the ability of F-1 to bind to R180A-
R255A hFFA2 provided the unique opportunity to assess whether other hFFA2 
antagonists are also able to bind to this hFFA2 mutant. Neither GLPG0974 nor 
CATPB were able to compete with F-1 for binding to R180A-R255A hFFA2 (Figure 
5.9A), confirming the hypothesis stated in chapter 4, which suggested that 
orthosteric antagonists do require at least one arginine residue to interact with 
 
Figure 5.9 Selected hFFA2 antagonists are able to compete with F-1 for binding to R180A-
R255A hFFA2 The ability of increasing concentrations of hFFA2 antagonists GLPG0974 and 
CATPB, and the allosteric hFFA2 ligands 4-CMTB and AZ1729 to compete with 500 nM F-1 for 
binding to R180A-R255A NLuc-hFFA2 is shown (A). The effect of increasing concentrations of 
GLPG-3, MeGLPG-3, MoGLPG-2 and LinkGLPG-3 on 100 nM (B) and 500 nM (C) F-1 binding to 
wild type (B) and R180A-R255A (C) NLuc-hFFA2 is shown. Nonspecific binding was determined in 
presence of 100 µM (A, C) or 50 µM (B) LinkGLPG-3 and subtracted from the total signal to obtain 
the specific signal. Data from representative experiments are shown. 
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hFFA2 (see section 4.2.1). Although allosteric ligands 4-CMTB and AZ1729 are 
able to activate R180A-R255A hFFA2, their binding site did not seem to overlap 
with that of F-1 as increasing concentrations of neither allosteric ligand were 
unable to compete with the fluorescent probe (Figure 5.9A). To examine the 
structural determinants that allow F-1 to interact with R180A-R255A hFFA2, a 
selection of different antagonist analogues with different carboxylate 
modifications were tested at wild type and R180A-R255A hFFA2: Carboxylate-
containing parent compound GLPG-3, methyl ester analogue MeGLPG-3, 
structurally related morpholine-containing compound MoGLPG-2 and synthesis 
intermediate LinkGLPG-3. At wild type hFFA2, all antagonist analogues were 
able to fully outcompete F-1 (Figure 5.9B) and replacement of the carboxylate 
moiety resulted in an approximately 10-fold reduction in affinity of all tested 
analogues (Table 5.4). However, the estimated affinity of compounds without 
carboxylates was not significantly different, suggesting that the size of the 
modification did not play an important role. At R180A-R255A hFFA2, Link-GLPG-3 
showed the highest affinity (Figure 5.9C), however, compared to wild type 
hFFA2, a 5.5-fold reduction in affinity could be observed (Table 5.4). In addition 
to LinkGLPG-3, MeGLPG-3 was also able to fully outcompete F-1 at R180A-R255A 
hFFA2 (Figure 5.9C), but the affinity of MeGLPG-3 was affected more by the 
dual arginine mutation than that of LinkGLPG-3 with a 46-fold decrease in 
affinity compared to wild type hFFA2 (Table 5.4). Carboxylate-containing 
GLPG-3 was unable to fully outcompete F-1 at concentrations of up to 100 µM, 
however, in contrast to GLPG0974 and CATPB, it appeared to have some affinity 
for R180A-R255A hFFA2 as 100 µM of GLPG-3 were able to induce approximately 
Table 5.4 Affinities of hFFA2 antagonists for wild type versus R180A-R255A hFFA2 
Receptor 
 
GLPG-3 
 
MeGLPG-3 
 
MoGLPG-2 
 
LinkGLPG-3 
Wild type 7.09 ± 0.16 6.10 ± 0.10*** 6.13 ± 0.09*** 6.20 ± 0.11*** 
R180A-
R255A 
< 4.00 4.44 ± 0.11$$$ < 4.00 5.50 ± 0.03$$$ 
* Comparison of pKi values at wild type hFFA2 one-way ANOVA followed by Dunnett’s test with the 
pKi of GLPG-3 as a reference with significant differences denoted as P = *** ≤ 0.001 
$ Comparison of pKi values of MeGLPG-3 and LinkGLPG-3 at wild type and R180A-R255A hFFA2 
by unpaired t test with significant differences denoted as P = $$$ ≤ 0.001 
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50% displacement of F-1 (Figure 5.9C). Interestingly, MoGLPG-2 behaved in a 
similar manner as GLPG-3, suggesting that the morpholine modification of 
GLPG-2 did not improve its ability to bind to R180A-R255A hFFA2. 
5.3 Discussion 
5.3.1 GLPG0974 analogue GLPG-3 provides a good backbone for 
NBD fluorophore attachment 
The most common strategy followed when designing fluorescent probes based on 
small molecules is to attach the fluorophore to a known pharmacophore using an 
appropriate linker (Stoddart et al., 2015b). The choice of linker and fluorophore 
can affect a multitude of properties of the resulting fluorescent ligand such as 
pharmacological behaviour, binding affinity and solubility (Baker et al., 2010, 
Vernall et al., 2013). Although fluorescent ligands are often designed with a 
rationale in mind, much of the development process comes down to trial-and-
error. Unlike radioligands, each newly synthesised fluorescent probe must be 
considered as a separate pharmacological entity distinct from its parent 
compound and needs to be characterised in detail prior to further application. 
This important consideration was exemplified by results described in this 
chapter that demonstrated the distinct effects of fluorophore attachment on the 
pharmacology of different FFA2 pharmacophores. 
To generate the antagonist-based fluorescent probes F-1 and F-2, the NBD 
fluorophore was attached via linkage to the carboxylate moiety, as this was 
previously shown to be dispensable for high-affinity binding of hFFA2 antagonists 
(see section 4.2.3). The parent molecules used to generate F-1 and F-2 were 
GLPG0974 analogue GLPG-3 and CATPB, respectively. Interestingly, although in 
ligand docking poses the carboxylate of GLPG0974 and CATPB adopted relatively 
similar conformations (see section 4.2.4), the attachment of NBD had different 
effects on the pharmacology of the respective fluorescent probes. F-1 retained 
the ability to inhibit the hFFA2 response to C3 with a relatively high pIC50 and 
showed good affinity for hFFA2 in [3H]-GLPG0974 competition and BRET binding 
assays. In contrast, the inhibitory action and binding affinity of F-2 was 
detrimentally affected. Furthermore, F-2 also showed behaviour typical of 
allosteric ligands in the [3H]-GLPG0974 competition binding assay, as increasing 
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concentrations of F-2 were unable to fully outcompete the radioligand. These 
observations suggest that F-1 and F-2 have distinct modes of binding, although 
their chemistry was based on parent molecules that are thought to interact in a 
similar way with the receptor, which highlights that it is indeed difficult to 
predict the behaviour of a fluorescent probe based on its parent compound. 
While the affinity of F-1 and F-2 for hFFA2 was in the high nM range, specific 
binding of agonist-based fluorophore F-3 could not be detected at 
concentrations of up to 2 µM in the BRET binding assay. The [3H]-GLPG0974 
competition binding assay suggested an estimated Kd of greater than 30 µM. 
Therefore, the point of fluorophore attachment in F-3 has likely affected binding 
affinity to an extent which makes it difficult to work with this fluorescent tracer 
and perhaps other points of attachment should be explored for generation of a 
fluorescent agonist ligand. 
Examination of F-1, F-2 and F-3 pharmacology highlights that it can be difficult 
to predict how fluorophore and linker attachment to a small molecule will 
change the pharmacology of the resulting fluorescent tracer. This was also 
reflected in the development of fluorescent ligands for other GPCRs (Vernall et 
al., 2014). In the case of the CB2 cannabinoid receptor, a conjugable analogue of 
the CB2-selective inverse agonist SR144528 was generated by synthesising an 
analogue with a primary amino group that allowed attachment of a linker arm 
(Bai et al., 2008). Following conjugation of a near-infrared dye resulted in a 
fluorescent tracer suitable for fluorescence imaging. However, exploration of 
other linker attachment points in SR144528 resulted in loss of ligand binding to 
the receptor (Sexton et al., 2011). These studies exemplify that the point of 
linker and fluorophore attachment needs to be structurally tolerated and 
selection of an appropriate point of modification is largely a process of trial-and-
error without additional structural information. A more detailed investigation of 
fluorescent ligands for the A1 adenosine receptor revealed that not only the 
attachment point itself is of crucial importance, but that the resulting 
fluorophore affinity is also highly dependent on the combination of fluorophore 
and linker employed (Baker et al., 2010). Although the most common strategy 
for development of fluorescent tracer is the conjugation of a known 
pharmacophore to a fluorophore using a linker, alternatively the fluorophore can 
also be incorporated as part of the pharmacophore, which is possible with 
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smaller fluorophores such as NBD. Although this approach was not successful in 
the case of the agonist-based F-3 fluorescent tracer described here, an isatin 
acylhydrazone-based CB2 antagonist was able to tolerate incorporation of NBD as 
part of its pharmacophore and, despite a slightly reduced affinity, specific 
binding of the resulting fluorescent probe to T-cells could be visualised with 
fluorescent confocal microscopy (Petrov et al., 2011). 
5.3.2 BRET binding assay utilising fluorescent ligand F-1 can be 
employed to screen hFFA2 antagonists 
From a drug discovery perspective, fluorescent ligands play an important role in 
the development of high-throughput screening formats (Janzen, 2014). Among 
the selection of synthesised fluorescent tracers, F-1 displayed the highest 
binding affinity, a good specific to nonspecific binding ratio and did initially not 
show allosteric behaviour. Therefore, F-1 was selected for further investigation 
and its suitability for screening of FFA2 ligands was assessed. In BRET-based F-1 
competition binding assays a similar trend as in [3H]-GLPG0974 competition 
binding assays could be observed when comparing the affinities of a 
representative carboxylate/methyl ester hFFA2 antagonist pair 
(CATPB/MeCATPB). However, increasing concentrations of FFA2 agonists C3 and 
compound 1 were unable to fully displace F-1 from hFFA2, which suggests that 
F-1 binding is negatively modulated in an allosteric fashion by FFA2 agonists, 
which will be discussed in more detail in the following section. 
Drug residence time is an increasingly important property to consider in drug 
development, as discussed in detail in chapter 4, and can be a deciding factor 
for therapeutic success (Guo et al., 2014). However, accurate monitoring of 
ligand binding kinetics using radioligand binding assays can be challenging. One 
of the most important advantages of fluorescent tracers is the possibility to 
monitor ligand binding kinetics in real-time, in particular as the competitive 
kinetic binding assay allows estimation of kinetic parameters of unlabelled 
ligands by assessing their effect on probe association (Dowling and Charlton, 
2006). Therefore, it was examined whether F-1 could be utilised in a BRET 
binding assay to determine the binding kinetics of hFFA2 antagonists. The 
qualitative differences in binding kinetics of GLPG0974 and CATPB that were 
observed in the radioligand-based assay (see section 4.2.6) were indeed mirrored 
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in the competitive kinetic binding assay using F-1. However, the estimated 
association and dissociation values were different, which may have been in part 
due to the increased temperature at which the assay was performed. 
Conceptually, the rate constants should increase with higher temperatures, but 
surprisingly this was not the case here. The association rates of GLPG0974 and 
CATPB were actually reduced rather than increased. Therefore, the F-1 
competitive kinetic binding assay could perhaps be useful to identify qualitative 
trends in binding kinetics, but to quantify rate constants the radioligand-based 
assay would be more appropriate. One limitation of the BRET binding assay is the 
depletion of the NLuc substrate employed in kinetic assays. With decreasing 
substrate concentration the data quality decreases, therefore the measurement 
error increases at later time points. Optimisation of substrate concentration and 
selection of a substrate that is more stable over time could improve data quality 
and potentially contribute to more accurate quantitative measurements. 
5.3.3 Fluorescent tracer F-1 does not behave as an orthosteric 
FFA2 ligand 
The first observation suggesting that F-1 may not be an orthosteric ligand was 
the partial competition with orthosteric FFA2 agonists in the competition binding 
assay, i.e. F-1 was able to occupy the receptor in the presence of SCFA C3 and 
synthetic agonist compound 1, albeit with reduced affinity. Such behaviour is 
typical for allosteric ligands, as partial competition in binding assays can be 
attributed to the negative cooperative effect of competing ligand binding on 
radioactive or fluorescent probe affinity (Gregory et al., 2007). Further support 
for an allosteric binding mode of F-1 was provided by its ability to bind to the 
dual mutant R180A-R255A hFFA2. Although binding of antagonists to hFFA2 was 
shown to be less dependent on the interaction between ligand carboxylate and 
the orthosteric arginine pair, binding of [3H]-GLPG0974 required at least one 
arginine to be present for a high-affinity interaction (see section 4.1.1). 
Furthermore, alanine replacement of single arginine residues had a modest 
negative effect on [3H]-GLPG0974 binding affinity. In contrast, the affinity of F-1 
for R180A and R255A hFFA2 was significantly increased. In the case of H242A 
hFFA2, F-1 binding affinity was unchanged compared to wild type hFFA2, while 
this mutation increased the binding affinity of [3H]-GLPG0974. Taken together, 
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these results suggest that the key determinants of F-1 binding may differ 
compared to orthosteric antagonist GLPG0974. 
How could F-1 be interacting with the hFFA2 binding pocket? This question is 
difficult to answer definitively without further site-directed mutagenesis and 
ligand docking studies. Competition binding studies with F-1 suggest that the 
binding sites of F-1 and orthosteric antagonists overlap, while orthosteric 
agonists exert an allosteric effect on F-1 binding and do therefore not bind to 
the same site. Previous [3H]-GLPG0974 binding studies and homology modelling 
suggested that the primary overlap of FFA2 agonist and antagonist binding sites 
is centred at the ionic interaction between the ligand carboxylate and the 
orthosteric Arg1805.39 and Arg2557.35 pair (see chapter 4). Furthermore, one 
hypothesis to explain the positive cooperative effect of agonists on 
[3H]-GLPG0974 dissociation implied that orthosteric agonists and antagonists 
bind to distinct sites in the receptor that both incorporate the orthosteric 
arginine pair, suggesting that orthosteric antagonists primarily interact with a 
secondary binding site (see chapter 4). As the core structure of F-1 is based on a 
GLPG0974 analogue, it may occupy such a secondary antagonist binding pocket, 
which lies outside of the defined orthosteric binding site and contains the 
additional residue contacts that are required for high-affinity binding of 
orthosteric antagonists (Figure 5.10). Linking of a fluorophore to the 
carboxylate moiety may force this region to adopt a different conformation 
compared to GLPG0974 to accommodate for its increased size, such that the 
interaction with the orthosteric arginines is lost (Figure 5.10). Thereby, C3 and 
compound 1 would be able to bind simultaneously with F-1 and exert the 
allosteric modulation observed in competition binding assays. Such a mode of F-1 
binding would also serve as an explanation as to why other allosteric FFA2 
ligands such as 4-CMTB and AZ1729 did not compete with F-1 binding to hFFA2 or 
indeed R180A-R255A hFFA2, as the allosteric binding pocket of F-1 is a 
component of the secondary binding site of orthosteric antagonists. The 
presence of several allosteric binding sites in FFA2 is not necessarily 
unexpected, as free fatty acid receptor FFA1 is also thought to contain multiple 
allosteric binding sites (Milligan et al., 2017). A recent crystal structure of FFA1 
revealed an allosteric binding site outside of the transmembrane helices to 
which allosteric agonist AP8 binds to exert its positive modulatory effects 
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Figure 5.10 Potential F-1 binding site in relation to FFA2 agonists and antagonists A hFFA2 
homology model constructed using a FFA1 crystal structure as a template is shown (see section 
4.2.4). Area occupied by agonists C3 and compound 1 (green) and antagonists GLPG0974 and 
CATPB (red) is illustrated. The binding site of the F-1 pharmacophore that was based on a 
GLPG0974 analogue likely overlaps with that of FFA2 antagonists in the area highlighted in blue, 
while the linker (blue line) and fluorophore (green) adopt an unknown conformation outside of the 
orthosteric Arg-His-Arg triad. 
 
(Lu et al., 2017). FFA1 is not the only GPCR with an extra-helical binding site; 
crystal structures of the glucagon (Jazayeri et al., 2016) and PAR2 (Cheng et al., 
2017) receptors in complex with allosteric antagonists revealed that allosteric 
ligands can interfere with active-state conformational helical rearrangements by 
binding outside of the transmembrane helical bundle. These studies highlight 
that areas apart from the ligand-accessible surface area need to be considered 
as potential allosteric binding sites, which can make it difficult to define the 
mode of allosteric ligand binding without structural information. 
5.3.4 Certain hFFA2 antagonists retain the ability to bind to 
R180A-R255A hFFA2 
Although the ability of fluorescent probe F-1 to interact with R180A-R255A 
hFFA2 complicates its pharmacological behaviour and indicates that F-1 is 
indeed not an orthosteric ligand, it provided an opportunity to examine whether 
other antagonists are able to bind to R180A-R255A hFFA2. Interestingly, distinct 
analogues of GLPG0974 have different affinities for the dual arginine mutant. 
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While GLPG0974 was unable to compete with F-1 for binding to R180A-R255A 
hFFA2 at concentrations of up to 30 µM, its analogue GLPG-3 was able to 
compete with F-1 at concentrations of over 3 µM. Replacement of the GLPG-3 
carboxylate with a methyl ester further increased the capacity of the ligand to 
bind to R180A-R255A hFFA2. It would be interesting to test a larger set of hFFA2 
antagonist analogues at R180A-R255A hFFA2, as it might provide information on 
the structural modifications that resulted in the switch from the orthosteric 
antagonist GLPG0974 to allosteric ligand F-1. To some extent the allosteric 
nature of F-1 ties in with the cooperative effect of agonists observed on 
[3H]-GLPG0974 dissociation. Perhaps the observations in this chapter provide 
support for the hypothesis that strong negative cooperativity between agonist 
and GLPG0974 binding masks the allosteric nature of GLPG0974. However, the 
lack of GLPG0974 binding to R180A-R255A supports an orthosteric mode of 
binding. The pharmacology of hFFA2 antagonists clearly appears to be complex 
and more detailed studies are necessary to fully understand their mode of 
binding, in particular outside of the orthosteric binding site. 
5.4 Conclusions 
Fluorescent ligands have become important tools for investigation of GPCRs and 
their ligands (Stoddart et al., 2015b). By taking advantage of previously obtained 
information on the structural requirements of hFFA2 antagonists, the fluorescent 
probe F-1 was identified. F-1 was utilised to develop a proximity-based BRET 
binding assay that monitors the resonance energy transfer between the NBD 
fluorophore linked to F-1 and NLuc fused to the N terminus of hFFA2 by following 
a strategy previously successfully applied for FFA1 (Christiansen et al., 2016). 
Although F-1 can be employed to determine unlabelled antagonist affinity and 
binding kinetics, a closer investigation of its binding site revealed that F-1 is 
likely not an orthosteric probe. This exemplifies that even though the initial 
characterisation of F-1 binding and function suggested orthosteric behaviour, 
this did not turn out to be the case. Closer assessment of the pharmacology and 
binding site of F-1 would definitely be necessary, if it should be employed for 
FFA2 ligand screening. Although the complex pharmacology of F-1 complicates 
the interpretations of competition binding assays, it is not guaranteed that other 
fluorescent tracers for FFA2 will not also show such effects. Furthermore, F-1 
could also serve as a useful tool for other applications. The NBD fluorophore was 
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in part selected due to its compatibility with NLuc for BRET binding assays, 
however other fluorophores can be more suitable for detection of direct 
fluorescent ligand binding. Attachment of a different fluorophore could 
therefore expand its range of application to e.g. study FFA2 expression in 
endogenous systems. In conclusion, work presented in this chapter only 
represents the beginning of the development of a fluorescent ligand tool kit for 
FFA2 and although further studies are necessary to understand the detailed 
pharmacology of F-1, it serves as a first step into the desired direction.
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6 Investigating the role of Lys65 in FFA2 signalling 
and ligand binding 
6.1 Introduction 
Since its deorphanisation, the SCFA receptor FFA2 has attracted attention as a 
potential drug target due to the nature of its ligands, which place it at the 
interface of gut microbiome activity and human health (Rowland et al., 2017, 
Sun et al., 2017). SCFAs are produced by the gut microbiome as a fermentation 
product of non-digestible carbohydrates that are present in dietary fibre. 
Therefore, dietary habits can influence gut microbiota composition and SCFA 
production by adjusting the level of fibre consumed (Sweeney and Morton, 
2013). However, defining the physiological role and function of FFA2 has proved 
more difficult than anticipated. The co-expression of FFA2 with the closely 
related SCFA receptor FFA3 in tissues of interest such as the gastrointestinal 
tract (Nohr et al., 2013, Karaki et al., 2006) has complicated the dissection of 
FFA2 versus FFA3 contribution to SCFA-mediated effects. To address this issue, 
significant effort has been invested over the last decade to develop specific tool 
compounds for SCFA receptors (Schmidt et al., 2011, Hudson et al., 2013a, 
Hudson et al., 2014, Brown et al., 2015, Park et al., 2016), but with mixed 
success. The majority of the work presented in previous chapters of this thesis 
has focussed on development of novel tool compounds and techniques to expand 
the toolkit for FFA2 research, as well as the definition of ligand structure-
activity relationships and agonist versus antagonist binding sites to serve as a 
guide for future drug development. However, the premise of the work described 
here was to solve some of the pressing issues that are limiting progress in FFA2 
research by utilising the tools developed in previous chapters. 
The role of hFFA2 in augmenting neutrophil chemotaxis in response to SCFA 
treatment suggests that treatment with antagonists could reduce inflammation 
by inhibiting recruitment of immune cells to chronic sites of infection, for 
example, in inflammatory bowel disease (Vinolo et al., 2011). With this potential 
application in mind the antagonist GLPG0974 was developed by the clinical-stage 
biotechnology company Galapagos (Pizzonero et al., 2014). Characterisation of 
GLPG0974 in human blood demonstrated that GLPG0974 was able to block 
migration of neutrophils induced by C2 and reduced expression of CD11b on 
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neutrophils, which is an activation marker for neutrophil migration and served as 
a means of confirming FFA2 engagement by GLPG0974 (Pizzonero et al., 2014). 
These results showed promise for GLPG0974 as a potential therapeutic. 
Traditionally the next step in the drug development process would include pre-
clinical studies in animals, usually rodents, to confirm the therapeutic potential 
of GLPG0974 in disease models of interest. However, one important limitation 
did not allow such progression: GLPG0974, and indeed all other known 
antagonists of FFA2 (Hudson et al., 2012b, Park et al., 2016, Milligan et al., 
2017), are species selective for the human orthologue of FFA2 and inactive at 
rodent forms of FFA2 (Pizzonero et al., 2014). GLPG0974 was also inactive at 
other more rarely employed animal model orthologues such as rabbits and 
canines (Beetens, 2013), therefore Galapagos decided to move on directly to 
first-in-man clinical trials in ulcerative colitis patients. In these studies 
GLPG0974 showed a good safety profile, but treatment over four weeks did not 
result in improvement of ulcerative colitis symptoms, although target 
engagement by GLPG0974 and reduction in neutrophil migration could be 
confirmed (Vermeire et al., 2015). This highlights that further research on FFA2 
is necessary to confirm its drug target potential and develop rational targeting 
strategies. Potentially the lack of GLPG0974 efficacy in the ulcerative colitis 
trial could have been anticipated if an animal model had been available for 
more detailed proof-of-concept studies. However, animal studies do not only 
allow validation of the therapeutic benefit of antagonist treatment, but they 
also represent an important means of confirming that effects observed in 
response to agonist dosing are specific to the targeted receptor. Considering the 
problems that arise from the lack of antagonists for rodent forms of FFA2, why 
have no cross-species antagonists been identified yet? Perhaps, the distinct 
pharmacology of human versus murine FFA2 prohibits this and it would be 
necessary to screen specifically for antagonists active at rodent orthologues to 
identify novel ligands (see chapter 3). Most importantly, the molecular basis of 
antagonist species selectivity, which might allow rational development of a 
rodent FFA2 antagonist, is not understood. One clear alternative to developing 
cross-species antagonists is the generation of a humanized mouse model that 
expresses the human orthologue of FFA2. Such a strategy was successfully 
applied previously to develop human glucagon-like peptide-1 (GLP-1) receptor 
knock-in mice (Jun et al., 2014). Although humanised mouse models are 
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undoubtedly a useful means of circumventing issues arising from species-specific 
receptor pharmacology, generation of knock-in mice is a costly and time-
consuming process that is not available to all research groups. Furthermore, 
depending on the disease of interest, knock-in animals need to be crossed with 
specific mouse models of human disease to assess the therapeutic potential of 
the receptor, which is also time-consuming and work-intensive. Therefore, 
dissection of the molecular basis for the selectivity of antagonists for the human 
versus rodent orthologues of FFA2 remains important and could contribute to the 
development of cross-species antagonists. 
A hFFA2 homology model constructed to assess agonist versus antagonist binding 
sites (see chapter 4) was employed herein to identify residues that might define 
antagonist species selectivity. This investigation resulted in the identification of 
a single lysine residue in TM2 that was predicted to interact with both GLPG0974 
and CATPB. Most importantly, rodent orthologues of FFA2 have an arginine 
residue in the equivalent position, which might affect antagonist binding. To 
explore whether species variation in this position indeed contributes to the 
species-selective pharmacology of FFA2 antagonists, a selection of point 
mutations was generated to explore their effect on antagonist function and 
binding, and further homology modelling was performed to rationalise resulting 
observations. 
In the process of investigating the role of the identified lysine residue in the 
species selectivity of antagonists, the effect of different alterations on agonist 
action was also assessed. Interestingly, the positive charge at this position was 
critical for agonist-induced coupling of hFFA2 to Gq/11, but not for coupling to 
Gi/o, while the affinity of agonists for the receptor was only modestly affected. 
FFA2 has previously demonstrated a relatively promiscuous signalling profile, as 
it could couple to multiple G protein subtypes, including Gi/o, Gq/11 and G12/13 
(Brown et al., 2003). This may be relevant in some physiological systems, where 
Gi/o versus Gq/11 signalling can promote opposing actions such as the regulation 
of insulin secretion in pancreatic β cells, which is enhanced by activation of Gq/11 
(Sassmann et al., 2010) and suppressed by Gi/o (Berger et al., 2015). Moreover, 
the recent identification of the allosteric agonist AZ1729, which is able to 
activate Gi/o but not Gq/11 through FFA2, demonstrated that FFA2 is capable of 
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biased signalling (Bolognini et al., 2016a). Therefore, examination of the 
molecular mechanisms underlying the promiscuous G protein coupling of FFA2 
would be highly interesting, in particular in context of the identified lysine 
residue, as it only seemed to play a role in FFA2 coupling to selective G protein 
subtypes. The role of this residue in hFFA2 coupling to different G proteins was 
explored here by utilising a variety of assays that reflect Gi/o and Gq/11 signalling. 
In addition, coupling of hFFA2 to G12/13 was also assessed by employing the 
recently developed TGFα shedding assay (Inoue et al., 2012) and a selection of 
genome-edited cell lines that lack expression of specific Gα subtypes. Thereby, 
work presented in this chapter encompasses numerous aspects of FFA2 structure 
and function, and provides valuable information that can be employed to 
validate FFA2 as a potential drug target. 
6.2 Results 
6.2.1 Assessment of the structural basis for the selectivity of 
FFA2 antagonists for the human versus mouse orthologue 
One limitation that has affected progress in understanding the physiological role 
of FFA2 is the species selectivity of antagonists for the human orthologue (see 
section 1.1.1). Multiple studies have demonstrated species-specific differences 
in FFA2 activity between human and rodent orthologues, including the distinct 
rank order of endogenous SCFA potencies and changes in constitutive activity 
levels (Hudson et al., 2012b), as well as differing signalling responses to the 
biased allosteric ligand AZ1729 (Bolognini et al., 2016a). Indeed, C3 was able to 
induce accumulation of IP1 in cells induced to express hFFA2 or mFFA2 (Figure 
6.1A). However, a 65-fold difference in C3 potency could be observed between 
the two orthologues with an estimated pEC50 of 4.36 ± 0.12 at hFFA2 and a pEC50 
of 2.54 ± 0.11 at mFFA2. Although C3 has previously been shown to be selective 
for human over murine FFA2, the potency of C3 at hFFA2 versus mFFA2 was only 
improved by 3-fold in a [35S]-GTPγS binding assay (Hudson et al., 2012b). 
Therefore, the substantial species-specific potency differences observed here 
might relate to distinct levels of receptor reserve. Increasing concentrations of 
the antagonists GLPG0974 (Figure 6.1B) and CATPB (Figure 6.1C) were able to 
inhibit the response of hFFA2 to an EC80 concentration of C3 but had no effect at 
mFFA2. Interestingly, the fluorescent tracer F-1, which previously behaved as 
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Figure 6.1 FFA2 antagonists display species selectivity for the human versus mouse 
orthologue The ability of varying concentrations of C3 to induce accumulation of IP1 in Flp-InTM T-
RExTM 293 cells induced to express hFFA2- or mFFA2-eYFP is shown (A). Increasing 
concentrations of GLPG0974 (B), CATPB (C) and F-1 (D) were able to inhibit the response of 
hFFA2 to 3 mM C3, but not the response of mFFA2 to 10 mM C3. All data are means pooled from 
independent experiments (n ≥ 3) that were performed in duplicate. 
 
an allosteric ligand and potentially has a distinct binding site from orthosteric 
antagonists GLPG0974 and CATPB (see section 5.3.3), was also not active at the 
rodent orthologue (Figure 6.1D). While F-1 is not likely to interact with the 
orthosteric arginine pair (see section 5.2.5) and contains a NBD fluorophore and 
linker in place of a carboxylate moiety, the remaining structure of F-1 is based 
on GLPG0974 analogue GLPG-3. Therefore, an interaction outside of the 
orthosteric site might be responsible for the lack of antagonist action at mFFA2. 
To identify additional points of antagonist interactions apart from the 
orthosteric Arg180-His242-Arg255 triad, the docking poses of GLPG0974 and 
CATPB to a hFFA2 homology model (see section 4.2.4) were explored in more 
detail. Two main residues outside of the orthosteric binding pocket were 
predicted to be important for positioning antagonists in the hFFA2 binding 
pocket, Lys652.60 and Phe893.28 (Figure 6.2). Lys652.60 forms a hydrogen bonding 
interaction with the amide in the central region of GLPG0974 and CATPB and is 
positioned by two glutamic acid residues, Glu682.63 and Glu166ECL2 (Figure 6.2). 
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Phe893.28 interacts with the aromatic functional groups of GLPG0974 and CATPB 
by forming a π-stacking interaction (Figure 6.2). While Phe893.28 is conserved 
between human and rodent FFA2, the residue at position 2.60 differs between 
the orthologues with an arginine residue in place of lysine in rodent forms of 
FFA2.  
 
Figure 6.2 Lys65 plays a role in anchoring antagonists in the hFFA2 binding pocket Docking 
of GLPG0974 (A) and CATPB (B) into a homology model of hFFA2 is illustrated. While the 
carboxylate moiety of GLPG0974 and CATPB is anchored by interaction with Arg1805.39 and 
Arg2557.35, Lys652.60 interacts with the central portion of the compounds and positions them in the 
hFFA2 binding pocket. Furthermore, Phe893.28 forms an aromatic interaction with GLPG0974 and 
CATPB. The inset in A highlights that GLPG0974 (cyan) and CATPB (green) adopt overlapping 
poses within the binding pocket despite their structural differences. 
 
6.2.2 Identity of residue 65 in human versus mouse FFA2 defines 
species selectivity of antagonists 
To examine whether the species variation in residues at position 2.60 is indeed 
responsible for selectivity of antagonists for human FFA2, the effect of different 
alterations of Lys652.60 on antagonist action was examined. The Lys652.60 mutants 
assessed include K65R, which is equivalent to the identity of this residue in 
murine FFA2; K65A, to assess the importance of a positive charge at position 
2.60; and K65E, which reverses the charge in this position. Prior to investigating 
the effect of respective mutations on antagonist action, the ability of the 
agonists C3 and compound 1 to stimulate accumulation of IP1 at Ly652.60 mutants 
of hFFA2 was assessed to determine appropriate EC80 concentrations to employ 
for antagonist inhibition assays. Increasing concentrations of C3 (Figure 6.3A) 
and compound 1 (Figure 6.3B) were able to induce IP1 accumulation via K65R 
hFFA2 with a minor reduction in potency by approximately 2-fold compared to  
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Figure 6.3 Species selectivity of antagonists for human FFA2 is defined by the identity of 
residue 65 in FFA2 The ability of increasing concentrations of C3 (A) and compound 1 (B) to 
induce production of IP1 in Flp-InTM T-RExTM 293 cells induced to express the specified variants of 
hFFA2 is shown. The capacity of varying concentrations of GLPG0974 (C) and CATPB (D) to 
inhibit IP1 production induced by respective EC80 concentrations of compound 1 is illustrated. The 
ability of GLPG0974 (E) and CATPB (F) to inhibit C3-mediated IP1 production at specified forms of 
mFFA2 is shown. All data are means pooled from independent experiments (n ≥ 3) that were 
performed in duplicate. 
 
wild type hFFA2 (Table 6.1). Interestingly, although Lys652.60 is not in close 
proximity to the core orthosteric binding pocket (Figure 6.2), charge-altering 
Lys65 mutations K65A and K65E had a detrimental effect on the potency of C3 
(Figure 6.3A) and compound 1 (Figure 6.3B) with a reduction in potency of at 
least 30-fold (Table 6.1). As compound 1 potency was affected by K65A and 
K65E mutations to a lesser extent than C3 (Table 6.1), the capacity of GLPG0974 
(Figure 6.3C) and CATPB (Figure 6.3D) to inhibit the IP1 response of those 
mutant forms of hFFA2 to an approximate EC80 concentration of compound 1 was  
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Table 6.1 Alterations of Lys65 in hFFA2 affect both agonist potency to generate IP1 and the 
ability of antagonists to inhibit this response 
Compound WT K65R K65A K65E 
Agonist 
(pEC50) 
C3 4.06 ± 0.08 3.71 ± 0.05* < 1.5 < 1.5 
Compound 1 6.98 ± 0.06 6.70 ± 0.07* < 5.5 < 5.5 
Antagonist 
(pIC50) 
GLPG0974 7.92 ± 0.19 < 4.5 7.36 ± 0.17$ < 4.5 
CATPB 7.72 ± 0.14 < 4.5 6.36 ± 0.19$$$ < 5.0 
* Comparison of pEC50 values at WT and K65R hFFA2 by unpaired t test with significant 
differences denoted as P = * ≤ 0.05 
$ Comparison of pIC50 values at WT and K65A hFFA2 by unpaired t test with significant differences 
denoted as P = $ ≤ 0.05 and P = $$$ ≤ 0.001 
 
examined. As predicted by docking poses in the homology model (Figure 6.2), 
the IC50 of GLPG0974 and CATPB was significantly affected by 3.9- and 23-fold, 
respectively, at K65A hFFA2 (Table 6.1). This observation suggested that the 
interaction of antagonists with Lys652.60 contributes to high-affinity binding, in 
particular in the case of CATPB. Interestingly, the K65R and K65E mutations also 
had a detrimental effect on antagonist action (Figure 6.3C and D) with an 
affinity loss of at least 500-fold (Table 6.1). As the inhibitory actions of 
GLPG0974 and CATPB were affected to such a substantial degree by the K65R 
mutation, which represents the rodent residue in position 2.60, the potential of 
the reverse mutation R65K in mFFA2 to rescue antagonist binding and function 
was assessed. Indeed, GLPG0974 (Figure 6.3E) and CATPB (Figure 6.3F) gained 
the ability to inhibit the response of R65K mFFA2 to an EC80 concentration of C3 
in an IP1 accumulation assay. The IC50 of CATPB at R65K mFFA2 (5.42 ± 0.10) was 
only 2.9-fold lower than that at hFFA2 (5.88 ± 0.17), while there was a larger 
difference between the IC50 of GLPG0974 at R65K mFFA2 (5.51 ± 0.12) and hFFA2 
(6.14 ± 0.09) of 4.3-fold. These results could relate to the fact that antagonist 
action of CATPB was affected to a greater extent by the K65A mutation than 
GLPG0974 (Table 6.1). This might suggest that Lys652.60 plays a more important 
role for CATPB binding and that GLPG0974 forms additional contacts with 
residues that are unique to the human orthologue of FFA2. 
To confirm whether the observed effect of Lys652.60 alterations on antagonist 
action are due to differences in antagonist affinity, [3H]-GLPG0974 equilibrium 
binding assays were performed in membranes containing the receptor of interest 
(Figure 6.4). No specific binding of [3H]-GLPG0974 to K65R hFFA2 could be 
detected at concentrations of the radioligand that were practical to employ 
(Figure 6.4B), while the affinity of [3H]-GLPG0974 for K65A hFFA2 (Figure 6.4C)  
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Figure 6.4 Binding of [3H]-GLPG0974 to various forms of human and mouse FFA2 confirms 
the importance of residue 65 for antagonist binding affinity Binding of increasing 
concentrations of [3H]-GLPG0974 to membranes isolated from Flp-InTM T-RExTM cells induced to 
express wild type hFFA2 (A), K65R hFFA2 (B), K65A hFFA2 (C), wild type mFFA2 (D) or R65K 
mFFA2 (E) is shown from representative experiments performed in duplicate. Nonspecific binding 
was determined in presence of 10 µM CATPB and subtracted from total binding to calculate levels 
of specific binding. 
 
was reduced by some 10-fold compared to wild type hFFA2 (Table 6.2). At 
mFFA2 only a minor level of specific binding of [3H]-GLPG0974 could be detected 
that did not approach saturation over the range of concentrations employed 
(Figure 6.4D), while the binding affinity of the radioligand for R65K mFFA2 was 
greatly increased and estimated to be in the region of 50 nM (Table 6.2). Taken 
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Table 6.2 Effect of Lys65 alterations in hFFA2 on the binding affinity of radioligand 
[3H]-GLPG0974 and fluorescent tracer F-1 
Compound 
hFFA2 (nM) mFFA2 (nM) 
WT K65R K65A WT R65K 
[3H]-GLPG0974 7.30 ± 0.36 > 1000 67.3 ± 8.6** > 1000 51.5 ± 10.6* 
F-1 66.5 ± 7.8 > 5000 > 10,000  954 ± 236$ 
* Comparison of Kd values at WT and mutant hFFA2 by one-way ANOVA followed by Dunnett’s test 
with WT hFFA2 as a reference with significant differences denoted as P = * ≤ 0.05 and P = ** ≤ 0.01 
$ Comparison of Kd values at WT hFFA2 and R65K mFFA2 by unpaired t test with significant 
differences denoted as P = $ ≤ 0.05 
 
together, these results indicate that Lys652.60 is indeed a defining residue for the 
species selectivity of orthosteric FFA2 antagonists for the human orthologue, 
whose replacement by Arg652.60 in rodent FFA2 is responsible for the loss of 
antagonist affinity. 
While GLPG0974 and CATPB represent orthosteric examples of FFA2 antagonists, 
fluorescent tracer F-1 clearly shows more complex pharmacology (see chapter 
5). However, despite the non-competitive relationship between F-1 and 
orthosteric agonists that indicated a distinct, allosteric mode of F-1 binding, the 
fluorescent tracer was also unable to inhibit the response of mFFA2 to C3 
(Figure 6.1D). To examine whether the binding affinity of F-1 was also affected 
by Lys652.60 mutations similarly to orthosteric antagonists, BRET binding assays in 
membranes containing the receptor of interest were utilised. Interestingly, 
while an F-1 saturation binding curve could be obtained for wild type hFFA2 
(Figure 6.5A), no specific binding of F-1 to K65R (Figure 6.5B) nor K65A (Figure 
6.5C) hFFA2 could be detected at concentrations of up to 500 nM. In contrast, 
F-1 was able to bind to R65K mFFA2, albeit with 15-fold reduction in affinity 
compared to wild type hFFA2 (Table 6.2). These observations demonstrate that 
Lys652.60 is essential for F-1 binding to hFFA2 and while F-1 is able to bind to the 
‘humanising’ mutant R65K mFFA2, the reduced affinity compared to wild type 
hFFA2 suggests that additional residues form the basis of the species selectivity 
of F-1. 
Can the gain of antagonist binding to R65K mFFA2 be rationalised structurally? 
To explore how arginine versus lysine at position 2.60 impacts the nature of the 
ligand binding pocket, homology models of wild type and R65K mFFA2 were 
generated. Interestingly, investigation of the wild type mFFA2 binding pocket 
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Figure 6.5 Binding of fluorescent tracer F-1 to hFFA2 is dependent on Lys65 Binding of 
increasing concentrations of F-1 to membranes isolated from Flp-InTM T-RExTM cells induced to 
express NLuc-tagged forms of wild type hFFA2 (A), K65R hFFA2 (B), K65A hFFA2 (C) and R65K 
mFFA2 (D) is shown from representative experiments performed in duplicate. Table 6.2 contains 
the Kd values derived from the illustrated data. The nonspecific BRET signal was determined in the 
presence of 50 µM LinkGLPG-3. 
 
revealed that Arg652.60 was predicted to be sequestered by an ionic interaction 
with Glu682.63 (Figure 6.6A inset). This likely results in a rearrangement of the 
ligand-accessible pocket of mFFA2 and does not provide a point of interaction 
for antagonists. Docking of CATPB into R65K mFFA2 suggested that CATPB adopts 
a similar binding pose as in wild type hFFA2 with the altered Lys652.60 forming an 
interaction with the central amide (Figure 6.6A). In contrast, GLPG0974 favours 
a binding pose distinct to that in wild type hFFA2 and the mutated Lys652.60 
anchors the ligand through interaction with its aromatic chlorobenzene group 
(Figure 6.6B). These predicted docking poses correlate well with the 
observation that inhibition of the C3 response by CATPB was restored to a 
greater extent by the R65K alteration in mFFA2 compared to GLPG0974. 
Therefore, it is likely that GLPG0974 binding has additional species-specific 
binding determinants. 
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Figure 6.6 Predicted binding poses of antagonists in R65K mFFA2 Docking of CATPB (A) and 
GLPG0974 (B) into a homology model of mFFA2 containing the humanising R65K mutation. The 
predicted binding pose of CATPB to hFFA2 (green) is overlaid with the low energy docking pose 
obtained for CATPB binding to R65K mFFA2 (yellow) (A). The inset in A illustrates the position of 
Arg652.60 in wild type mFFA2, which is fixed through an ionic interaction with Glu682.63. Although 
the binding position of GLPG0974 to R65K mFFA2 differs compared to hFFA2 (Figure 6.2), K652.60 
is important for positioning the chlorobenzene moiety of GLPG0974 (B). 
 
6.2.3 Charge-altering Lys65 mutations in hFFA2 affect Gq/11- but 
not Gi/o-mediated responses to agonists 
Although Lys652.60 is not a component of the core orthosteric binding pocket, 
charge-modifying alterations of this residue had a detrimental effect on the 
ability of C3 (Figure 6.3A) and compound 1 (Figure 6.3B) to activate hFFA2. To 
examine whether this observed loss in potency was due to a loss of agonist 
binding, [3H]-GLPG0974 competition binding assays at K65A hFFA2 were 
performed. Interestingly, C3 (Figure 6.7A) and compound 1 (Figure 6.7B) were  
 
Figure 6.7 FFA2 agonists are able to bind to K65A hFFA2 with modest loss in affinity The 
ability of increasing concentrations of C3 (A) and compound 1 (B) to compete with approximate Kd 
concentrations of [3H]-GLPG0974 to bind to membranes isolated from Flp-InTM T-RExTM cells 
induced to express wild type or K65A hFFA2 is shown from representative experiments performed 
in duplicate. 
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able to fully outcompete the radioligand at K65A hFFA2 with a modest effect on 
their estimated affinity. The Ki of C3 at K65A hFFA2 (2.12 ± 0.10) was reduced 
by 4.1-fold compared to wild type hFFA2 (2.73 ± 0.08), while in the case of 
compound 1 the effect was more pronounced with a 5.4-fold reduction in Ki at 
K65A hFFA2 (6.29 ± 0.18) compared to wild type hFFA2 (7.02 ± 0.09). Analysis of 
pKi values at wild type versus K65A hFFA2 with an unpaired t test yielded a 
P value of less than 0.05, confirming statistical significance of the observed 
differences in affinity. Therefore, although the affinity of C3 and compound 1 
for K65A was modestly reduced, both agonists retained the ability to bind to this 
mutant of hFFA2. Conceptually, this suggests that the detrimental impact of the 
K65A alteration on the potency of agonists in the IP1 accumulation assay could 
not be explained by a loss of agonist binding. It is more likely that charge-
altering alterations of Lys652.60 affected the ability of agonists to induce specific 
G protein coupling. 
While IP1 accumulation is induced by activation of Gq/11 G proteins, the ability of 
hFFA2 to couple to Gi/o G proteins is also well established (Brown et al., 2003, 
Schmidt et al., 2011, Hudson et al., 2012b). Therefore, the effect of different 
Lys652.60 alterations on the ability of C3 and compound 1 to promote activation 
of Gi/o-mediated signalling was examined. Interestingly, C3 (Figure 6.8A) and 
compound 1 (Figure 6.8B) were able to induce a concentration-dependent 
inhibition of cAMP production at hFFA2 with all tested alterations of Lys652.60, 
including K65A and K65E. While the potencies of compound 1 at wild type, K65R, 
K65A and K65E hFFA2 were not significantly different, C3 displayed a minor 3.0- 
and 5.0-fold reduction in potency at K65R and K65A hFFA2, respectively (Table 
6.3). These observations were mirrored in the [35S]-GTPγS binding assay, which 
also primarily detects coupling of GPCRs to Gi/o G proteins (Milligan, 2003). C3 
retained the ability to induce [35S]-GTPγS binding through K65R, K65A and K65E 
hFFA2 (Figure 6.8C), with minor, but significant, reduction in potency at all 
three mutant forms compared to wild type hFFA2 (Table 6.3). This was also the 
case for compound 1, which produced a concentration-dependent response in 
the [35S]-GTPγS binding assay at all tested alterations of Lys652.60, with a 
significant reduction in potency at K65A (6.0-fold) and K65E (3.0-fold) (Table 
6.3). The minor loss in agonist potency observed at K65A hFFA2 correlates well 
with the reduction in affinity demonstrated in radioligand competition assays. 
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Figure 6.8 Activation of Gi/o G proteins by FFA2 agonists is only modestly affected by 
charge-altering mutations of Lys65 The ability of C3 (A, C) and compound 1 (B, D) to inhibit 
forskolin-stimulated production of cAMP in Flp-InTM T-RExTM 293 cells induced to express mutant 
forms of hFFA2 (A, B) or to induce binding of [35S]-GTPγS in membranes isolated from respective 
cell lines (C, D). All data are means pooled from independent experiments (n ≥ 3) that were 
performed in triplicate. 
 
Therefore, the impact of charge-altering Lys652.60 mutations on hFFA2 agonist 
potency seems to depend on the subtype of G protein whose coupling is being 
assessed. This would suggest that Lys652.60 has an important role in translating 
agonist binding to coupling of hFFA2 to Gq/11, but not Gi/o G proteins. 
Table 6.3 Alterations of Lys65 in hFFA2 have modest effects on agonist potency in Gi/o-
coupled assays 
Assay Compound WT K65R K65A K65E 
cAMP 
C3 3.90 ± 0.09 3.42 ± 0.06** 3.20 ± 0.1*** 3.79 ± 0.08 
Compound 1 6.37 ± 0.06 6.18 ± 0.08 6.54 ± 0.10 6.47 ± 0.13 
AZ1729 6.35 ± 0.13 6.47 ± 0.15 6.42 ± 0.03 6.45 ± 0.15 
GTPγS 
C3 3.59 ± 0.08 3.29 ± 0.08* 2.83 ± 0.06*** 3.21 ± 0.05** 
Compound 1 6.46 ± 0.04 6.52 ± 0.06 5.68 ± 0.08*** 5.98 ± 0.07*** 
AZ1729 6.97 ± 0.02 6.79 ± 0.07 6.94 ± 0.14 6.79 ± 0.12 
Expression (% of WT) 100 ± 1 187 ± 3 96 ± 1 97 ± 1 
* Comparison of pEC50 values of one compound at different forms of hFFA2 by one-way ANOVA 
followed by Dunnett’s test with WT hFFA2 as a reference with significant differences denoted as P 
= * ≤ 0.05, P = ** ≤ 0.01 and P = *** ≤ 0.001 
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6.2.4 Alterations of Lys65 do not affect response of hFFA2 to Gi/o-
biased allosteric ligand AZ1729 
The distinct effect of charge-altering Lys652.60 mutations on Gq/11 versus Gi/o 
coupling of hFFA2 suggests that this residue may regulate coupling to different G 
protein subtypes in a biased fashion. Therefore, K65A and K65E hFFA2 may 
represent a biased form of the receptor that retains the ability to transduce 
signals via Gi/o G proteins, but couples more poorly to Gq/11 G proteins. To test 
this hypothesis the recently identified allosteric ligand AZ1729 was employed, 
which previously showed a biased signalling profile as it was able to promote 
Gi/o- but not Gq/11-mediated hFFA2 signalling (Bolognini et al., 2016a). Indeed, 
AZ1729 was able to promote Gi/o-coupled [35S]-GTPγS binding and inhibition of 
cAMP production in a concentration-dependent fashion, while a Gq/11-coupled IP1 
accumulation response to increasing concentrations of AZ1729 could not be 
detected (Figure 6.9A). Lys652.60 mutations K65R, K65A and K65E did not result 
in a gain of AZ1729 ability to induce IP1 accumulation (Figure 6.9B) and the 
 
Figure 6.9 Signalling of the allosteric ligand AZ1729 is unaffected by mutation of Lys65 in 
hFFA2 The ability of increasing concentrations of AZ1729 to inhibit cAMP levels stimulated by 
forskolin, promote binding of [35S]-GTPγS and induce production of IP1 in Flp-InTM T-RExTM 293 
cells induced to express wild type hFFA2 is illustrated (A). The effect of Lys65 alterations on the 
response to AZ1729 in IP1 accumulation (B), [35S]-GTPγS binding (C) and cAMP inhibition (D) 
assays is shown. All data are means pooled from independent experiments (n ≥ 3) that were 
performed in duplicate (B) or triplicate (C, D). 
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potency of AZ1729 in the [35S]-GTPγS binding (Figure 6.9C) and cAMP inhibition 
(Figure 6.9D) assay was not significantly affected (Table 6.3). These results 
confirm that Lys652.60 alterations do indeed not intrinsically affect coupling of 
hFFA2 to Gi/o G proteins.  
6.2.5 A TGFα shedding assay can be employed to assess impact 
of Lys65 mutations on signalling of hFFA2 via Gq/11 and G12/13 
To examine the role of Lys652.60 in selective G protein coupling in more detail, a 
recently developed cell-based assay was employed, which detects shedding of 
TGFα into the cell medium (Inoue et al., 2012). The TGFα shedding assay 
required co-transfection of AP-tagged TGFα and the receptor of interest into 
HEK293 cells. Following compound treatment, the conditioned medium was 
separated from the cells and the percentage of AP-TGFα released into the 
medium was quantified by measuring the conversion of the AP substrate 
p-nitrophenyl phosphate into p-nitrophenol, which absorbs light at 405 nm. 
Shedding of TGFα occurs in response to activation of Gq/11 and G12/13 G proteins 
and as coupling of hFFA2 to Gq/11 and G12/13 could be detected in a yeast-based 
chimeric G protein assay (Brown et al., 2003), this should be a suitable assay to 
detect hFFA2 activation. Indeed, increasing concentrations of C3 were able to 
induce shedding of TGFα (Figure 6.10A) with a 10-fold increase in potency 
(Table 6.4) compared to the IP1 accumulation assay (Table 6.1). To dissect the 
contribution of Gq/11 and G12/13 to the TGFα shedding response of hFFA2, 
genome-edited HEK293 cell lines were employed. These cells were engineered to 
either lack expression of Gαq and Gα11 (ΔGq/11) or of Gα12 and Gα13 (ΔG12/13), such 
that the respective remaining G protein subtypes are responsible for inducing 
the observed TGFα shedding response: G12/13 in ΔGq/11 cells (Schrage et al., 2015, 
Alvarez-Curto et al., 2016), and Gq/11 in ΔG12/13 cells (O'Hayre et al., 2016). In 
agreement with hFFA2 coupling to both Gq/11 and G12/13 G proteins, C3 was able 
to induce a concentration-dependent TGFα shedding response via hFFA2 in each 
of ΔGq/11 and ΔG12/13 cells (Figure 6.10A), albeit with minor reduction in potency 
by approximately 3.5-fold in comparison with parental HEK293 cells (Table 6.4). 
In cells with deletion of all four G protein subtypes Gαq, Gα11, Gα12 and Gα13 
(ΔGq/11/12/13 or ΔΔ) (Devost et al., 2017) increasing concentrations of C3 did not 
induce TGFα shedding (Figure 6.10A), confirming that shedding of TGFα lies 
downstream of activation of Gq/11 and G12/13 only (Inoue et al., 2012). 
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Figure 6.10 FFA2 agonists C3 and compound 1 induce a TGFα shedding response through 
Gq/11 and G12/13 Increasing concentrations of C3 (A) or compound 1 (D) are able to promote 
shedding of TGFα in parental HEK293 cells and those genome-edited to lack expression of Gαq/11 
(ΔGq/11), Gα12/13 (ΔG12/13) or Gαq/11/12/13 (ΔΔ), which were transfected with hFFA2. Reintroduction of 
Gαq, Gα11, Gα12 and Gα13 into ΔΔ cells resulted in rescue of TGFα shedding via hFFA2 by C3 (B) 
and compound 1 (E). Introduction of chimeric Gαq-12 and Gαq-13 into ΔΔ cells resulted in an 
increased TGFα shedding response to C3 (C) and compound 1 (F) compared to reintroduction of 
native Gα12 and Gα13. All data are means pooled from independent experiments (n ≥ 3) that were 
performed in triplicate. 
 
To assess the contribution of single G protein subtypes to the TGFα shedding 
response, native G protein subunits Gαq, Gα11, Gα12 and Gα13 were reintroduced 
into the ΔGq/11/12/13 cells background. C3 was able to promote shedding of TGFα 
via hFFA2 when each of the four G protein subtypes were reintroduced into the 
cells (Figure 6.10B). However, the level of TGFα shedding induced by activation 
of different G protein subtypes was different, with the signal produced by Gαq 
and Gα11 being substantially greater than the signal observed upon 
reintroduction of Gα12 and, to a lesser extent, Gα13. This observation may reflect 
Chapter 6  179 
 
weak coupling of hFFA2 to Gα13 and, in particular, Gα12 compared to Gαq and 
Gα11, but it could also result from poor coupling efficiency of Gα12 and Gα13 to 
the downstream mechanisms that lead to TGFα shedding. To understand which 
of these hypotheses was true, chimeric G proteins were utilised that were 
composed of a Gαq backbone with substitution of its six C-terminal residues with 
the corresponding sequence from Gα12 or Gα13, as this region represents the part 
of the C-terminal α5 helix that is a defining factor for G protein selection 
(Milligan and Kostenis, 2006). Upon introduction of Gαq-12 and Gαq-13 chimeric G 
proteins instead of full-length Gα12 and Gα13, the TGFα shedding response 
induced by C3 was substantially increased (Figure 6.10C).This result suggests 
that the efficiency of Gα12, and to some extent also Gα13, to promote TGFα 
shedding is indeed relatively poor compared to Gαq and Gα11, but that hFFA2 is 
able to couple effectively to both Gα12 and Gα13. When employing synthetic 
agonist compound 1 instead of C3 in the assay formats described above, 
equivalent results were obtained. As for C3, increasing concentrations of 
compound 1 were able to promote a TGFα shedding response (Figure 6.10D) 
with potency that was 10-fold higher (Table 6.4) than in the IP1 assay (Table 
6.1). In studies utilising full-length (Figure 6.10E) and chimeric (Figure 6.10F) 
G proteins, a similar contribution of each G protein to the TGFα shedding 
response was observed. This suggests that, at least in this assay system, C3 and 
compound 1 produce similar hFFA2 signalling profiles. 
Table 6.4 Effect of Lys65 mutations on FFA2 agonist potency in the TGFα shedding assay 
Cells Compound WT K65R K65A K65E 
Parental 
C3 4.93 ± 0.04 4.68 ± 0.09 2.23 ± 0.13*** 2.79 ± 0.07*** 
Compound 1 8.12 ± 0.08 8.14 ± 0.03 6.88 ± 0.04*** 6.88 ± 0.04*** 
ΔGq/11 
C3 4.40 ± 0.07$$$ 3.98 ± 0.04* 2.67 ± 0.17*** 2.39 ± 0.07*** 
Compound 1 7.84 ± 0.08$ 7.51 ± 0.10 6.02 ± 0.11*** 5.94 ± 0.08*** 
ΔG12/13 
C3 4.38 ± 0.10$$$ 4.11 ± 0.09 2.14 ± 0.08*** 2.52 ± 0.05*** 
Compound 1 7.49 ± 0.08$$$ 7.33 ± 0.11 6.23 ± 0.11*** 6.16 ± 0.13*** 
*/$ Comparison of pEC50 values of one compound at different forms of hFFA2 by one-way ANOVA 
followed by Dunnett’s test with WT hFFA2 (*) or parental cells ($) as a reference with significant 
differences denoted as P = */$ ≤ 0.05, P = **/$$ ≤ 0.01 and P = ***/$$$ ≤ 0.001 
 
As the TGFα shedding assay allows dissection of Gq/11 and G12/13 signalling when 
employed in combination with appropriate genome-edited cell lines, the assay 
system was utilised to assess whether charge-modifying alterations of Lys652.60 
had a similar impact on hFFA2 coupling to G12/13 as they do Gq/11. Indeed, the 
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ability of C3 (Figure 6.11A) and compound 1 (Figure 6.11B) to induce a TGFα 
shedding response in parental HEK293 cells was severely impaired by K65A and 
K65E mutations, while at K65R hFFA2 only a very limited effect on agonist 
potency was detected (Table 6.4). A similar impact of the various Lys652.60 
mutations could be observed in ΔGq/11 (Figures 6.11C and D) and ΔG12/13 
(Figures 6.11E and F) cell backgrounds. This suggests that not only hFFA2 
coupling to Gq/11 G proteins is affected by charge-altering Lys652.60 mutations, 
but also coupling to G12/13 G proteins. To confirm that the TGFα shedding 
responses detected indeed represented coupling of hFFA2 to Gq/11 and/or G12/13, 
equivalent experiments were performed in ΔGq/11/12/13 cells and as anticipated 
increasing concentrations of C3 (Figure 6.11G) and compound 1 (Figure 6.11H) 
did not change basal levels of TGFα shedding. 
The higher potency of C3 and compound 1 in the TGFα shedding compared to the 
IP1 accumulation assay allowed effective quantification of agonist potencies at 
K65A and K65E hFFA2 (Table 6.5). By comparing agonist potency values at the 
various mutant forms of the receptor in Gi/o- versus Gq/11- and G12/13-coupled 
assays, the degree of bias imbued by charge-altering mutations of Lys652.60 could 
be calculated (Table 6.5). Three common approaches exist that can be utilised 
to assess signalling bias (Rajagopal et al., 2011): Equimolar comparison (Gregory 
et al., 2010), equiactive comparison (Ehlert, 2008) and the operational model 
(Evans et al., 2011). Equimolar comparison involves plotting of concentration- 
response curves of a selected ligand in two different assay systems against one 
another and comparison of the curve shape to a reference agonist can provide 
information on whether it shows biased signalling behaviour (Gregory et al., 
2010). However, this method is more visual than quantitative, and it is less 
suitable for separating system bias (Rajagopal et al., 2011), therefore this 
method was not employed here. Instead agonist potencies were analysed by 
equiactive comparison (see section 2.7.4), which traditionally involves the 
comparison of the potency and efficacy of the potentially biased ligand in 
different assay systems to a reference compound (Ehlert, 2008). However, in this 
case the intrinsic activity of agonists at Lys652.60 mutants of hFFA2 was 
compared to their effect at the wild type receptor, which served as a reference. 
Applying this analysis to C3 concentration response curves suggested that hFFA2 
function was biased between 41- and 60-fold by K65A and K65E mutations to 
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Figure 6.11 Charge-modifying mutations of Lys65 have a detrimental effect on hFFA2 
response to agonists in Gq/11- and G12/13-coupled TGFα shedding assays The effect of different 
Lys65 alterations on the response of hFFA2 to C3 (A, C, E, G) or compound 1 (B, D, F, H) in 
parental HEK293 cells (A, B) or those genome-edited to lack Gαq/11 (C, D), Gα12/13 (E, F) or 
Gαq/11/12/13 (G, H) is illustrated. All data are means pooled from independent experiments (n ≥ 3) 
that were performed in triplicate. 
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Table 6.5 Agonist bias factor calculation for Lys65 mutants of hFFA2 
   β factor (compared to WT) 
Pathway 1 Pathway 2 Agonist K65R K65A K65E 
cAMP 
TGFα 
shedding 
C3 -0.30 2.00 2.10 
Compound 1 -0.39 1.44 1.33 
GTPγS 
TGFα 
shedding 
C3 -0.10 1.78 1.62 
Compound 1 -0.03 0.36 0.59 
 
favour Gi/o-mediated signalling when utilising data from the [35S]-GTPγS binding 
assay, or between 100- and 125-fold when comparing TGFα shedding with the 
cAMP inhibition assay (Table 6.5). Equivalent results could be obtained when 
performing calculations based on compound 1, however the quantified bias 
towards Gi/o-coupled pathways was less extensive as it was estimated to be 21- 
to 27-fold when employing values from the cAMP inhibition assay (Table 6.5). 
Although conceptually the operational model might yield a better estimate of 
bias (Rajagopal et al., 2011), affinity measures of FFA2 agonists at all forms of 
FFA2 were not available due to the loss of antagonist binding to K65R and K65E 
hFFA2, prohibiting the use of sigma comparison (Brust et al., 2015). In contrast, 
the transduction coefficient model derives ligand dissociation constants directly 
from concentration responses (Kenakin et al., 2012). However, when agonist 
concentration response curves yield slopes that approach unity, results from 
equiactive comparison and transduction coefficient calculation become nearly 
identical (Kenakin and Christopoulos, 2013). In the case of this study, agonist 
concentration response curves were fit using a three-parameter model that 
constrains the slope of the sigmoidal curve to unity, therefore equiactive 
comparison was selected for signalling bias quantification. 
6.2.6 Use of chimeric G proteins to examine the diverse effect of 
charge-altering Lys65 mutations on hFFA2 signalling 
Chimeric G proteins with a Gαq backbone and a six-residue substitution at the C 
terminus were employed in the previous section to demonstrate that hFFA2 
indeed couples efficiently to G12/13 and that reduced agonist responses upon 
reintroduction of full-length Gα12 and Gα13 were likely due to the poor coupling 
of these Gα subtypes to mechanisms that result in shedding of TGFα (Figures 
6.10C and F). To examine whether this strategy could also be utilised to detect 
coupling of hFFA2 to G proteins that do not naturally promote TGFα shedding, 
Gαq-i and Gαq-o chimeras were co-transfected into ΔGq/11/12/13 cells with AP-TGFα 
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Figure 6.12 Introduction of chimeric Gαq-i and Gαq-o allows detection of hFFA2-mediated Gi/o 
signalling in TGFα shedding assay The ability of increasing concentrations of C3 and compound 
1 (A) or AZ1729 (B) to promote shedding of TGFα in cells genome-edited to lack Gαq/11/12/13 when 
transfected with chimeric Gαq-i and Gαq-o G proteins is illustrated. The agonist response in cells 
transfected with full-length Gαq from figure 6.10 is shown for comparison (- -). All data are means 
pooled from independent experiments (n ≥ 3) that were performed in triplicate. 
 
and hFFA2. Now, increasing concentrations of C3 and compound 1 were able to 
promote TGFα shedding via hFFA2 activation of the Gαq-i and Gαq-o chimeras 
(Figure 6.12A). However, agonist potency at hFFA2 in Gαq-i- and Gαq-o-
transfected cells was reduced compared to that in those transfected with full-
length Gαq (Table 6.6). Interestingly, the maximal response to agonists upon 
Gαq-o reintroduction was doubled compared to Gαq, which may reflect improved 
coupling of hFFA2 to this G protein subtype. 
The allosteric ligand AZ1729 displayed a biased signalling profile in previous 
studies, as it was able to promote activation of Gi/o but not Gq/11 signalling 
pathways (Bolognini et al., 2016a). To examine whether this signalling bias could 
be detected by the TGFα shedding assay when utilising chimeric G proteins, the 
response of ΔGq/11/12/13 cells transfected with hFFA2 and Gαq, Gαq-i or Gαq-o to 
increasing concentrations of AZ1729 was assessed (Figure 6.12B). In agreement 
with the lack of AZ1729 action in Gq/11-coupled assays, AZ1729 was unable to 
produce a response upon reintroduction of Gαq. In contrast, a concentration-
dependent response to AZ1729 could be detected in Gαq-i-transfected cells with 
a pEC50 of 7.01 ± 0.16, similar to the potency of AZ1729 measured in the 
[35S]-GTPγS binding assay (Table 6.3). Interestingly, reintroduction of Gαq-o did 
not result in a gain of AZ1729 agonism (Figure 6.12B), which may suggest that 
AZ1729 is biased towards activation of Gi specifically, rather than the entire Gi/o  
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Table 6.6 FFA2 agonists display increased potency at charge-altering mutations of Lys65 
when Gαq-i versus Gαq or Gαq-o is reintroduced into cells with a ΔGq/11/12/13 background
Transfection Compound WT K65R K65A K65E 
Gαq 
C3 5.21 ± 0.03 4.90 ± 0.14 2.61 ± 0.06 2.90 ± 0.04 
Compound 1 8.83 ± 0.03 8.76 ± 0.09 6.66 ± 0.14 6.91 ± 0.02 
Gαq-i 
C3 5.18 ± 0.06 4.79 ± 0.06 3.21 ± 0.02*** 3.38 ± 0.10* 
Compound 1 7.89 ± 0.04*** 8.81 ± 0.09 7.49 ± 0.04** 7.44 ± 0.03*** 
Gαq-o 
C3 4.37 ± 0.04*** 3.52 ± 0.02*** < 2 < 2 
Compound 1 8.22 ± 0.12*** 7.84 ± 0.07*** < 6 < 6 
* Comparison of C3 or compound 1 pEC50 values at different G protein transfections by one-way 
ANOVA followed by Dunnett’s test with Gq transfection as a reference with significant differences 
denoted as P = * ≤ 0.05, P = ** ≤ 0.01 and P = *** ≤ 0.001 
 
subfamily. Regardless, the ability of AZ1729 to promote TGFα shedding in 
ΔGq/11/12/13 cells transfected with Gαq-i confirmed that this experimental setup 
could be utilised to detect Gi signalling. 
As results discussed in previous sections suggested that charge-altering 
alterations of Lys652.60 can generate a hFFA2 receptor that displays signalling 
bias towards Gi/o-coupled pathways, the effect of Gi/o chimera reintroduction on 
the agonist response at Lys652.60 mutants of hFFA2 was assessed (Figure 6.13). 
At K65R hFFA2, C3 behaved in a similar fashion as at wild type FFA2 (Figure 
6.13A) with the highest potency observed upon Gαq reintroduction (Table 6.6). 
Interestingly, the potency loss with Gαq-o compared to Gαq, which was observed 
at wild type hFFA2, was enhanced at K65R hFFA2 with a 24-fold loss compared to 
6.9-fold at wild type hFFA2. At K65A (Figure 6.13B) and K65E (Figure 6.13C) 
hFFA2, the reintroduction of the G protein chimeras had a substantially different 
effect. In agreement with the hypothesis that K65A and K65E hFFA2 display 
improved coupling to Gi/o G proteins, transfection of Gαq-i did result in an 
improved response to C3 with potency increased by 4.0- and 3.0-fold at K65A 
and K65E hFFA2, respectively, compared to transfection of Gαq (Table 6.6). 
Surprisingly, in Gαq-o-transfected cells increasing concentrations of C3 failed to 
promote shedding of TGFα (Figures 6.13B and C). This may suggest that, 
charge-altering Lys652.60 mutations bias hFFA2 towards coupling to Gi 
specifically. Equivalent experiments performed with compound 1 led to a similar 
conclusion with K65R hFFA2 behaving in a comparable fashion to wild type 
receptor (Figure 6.13D), while at K65A (Figure 6.13E) and K65E (Figure 6.13F) 
hFFA2 reintroduction of Gαq-i, but not Gαq-o, resulted in an improved response to 
compound 1 compared to Gαq transfection. 
Chapter 6  185 
 
 
Figure 6.13 Charge-modifying Lys65 mutants of hFFA2 show enhanced TGFα shedding 
response to agonists upon introduction of chimeric Gαq-i but not Gαq-o The ability of varying 
concentrations of C3 (A, B, C) and compound 1 (D, E, F) to induce shedding of TGFα in cells 
transfected with K65R (A, D), K65A (B, E) and K65E (C, F) hFFA2 is shown. The HEK293 cell line 
employed was genome-edited to lack Gq/11/12/13 and respective Gα subunits were reintroduced prior 
to performing the experiment. All data are means pooled from independent experiments (n ≥ 3) that 
were performed in triplicate. 
 
6.2.7 Allosteric modulation of hFFA2 response to C3 by AZ1729 
may differ between Gq/11- and G12/13-mediated signals 
Previous characterisation of AZ1729 revealed that in addition to displaying 
biased agonism, its ability to modulate the response of hFFA2 to C3 was also 
dependent on the coupled G protein subtype examined (Bolognini et al., 2016a). 
While AZ1729 acted as a positive allosteric modulator of C3 potency in Gi/o-
coupled assays, it had a negative modulatory effect on C3 efficacy when Gq/11-
Chapter 6  186 
 
mediated responses were assessed. However, due to the lack of an appropriate 
assay system, it was not examined if and how AZ1729 may modulate G12/13-
mediated hFFA2 responses to C3. Therefore, the effect of increasing AZ1729 
concentrations on the C3 concentration response curve was assessed in the TGFα 
shedding assay employing parental and the genome-edited cell lines ΔGq/11 and 
ΔG12/13 (Figure 6.14). Visual inspection of the effect of AZ1729 allosteric 
modulation of the C3 concentration response in parental cells showed AZ1729 to 
behave simply as a negative allosteric modulator of C3 efficacy (Figure 6.14A), 
as observed in other Gq/11-coupled assays (Bolognini et al., 2016a). However, 
increasing concentrations of AZ1729 resulted in an increased basal signal, which 
may indicate low levels of intrinsic agonism (Figure 6.14A). Furthermore, with 
increasing AZ1729 concentration the potency of C3 displayed a small increase 
(Figure 6.14A) that was reflected by an increase in pEC50 values (Table 6.7). 
 
Figure 6.14 Differences in AZ1729 allosteric modulation of Gq/11- and G12/13-mediated hFFA2 
response to C3 in TGFα shedding assay The effect of varying AZ1729 concentrations (A) on the 
ability of C3 to induce shedding of TGFα via hFFA2 in HEK293 cells with parental background (A) 
or genome-edited to lack G12/13 (B) or Gq/11 (C) is illustrated. All data are means pooled from 
independent experiments (n ≥ 3) that were performed in triplicate. 
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Table 6.7 Effect of AZ1729 on the potency of C3 in the TGFα shedding assay in different cell 
backgrounds 
 Cellsa 
AZ1729 (nM) Parental ΔGq/11 ΔG12/13 
0 4.67 ± 0.06 4.12 ± 0.09 4.54 ± 0.04 
56 4.67 ± 0.08 4.22 ± 0.05 4.43 ± 0.15 
100 4.76 ± 0.09 4.58 ± 0.13 4.56 ± 0.16 
320 5.19 ± 0.18 4.96 ± 0.21 4.37 ± 0.23 
560 5.08 ± 0.33 5.15 ± 0.33 3.89 ± 0.40 
1000 5.08 ± 0.24 5.19 ± 0.18 4.36 ± 0.26 
1800 5.74 ± 0.43 5.33 ± 0.42 4.60 ± 0.22 
a Data shown as pEC50 values of C3 with respective concentrations of AZ1729 co-added 
 
These observations differ from results obtained in other Gq/11-dependent assay 
systems, however the TGFα shedding assay incorporates signals from both Gq/11 
and G12/13 activation. To dissect how Gq/11 and G12/13 coupling might contribute 
to the allosteric effect observed, equivalent experiments were performed in 
genome-edited ΔGq/11 and ΔG12/13 cells. In ΔG12/13 cells, in which the TGFα 
shedding signal is exclusively mediated by activation of Gq/11, AZ1729 behaved as 
in other Gq/11-mediated assay systems (Figure 6.14B). Increasing concentrations 
of AZ1729 resulted in reductions of the maximal C3 response with no alteration 
in potency (Table 6.7). In contrast, in ΔGq/11 cells, where TGFα shedding occurs 
exclusively through G12/13 activation, equivalent concentrations of AZ1729 
resulted in a smaller reduction in the maximal C3 response (Figure 6.14C) and a 
leftward shift of C3 potency with increasing AZ1729 concentration was observed 
(Table 6.7). These results suggest that AZ1729 may not only show biased 
allosteric modulation of the C3 response between Gi/o- and Gq/11–mediated 
signalling, but AZ1729 potentially also displays a different allosteric mechanism 
in G12/13-coupled assays. 
6.2.8 Loss of positive charge at position 65 also affects β-arrestin 
recruitment by FFA2 
The investigation of the role of Lys652.60 in FFA2 signalling has focussed primarily 
on the altered coupling to different G protein subtypes compared to the wild 
type receptor. If charge-altering mutations of Lys652.60 indeed change the 
capacity of FFA2 to couple to specific G protein subtypes, this suggests that the 
active conformation of such mutant forms of FFA2 will differ to the wild type 
receptor and likely be most prominent in the intracellular portion of the  
Chapter 6  188 
 
 
Figure 6.15 Recruitment of β-arrestin in response to FFA2 agonists is affected by charge-
altering mutations of Lys65 The ability of C3 (A) and compound 1 (B) to induce recruitment of 
β-arrestin 2 in HEK293T cells transiently transfected with RLuc- β-arrestin 2 and either wild type, 
K65R, K65A or K65E hFFA2 is shown. Results were normalised to the maximal agonist response 
at the wild type receptor. All data are means pooled from independent experiments (n ≥ 3) that 
were performed in triplicate. 
 
receptor that mediates the interaction with G proteins. However, FFA2 is also 
able to interact with β-arrestin 2, whose recruitment may also be affected by 
such conformational rearrangements. To investigate this hypothesis, the impact 
of Lys652.60 mutations on β-arrestin 2 recruitment was assessed. Interestingly, as 
in the case of Gq/11-coupled signalling assays, charge-altering mutations K65A 
and K65E affected the response of FFA2 to both C3 (Figure 6.15A) and 
compound 1 (Figure 6.15B). In contrast, at the positive charge-retaining mutant 
K65R hFFA2 both agonists displayed the same potency as at the wild type 
receptor (Table 6.8). Unfortunately, the lack of a saturable response at the 
charge-altering mutants did not permit calculation of potency values, therefore 
bias factors could not be generated to compare coupling of mutants of interest 
to Gi G proteins versus β-arrestin. However, the loss of FFA2 agonist response in 
this assay supports the hypothesis that the loss of the positive charge in position 
65 may lead to an intracellular conformational rearrangement that does not only 
affect recruitment of specific G proteins, but also other signalling partners such 
as β-arrestin. 
Table 6.8 Effect of Lys65 mutations on FFA2 agonist potency in the BRET-based β-arrestin 
recruitment assay 
Compound WT K65R K65A K65E 
C3a 3.40 ± 0.07 3.51 ± 0.05 < 2 < 2 
Compound 1a 6.34 ± 0.04 6.56 ± 0.05 < 5 < 5 
a Data shown as pEC50 values 
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6.3 Discussion 
6.3.1 Lys65 defines a secondary binding site that is unique to the 
human orthologue of FFA2 
Differences in pharmacological properties and ligand efficiency at species 
orthologues of GPCRs do not always present an issue for research progress and in 
some cases, such as SCFA receptor FFA2, it makes sense from an evolutionary 
perspective that species orthologues display distinct behaviour. Invariably the 
composition of the gut microbiome will differ between humans and rodents, and 
the role that SCFAs play in respective species may differ depending on distinct 
requirements of metabolic regulation (Nguyen et al., 2015). This hypothesis 
would provide an explanation for the various differences observed between 
human and murine FFA2, including different rank orders of SCFA potency and 
constitutive activity levels (Hudson et al., 2012b). Although the impact of 
species-specific FFA2 pharmacology on its function in humans versus rodents is 
not fully understood, it is very important to consider when drawing conclusions 
from studies in animal models. The validation of FFA2 as a therapeutic target 
using animal models is complicated further by the lack of FFA2 antagonist action 
at the rodent orthologues. As an alternative means of assessing the impact of 
FFA2 inactivity, transgenic knock-out mouse lines that do not express FFA2 have 
been employed to help define physiological roles of FFA2 (Psichas et al., 2015, 
Kimura et al., 2013, Maslowski et al., 2009). However, in at least one study 
knock-out of FFA3 altered expression levels of FFA2 (Zaibi et al., 2010), which 
complicated interpretation of resulting observations. Using an antagonist to 
confirm receptor-specific effects would be less costly than transgenic animal 
development and avoid limitations of knock-out animal models. Therefore, 
development of an antagonist active at mFFA2 would contribute to furthering 
FFA2 research and understanding the molecular basis for antagonist species 
selectivity could represent the first step in such efforts. 
Previous assessment of antagonist binding to hFFA2 included examination of the 
binding pocket using functional and binding studies, and construction of a hFFA2 
homology model to computationally predict antagonist binding poses (see 
chapters 3 and 4). These studies revealed that the carboxylate moiety of the 
most widely employed antagonists CATPB and GLPG0974 was anchored by the 
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orthosteric arginines Arg1805.39 and Arg2557.35. However, each antagonist class 
preferred different arginine residues, CATPB interacting preferentially with 
Arg2557.35 and GLPG0974 with Arg1805.39, and interaction with a single arginine 
residue was sufficient for high-affinity binding (see chapter 4). Furthermore, 
replacement of the carboxylate moiety with a methyl ester or morpholine had 
only a modest effect on antagonist action and affinity (see chapters 3 and 4). 
This implied that CATPB and GLPG0974 likely form additional important contacts 
with hFFA2, which define high-affinity binding and may be responsible for the 
species selectivity of these antagonists. However, initial alignment of human and 
rodent orthologues of FFA2 did not reveal residues that could be responsible for 
antagonist species selectivity, as the core ligand binding pockets of these 
orthologues mostly contain residues with similar properties (Figure 6.16). 
Therefore, docking poses of GLPG0974 and CATPB in the hFFA2 homology model 
were explored in detail for residues that may form an interaction with both 
antagonists and where the equivalent residue in rodent FFA2 might limit 
antagonist binding. This assessment led to the identification of a lysine residue 
at the top of TM2, which participated in a hydrogen bond with the central amide 
moiety in GLPG0974 and CATPB. Lys652.60 is conserved across the majority of 
FFA2 orthologues, however rodent FFA2 contains an arginine in this position 
 
Figure 6.16 Sequence alignment of FFA2 orthologues with focus on residue 65 Alignments of 
the primary amino acid sequence of various orthologues of FFA2 were performed with the human 
residues as the reference sequence using Clustal Omega (Sievers et al., 2011) and residues 60 to 
119 are shown. Presence of lysine (yellow) or arginine (green) in position 652.60 is highlighted in 
colour. Glu682.63, which forms an ionic interaction with Arg652.60 in the mFFA2 homology model 
(Figure 6.6), is fully conserved and Phe893.28, which appears to be important for anchoring 
antagonists in the hFFA2 binding pocket (Figure 6.2), is mostly conserved apart from in kangaroo 
rat, western clawed frog and channel catfish. 
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(Figure 6.16). This variation has previously not attracted much attention as 
arginine and lysine are considered similar amino acids due to their fixed positive 
charge, but a homology model of mFFA2 revealed that Arg652.60 is likely to form 
an ionic bond with Glu682.63. This interaction could result in a structural 
rearrangement of the binding pocket and may thereby affect antagonist binding. 
To examine the importance of Lys652.60 for antagonist binding in more detail, 
mutant forms of hFFA2 were generated with different alterations of Lys652.60, 
specifically to arginine, alanine and glutamic acid. Interestingly, CATPB and 
GLPG0974 lost the ability to inhibit the response of K65R and K65E hFFA2 to C3 
and displayed a reduction in potency at K65A hFFA2. Furthermore, 
[3H]-GLPG0974 binding assays demonstrated that the observed lack of inhibition 
of agonist function was caused by a reduction in antagonist affinity. Therefore, 
the employed homology model was indeed able to accurately predict an 
important interaction of antagonists with hFFA2. Most importantly, the 
alteration of Lys652.60 to arginine, which reflects the identity of the equivalent 
residue at mFFA2, had a detrimental effect on antagonist binding. To assess 
whether species variation in position 2.60 could be responsible for antagonist 
selectivity, a form of mFFA2 containing the ‘humanising’ R65K mutation was 
generated and utilised in functional and binding studies. In agreement with the 
proposed hypothesis, CATPB and GLPG0974 gained the ability to inhibit the 
response to C3 at R65K mFFA2 and [3H]-GLPG0974 was able to bind with high 
affinity to R65K mFFA2. Interestingly, affinity of CATPB was almost fully restored 
to hFFA2 levels by the R65K alteration of mFFA2, while the pIC50 and binding 
affinity of GLPG0974 remained reduced at R65K mFFA2 compared to wild type 
hFFA2. Furthermore, docking of antagonists into R65K mFFA2 suggested that 
CATPB adopts a similar binding pose in R65K mFFA2 as in hFFA2 with an 
interaction between the modified Lys652.60 and the CATPB amide moiety. In 
contrast, GLPG0974 adopted a low-energy pose that differed substantially from 
that in hFFA2. This suggests that there may be differences in the defining factors 
of CATPB and GLPG0974 species selectivity and additional human orthologue-
specific residues are likely important for GLPG0974 binding. Perhaps this 
divergence is not entirely unexpected, as previous investigations also suggested 
distinct modes of CATPB and GLPG0974 binding, such as their preference to 
interact with different orthosteric arginine residues and the difference in 
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binding kinetics (see chapter 4). Furthermore, GLPG0974 has also been reported 
to be inactive at rabbit and canine orthologues of FFA2 (Beetens, 2013). Both 
contain a lysine at position 2.60 (Figure 6.15), suggesting that further studies 
may be necessary to fully understand the species selective behaviour of 
GLPG0974. 
Interestingly, Lys652.60 was essential for binding of the fluorescent tracer F-1 to 
hFFA2. Previous characterisation of F-1 revealed that it is likely an allosteric 
ligand, whose allosteric binding site overlaps in part with that of orthosteric 
antagonists (see chapter 5). The lack of F-1 binding to K65R and K65A hFFA2 
suggests that Lys652.60 lies within the area of overlap between F-1 and 
orthosteric antagonist binding sites. F-1 shares part of its structure with the 
GLPG0974 analogue GLPG-3, which also contains a central amide moiety, 
therefore F-1 might interact in a similar fashion with Lys652.60 as CATPB and 
GLPG0974. However, further work would be required to confirm this hypothesis. 
Interestingly, a role of Lys652.60 in defining an allosteric binding site of hFFA2 
was suggested previously in a study designed to define the binding mode of the 
allosteric agonist 4-CMTB (Grundmann et al., 2016). It was proposed that 4-CMTB 
binds in a sequential fashion to hFFA2 by initially occupying the orthosteric 
binding pocket for a short period of time and then transitioning to an allosteric 
binding site from which it exerts its allosteric modulation of the C3 response. To 
support this hypothesis, two mutants of hFFA2 were studied: R255A, to prohibit 
binding to the orthosteric site; and K65R, to disrupt allosteric binding of 4-CMTB 
(Grundmann et al., 2016). However, 4-CMTB was unable to compete with F-1 
binding to hFFA2, which makes it unlikely that 4-CMTB interacts directly with 
Lys652.60. Homology models described here suggest that the K65R alteration in 
hFFA2 may result in Arg652.60 forming an ionic interaction with Glu682.63. 
Conformational changes that could occur in response to this ionic bond being 
formed may indirectly result in a disruption of the allosteric 4-CMTB binding site. 
Assessment of the structural changes that occur upon mutation of Lys652.60 to 
arginine in hFFA2 could therefore provide additional information on the binding 
sites of 4-CMTB. 
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6.3.2 Generation of a biased form of hFFA2 by modifying the 
positive charge of the residue in position 2.60 
GPCRs are often defined by their ability to transduce signals through activation 
of specific G protein subtypes within the Gs, Gi/o, Gq/11 or G12/13 families. 
However, several GPCRs have the capacity to activate more than one family of G 
proteins and this can have important implications for their physiological role. 
FFA2 represents one such example, as it is well established that it is able to 
couple to G proteins of the Gi/o and Gq/11 families, and responses mediated by 
these G proteins are routinely assessed in assay systems that measure changes in 
secondary messengers such as cAMP or IP1 (see chapter 3). Coupling of hFFA2 to 
G12/13 G proteins was also demonstrated in a study that employed chimeric G 
proteins in a yeast-based assay to identify G protein subtypes that interact with 
hFFA2 (Brown et al., 2003), however this avenue of FFA2 signalling has not been 
explored further since. This is likely due to the fact that assay systems that 
allow straightforward detection of G12/13 activation were not readily available. 
However, recent development of the TGFα shedding assay has changed this 
situation, as it can be employed to detect signalling through Gq/11 and G12/13. 
Combination of the TGFα shedding assay with a set of recently developed 
genome-edited cell lines that lack specific G protein subtypes, such as Gαq and 
Gα11 (Alvarez-Curto et al., 2016), allows specific detection of the G12/13-
mediated response of hFFA2. Prior to generation of these cell lines, bacterial 
toxins such as PTX were employed to dissect contributions of specific G proteins 
to downstream signals or small molecule inhibitors of Gq/11 (Schrage et al., 
2015). However, treatment with toxins such as PTX also affects other cellular 
processes such as activation of tyrosine kinases (Mangmool and Kurose, 2011). 
Therefore genome-edited cell lines represent a complimentary approach to 
dissecting contribution of G protein subtypes to signalling responses, in 
particular for G proteins that cannot be blocked by known toxins such as G12/13. 
The recent identification of the allosteric agonist AZ1729, which is able to 
activate Gi/o but not Gq/11 through FFA2, demonstrated that the signalling 
pathways induced by FFA2 activation differ depending on the cell type (Bolognini 
et al., 2016a). Treatment of primary mouse adipocytes with AZ1729 resulted in 
inhibition of lipolysis and migration of isolated human neutrophils was enhanced 
in the presence of AZ1729, suggesting that these processes are mediated by Gi/o 
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G proteins (Bolognini et al., 2016a). In contrast, murine colonic crypts, which 
have been shown to release GLP-1 in response to FFA2 activation by SCFAs 
(Tolhurst et al., 2012), did not respond to AZ1729 treatment, and in concert 
with G protein inhibitor studies confirmed that GLP-1 release is mediated 
through a Gq-coupled mechanism. Therefore, the contribution of Gq/11 versus Gi/o 
signalling to FFA2 function in different tissues is relevant to its physiological 
role. Although a biased ligand such as AZ1729 is undoubtedly of great use to 
dissect FFA2 signalling, the underlying mechanism that defines its biased 
behaviour has not been explored. Understanding how promiscuous GPCRs couple 
to multiple G proteins and the means by which biased ligands can promote 
specific downstream signalling is important to expand our knowledge of the 
relationship between GPCR structure and function, but, as discussed above, can 
also have important therapeutic implications. 
Here, the importance of Lys652.60 in regulating hFFA2 signalling through a range 
of different G proteins was examined in detail by utilising a selection of assay 
systems, including conventional measures of second messenger regulation 
generated by Gi/o and Gq/11 activation and the TGFα shedding assay to detect 
Gq/11 and G12/13-mediated responses. During the assessment of antagonist action 
at different Lys652.60 mutants of hFFA2, a detrimental effect of charge-modifying 
alterations on agonist responses in the Gq/11-coupled IP1 accumulation assay was 
observed. However, despite this, in [3H]-GLPG0974 competition binding assays 
agonists retained ability to compete with the radioligand for binding to K65A 
hFFA2. These observations provided the first indication that Lys652.60 alterations 
may only contribute in a minor fashion to agonist binding affinity and Lys652.60 
may instead play a role in hFFA2 coupling to G proteins. Interestingly, the 
detrimental effect of charge-altering Lys652.60 mutations K65A and K65E was 
exclusive to Gq/11- and G12/13-coupled responses. In assays that detect activation 
of Gi/o G proteins mutation of Lys652.60 had at most a minor effect on responses 
to agonists. Taken together, this suggested that signalling of K65A and K65E 
hFFA2 is biased towards activation of Gi/o compared to Gq/11 and G12/13 and 
calculation of the bias factor β confirmed that K65A and K65E indeed show a 
level of signalling bias compared to wild type hFFA2 that could be quantified. 
Chapter 6  195 
 
To explore the Gi/o bias induced by charge-altering mutations of Lys652.60, a 
genome-edited cell line lacking expression of each of Gαq, Gα11, Gα12 and Gα13 
(Devost et al., 2017) was employed in the TGFα shedding assay. In these cells 
FFA2 agonists did not produce a TGFα shedding response as they do not express 
the G proteins that mediate this response, but upon co-transfection of Gα 
subunits the TGFα shedding response mediated specifically by the reintroduced 
G protein can be detected. Such assessment of the contribution of Gαq, Gα11, 
Gα12 and Gα13 to TGFα shedding in response to FFA2 agonists revealed that while 
all G protein subunits couple to hFFA2, they have different capacities to 
promote shedding of TGFα. Therefore, chimeric Gα proteins with a backbone 
based on Gαq and substitution of the six C-terminal amino acids with the Gα 
protein of interest were utilised to compare FFA2 coupling to different G 
proteins. Furthermore, the use of such chimeric Gα proteins also allowed the use 
of the TGFα shedding assay to detect coupling of FFA2 to Gi/o G proteins, which 
do not naturally promote shedding of TGFα. In agreement with the signalling 
bias induced by charge-altering Lys652.60 mutations, K65A and K65E hFFA2 
displayed an improved TGFα shedding response when the Gαq-i chimera was 
reintroduced. In contrast, reintroduction of Gαq-o resulted in a reduced response 
compared to co-transfection of Gαq. This may suggest that charge-modifying 
Lys652.60 alterations do not only bias hFFA2 signalling toward coupling to the Gi/o 
family but result in the receptor specifically favouring interaction with Gαi and 
not Gαo. HEK293 cells that were employed throughout the work presented do not 
express Gαo (Atwood et al., 2011). Therefore, the bias factor β that was 
calculated to assess the degree of bias displayed by K65A and K65E hFFA2 for 
signalling through cAMP inhibition and [35S]-GTPγS binding assays rather than the 
TGFα shedding assay, actually compares exclusively Gi coupling with Gq/11 and 
G12/13 activation. Although selection between G proteins within one subfamily is 
not common, there are other examples of GPCRs that display such a signalling 
profile. While the dopamine D2 receptor is able to activate multiple G proteins 
within the Gi/o subfamily, the dopamine D3 receptor has been shown to 
selectively couple to Gαo with the third intracellular loop of the D2 receptor 
playing a role in defining the promiscuity of its G protein coupling profile (Lane 
et al., 2008). G protein coupling bias has also been observed within the G12/13 
subfamily in the case of chemokine receptors CCR5 and CCR2, where chemokines 
promoted activation of Gα12, but not Gα13 (Corbisier et al., 2015), and the 
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orphan GPCR GPR35 was shown to selectively couple to Gα13, but not Gα12, in 
response to synthetic ligand zaprinast and endogenous tryptophan metabolite 
kynurenic acid (Jenkins et al., 2011). These studies indicate that it is certainly 
possible for GPCRs to select between Gα proteins within a single subfamily 
family. However, additional studies on K65A and K65E hFFA2 would certainly be 
required to confirm G protein bias within the Gi/o family. Nowadays there are 
well-established approaches that can be employed to monitor interactions 
between GPCRs and specific G protein subunits (Gales et al., 2005), and applying 
such techniques to investigate Lys652.60 could yield interesting results. 
Even though GPCR signalling bias based on the selection between different G 
protein subtypes has been the focus of this chapter and has been described 
previously in other studies (Bolognini et al., 2016a; Goupil et al., 2010), 
signalling bias between G protein-dependent and β-arrestin-mediated pathways 
is also an established concept with therapeutic relevance (Oh et al., 2010; Carr 
et al., 2016; Ranjan et al., 2017). FFA4 is a prominent example within the FFA 
receptor family for which it has been demonstrated that therapeutically 
beneficial anti-inflammatory effects are mediated by β-arrestin-dependent 
signalling (Oh et al., 2010). Although the structural basis for the preferred 
interaction between GPCRs and G proteins versus β-arrestins is not fully 
understood, there are some factors that are known to regulate β-arrestin 
recruitment, such as the phosphorylation state and nature of the C-terminal tail. 
Different patterns of phosphorylation and presence of negatively charged 
residues in the C-terminal tail of FFA4 have been shown to define the interaction 
of the receptor with β-arrestin 3 (Butcher et al., 2014). The ability of charge-
altering mutations in position 65 to affect the recruitment of β-arrestin in 
addition to coupling to Gq/11 and G12/13 G proteins, suggests that the 
conformational rearrangements imposed on the active form of the receptor by 
K65A and K65A mutations occur in a region that affects interaction with both 
signalling partners. This would support observations from other studies that have 
suggested that the site of β-arrestin interaction with GPCRs overlaps with that of 
the α5 helix of G proteins, which lies within the crevice formed by the 
rearrangement of TM3, TM5 and TM7 upon receptor activation (Szczepek et al., 
2014, Kang et al., 2015). 
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6.3.3 Complex allosterism of biased FFA2 ligand AZ1729 
GPCR ligands that display signalling bias have recently attracted much attention 
and in particular the selective activation of G proteins or β-arrestins has been 
demonstrated to result in different downstream effects (Whalen et al., 2011). 
However, in the context of promiscuous receptors such as FFA2, a ligand that 
displays bias between different G protein subtypes would be of great use to 
dissect the contribution of respective G proteins to FFA2 signalling and 
respective physiological outputs. Indeed, the identification of allosteric ligand 
AZ1729, which acted as an agonist in Gi/o- but not Gq/11-coupled assays, helped 
to confirm which FFA2-mediated physiological effects resulted from activation of 
Gi/o or Gq/11 (Bolognini et al., 2016a). This biased signalling behaviour of AZ1729 
was also useful in the study described here, as it was utilised to confirm that 
charge-altering Lys652.60 mutations do not intrinsically affect Gi/o-coupled 
signalling by hFFA2. Interestingly, when chimeric G proteins Gαq-i and Gαq-o were 
reintroduced into ΔGq/11/12/13 cells to detect Gi/o activation in the TGFα shedding 
assay, AZ1729 was only able to produce a shedding response in cells transfected 
with Gαq-i and not Gαq-o. As in discussed in the case of K65A and K65E hFFA2, 
selection between coupling to Gi versus Go would certainly be an interesting 
hypothesis to investigate further. However, more detailed assessment of hFFA2 
coupling to different G protein subtypes will be necessary to confirm these 
observations. 
While AZ1729 activation of Gi/o and Gq/11 has previously been well characterised 
(Bolognini et al., 2016a), there was little information on the effect of AZ1729 in 
G12/13-mediated pathways. Therefore, the TGFα shedding assay was employed to 
examine the allosteric modulation of C3 by AZ1729 in a G12/13-coupled assay 
system. In a previous study AZ1729 also displayed biased behaviour in its ability 
to modulate the response of hFFA2 to C3, in acting as a positive allosteric 
modulator of C3 potency in Gi/o-coupled assays and a negative allosteric 
modulator of C3 efficacy in Gq/11-coupled assays. When assessing the effect of 
AZ1729 on the ability of C3 to induce a shedding response in ΔG12/13 cells, in 
which this response is mediated exclusively by Gq/11, a similar effect could be 
observed with a concentration-dependent reduction in the maximal response to 
C3. In contrast, in parental cells and ΔGq/11 cells, in which the TGFα shedding 
response is induced exclusively by G12/13, a different pattern emerged. While a 
Chapter 6  198 
 
concentration-dependent reduction in the C3 efficacy could still be observed in 
response to AZ1729, a leftward shift of the C3 concentration-response could also 
be detected. This would suggest that in G12/13-coupled systems AZ1729 acts 
simultaneously as a negative allosteric modulator of C3 efficacy and a positive 
allosteric modulator of C3 affinity. Although such allosteric behaviour is unusual, 
it was observed previously in negative allosteric modulators of the cannabinoid 
CB1 receptor (Price et al., 2005) and a compound series developed for FFA3 
(Hudson et al., 2014). Selected analogues within the investigated FFA3 
compound series also had the capacity to reduce the maximal C3 response while 
producing a leftward shift of the C3 concentration response curve in [35S]-GTPγS 
binding assays. While the complex allosteric modulation of C3 responses by 
AZ1729 is certainly of pharmacological interest, the comparably minor increase 
in C3 potency induced by AZ1729 in G12/13-coupled assays is not likely to 
translate into a strong effect in physiological systems and it would be 
challenging to differentiate between Gq/11- and G12/13-mediated responses as 
AZ1729 has a negative modulatory effect on C3 efficacy in both. 
6.4 Conclusions 
Although the work described in this chapter was originally designed to uncover 
the molecular mechanisms underlying the species selectivity of FFA2 
antagonists, it expanded into a study that assessed a range of different aspects 
of FFA2 function. Initially, close investigation of a hFFA2 homology model 
facilitated the identification of Lys652.60 as a residue that defines species 
selectivity of FFA2 antagonists for the human versus murine orthologue. The 
interaction between the central amide moiety present in GLPG0974 and CATPB 
with Lys652.60 contributed significantly to high-affinity binding and the 
replacement of lysine with arginine at position 2.60, as in rodent forms of FFA2, 
resulted in loss of antagonist binding. Moreover, introduction of the ‘humanising’ 
R65K mutation in mFFA2 led to a gain of antagonist function with the inhibitory 
action of CATPB comparable to that at wild type hFFA2. Using this information, a 
homology model of R65K mFFA2 was constructed to understand how the R65K 
mutation might alter the receptor binding pocket to allow for ligand binding. 
Conceptually, taking experimental observations and computational ligand 
docking into account, it should now be possible to rationally design an antagonist 
that binds to both human and rodent FFA2 with high affinity. However, the 
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replacement of lysine with arginine at position 2.60 in mFFA2 may result in 
major conformational rearrangements, if Arg652.60 indeed forms an ionic bond 
with Glu682.63, which may inherently change the nature of the ligand-accessible 
binding site. Molecular dynamics simulations could contribute to defining the 
structural changes that occur when such an ionic lock is formed and this may 
provide some guidance for the design of an antagonist active at rodent forms of 
FFA2. Should design of an antagonist for rodent forms of FFA2 not be possible, 
the use of transgenic animals represents an alternative approach. Introduction of 
the R65K alteration in mFFA2 should theoretically not disrupt endogenous 
signalling, as long as a positive charge at position 2.60 is retained, and would 
allow specific inhibition by available antagonists. It would be interesting to 
perform parallel studies in mice expressing R65K mFFA2 versus humanised mice 
expressing hFFA2 to assess whether the differences in pharmacology observed 
between species translate into distinct physiological function.  
Interestingly, Lys652.60 also plays a role in selectively regulating activation of G 
proteins by hFFA2. A positive charge at position 2.60 was required for hFFA2 
coupling to Gq/11 and G12/13, but not Gi G proteins. There is a growing interest in 
understanding the molecular mechanisms behind GPCRs coupling to multiple G 
proteins. Novel structural and informatics approaches have been employed to 
dissect promiscuous GPCR coupling, including studies that use specific “mini-G 
proteins” in crystallography to detect G protein subtype-specific structural 
changes in active-state receptors (Carpenter and Tate, 2016) or investigations 
that utilise an informatics approach to identify residues across the family of 
Class A GPCRs responsible for conducting activation pathways (Venkatakrishnan 
et al., 2016). However, in many cases the focus lies on residue networks near 
the intracellular surface mediating potential interactions with coupled G 
proteins or along the transmembrane domains guiding rearrangements resulting 
in an active-state conformation upon ligand engagement. In contrast, here a 
residue near the extracellular portion of the receptor was identified, whose 
positive charge is essential for maintaining promiscuous G protein coupling of 
the receptor and alteration resulted in G protein coupling of hFFA2 being biased 
towards the Gi subtype within the Gi/o family. The fact that the positive charge 
at position 2.60 is conserved among species orthologues, suggests that it is 
essential for endogenous FFA2 function. Taken together, this provides an 
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interesting basis for the selection of GPCR coupling between G protein subtypes. 
The generation of a model animal that expresses a Gi-biased form of FFA2, by 
replacing lysine or arginine at position 2.60 with alanine or glutamic acid, could 
be an interesting approach to explore the contribution of respective G protein 
signalling to the physiological function of FFA2. However, in future studies that 
employ these biased FFA2 mutants as a tool it will be important to consider that 
β-arrestin recruitment was also affected by charge-altering mutations. 
Additional avenues of investigation should be explored to assess whether 
receptor internalisation and desensitisation is affected by the impaired 
recruitment of β-arrestin. It may also be of interest to assess if mutation of 
Lys652.60 affects β-arrestin recruitment directly by altering the affinity of 
β-arrestin for the altered active conformation of FFA2 or whether K65A and K65E 
mutations exert an indirect effect by e.g. altering phosphorylation of the C-
terminal tail of FFA2 that would result in reduced β-arrestin recruitment. 
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7 Final discussion 
The GPCR family represents the largest group of transmembrane receptors in the 
human genome (Fredriksson et al., 2003) and includes some of the most 
successfully utilised therapeutic targets, with a third of all approved small-
molecule drugs targeting GPCRs (Santos et al., 2017). The success of GPCRs as 
drug targets is undoubtedly linked to their ability to sense an extraordinary 
range of extracellular stimuli and translate environmental changes into a cellular 
response by inducing an appropriate signalling cascade (Lagerstrom and Schioth, 
2008). Therefore, GPCR research is often conducted with future drug discovery 
in mind. The deorphanisation of SCFA receptors generated much excitement due 
to their ability to respond to by-products of gut microbiome activity. The 
contribution of the gut microbiota to human health is well-established, in 
particular its involvement in the pathogenesis of inflammatory bowel disease 
(Zhang et al., 2017), and modulation of SCFA receptor signalling may represent a 
novel approach to therapeutically targeting the gut microbiome (Husted et al., 
2017). Studies investigating the physiological role of SCFA receptors have 
confirmed their involvement in a range of gut microbiome-related processes 
including the ability of SCFAs to modulate gut hormone release (Tolhurst et al., 
2012), insulin secretion (Priyadarshini et al., 2015) and immune cell recruitment 
(Maslowski et al., 2009). Despite the potential involvement of SCFA receptors in 
the pathogenesis of diseases with a great need for novel therapeutics, SCFA 
receptors remain far from fully validated as drug targets. The co-expression of 
SCFA receptors FFA2 and FFA3 in tissues of interest such as the gastrointestinal 
tract (Nohr et al., 2013) and pancreatic β cells (Priyadarshini et al., 2015), 
makes it difficult to dissect contributions of the respective receptors to the 
physiological effects of SCFAs. Therefore, development of specific tool 
compounds for FFA2 and FFA3 is crucial for understanding their physiological 
role. While the only available tool compounds for FFA3 display complex 
allosteric behaviour (Hudson et al., 2014), a larger selection of orthosteric 
agonists (Hudson et al., 2013a, Forbes et al., 2015), orthosteric antagonists 
(Hudson et al., 2012b, Pizzonero et al., 2014) and allosteric ligands (Smith et 
al., 2011, Bolognini et al., 2016a) have been developed and characterised in the 
last decade to investigate FFA2. However, pharmacological variations in species 
orthologues have limited the application of such tool compounds (Hudson et al., 
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2013b). Human and rodent orthologues of FFA2 display distinct properties 
including different rank orders of SCFA potencies, variation in constitutive 
activity and, perhaps most importantly, there is a lack of FFA2 antagonists 
active at rodent orthologues (Hudson et al., 2012b, Pizzonero et al., 2014). 
The work described in this thesis has focussed on investigating the pharmacology 
of FFA2 with the aim of providing a guide for the design of future tool 
compounds and potential therapeutics. In contrast to endogenous small-
molecule GPCR ligands that contain multiple functional groups and occupy a 
large portion of the ligand-accessible binding pocket, SCFA are small molecules 
that essentially only interact with the orthosteric Arg-His-Arg triad (Stoddart et 
al., 2008). Therefore, synthetic ligands for FFA2 invariably have to interact with 
additional regions of the binding pocket to achieve high-affinity binding, which 
may contribute to the complex pharmacology of FFA2 antagonists. Functional 
and binding studies employed throughout all chapters confirmed the main 
defining factor for agonist versus antagonist action at hFFA2: Interaction 
between the ligand carboxylate moiety and the orthosteric arginines Arg1805.39 
and Arg2557.35. These interactions are required for FFA2 agonist binding, as 
alanine replacement of either arginine residue (see chapter 4) or modification of 
the agonist carboxylate (Schmidt et al., 2011, Hudson et al., 2013a) resulted in 
loss of agonist binding and action, and may therefore confer the first step in the 
conformational changes required for an active-state receptor. A comparison of 
inactive and active state crystal structures across the GPCR family revealed that 
while activation-dependent structural changes at the extracellular face are 
usually highly receptor-specific, rearrangements that occur at the intracellular 
side upon receptor activation are in part conserved within the Rhodopsin family 
(Venkatakrishnan et al., 2016). Interestingly, the orthosteric arginine pair is 
conserved between free fatty acid receptors FFA1 (Sum et al., 2007), FFA2 and 
FFA3 (Stoddart et al., 2008), which may suggest that these receptors share a 
mechanism of receptor activation by agonist engagement of these residues, 
perhaps due to the fact that they arose by gene duplication given that FFA1, 
FFA2 and FFA3 are tandemly located on chromosome 19. However, the coupling 
of FFA2 and FFA3 to G proteins differs, with FFA2 signalling through multiple G 
protein subtypes including Gq/11, G12/13 and Gi/o, while FFA3 only couples to Gi/o 
G proteins (Brown et al., 2003). Therefore, part of the activation network that 
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translates agonist binding to G protein coupling likely differs between FFA2 and 
FFA3. However, investigation of the role of Lys652.60 in hFFA2 coupling to G 
protein subtypes revealed that it selectively regulates coupling of hFFA2 to Gi, 
but not Gq/11 or G12/13, while leaving agonist binding mostly unaffected (see 
chapter 6). Interestingly, Gi/o-coupled FFA3, and indeed FFA1, both contain a 
positively charged residue at position 2.60 and it may be interesting to explore 
whether G protein coupling at these free fatty acid receptors is also affected by 
charge-altering mutations of the equivalent residue.  
In contrast to agonists, FFA2 antagonist action does not rely to the same extent 
on the interaction between ligand carboxylate and the orthosteric arginine pair. 
While the interaction certainly contributes to anchoring antagonists in the 
binding pocket, it is not essential. Analogues of the representative FFA2 
antagonists GLPG0974 and CATPB with modifications at the carboxylate moiety 
retained their ability to bind to and inhibit agonist responses at hFFA2 and only 
required one arginine residue for high-affinity binding (see chapters 3 and 4). 
Regardless, assessed antagonists were competitive with FFA2 agonists and 
behaved as orthosteric ligands. Furthermore, high-affinity binding of the 
radioligand [3H]-GLPG0974 was lost upon mutation of both arginine residues to 
alanine (see chapter 4), confirming that at least one orthosteric arginine residue 
is required for antagonist binding. This structure-activity information was 
utilised to develop the fluorescent tracer F-1, which was generated by linking a 
NBD fluorophore to the carboxylate moiety of the GLPG0974 analogue GLPG-3 
(see chapter 5). Using fluorescent tracer F-1, a BRET binding assay utilising a 
Nanoluciferase-tagged form of FFA2 was successfully developed that allowed 
determination of unlabelled antagonist binding affinity and kinetics. However, in 
contrast to its parent molecule, F-1 was non-competitive with FFA2 agonists and 
behaved like to an allosteric ligand, while antagonists retained the ability to 
fully outcompete F-1 binding to hFFA2. Examination of the F-1 binding site by 
measuring its affinity at key orthosteric binding site mutants revealed that F-1 
retains the ability to bind the dual R180A-R255A mutant of hFFA2, albeit with 
reduced affinity. Interestingly, assessment of GLPG0974 analogues with 
modifications of the carboxylate region in F-1 competition binding assays 
demonstrated that analogues of the same parent compound with larger 
modifications showed increased affinity at R180A-R255A hFFA2. However, 
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neither GLPG0974 nor CATPB were able to compete with F-1 for binding to the 
dual arginine mutant of hFFA2, confirming that interaction with at least one 
orthosteric arginine residue is required for binding of the parent compounds of 
the two most commonly employed orthosteric hFFA2 antagonist series. 
Taken together, these observations suggest that orthosteric FFA2 antagonists are 
most likely bitopic ligands that interact with the orthosteric site comprised of 
Arg1805.39 and Arg2557.35 with their carboxylate moiety. The remaining part of 
the orthosteric antagonist molecule occupies a secondary binding site, which is 
shared with allosteric fluorescent tracer F-1, resulting in a competitive 
relationship between orthosteric antagonists and F-1 in BRET binding assays. The 
replacement of the F-1 carboxylate region with a linker and fluorophore NBD 
resulted in the loss of orthosteric interactions, thereby making F-1 an allosteric 
ligand. This hypothesis was supported by identification of Lys652.60, a residue 
that defines the species selectivity of antagonists for the human versus rodent 
orthologues of FFA2 (see chapter 6). Molecular modelling suggested that 
GLPG0974 and CATPB form an interaction with Lys652.60, which is lost in rodent 
forms of FFA2 due to an alteration of Lys652.60 to Arg652.60, which is likely 
sequestered in an interaction with Glu682.63. Thereby the mFFA2 binding site 
may be restructured in a fashion that prohibits antagonist binding. The role of 
Lys652.60 in defining the species selectivity of antagonists was confirmed by 
generating a ‘humanised’ R65K mFFA2 mutant at which FFA2 antagonists gained 
binding affinity and function. Docking of CATPB and GLPG0974 into a R65K 
mFFA2 homology model suggested that CATPB adopts a binding pose similar to 
that in hFFA2. However, this was not the case for GLPG0974 and there are likely 
additional species-specific residue contacts that define GLPG0974 binding to 
hFFA2. Interestingly, Lys652.60 was not only important for activity of orthosteric 
antagonists GLPG0974 and CATPB, but also essential for binding of F-1. This 
suggests that Lys652.60 lies within the secondary antagonist binding site shared 
between orthosteric antagonists and the allosteric fluorescent tracer. Therefore, 
extensive modifications of the antagonist carboxylate moiety may facilitate a 
switch from an orthosteric to an allosteric mode of binding. 
The studies presented in this thesis have not only provided information on how 
agonists and antagonists bind to FFA2 and why antagonists display species 
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selectivity for the human orthologue of FFA2 (see chapter 6), but also 
contributed to understanding the mechanisms underlying FFA2 activation (see 
chapter 4) and G protein coupling (see chapter 6). Considering the conclusions 
described above, which directions may be of interest to explore further? From a 
basic research perspective, to further the understanding of GPCR structure and 
function, FFA2 is an interesting receptor to explore due to its promiscuous G 
protein coupling profile. Identification of Lys652.60 as a residue at the 
extracellular portion of the receptor that may selectively regulate G protein 
coupling may facilitate examination of the molecular basis of biased signalling. 
Recent studies aiming to understand the mechanism of G protein coupling to 
GPCRs have explored the role of hydrogen bond networks, mediated by water 
molecules within the neurokinin-1 receptor, in defining biased G protein and 
β-arrestin coupling (Valentin-Hansen et al., 2015) and attempted to define the G 
protein subtype-specific interactions between GPCRs and Gαq versus Gαs proteins 
(Semack et al., 2016). Molecular dynamics simulations and more detailed 
investigations of the neighbourhood of Lys652.60 may be of interest to define the 
role of Lys652.60 in the activation pathway that contributes to Gq/11 and G12/13, 
but not Gi coupling, of hFFA2. Although the loss of β-arrestin recruitment at 
charge-altering mutants of Lys652.60 adds a further layer of complexity to the 
importance of this residue for FFA2 signalling, molecular dynamics simulations of 
respective mutants may shine some light on the structural determinants that 
G protein and β-arrestin coupling have in common. Comparison of results from 
such studies to equivalent investigations at FFA3 may also help to understand 
the distinct signalling profile of these two SCFA receptors.  
In addition to providing an opportunity to explore the mechanism of GPCR 
coupling to G proteins, findings discussed above can also be applied in 
translational studies to validate the potential of FFA2 as a therapeutic target. 
The broad expression profile of FFA2 and its ability to couple to multiple G 
protein subfamilies has made dissection of its physiological roles difficult and in 
some cases, studies have yielded contradictory results (Milligan et al., 2017). 
One prominent example is the effect of SCFAs on glucose-stimulated insulin 
secretion in the pancreas, in which independent studies observed activation 
(Priyadarshini et al., 2015) and inhibition (Tang et al., 2015) of insulin secretion 
in response to SCFA treatment. These observations may relate to the opposing 
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effects of Gq/11 (Sassmann et al., 2010) versus Gi/o (Berger et al., 2015) 
activation on glucose-stimulated insulin secretion, however, the G protein 
coupling of FFA2 in pancreatic β cells remains undefined (Milligan et al., 2017). 
The identification of the charge-altering mutations at position 2.60 that biased 
FFA2 signalling towards Gi G proteins (see chapter 6) may represent a convenient 
means of exploring the contribution of FFA2 signalling through Gq/11 versus Gi/o 
to biological outcomes. Generation of a rodent model expressing K65A or K65E 
hFFA2 could allow assessment of the impact of FFA2 signalling exclusively 
through Gi on physiological processes. Furthermore, in combination with FFA2-
specific tool compounds, important questions could be addressed, such as 
whether FFA2 is capable of inhibiting insulin secretion by activating Gi signalling 
in pancreatic β cells. To initially assess whether such a strategy is feasible, the 
genome of an immortalised cell line of interest, such as the pancreatic β cell 
line MIN-6 (Ishihara et al., 1993), could be edited using CRISPR/Cas9 
(Tschaharganeh et al., 2016) to knock-in a Gi-biased form of FFA2. Such a rodent 
model could then be utilised to examine how responses to SCFAs and tool 
compounds compare to cells expressing the wild-type receptor.  
While the complex signalling profile of FFA2 complicates the understanding of its 
physiological roles, the species-specific differences between human and rodent 
orthologues raise more fundamental questions regarding the usefulness of animal 
models. In addition to the selectivity of FFA2 antagonists for the human form of 
FFA2, assessment of the structure-activity relationship of a novel agonist series 
at human and murine FFA2 also revealed species differences (see chapter 3). 
Therefore, optimising compounds at hFFA2 in heterologous expression systems 
with the aim of developing a potential therapeutic and performing pre-clinical 
testing in rodent models does not seem to be a suitable strategy for FFA2. 
Transgenic animal models may be an alternative, as generation of a rodent 
model that expresses the human form of FFA2 would circumvent issues arising 
from species-specific pharmacology. However, it is also crucial to address 
whether differences in human versus murine FFA2 pharmacology translate into 
distinct physiological function. There are also general concerns regarding the 
reliance on mouse models for gut microbiota-related research, as variations in 
experimental conditions can affect microbiome composition and activity (Nguyen 
et al., 2015). Therefore, establishing a controlled experimental setup and being 
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aware of the limitations of animal models when translating results from mouse 
models to humans is highly recommended for future research on FFA2. In 
addition, a recent investigation of the GPCR repertoire expressed in human 
versus murine islets demonstrated differences in expression levels of the 
adenosine A3 and galanin receptors (Amisten et al., 2017), hence species-specific 
expression profiles in certain tissues should also be considered. Apart from such 
general considerations, the known pharmacological differences in endogenous 
FFA2 pharmacology in mice versus humans are comparably minor, with distinct 
rank orders of SCFA potency and differences in constitutive activity (Hudson et 
al., 2012b). The best approach is likely to compare results obtained from studies 
in animal models to those performed using isolated human tissue or cells, such 
as immune cells isolated from whole blood (Pizzonero et al., 2014, Bolognini et 
al., 2016a). The activation or inhibition of FFA2 will likely have an effect across 
multiple tissues involved in metabolic regulation, therefore observing the 
systemic impact of tool compounds in models of disease may be necessary to 
confirm whether targeting of FFA2 indeed provides a therapeutic benefit. 
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